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ABSTRACT
This study compare information flows in China and the UK with the example of pharma-
ceutical information. The general objective is to explore the relationship between infor-
mation situation and the status of science and industry in a country. In China scientific
information has long dominated information flows while in the UK scientific information
in dominance has gradually been changed to industrial information flow in dominance (i.e.
information work by, for and associated with industry).
After background study of information communication environment and medicines
research in China and the UK, scientific communication and S&T information flow are
firstly studied, taking examples from pharmaceutical sciences.
Then the thesis proceeds into studying pharmaceutical information flow which includes
not only scientific information but also business information, drug information, patent
information and statutory information. A systematic comparison has been carried out to
describe pharmaceutical information flow infrastructure; wider system of the information
flow; information flow performance; relations among scientific information, business
information, drug information, patent information and statutory information; relationships
among system (pharmaceutical information flow), wider system (national pharmaceutical
industry), general information environment, and special environment "national drug
situation/pharmaceutical activity".
The industry's role in pharmaceutical information flow in Britain and China reflects the
fundamental difference in the two countries' situation. In the UK, pharmaceutical industry
playa central role in the pharmaceutical information flow. Some information are directly
related to the industry such as S&T information, patent information and business infor-
mation, some are indirectly associated with the industry such as drug information and
statutory information. The big industry, big science and big information may reflect the
UK situation. On the other hand, pharmaceutical information flow in China is mainly S&T
information flow and is not closely linked with the industry. The less sophisticated phar-
maceutical industry has a premature "nerve system"- information flow. The very limited
industry involvement in R&D and therefore in information work reflects the little industry,
little science and little information in China.
. .
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Chapter 1 Introduction
1.1 Science and Communication, Industry and Information Flows
Science is a process which does not proceed by simple cumulation of knowledge but
by creating a sequence of theories which continue to refine, extend or replace each other.
Science is an activity, in which scientists generate, disseminate information on one hand,
search, use and assimilate information on the other. Just like science and its com-
munication always go hand in hand, modem industry and information are usually bonded
together. Some studies divided the modem history into pre-industry, industry and
post-industry phases and characterized the post-industry phase by so-called "info-
nnation society" (Vickery, 1987).
After the World War II, along with the industrialization movement world-wide, there
is a trend from "little science, little industry" towards "big science, big industry". This
transition is reflected not only from the exponential growth in the size of science but
also from the ever tightening link between national R&D and national economy. (Price,
1963) In this movement, in the industrial developed countries, scientific information in
dominance has been changed to industrial information in dominance (i.e. information
work for, by and associated with industry). The wide application of information tech-
nology (IT) and great information demands from industry, i.e. the technology push and
the market pull, have enabled information flow in industry and information flow
associated with industry to grow very rapidly. We may call this as industry led, driven
and oriented information flow.
In developing or less industrialized countries like China, the situation of information
flow is quite different. Lack of the technology push and market pull prevents the
information flow from quick growing. Purely scientific information has long dominated
the information flow in China. Information work is confined to libraries and S&T
information institutes.
Nowa few words on the term "information flow" are needed. There are two definitions-
one is narrow and one is broad. A common and narrow use of the term implies the
spontaneous or automatic spread of information. The term "information flow" could
also be used in the other broader sense of information transmission whether from person
to person direct or via some intermediary store such as a book. journal article or com-
puterized file (Hill, 1987). In this thesis, the latter meaning of information flow is adopted
as an analogy with water flow.
Before proceeding to describe the whole study, we still need to explain the term
"pharmaceutical information" firstly.
1.2 The Many Faces of Pharmaceutical Information
A person unfamiliar with the modem pharmaceutical industry and pharmaceutical
activity, is more likely to understand pharmaceutical information as that contained in
drug compendiums or medical handbooks. To a person familiar with the pharmaceutical
industry and pharmaceutical activity, however, pharmaceutical information means many
things relating to the industry and national pharmaceutical activity. It may be scientific
and technological (S&T) information for drug research and development (R&D), or
business information for finance, project or marketing managers in companies, or
product information stored and managed by company information scientists who provide
drug information service to the health professionals or sometime to the public. Moreover,
pharmaceutical information is also connected with drug legislation and regulation in
countries. Finally, the pharmaceutical patent is of great value to the industry both as one
kind of information source and in the sense of intellectual property protection.
In this thesis, a rough definition is given of pharmaceutical information as the infor-
mation related to pharmaceutical research and development or to pharmaceutical
products. It consists of five major types: S&T information, business information, drug
information, patent information and statutory information. Sequentially, pharma-
ceutical information flow is composed of the five types of information flows.
Although this definition of pharmaceutical information may seem to be too broad, it
does suit the unique purpose of this thesis, that is to compare information flow in China
and UK with pharmaceutical information as the example.
1.3 A Comparative Study on Information Flows in Britain and China
- with pharmaceutical information as the example
The stimulus to this project was the original idea of a comparative study on S&T
information systems between China and UK proposed by the Library of Chinese
Academy of Science (Academia Sinicai which is the sponsor for this Ph.D study. Such
2
a project was expected to produce some useful recommendations on information issues
for the undergoing S&T system reform in China. It has been recognized that only to
enforce and enhance current S&T information work is not enough. There is a need to
build up information flow for industrialization rather than simply for S&T.
In 1978, China launched the greatest economic reform since the foundation of P. R.
China in 1949. Some major aims of this economic reform are to encourage foreign
investment, to promote the trade with foreign countries; and to let market forces, beside
the central planning, to determine the pattern of industrial production. Following the
economic reform, in 1985 China started its S&T reform to orient the national S&T to
the national economic reconstruction.
Some steps were planned to implement the S&T reform:
- to remedy the drawback ofresearch institutes being isolated from industrial
enterprises, scientists are encouraged to undertake projects with industrial
potential. Whilst some projects with national priority will remain under the
control of the State, most of R&D activities are to be undertaken according
to the industry demands;
- the R&D budget will no longer be allocated by the central government as
an average according to the number of staff in institutes, instead, R&D
projects in applied science will be funded by project sponsors (mainly
industrial sponsors) under the contracts;
- directors of research institutes will be given more power by the central
government in deciding the research directions in their institutions;
- a new type of research institutions: National Open Laboratories will be
set up for visiting scientists from the country and abroad, so that a better
scientific communication environment will be established for Chinese
scientists (White Paper, 1987 & 1990).
It seems that China is facing a turning point in its S&T history now. So far. many S&T
administrative officials and scholars have been travelling around the world to learn other
countries' experience in how to manage the national S&T under the industrialization
process.
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The worldwide modern industrial revolution started in Britain three hundred years ago.
The UK remains as one of the most developed industrial countries in the world today.
With respect to this, a comparative study on British and Chinese S&T information system
surely is a very interesting and promising topic.
However, there are two problems in this comparison of S&T information system in
China and UK, which cause some concern.
Firstly, in China S&T information is, at present, the most comprehensive or the highest
level tenn for all kinds of information activities. In 1986, an international ｭ ･ ･ ｴ ｩ ｮ ｾ cl
experts Q!l natiQnal scientific .and technical infQrmatiQn pQlicy in China gave the defi-
nition of scientific and technical (S&T) information. It was agreed that scientific,
technical and economic information, encompassing purposive messages relevant to
technical problem solving and decision making will constitute the definitive framework
(ISTIC, 1986). However, in UK scientific information is mainly confined to information
associated with science and technology. There are other kinds Qf information such as
business information, statutory information etc. which are related with industry and are
not usually included in the term of S&T information.
Hence, it would be better to avoid using "S&T information system ", since S&T infor-
mation does nQt mean exactly the same thing in the two counties. Instead, we use
"scientific communication, information flows in industry" to describe the information
situation in industrialization process in the two countries.
Secondly, such a study which is still too wide in subject, may nor be suitable for a Ph.D
study with very limited time and resource (manpower and funds etc.). With the help Qf
the supervisor Professor R. T. Bottle, the author confined the topic to a subject area:
pharmaceutical information under a principal guide-line that such a comparison, Qn
one hand, should be able to best represent the modern information practice in the
developed industrial country UK, so that China could learn the most from the selected
model; and on the other hand. the comparison should be able to best reflect the situation
of China' s S&T information infrastructure as well as the trend of the reform in national
economy and national S&T. so that information scientists in the UK and other countries
could become familiar with the growth and development in science, industry and
information flow in China.
The first year study, including literature survey and extensive consultation with Professor
Bottle, other academic staff in the department of information science at the City Uni-
versity, and some information specialists in the UK pharmaceutical industry and
information industry, has convinced the author that such "a comparison of
pharmaceutical information flows in Britain and China" could meet the above
principal guide-line nicely for the following two reasons:
First, the UK pharmaceutical industry has been in the world leading position for more
than half a century. It is well known that the UK pharmaceutical industry is one of the
information intensive industries in the country, because of its characteristics of heavy
competition world-wide, high risk in business, heavy R&D investment and high profit.
On the par with scientific information flow, other information flows have been growing
significantly for the past few decades. All these information flows are either directly
related with the industry such as scientific information, business information, patent
information; or indirectly related with the industry such as drug information and statutory
information. In this thesis, all these information come under the name "pharmaceutical
information". The pharmaceutical information flow in UK may be called industry
led information flow and reflects the situation in today's "information society".
Secondly, China is a country with five thousand year of civilization history and
experience in using traditional Chinese medicines (TCM). Its pharmaceutical industry
has experienced a rapid growth for the past forty years (over 10% growth rate per year
during the last twelve years, seeing Chapter 3). Meanwhile, the medicines research has
also developed very quickly, walking on the two legs of traditional Chinese medicine
(TCM) and western medicine (WM). A national S&T information system has already
been built up in the pharmaceutical field since 1949. And it is now facing the historical
change under today' s economic and S&T reform waves. Pharmaceutical information
flow in China is mainly S&T information flow; it is not closely linked with the
pharmaceutical industry and reflects the information situation in less industrial-
ized countries.
To draw such a comparison and to make some recommendations for the Chinese S&T
information reform is difficult and would be aided by an appropriate methodology. The
soft systems methodology described by Checkland (1981) was used to complement the
other more traditional methodologies used in this study.
1.4 A Soft Systems Approach
Systems engineering comprises the set of activities which together lead to the creation
of a complex man made entity and/or the procedures and information flows associated
with its operation. System analysis is the systematic appraisal of the cost and other
implications of meeting a defined requirement in various ways. "Hard" systems thinking
is goal-directed, in the sense that a particular study begins with the definition of the
desirable goal to be achieved. The application of such methods to management problems,
to "soft" problems in social systems where goals are often obscure, is called "Soft
Systems" methodology (Checkland, 1981).
It is said that in engineering, hard system thinking is used to solve structured problems
which can be explicitly stated. However, in social sciences, soft systems methodology
must be applied to unstructured and ill-defined problem situations. Here, "what is a
problem ?" itself becomes a part of the research.
The soft systems approach includes the following three major steps:
1. An expression to build up the richest possible picture of the problem situation.
2. Definition of a conceptual system model with the major features including system
mission. measure of performance, decision taking process, subsystems, wider system-
/environment, and resources.
3. Comparison of the system model and the problem situations and proposals for feasible
and desirable changes.
As it is said before, this project is expected to provide some recommendations for the
Chinese S&T information reform by learning from the advanced UK model. This study
takes pharmaceutical information as an example. There are three reasons for the
application of soft systems methodology in this project.
Firstly there some unstructured problem situations (see "Description of the Studies in
This Project").
Secondly. a conceptual system model could be drawn from the existing advanced UK
pharmaceutical information flow infrastructure. In fact "pharmaceutical information"
is very much a western concept. Pharmaceutical information is not commonly recog-
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nized in China as having 5 elements (scientific, business, drug, statutory and patent
information) normally associated with it in the West. In the UK, pharmaceutical
information flow is associated and linked with the research based industry and the
sophisticated national drug situation. Such kinds of pharmaceutical information flow
do not exist in China where only S&T information flow is relatively well developed.
Thirdly, by comparing the Chinese problem situations with the system model drawn
from the UK pharmaceutical information flow, we could "image" a hypothetical system
for the pharmaceutical information flow in future China, and propose feasible and
desirable changes to the current situations.
Accordingly this project is divided into three sequential parts: expression of problem
situations in China compared with UK (Chapters 2-6); illustration ofan advanced system
(UK pharmaceutical information flow in Chapter 7) and a less developed system (the
Chinese pharmaceutical information flow in Chapter 8); definition of a conceptual
system model based on the UK situation, comparison of the system model with the
Chinese problem situation and recommendation for the future system in China (in
Chapter 9).
1.5 Description of the Studies in This Project
In soft systems thinking, to find out what are problems and to give the richest possible
picture of problem situations is the first and the most important part of research. Chapters
2-6 will undertake the task of "drawing pictures".
Chapter 2 Different Information Communication Environment in Britain and China
Information is a social practice which exists in its environment. Chapter 2 gives the
demographic and economic background of the two countries, a historic study of
information communication in the two countries, and current communication envi-
ronment (including mass media, transportation, information technology) in the two
countries. This chapter provides a picture of general information environment for the
soft systems study.
Unstructured problem situation-
Information environments in the two countries are in different stages of development.
on different social economic bases. What are influences on pharmaceutical information
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flows in the two nations?
Chapter 3 Medicines Research in Britain and China
If the pharmaceutical information flow is taken as a system, the nation's drug situa-
tion/pharmaceutical activity (including consumption, production, and trade) is the
special environment for the system. Furthermore, the national pharmaceutical industry
is its wider system which will greatly determine the pattern of the pharmaceutical
information flow.
The UK pharmaceutical industry has 4 major features: its products are the results of
extensive R&D, are patent protected, are available on prescription only, and have sig-
nificant world market share. The Chinese pharmaceutical industry mainly operates in
the domestic market. Its products are not patent protected. It has only a small R&D
capacity and international marketing capacity. UK has a well developed drug distribution
and legislation system whereas China is developing its system up to the international
standards.
In Chapter 3, the drug situation/pharmaceutical activity, the pharmaceutical industry
and the features (organization, status and size) of modem pharmaceutical R&D in the
two countries will be compared. Such an approach will serve as a special background
to the study on pharmaceutical information flow in Britain and China.
Unstructured problem situation-
IfChina modernizes its pharmaceutical industry, do its information flows need to change
into the UK pattern?
The soft systems approach needs to "measure" the performance of existing system. This
will provide some data for planning the reform of the current system and some
experiences for operations research and system evaluation in the future system. Chapters
4-6 will describe the Chinese problem situations by "measuring" scientific communi-
cation performance in comparison with UK situation.
Chapter 4 The Growth of Science
One effect of the exponential growth in science world-wide since the 17th centurv is
the so-called "information explosion". To study S&T information flows in China and
UK, it is necessary to have an overlook on the scientific growth in the two countries as
well as in the world. Chapter 4 measures the growth in the world and a few major
countries (USA, UK and China etc.) in S&T manpower, literature. expenditure and
studies impacts of the scientific growth on S&T information communication.
Chapter 5 Scientists' Information Needs Searching and Accessing Ability
In Chapter 5, the scientific information communication is to be studied from the input
side (i.e. the information access). Two countries' scientists information need, searching
ability and accessing ability are compared.
Unstructured problem situation-
Are Chinese scientists satisfied with the S&T information services? How effective is
scientific communication in China?
Chapter 6 Scientists' Information Using Disseminating Ability
In Chapter 6, the scientific information communication is to be studied from the output
side (i.e. the information use and dissemination). Scientific literature production in the
two countries is first studied. Two countries' scientists' ability in disseminating infor-
mation is compared. This chapter also discusses scientists citing behaviours and lit-
erature aging issues to study scientists' information using ability in the two countries.
Unstructured problem situation-
Is the capacity of Chinese scientists in disseminating and using information lower than
British scientists? What are the causes or influencing factors?
Before the definition of a conceptual system model based on the UK situation, Chapters
7 and 8 will illustrate an advanced pharmaceutical information flow in UK and a less
developed pharmaceutical information flow in China.
Chapter 7 Pharmaceutical Information Flow Infrastructure in Britain
As was said earlier, the pharmaceutical information includes not only the scientific
information but also other information related to pharmaceutical industry and phar-
maceutical activity. Chapter 7 includes the following sections: S&T information system
in UK, business information in UK, information work in UK pharmaceutical companies.
drug information system in UK. statutory information and regulatory system in UK,
patent information and patent system in UK.
Chapter 8 Pharmaceutical Information Flow Infrastructure in China
In Chapter 8 the following sections are included: scientific information flow, business
information flow, drug information flow, statutory information flow and Chinese
regulatory system, patent information flow and Chinese patent system.
Unstructured problem situation-
Is it right to say that there is a little science (isolated from industry), a little industry (not
research based) and a little information (not linked with industry activity) in China vs
a big science, a big industry and a big information in the UK ?
Chapter 9 Pharmaceutical Information Flow in China Today and in the Future
Chapter 9 carries out a comparison of pharmaceutical information flows in the two
countries within a systematic framework. It finally tends to draw some recommendations
for a future pharmaceutical information flow system in China.
First the UK pharmaceutical information flow is assigned to a conceptual system S.
Such a system has its infrastructure, purpose/mission, measures of performance,
boundary, wider system, environment, and subsystems etc .. Second, pharmaceutical
information flow infrastructures in the two countries is compared. Third, we compare
the wider system "national pharmaceutical industry" in the two countries. Fourth, we
compare the purpose/mission of the system S "pharmaceutical information flow" in the
two countries. Fifth, from the stand-point of scientist as information generator and user,
we will compare the performance of information flow in the two countries. Sixth, we
will compare the information resources in the two countries. Seventh, there are five
information flows (subsystems) interacting with each other in the whole pharmaceutical
information flow (system). The relationships among subsystems will be studied. Eighth,
pharmaceutical information flow exists within its special environment "national phar-
maceutical activity", its wider system "national pharmaceutical industry" and its general
infonnation/communication environment in a country. The relationships among system.
wider system and environment will be studied.
Finally. there will be some recommendations for the reform of current S&T information
system and for the future pharmaceutical information flow system in China.
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1.6 Other Methodologies Used in This Project
Apart from the soft systems method, the following methods are used in this project: (i)
social survey (literature survey, questionnaire, interview, and personal contact for data
gathering) (ii) data processing (iii) bibliographical studies (or bibliometrics). Because
there will be detailed description of the methods or techniques in each of the following
chapters, here we just discuss and assess these research methods generally.
(i) Social survey (literature survey, questionnaire, interview, and personal contact for
data gathering)
The first and the most important problem encountered was collecting information or
data for research. The major method of data collecting in this project is social survey.
To carry out a comparative study on information flow at such a wide scale, the literature
survey has proved the most efficient way of data collection. In the UK studies. more
data are collected from literature source, because many researches have been done in
pharmaceutical information areas (Pickering, 1990, Jackson, 1987 etc.). The principal
method for this project is to collect data firstly from the existing literature sources and
secondly, when there is no literature source available, to collect data by means of
questionnaires, interviews and case studies. In the China studies, more efforts have been
made to collect first hand information by the author by means of questionnaire and
interview, because there have been few studies on pharmaceutical information in China
so far. Most of information or library studies are still concentrating on S&T information
generally (Gong, 1990).
The literature survey was conducted under the subject Pharmaceutical Infonnation by
using the Library and In/ormation Science Abstracts (LISA, UK) and scanning Chinese
library and information journals.
Pharmaceutical information is one of the biggest subject area in information studies.
Every year, there are hundreds of papers in this subject being indexed in LISA. The
majority of them are written by the information scientists in the developed countries
such as USA, UK, Germany, Italy, Japan etc., corresponding to the leading position of
these countries in the world pharmaceutical industry. Generally the literature on this
subject may be divided into the following five categories:
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(1) Literature or information guide books such as Guide to the Literature ofPharmacy
and Pharmaceutical Sciences (Andrews, 1986), Information Sources in Pharmaceuti-
cals (Pickering, 1990), Drug Information Sources (Revill, 1984), Informarion Sources
in Medical Sciences (Morton & Godbolt, 1984) and Use ofChemical Literature (Bottle.
1979 & 1991). These comprehensive books provide not only guidance in the use of the
literature in the pharmaceutical field, but also an introduction to or overview on the
information flow, work and practice in the developed industrial countries.
(2) Literature on information work and practice in the modern pharmaceutical industry.
There are lots of papers of such kinds written by experienced information scientists in
the industry (Brown, 1985; Cuddihy, 1975; Williams, 1984; Jackson, 1987 etc ..) In the
UK, there is a professional association for pharmaceutical information officers (AIOP!).
Since the early 1970s, it has held conferences annually to discuss the current issues in
information work in pharmaceutical industry and related areas. The most current issues
include inhouse database system ｭ ｡ ｮ ｡ ｾ ･ ｭ ･ ｮ ｴ Ｌ CD-ROM .and ｾ a.wllications.
interlibrary 1illm .a.n.d BLDSC. ｾ ｣ ｨ ｡ ｮ ｾ ｩ ｮ ｾ NHS environment, ADR ｭｯｮｩｴｯｲｩｮｾＮ
ｰｯｳｴｭ｡ｲｾ surveillance. patent and ｾ ｊ･ｾｩｳｬ｡ｴｩｯｮ etc (AIOPI annual conference
papers, 1985-1988),
(3) Literature on information work and practice in the National Health Service in UK
(NHS). Many studies have been done on the national drug information network and
information services provided by pharmacists. Some important authors include McNulty
(1984), Hibberd (1980), Smith (1982) etc.
(4) Research papers on pharmaceutical information by the students of Department of
Information Science at the City University, London. This department has provided post
graduate education in information science for nearly two decades. Pharmaceutical
information has long been one of the major directions of education and research of this
department. Some research work have been accomplished by this department covering
broad fields such as information work in the industry (Clark, 1985). information
scientists in the industry (Jackson, 1975 & Augustus, 1981), IT in the industry (Byway,
1988) etc..
(5) Finally, about pharmaceutical patent and drug legislation/regulatory, many papers
may be found from organizations such as Association of British Pharmaceutical Industry
(ABPI), Centre for Medicines Research (C\1R), Royal Pharmaceutical Society
(RPSGB) etc ..
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In China, the information journal most relevant to pharmaceutical work is the Medical
Information Work Journal published by the Ministry of Public Health Ｈ ｾ ｴ ｐ ｈ Ｉ Ｎ :\
scanning of this journal for the period of 1985-1989 shows that the majority of papers
are concentrated in the S&T information work in academic institutions in China. The
term "pharmaceutical information" is rarely used as it has been used in the UK and the
West for so many years. This reflects the premature status of pharmaceutical information
work in China. As a matter of fact, very few Chinese studies have looked at pharma-
ceutical information from the stand-point of this thesis, though it is a com mon stand-point
in the West.
Questionnaire provides an economic method for large sample survey. In this project,
five series of questionnaire have been designed and sent out to investigate the following
situation in China: (l) scientists information need and satisfaction, (2) doctors drug
information need (3) hospital pharmacists role in drug information provision (4) phar-
maceutical manufacturers role in and need for information (5) information services in
pharmaceutical industry (Appendix 5.1-5.5).
The above five series of questionnaire were designed against the existing similar survey
in UK (Royal Society, 1981; McNulty, 1984; Williams, 1984 etc ..); so that the com-
parison could be carried out correspondingly.
During the period of October - December, 1989, the author has conducted the ques-
tionnaire and interview survey in China. During which just under 500 questionnaire
forms have been sent out with a response rate of nearly 50%. Additionally, the author
visited all the major government departments in pharmaceutical field: Ministry of Public
Health (MPH), State Pharmaceutical Administration of China (SPAC), State Admin-
istration of Traditional Chinese Medicines (SATCM); the major academic institutions
in the field such as Shanghai Institute of Pharmaceutical Industry, the chemistry branch
and the life science branch of Academia Sinica, Chinese Academy of Medical Science
and Research Institute of Clinical Pharmacology at Beijing Medical University etc.; and
six largest pharmaceutical manufacturers in Beijing and Shanghai. In addition. the
national S&Tinfonnation centres or libraries such as Institute of Scientific and Technical
Information of China (1ST/C), The National Library of China (NL). and Chinese Patent
Office (CPO) have also been visited for data collection. Being aware of the cultural
difference betwec n Chinese people and Westerners in their attitudes towards ques-
tionnaire, all the 5 series offonns were distributed and collected by the author personally
in order to get the best possible response.
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Throughout the three year study, with the help of Professor Bottle, the author has selected
several typical information organizations for the UK case studies. In the national S&T
information system, the author focused on the British Library, especially the unique
central document supply system BLDSC. In 1990, the author visited the British Library
Document Supply Centre (BLOSe) and the Scientific Reference Information Service
(SRIS) for data collection. Furthermore, some academic libraries (Loughborough Uni-
versity, Southampton University and School of Pharmacy of UeL) have been visited
and studied as examples of S&T information services in UK. In the study on information
services and work in pharmaceutical industry, the author visited one UK owned large
company Glaxo and the UK subsidiary of one multinational company (Farmitaliai.
Furthermore, the author has collected data directly from ABPI and AIOP/. To study the
drug information service in UK, the author has visited and interviewed the information
officer at the Royal Pharmaceutical Society. Business information for the pharma-
ceutical industry has a pivotal position in the UK pharmaceutical information flow.
However, studies on this issues have been very scattered. Some case studies on
information specialists (PJB, Disclosure, SVP and IMS) have been done by the author
by means of visiting, interviewing, mailing enquiries, and personal contacts. Finally,
the Centre for Medicine Research CCMR), as an unique information and scientific
research resource in Europe on some aspects of pharmaceutical industry, was visited
by the author in October, 1991. CMR was established by the ABPI in 1981 as an
independent scientific unit to undertake research into the development and safe use of
medicines.
(ii) Data processing
The second problem in methodology is the analysis of data.
The most widely used data processing method in this project is tabulation. To supplement
the tables, some sorts of graphs have been drawn such as curve. bar, line and pie to
demonstrate trend, composition, or share.
The Lotus Manuscript and Harvard Graphic software packages have been used in this
project for data presentation and statistical analysis. The regression technique has been
used in drawing trend curve or line particularly in the literature aging analysis in Chapter
6.
(iii) Bibliographical Studies
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To study scientific communication, quite different from the above social survey
methods, there is a quantitative or statistical method in information science namely
bibliometric studies. Among the bibliometric studies, Bradford's law is about the
concentration and dispersion ofpapers injournals; Lotka's law is about the concentration
of scholarly productivity; the aging of literature is about the utility of literature over
time; the citation analysis studies the relationship between citing papers or authors or
journals and cited papers or authors or journals. In this project (Chapter 6), the biblio-
metric methods are to be applied to compare the scientific literature production by the
two countries' scientists.
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Chapter 2 Different Information Communication Environment
in Britain and China
Information is a social practice which emerges from and develops always within the social
environment that gives rise to demands for information. It is necessary that the general
environment of information communication be explored carefully before the information
flows be studied.
2.1 Demographic and Economic Background
China has an area of nearly 9.6 million square kilometres and a coastline extending to
18,000 kilometres. An official estimate in 1988 put the population at 1,096 millions.
The mean rate of increase over the past decade is estimated to be a little over 1% per
year. Six per cent of Chinese people belong to one of fifty-five ethnic minorities. the
rest being of the Han race (Far East, 1989).
There are 26 provinces and autonomous regions (not including Taiwan) and three
municipalities. The breakdown of the area and the population by administrative divisions
is shown in Appendix 2.1. Xizang (Tibet), Xinjiang and Inner Mongolia autonomous
regions and Qinghai province are huge but sparingly inhabited. Disregarding them,
Sichuan province is the largest in both area and population. The three most populous
cities ofBeijing (the national capital), Shanghai and Tianjin together with their respective
surrounding counties, have been administratively made into municipalities, which
command provincial status. A region or province consists of prefectures, themselves
made up of counties and cities. Several towns comprise a provincial county, and are in
turn composed of villages.
China has a broadly based economy with expanding mining and industrial sectors;
production of crude oil increased markedly in the 1970s. Since China started the
economic reform in 1978, "Special Economic Zones" have been set up to encourage
foreign investment for expansion of manufacturing; the inflow of capital was about
$4,400 million in 1985 (including loans and direct investments) and has kept increased
ever since. China's visible trade turnover totalled $102,790 million in 1988 which is
about one third of the UK turnover. Major exports include crude oil, petroleum products
and textile goods which account for half the total export volume (Howe. 1989 &
Economists, 1987). About 61% of the Chinese labour force is engaged in agriculture
and fishery. which accounts for 45% of the Gross Domestic Product (GOP) (Far East.
1989).
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Britain comprises Great Britain (England ,Wales and Scotland) and Northern Ireland.
and is one of the 12 member states of the European Community. Britain constitutes the
greater part of the British Isles, a geographical term for a group of islands lying off the
north-west coast of mainland Europe. With an area of some 244,100 sq. krn .. Britain is
about the same size as the Guangxi Zhuang Autonomous Region or Guangdong Prov-
ince, and half the size of Sichuan Province or Heilongjiang Province of China. The
climate is generally mild and temperate. The population in Britain is estimated to be
57,065,000 in 1988 (Britain 1990).
Britain has an industrialized economy with machinery, chemicals and motor vehicles
accounting for over one-third of exports - and a wide range of other manufactures.
Manufacturing occupies about one-fifth of the labour force and provides about one-
quarter ofGross Domestic Product. There is a substantial service industries sector which
absorbs about 50% of the employed labour force (Economists, 1987).
Britain's visible trade turnover totalled £180,871 million ($325,568 million) in 1988
with a trade deficit of £20,557 million ($37,003 million) (Britain 1990). The volume of
Britain trade is more than three times China's trade volume.
China's land is 39 times the area of Britain. And its population is 19 times the British
population (Table 2.1). However, under the economic measure, the Gross Domestic
Product (GOP) of Britain is 1.5 times the GOP of China. Furthermore. in terms of
National Income Per Person, Britain is 26.5 times China (Table 2.1 and 2.2).
In terms of national income per capita. the UK belongs to the top thirty of the most
developed industrial countries in the world, while China is classified as a third world
developing country. ranking the 176th in the world.
By analysing the labour composition and production composition of the two countries
( Table 2.3), we could find that in the Chinese economy agriculture is the dominant
sector with industry at the second place. In the UK, service is the most dominant sector
with industry in the second place. It reflects that Britain has entered the post-industrial
era. while China is still in its pre-industrial phase.
Although it is still poor. China has been outstandingly successful in reducing extreme
poverty. Although there is substantial income inequality between urban and rural areas
and among different rural localities. the huger, disease. high birth and infant death rates.
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Table 2.1 The World Gross Domestic Product, Population and Labour Force
(Economist, 1987 & 1986)
Gross Domestic Product Population Labour Force
(1) (2) (3) (4) (5) (6) (7) (8) (9)
World 12,820,000 2.0 4,820,000 1.7 1,670,CXX> 41
China 9 310,000 9.6- 1 1,040,600 1.3 1 400,CXX> 47
India 11 186,000 5.5 2 750,900 2.5 2 180,373 33
Japan 2 1,325,430 3.9 6 120,754 0.7 5 53,780 48
U.K. 6 455,622 1.9 14 56,618 0.1 9 26,258 47
U.S.A 1 3,947,000 2.4 4 239,283 1.0 4 96,917 45
(1) Rank by GDP in 1985
(2) GDP (in $ mn) in 1985
(3) GDP GrowLh Rate (% p.a.) for 1980 - 1985
(4) Rank by Population in 1985
(5) People (in thousand) in 1985
(6) PopulationGrowth Rate (% p.a.) for 1980 - 1985
(7) Rank by LabourForce in 1976
(8) Labour Force (in thousand) in 1976
(9) Percentageof total Population in 1976
* China's GDP growth rate for the period of 1978-1988 (Peoples' Daily. 9 Jan. 1990).
Table 2.2 The World Standard of living (National Income per person ($) in 1985)
(Economist, 1987)
Rank Income per person ($)
World 2,380
China 176 270
India 188 226
Japan 18 9,452
U.K. 33 7,156
U.S.A 2 14,565
Table 2.3 Structure of Employment and Production in China and U. K.
Data in 1984, (Economist,1987)
Percentageof Employees Percentageof Production (GDP)
Agr. Indus. Services Agr. Indus. Services
China 61" 2f 11· 45 42 13
U.K. 2 34 51 2 49 49
* Data in 1986, Source from "The Far East & Austrilasia 1990" (Far East, 1989)
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general illiteracy, and constant fear of destitution and starvation that haunt very poor
people in other countries have been more or less banished. Partly due to that. Chinese
people usually live longer than people in other developing countries. In terms of
expectation of life, China (69 years) is above the world average 63 years and middle-
income country (62 years) and ranks the 43rd in the world. (People's Daily. 5 Jan .. 1990)
Furthermore, the economic growth of China in the last forty years is quite encouraging.
From 1952 to 1982, despite relatively rapid population growth and periods of acute
economic mismanagement, per capita national income grew at an average annual rate
of 4.0 per cent, with phases of significantly faster growth. Of particular relevance is
China's performance during the last decade of economic reform: from 1979 to 1984 per
capita national income grew at 6.8 per cent per year (World Bank, 1985). From 1986
to 1990, per capita national income grew at an average annual rate of 4.1% (People's
Daily, 14 March, 1991).
In terms of average annual growth rate of GDP, China has maintained a relatively high
record in the world for the last forty years- 6.1 % for 1953-1978,9.6% for 1978-1988
and 7.5% for 1986-1990 (Peoples' Daily, 5 Jan. 1990 and 30 Nov. 1990); while the
world average was only 3.9% for the period of 1971-1980 and 2.9% for 1981-1990 (UN
World Economic Survey 1989/1990).
It is now exactly ten years since the Chinese economy began a process of profound
reform and re-orientation. The record of China's first decade was mixed. Accom-
plishments were sizable and obvious- a surge of production, a rise in living standards,
and an explosion in foreign trade.
During 1979-1988. the export increased at an average annual rate of 15.40C while the
import at 16.5% (Hartland-Thunberg, 1990).
During 1986-1990, the inflow of foreign capital was $46 billion. The annual inflow in
the last five years is twice the annual figure in the first five years of the 1980s. (People's
Daily, 14 March, 1991)
However. it must be noticed that since 1985, the Chinese economy has experienced
severe problems of economic control, especially control of investment. The balance of
payment has become a problem, foreign borrowing has accelerated, and foreign
investment has been much lower than desired. The crisis was recognized by the auth-
orities by the end of 19H8 when its principal indicator- the inflation rate- has risen by
27% throughout the year. That was the worst figure for the last ten years (Howe. 19X9).
19
From 1981, the British economy has grown at an annual average rate of 3%- which is
just above the world average rate for that period. Investment, export volume. the number
of jobs and productivity have all risen substantially. However. after falling sharply in
the early 1980s, the rate of inflation has risen since early 1988. By the August 1990, it
was 10.6% at an annual rate. The current account of the balance of payment has been
in deficit since 1986, following six successful years of surplus (Britain 1991).
The economic perfonnance in UK and China for the period of 1978-1989 may be
reflected from the index of inflation rate (Appendix 2.2).
2.2 A Brief Historic Study of Information Communication
Information communication in human society has a long history of several thousand
years. Table 2.4 gives an approximate time chart with the emphasis on UK developments
since 1500 in the left column and developments in China in the right column. (Vickery,
1987 and Infor. China, 1989)
Ancient Chinese people contributed a lot to the civilization of the world. The invention
of paper and printing have made printed materials the most important medium for the
storage and transfer of information for more than five centuries. Even in today 's com-
puter era, printed materials still remains one of the most important information media.
The Renaissance in Europe in the 14th and l Sth centuries was a prelude to the indus-
trialization and modern science and technology. However, China's development during
that period still remained within the thousand year old feudal frame which sought to
limit the Western influence. As shown in Table 2.4 from 1250 until the middle of 18oos,
most innovations were made in the West rather than in China.
The 1840 Opium War between China and Britain shook and at last destroyed the thousand
year old Chinese feudal society. With the downfall of the last dynasty - Qing in 1911.
China set off on the journey of industrialization and modernization, somewhat three or
four hundred years later than the advanced countries. Since then. the Western sciences
and technologies (S&T) have been gradually introduced into China. Ever since. the gap
in S&T between China and the advanced countries has been reduced. The modernization
trend has been greatly accelerated since 1949 when the Peoples Republic of China was
born.
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Table 2.4 An Approximate Time Chan
Source from (Vickery, 1987) and (Infor. China, 1989)
Year Events in the World- Events in China
-3500BC
Inscriptions on animal bones
and tortoise shells
-3000 Writing:clay tablets, papyrus rolls
Temple and palace archives
-2000 Horse transport
Alphabet
-1000 clay tablets in Assyria Documents written on bamboo slip
silk Royal and Private libraries
-500 Official couriers in Persia Postal delivery stations
Scholarly libraries (e.g. Alexandria
Museum)
Parchment roll, manuscript trade
private libraries in Rome
0 Roman roads facilitate transport Paher invention
'Public' libraries, Acta diurna in Qi Lue - C inese first classified
Rome bibliography
Encyclopedias
Codex book
500AD Monasteries and scriptoria Blockprinting invention
The first newspaper- Chinese Court Paper
1000 Spread of papermaking movable type invention
Cathedrals and their libraries
1250 Universities, manuscript trade Postal delivery route throughout China
Humanist scholars and connected with Europe and Asia
Commercial couriers Private and official publishing houses
Printed book
1500 Bibliographies
Pamphlets, patents, newsletters
State archives
Legal and medical libraries
1600 Royal libraries Si Ku Quan Shu -
Town libraries the biggest national bibliography
Postal service (comgrising 3,503 title books of
Royal Society of London 3 ,300 volumes or parts)
Scientific Periodicals
1700 Newspapers
Circulating and subscription libraries
Agricultural and other societies
National libraries (e.g. British
Museum)
Roads and Canal, mail coaches
continued
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1800 Trades unions Modem newspapers and Periodicals,
Abstracts journals, annual reviews most published by foreign residents
Lithography
Parliamentary reform
Steamships, railway
Government libraries
Public Record Office
Photography
Telegraph
1850 Public Libraries Act Cables, telephone in a small scale
News agencies Modem colleges and universities
Professional societies First big group of Chinese students
Microfilm (120 people) sent abroad (USA)
RotfuL printing press by government for study
E ucation Act
Telephone, typewriter
Parhamentary reform
Civic universities
Major library classifications
Punched records
Disc audio records
Linotype, Monotype
1900 International associations The Qing government founded
Office dURlicators the ｦｩｲｳｴｾｵ｢ｬｩ｣ library in 1904
Cine ilms The first hinese news agency in
Industrial research Guanftzhou (Canton) in 1904
Aircraft Radio irst used in China (1905)
Photostat Radio ｢ ｲ ｯ ｡ ､ ｣ ｡ ｳ ｴ ｩ ｮ ｾ
Women's franchise in SHANGHAI in 1 22
Radio broadcasts
Interlending, special libraries
Facsimile transmission
Tape records
Television Broadcasts
Information centres
Technical reports
Phototypesetting
Xerography
Education Act
UNESCO
1950 Digital computer TV broadcasting
New Universities and polytechnics Institute of S&T infor. of China CISTIC)
British Library Chinese abstracting journals
Communication satellites library automation in small scale
Timesharing computers communication satellite
Combuter typesetting 60 international online terminals
Data ases, databanks wide application of PC and microcomputer
Computer networks computer aided secondary publication
Videotapes S&T numerical and fact databases
Microprocessors S&T bibliographic databases
Video discs China Patent Office and Patent Law
Expert systems
*After 1500, the emphasis in the left column is on the developments in U. K.
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Modern newspaper and periodical first appeared in China in the late 19th century which
was somewhat one hundred year later than in the West. However, the radio and TV
broadcasting appeared respectively just twenty years later in China than in the West.
China commenced its first experiment on computer in the mid 1950s which was only
ten year later than the West. In 1970, China launched its first satellite, and today it is
among a handful of nations in the world that hold this high technology.
In the developed western countries in the 20th century, developments in scientific and
industrial research, with a consequent vast increase in the publication, on a world-wide
basis, of specialized information - have led to a demand for rapid and easy access to a
wide range of periodical literature and information services that could furnish references
and bibliographies on specific subjects.
One of the most significant features in the century is the growth and blossoming of
special libraries, often connected with commercial enterprises or specialized pro-
fessional bodies and financed by them. The studies in Chapter 7 will show the heavy
investment in information work by the UK pharmaceutical industry.
In the early 20th century, library reference services, interlibrary cooperation (e.g.
interlending, acquisition cooperation, national union catalogue, etc.), photocopying and
microphotographs had become common in the USA and Europe.
Another major feature of the century is information centres. While libraries, as a matter
of both economic necessity and basic philosophy, attempted to guide the reader to the
materials he desired without influencing his own evaluation of them, information centres
undertake to analyse, evaluate, select, and even on occasion to synthesize answers to
questions by users. In Chapter 7, some kinds of information centres in the UK phar-
maceutical information flow, such as business information specialists, drug information
centres, etc. will be studied.
One of the most significant achievements is the wide spread of library automation during
a relatively short period in the 1980s. Furthermore, Information Technology (IT) during
the last thirty years has made significant changes in the storage and retrieval of infor-
mation.
During the 1960s, computer typesetting methods began to be introduced for the pro-
duction of printed publications. Specially, these methods were applied to the production
of secondary publicationx: abstracting and indexing journals, etc.
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As a by-product of the typesetting magnetic tapes became available containing com-
puter-processable versions of the text/data in the secondary publications. It was then
possible to search this text/data satisfying certain criteria. Initially such information
retrieval was carried out off line: the questions were submitted to computer centre by
hand or by post.
Gradually, with improvements in both computer and telecommunication technology
Online information retrieval became possible. Special organizations were created that
regularly acquired each magnetic tape of text/data as it became available from several
different publishers; these organizations then added this text/data to the "database"
already stored on their own large computer. These host organizations (later known as "
the hosts") then provided increasingly sophisticated database searching facilities to
anyone with a suitable computer terminal and access to the telecommunications facilities
needed to link the terminal with the host computer. One host could provide access in
this way to several databases acquired from different publishers, each being searchable
with the same information retrieval computer programs.
Since the mid 1980s, optical storage technology has been rapidly emerging as a note-
worthy factor in recording and distribution of information. CD-ROM is the latest
technology to capture the imagination of information professionals. It is now not only
possible but economically viable to store an entire database such as EI, Medline, SCI
etc. on a single 13cm compact disc. Vast stores of information, which previously could
only be searched using mainframe machines, can now be searched and manipulated
conveniently and effectively using a personal computer.
By the end of the 19th century, China seemed to be backward almost in every field of
science and technology, including information services and technologies. Since the
1949, however the world has seen China's relatively rapid development in its current
S&T history.
In the 1950s, the national infrastructure of libraries and scientific and technical infor-
mation institutes was planned and built up. The Institute of Scientific and Technical
Information of China (ISTIC) began to compile national abstracting and indexing
journals for the first time in China. The use of microform and photocopy machines
became popular in more and more big libraries.
From the middle of the 1970s, Chinese scientists started experiments on computerized
information storage and retrieval as well as library automation.
Since the early 1980s, more than sixty online retrieval terminals have been installed
in 27 Chinese cities, which enable Chinese users to search hundreds of S&T databases
through 8 major international hosts (such as DIALOG, ESA-IRS, STN etc.). Apart
from online searching, China has also imported 52 S&T databases on tape on which a
few big information organizations and libraries run the "off line" information retrieval
services (Zhou, 1987). Generally speaking, the application of computers both in
accessing international databases and in processing domestic documents are still in the
beginning stages in China, partly owing to the inability to spread computer application
in library and information organization, partly because of the lack of effective tele-
communication networks.
In China now there is a mixture of various levels of information technology: from the
1980s' technology of online and CD-ROM searching, to the 1970s' offline information
retrieval; from manual abstracting and indexing services to computer aided abstracting
and indexing services. The imbalance in IT application between big libraries or infor-
mation organizations and small ones, between developed regions and underdeveloped
regions is serious. A more detailed description is given in §2.3.3.
2.3 Current Communication Environments in Britain and China
This section takes us to the following environmental sectors of information
communication- mass media, transportation and information technology (IT).
Since cities are distinctive and important in information generation, dissemination and
communication in comparison with other forms of social organization, we will give
more attention to the urban environment than the rural in the two countries. The UK is
an urban country, three quarter of the population living in urban areas. (Rose, 1982)
China is a rural country with seventy to eighty percent of the population living in rural
areas. On the other hand, however, China has a huge number of urban residents. A
steady but rapid move from rural to urban has been seen especially since 1949. In 1949,
there were 69 cities] including 16 with a population exceeding 500,000. By the end of
1990, however, the numberof cities had grown to 461, with a population of 331 ,857,000
1 Chinese cities are divided into three tiers: centrally administered cities which enjoy the
same status as provincial and autonomous regional governments (at present there are three
such cities Beijing, Shanghai and Tianjin); cities under the direct administration of prov-
incial or autonomous regional governments, which enjoy the same status as prefectures:
and county level cities under the administration of prefecture- which have the same xtatus
as counties (lnfor China, I9R9).
(almost 6 times of the UK total population). Of them there were 98 cities with more
than 1 million people, 153 cities with more than 0.5 million people. (People's Daily.
14 March 1991)
2.3.1 Mass Media
Periodicals
The terms" periodicals" and" serial" include newspapers, magazines, trade journals,
and annual reports, as well as learned or scholarly journals. Willings Press Guide
for 1991 lists 8904 UK periodicals and 1654 annuals.
China's figure in 1985 was 4,705 journals and magazines and 2,191 newspapers
(Infor. China, 1989). The difference in number of periodicals between the two
countries is not very significant. However, if we consider the circulation among the
population, the information deficiency in China will become astonishing. For
example, Table 2.5 shows that in the UK every 1000 people have 411 titles of
newspapers whereas every 1000 Chinese people have only 29 titles.
Table 2.5 Newspaper Circulation in 1985 (number of copies per 1,000 people)
(Economist, 1987)
USA U.K. China India
Rank 23 10 99 106
Number 267 411 29 21
Radio and Television
In China, although radio and TV broadcasting were started respectively in 1922 and
195R, the former were not popular until 1960s, while the latter not until 1980s.
Table 2.6 gives the radio and TV sets ownership in four selected countries.
Table 2.6 Radio and TV Sets Ownership in 1985 (number per 1.000 people)
(Economist. 1987)
Radio elevision
Rank Number Rank Number
World 310 135
U.S.A. I 2030 1 785
U.K. 8 993 25 32H
China 172 68 134 6.8
India 178 55 146 3.8
The above figures of periodical circulation and radio or TV sets ownership could
show general information deficiency in China. However, on the other hand, one may
argue that because of the nature of mass media and the dense population in China
urban area and cultivable area (it is estimated about eighty percent of China's
population are concentrated in one fifth of its land; see Appendix 2.1), mass media
could be more effective in China than in other countries with low dense population.
In the UK apart from the four national channels of BBC radio, there are over 40 local
radio stations and four television channels. It is estimated that about 42 million (740'(1
of population) people watch TV each day and 25 million (44% of population) listen
to the radio (Vickery, 1987).
In China, the central government supervises and administers broadcasting throughout
the country. Directly under its control are the Central People's Broadcasting Station
(CPBS) and the China International Broadcasting Station (CIBS), China Central
Television (CCTV). Most of big cities have their own radio and TV broadcasting
stations. In China now there are 204 TV broadcasting stations, 507 TV transmitting
and relay stations, 215 radio broadcasting stations and 575 radio transmitting and
relay stations. According to the official estimate, by 1990, radio will have reached
about 80% of the population and television 75lJr (Infor. China, 1989).
2.3.2 Transportation
Here we should put some emphasis on the transport situation in China comparing to
the UK, because today getting documents from one place to another sti 11 has to mainly
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depend on transportation (particularly ground transport), and people need to travel
to communicate with others under certain circumstances. Table 2.7 is a comparison
of transportation in the UK and China.
Table 2.7 Transportation in China and UK
Source from
Far East and Australia 1990; Britain 1990; Jane's World Railaways 1989-1990
(Allen,1989); British Airway Annual Report 1987-1988,' and British Waterway
Board Annual Report 1987-1988
China( 1984 or Britain (19gS)
1988)-
Rail: total 51 16.6
electrified 3 4.46
Length Road: total 1,500 378
(103 km) motorway 0 3
waterway 109 3.2
Railway 978,600 43% 18,103 12.5%
Freight Road 287,1 00 13% 108,600 75.4%
(l06 ton-km) Waterway 996,400 44% 60 /
Air 740 / 17,225 12%
Railway 326,000 54% 34,321 8.Yk
Passenger-km Road 238,200 39% 332,500-- 80%
(106) Waterway 20,400 3% / /
Air 21,400 4% 49,123 11.7%
* the Chinese length data in 1984
the Chinese freight and passenger data in 1998
** No British road passcnger-krn data available.
the data above is the British vehicle-km (million).
Although China is 39 times the UK in area, 19 times the CK in population. its GDP
is only 68% of the British figure. The weakness in its transportation is one of the
major blames for the economic backwardness. Its railway length is too short to cover
its vast land - only 3 times the British railway mileage.
Although its road length is 5 times the British, its road haulage and passenger-km
are respectively only 2.6 times and 20% ofthe British figures, because of the relatively
poor road conditions.
Engineering expertise is lacking in connection with trunk motorway traffic, railway
electrification and aviation. The ratio of railway electrification is 5.9% in China in
comparison with 27% in the UK.
In the UK, although motorways and trunk roads account for 4% of road mileage,
they carry 34% of road traffic, including nearly 61% of heavy goods vehicle traffic.
In China by the end of 1980s there has not yet been any motorways in use, though
several joint ventures on motorway building have been signed since the late 1980s.
In the UK, road haulage has a dominant position in the movement of inland freight,
accounting for about 75% of tonne-km. Railways, inland waterways and other
transport are important in carrying certain types of freight. On the contrast, in China,
lorries and buses are regarded as constituting merely a supplement to rail and
water-bone transport, respectively accounting for 12.7% of tonne-km and 39.3% of
passenger-krn (Table 2.7).
The whole Chinese transport system is very inadequate in general and for the need
of the energy sector in particular. To take the example of railway, relentlessly rising
demand for passenger and freight transportation outstrips both railway infrastructure
and rolling stock capacity. Passenger traffic has quadrupled since 1960, whereas the
number of train run has risen by only 1.7%. Consequently severe overcrowding is
common, inability to buy a ticket likewise in some major cities. Freight tonnage was
rising by a similar ratio during that period. Here too, shortage of capacity had led to
inability to supply raw materials to some manufacturing plants. driving them to
temporally closure (Allen, 1989).
There are the same difficulties in road, waterway and air transport in China. Inev-
itablv, these weakness in transport sector have long been disturhing normal travelling
and made nationwide documents interlending in fact impossible.
2.3.3 Information Technology
I. World IT situation
Each year the information technology industry trade press reports on the size of the
industry. It is reported that between 1980 and 1989, sales of PCs increased more
than 30 fold, from fewer than half a million US dollars to more than 15 million
(according to PC Week, Dec 25 1989 pl0); the number of databases grew 10 fold,
from 400 to just over 4000 (according to Cuadra's Directory of Online Databases
1991; see Table 2.8); at the same time, the use of databases in the information
centre/library market as measured by the number of online searches grew 6 fold,
from 5 million to 32 million (according to Williams as reported to the Wall Street
Journal, April 3, 1990).
Table 2.8 The Growth of Online Databases in the World
(Cuadra's Directory of Online Databases 1991)
year No. of databases No. of producers No. of hosts
1979/1980 400 221 59
1980/1981 600 340 93
1981/1982 965 512 170
1982/1983 1350 718 213
1983/1984 1878 927 272
1984/1985 2453 1189 362
1986 2901 1379 454
1987 3369 1568 528
1988 3699 1685 555
1989 4062 1813 600
1990 4465 1950 M)
1991 4869 2120 718
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During the 1980s the world has seen the online industry developing into mature
status. In the early 1980s, there were a small market confined almost entirelv to
research and library users; databases then were predominantly S&T; databases were
almost wholly bibliographic; most users of online databases accessed the systems
from "dumb" terminals.
By the end of the 1980s, the picture has changed significantly. There is a large
world-wide market for business databases. S&T databases comprise a very small
percentage of total revenues of online industry - less than 10% of revenues are from
S&T databases whereas other 90% are from business databases (Fischer. 1990). The
present world online database revenues is $4 billion (According to Information
Hotline, Vol 22 No.2, Feb.,1990); while in Europe alone, the market for business
information databases is estimated at £ 1 billion (or $1.8 billion) (Online Business
Source book 1990).
Bibliographic databases comprise a small percentage of total revenues of online
industry. Furthermore, numeric databases are likely to experience more rapid growth
than either bibliographic or full text databases in the 1990s. A report estimates that
bibliographic databases will decline from the present third of total offerings to about
a quarter by 1994. Numeric databases will grow from 36.60/0 presently to 41.5%
in the same period, and full text databases will grow only marginally from 29.6%
to 31.9% (According to Information Hotline, Vol 22 No.2, Feb.,1990).
The late 1980s has also seen the new generation of British and Europe-wide online
databases starting to provide a rich alternative to US products. The European user
market has grown rapidly in size (some 20% per year) and sophistication (Online
Business Source book 1990).
In the last few years of the 1980s, CD-ROM as a new generation of information
storage and retrieval medium has made a great impact on IT market. The CD-ROM
Directory 1990 the 4th edition published by TEPL, provides information on 816
CD-ROM products (mostly US made) comparing to only 390 a year ago.
II. UK
In 1989, Aslib conducted a survey into the use of information technology by
information services of its UK membership (Ramsden, 1990). Total 373 question-
naire forms were returned from 1853 sent out.
About 96% ofrespondents reported using some form ofIT, reflecting high application
rate of IT. That 37% of IT users had started using IT in the last two years suggests
rapid movement among information services from non-user of IT towards user of
IT. About 91.5% of respondents reported using computers. Of them. 22% use
mainframe, 44% minicomputer, 94% micro-computer.
About 24.6% of respondents stated that they were using some form of optical disk
drive. This is a massive increase when compared with 1% in 1986. About 93% of
optical drive users had CD-ROM.
About 63% of respondents were using some type of microform reader/printer.
About 82% of respondents were using online retrieval systems, an increase of 8%
since 1986. And 8% of respondents stated that they planned to start using online
systems in the next two years.
The survey also shows a drop in the literature searching user proportion of online
users (from 99% in 1986 to 90% in 1989) and an increase in fact retrieval user
proportion ofonline users (from 64% in 1986 to 70% in 1989); reflecting the growing
number and use of business databases.
Generally information users in industry especially in the pharmaceutical industry
use online much more than users in academic or public sector.
A survey on UK academic institutions and public libraries market for online service
was currently carried out during 1987-1988 (East, 1990). It was reported that in 1989,
the average annual online expenditure was £4,000 per service among public libraries,
£6,700 per service among polytechnic libraries, and £9,600 per services among
university libraries.
According to the estimate of the survey, the total annual expenditure in online service
by all UK academic institutions and public libraries (some 160 at present) is between
£1.7-5.2 million per year by the end of the 1980s.
A survey on UK pharmaceutical companies shows that in the mid 1980s. the average
online expenditure in a large company was over £100,000 per year: the expenditure
was £10,000-20,000 per year in a medium sized company: the expenditure was a
few thousand pounds per year in a small company (Clark, 1985).
For example, in Pfizer Central Research UK, the online searching volume and
expenditure have grown greatly from 131 searches and £7,000 in 1976n to 1163
searches and £66,000 in 1984/5 (Bawden, 1989). The online expenditure in Pfizer
is seven times the average figure in academic libraries.
In a medium sized university library Pilkington Library in Loughborough University,
the annual volume of online searching in 1990/1991 was 36J searches (the last year
figure was 290 searches), and about £16,000 (data from the Information Officer in
the Pilkington Library). Although the online volume in this library is higher than the
average figure in UK university libraries, it is only one third of the volume in a middle
sized pharmaceutical company in UK (Pfizer UK).
III. China
Despite of the rapid progress since 1949, telecommunication are generally in short
supply. The telecommunication network, except TV and radio broadcasting, cannot
reach the remote areas. At present, telephones are available in cities, townships and
half of the villages. An average of 0.6% of the population have phones, a ratio of
200 people per phone, which is lower than the world average of 13% as well as
lower than the UK figure of 52% (Economist, 1987). Even the residents in big cities,
like Beijing, find it difficult to make a local call and the situation is even worse in
respect of long-distance call when there is no direct-dial long-distance phone system
existing.
As far as the capacity of telecommunication channels is concerned, the British
Telecom has about 610,000 km. of optical fibre laid in its network in Britain. The
combination ofdigital exchange switching and digital transmission techniques, using
optical fibre cable and microwave links, is substantially improving the quality of all
telecom services (Britain 1990).
In China, digital transmission using optical fibre cables is still at trial ｳｴ｡ｾｾＬ Only
local telephone communication systems have applied microwave links, Long dis-
tance telecommunication are mainly transmitted hy open \\ Ire with the supplement
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of underground low speed transmit cables. By 1985, China has built up 179.000 km.
of underground long distance cables which are only one third of the British optical
fibre cable length even without mentioning the significant difference in the trans-
mission speed between optical fibre cable and non-optical fibre one (Infor. China,
1989). These underground cables in use in China only have up to 4,380 Channels of
capacity, whereas optical fibre cables in use in the UK has already reached the
capacity of 107 channels (Infor. China, 1989 & Vickery, 1987).
Relatively China has a small computer industry compared with the developed nations
in the world. In 1984, China had an annual production of 400 sets of large, medium
and small computers and about 30,000 micro-computers (Tang, 1984). Although its
annual micro-computer production has risen to 100,000 by 1989 (People's Daily,
29 May 1990), it is still far from meeting the domestic market demands. Each year,
China has to use some of its very limited hard currency to import a certain amount
of computers. As a result, total number of computers in the country is very small.
According to an ISTIC survey (1985) on 3888 scientific and technical information
services and libraries in 1985, only 25% of information services using computers.
The growth in IT application has been very slow since then, because of lack of funds
(White Paper, 1990 & Academia Sinica, 1991).
Of the very small group of computer users, only 0.25% have mainframes. only 6%
were using minicomputers while the other 94% were using micro-computer.
Compared with the Aslib survey in UK (22% using mainframes, 44ek using mini-
computers, 94% using micro-computers), it is quite clear that the application of
computer is at a very low level in China.
During the 1980s, China has imported about 52 foreign bibliographic databases with
a total 30,000,000 records. One example is the Medlars centre in the Chinese
Academy of Medical Science (1987-). The Chinese Medlars centre has a IB\1-4361
computer which stores the MEDLINEdatabase (1966-) in tapes. There are 5.5 million
records since 1966 with an annual input of 400,000 new records. During the first
one and half year of the operation of Chinese Medlars. it has conducted 25(X) searches
for 600 users and built up 500 SDI profiles for 100 users nationwide.
By the end of 1989. there are 262 domestic S&T databases - half are bibliographic
and half are numeric or factual. Among them only 60 have more than S(X)O records.
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All these imported or domestic S&T databases are mainly providing inhouse
searches. Only few large databases such as Medlars in Chinese Academy of Medical
Sciences could provide offline searches to external users.
By the end of 1989, 60 information organizations in 27 Chinese cities have installed
international online terminals connecting through satellite with a few large hosts
such as DIALOO, STN, ISA-IRS, etc ..
Only 1.5% of Chinese information services have direct access to international online
databases. Less than 1% of Chinese information services have imported foreign
databases in tape and built up inhouse retrieval system on them. Less than 6% of
Chinese information services have built up domestic S&T databases and provided
inhouse searches to users. By comparison, 76% (in 1986) and 82 % (in 1989) of UK
information services have been using online systems.
In 1988, China has made 20931 international online searches (3/o/r of total searches
in China), 37,108 inhouse domestic database searches (55% of total) and 9026
inter-organization searches (13% of total) within the country (Academia Sinica,
1991).
The annual volume of 20,931 international online searches made in China accounts
for only 0.1 % of 32 million searches in the world. The total number of online
searching in China is only 4 times the volume of a UK pharmaceutical company
Glaxo (about 5,000 searches per year, see Chapter 7).
The biggest online searching centre of total 60 in China is at ISTIC in Beijing. Its
annual online searching volume is three thousand searches which is less than the
volume in Glaxo (about 5,000 searches per year). It was estimated that ISTIC annual
online searching expenditure was $34,600 in 1986 accounting for about 15% of
annual online expenditure (£ 128,800 or $241,049 exchange rate in 1987) in SR1S
of British Library in 1986/1987 (BL 14th annual report 1986-87). The annual online
expenditure at SRIS of BL in 1989/90 is £127,528 (or $204,746 exchange rate in
1989) (BL 17th annual report 1989-90).
Other 60 international online searching centres each has a volume of 200-300
searches per year (Zhou,1987). The annual online volume in one of these Chinese
online centres equals to that in a medium sized academic library in CK (according
to the Information Service statistics (1989 & 1990) at Pilkington Library. Lough-
borough University).
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One expert estimated that today 's annual volume of online searching in China equals
to that in Europe in the early 1970s (Zhou, 1987).
Above all, due to the backwardness in computer and telecommunication technolozv
'-. '
China is far from entering the "telematics stage".
2.4 Concluding Notes
Above all, the information environments in China and UK have experienced different
evolution, are in different stages of development, on different socio-economic bases,
and are bound to influence and affect pharmaceutical information flow quite differently
in the two countries.
The mass media is relatively well developed in China compared with other two sectors
"transportation" and "information technology". TV and radio have a coverage as high
as that in developed countries. The backwardness in telecommunication has serious
impacts on IT sector in China. One estimation is that today the annual online volume
in China equals to that in Europe in the early 1970s. The shortage of computers is the
major cause for low computer application in Chinese S&T information services such
as domestic S&T information database etc .. The serious difficulties in road, rail, and
other transportation are considered as one of major causes for lack of interlending
networks in China.
The information environment in a country greatly depends on the national economic
capacity. The environmental influences on pharmaceutical information flow in China
and the UK will be explored in the final part of the thesis (Chapter 9).
There is no doubt that the current information environment in China is not so good as
that in UK and other developed countries. To improve information environment needs
sufficient financial support. China's limited economic capacity has prohibited a quick
progress. In China now there is a plight of many sectors of activities competing for a
very small amount of hard currency reserve. For example. the low application rate of
computers in S&T information services is caused by limited domestic production and
limited import of computers.
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The powerful central government of China, however, could set priori ties in development
on the most important projects. There has been a rapid progress in China's telecom-
munication and road transportation for the last five years.
Telecommunication has become the most rapid developed field in China for the last five
years by getting an investment which exceeded the total amount of previous 36 years.
As a result, the average telephone ownership by China's population has risen from 0.6%
in 1985 to 1% in 1990. The number of cities with digital telephone exchange systems
has risen from 20 in 1985 to 300 in 1990 (Infor. China, 1989 & People's Daily, 15 Dec.
1990).
Because of the increase in investment at road building, the proportion of higher standard
road has been doubled in China for the last five years. The first modern motorway,
although very short (only 500km., comparing to 3000 km. in UK) has been completed
by 1990. It is estimated that for the past five years China's road transport capacity has
been increased by 50% (Peoples' Daily, 1 Feb. 1991). To improve the Chinese infor-
mation environment, the government still needs to stimulate the national computer
industry to meet the great demands of domestic market.
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Chapter 3 Medicines Research In Britain And China
Pharmaceutical information flow system exists within the special environment "national
drug situation" and the wider system "national pharmaceutical industry". The mission of
this information flow system is determined by its wider system and is influenced by its
special environment. Chapter 3 describes the special information environment and the wider
system. The great emphasis is on medicines research or pharmaceutical R&D - the most
important feature of the modern pharmaceutical industry and drug situation. In this chapter,
we will approach to the comparison along the following lines-
A. Drug situation and pharmaceutical industry in China and the UK,
B. Organization of medicines research in China and the UK,
C. Status of medicines research in China and the UK ,
D. Size of medicines research in China and the UK.
3.1 Drug Situation and Pharmaceutical Industry in Britain and
China
In 1977, the World Health Organization (WHO) published the first model list of essential
drugs. Since then a large number of countries have adopted an essential drug policy.
The progress achieved in these countries have been reported in a document "The World
Drug Situation" (WHO, 1988). Describing the world drug situation, this report overlooks
on the broad aspects of drug consumption, production, and trade. We believe that such
an approach will serve as a background to the study on pharmaceutical information flow
in Britain and China. So in this first section of Chapter 3, the drug situation and the
pharmaceutical industry in the two countries are to be addressed.
World Drug Situation and Pharmaceutical Industry
According to the WHO report, at present 75% of the world population living in
developing countries consumed only 21% of the world's drugs. The twenty largest
markets accounted for 80% of world consumption in 1985, among which there were
only 8 developing countries who accounted for 64% of the drugs available in the
developing world. Among the top 20 markets. China ranked at the 4th and UK at the
seventh. However, as far as the huge population in China is concerned, the average drug
consumption per head in China is much lower than in the UK.
3H
In 1989, drug consumption in UK was 60 Pound whereas it was only 21 Yen (3.1 Pound)
in China" (See following sections about UK and China)
The patterns of drug consumption, production and trade are very different between the
developed part and the underdeveloped part of the world. Developed countries include
the western European countries, the north American countries and Japan.
Global pharmaceutical sales are expected to reach $140 billion in 1991, at wholesaler
selling prices, excluding the communist world and Eastern Europe. The three major
trading blocs, the US, Japan and Europe account for 30%,20% and 30% of the total
market respectively. The top three markets, in order, are the US. Japan, and Germany
(Scrip, Sept. 18th, 1991 No. 1652).
The uneven distribution of world drug consumption is associated with uneven dis-
tribution of drug production which concentrated in seven developed countries
throughout the 1980s - USA, Japan, West Germany, France, UK, Italy and Switzerland.
The analysis suggests that British inventions accounted for 31 % of the estimated £95
billion world-wide prescription drug sales in 1989. with the US accounting for 42 %,
the rest Europe 19% and Japan 8% (ABPI Pharm. Facts and Figures, 1990).
There are 3 types of pharmaceutical companies. First type is the ethical drug company
whose products are the result of R&D, are patent protected and are available on
prescription only. The second type is generic drug company. They produce off patent
prescription products and hence have no research and only limited product development
expenditure. The third type provides non prescription over the counter (OTC) medicines.
Some companies have divisions which operate in both the ethical and OTC markets and
a few also have generic divisions. However, the bulk of the pharmaceutical market in
revenues is made up of ethical products.
Although the pharmaceutical industry comprises 10,000 companies world-wide, no
more than 100 companies, the large R&D oriented firms, have a significant share of the
international market, and over the years, they have tended to remain the market leaders,
only their rank shifting. Chinese pharmaceutical manufacturers mainly supply the
domestic market and export bulk pharmaceuticals (intermediates) and TCM raw material
with no participation in world ethical drug market (WHO, 1988). Accordingly this thesis
2 In fact, the above figures are not so valid for direct comparison ｢ ｣ ｣ ｡ ｾ ｳ ･ ｴ ｨ ｾ ｴ the drug
price in China is ｭｵｾｾ ｬｯｾ･ｲ ｴｨｾｮ ｴｾ･ drug ｰ ｲ ｩ ｾ ･ ｳ in many ｯ ｴ ｨ ･ ｾ countries. It IS ｾ･ｰｯｮ･､
that the pnce of medicines In China IS only 10\1l of that charged In the West. (Scrip, Sept.
18th }t>91, No. 1652)
concentrates on the ethical pharmaceutical industry in L'K comparing to a different
type of pharmaceutical industry in China where there is no patent protection and
is little R&D.
For many years, the ethical pharmaceutical industry has been in the unique position in
most developed countries of having customers (physicians) who are neither responsible
for paying for their products (funded by government) or consuming them. The world
healthcare market has been growing since the World War II. Also the industry has been
protected form competition from non branded substitutes by legislation introduced in
the 1950s. Hence the pharmaceutical industry in the West has sustained profitable growth
for the past 50 years.
By the end of the 1980s, however, it seems that the R&D based pharmaceutical industry
has been faced with some challenges. Increasing generic prescribing (as governments
try to contain rapidly rising healthcare costs), coupled with the escalating cost of R&D
and diminishing returns in terms of NCEs reaching the market, are central to the
industry's case for longer patent life, a relaxation of pricing controls and faster US and
Europe approvals.
China'
The main objectives of the Chinese pharmaceutical industry have been to meet the
priority needs of the population through local production and to develop the country's
export potential. Major problems encountered are related to the need to improve quality
control, to increase research and to strengthen international marketing capacity. Today,
China is 90% self sufficient in drug consumption. In the 1950s, priority in production
was given to bulk antibiotics, sulphonamides, antipyretics, vitamins and drugs for
endemic diseases and tuberculosis. In the 1960s and 1970s, production was expanded
to include steroids, anticancer agents, drugs for cardiovascular diseases, products for
upper respiratory tract infections and asthma etc ..
Currently there are about two thousand pharmaceutical manufacturers or factories in
China, of which about 900 produce western medicines (WM)- bulk pharmaceuticals
and western medicine finished products; about 500 produce TCM brand products (TCM
standing for Traditional Chinese Medicines).
3 Data and facts in this section are from China Pharmaceutical Yearbook I ()X7, and SPAC
1989 Hooklet, unless otherwise indicated.
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In pharmaceutical chemical production sector, China now is able to produce 24 thera-
peutic categories of medicines, 3500 finished products and 1300 different bulk phar-
maceuticals.
In TCM production sector, China is able to produce 4000 brand products using 40
different dosage forms.
Since 1978, great growth in Chinese pharmaceutical industrial production has been
achieved. The average annual growth rate of industrial output in value has exceeded
10% for the last 12 years.
In 1987, the gross value of industrial output (including bulk pharmaceuticals, WM
finished products, TCM raw materials and TCM brand products) amounted to ¥21 billion
whereas the domestic sales added to V18 billion, accounting for 86% of the industry's
gross output. The industrial output ratio of chemical pharmaceuticals (bulk and finished
products), TCM raw material and TCM brand products was 15 : 2 : 4.
Importation of drugs is regulated by law and restricted to small quantities. China is a
major international supplier of pharmaceutical chemicals and also one of the largest
producers of antibiotics, vitamins, and sulphonamides. In the 1980s, it annually exports
approximately 40% by weight (23 million kg) of all bulk pharmaceutical chemicals
produced. This however accounts for only 7% of the yuan value of annual sales. because
of the low price of bulk pharmaceutical in the world market (WHO, 1988).
In 1986, exports of pharmaceuticals and TCM were worth $600 million, an increase of
17% over 1985 whereas in 1985 the increase was 11.5% over 1984. TCM herbals
accounts for approximately 60% of exports whereas bulk pharmaceuticals for 40% (i.e.
$240 million). Overall, China has a strong favourable trade balance for health care
products, of $200-300 million a year. Major imported products are S&T instrument and
production machines (WHO. 1988).
The pharmaceutical (bulk pharmaceuticals) export by China has risen from $240 million
in 1985 to $400 million in 1987. The export capacity of the Chinese pharmaceutical
industry (WM) ($4()() million or V1.5 billion in 1987. for exchange rate see Appendix
2.3) accounts for about 10% of the industry gross output ( "015.6 billion for the phar-
maceutical industry (WM) in 1987).
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The economic reform (1978-) has expanded the sector of transnational pharmaceutical
production in China. A number of joint venture contracts have been completed. First
two had started production in 1986. Since then, there have been several dozen new joint
ventures adding in. The world pharmaceutical industry newsletter Scrip ofPJB has been
monitoring the progress of joint ventures in China (see Chapter 7).
There is no doubt that the Chinese population has benefited from the boom in phar-
maceutical production and now has access to a much wider range of drugs including
sophisticated drugs. As having been reported above, the drug consumption per capita
has almost doubled during the four year period (1985-1988), from ¥11.53 to ¥21.06
(China Medicines Economic News, No. 39 Oct. 1 1989).
There are two types of medicines co-existing in China at present, traditional Chinese
medicines (TCM) and Western medicines (WM). Generally, TCM is the major source
of care for most peasants in rural areas today. However, WM is more popular in urban
areas. Doctors, institutions and hospital beds of WM strikingly out-number doctors,
institutions and hospital beds of TCM. A current survey shows that in 1985 there were
92 WM universities with 128,937 students enrolled while there were only Ｒ ｾ TCM
universities with 28,450 students enrolled. In China in 1985, there were 336,224 TCM
doctors accounting for only 2% of total 1,413,000 doctors in China: there were 1,485
TCM county and large hospitals accounting for only 2.5% of total 59,614 county and
large hospitals in China (Shao, 1988).
Eighty percent of people in China live in the countryside. Before 1949, health services
were almost unavailable for rural people. Since 1949, the national health care system
(see Fig 3.5 in §3.2) has been built up which met the basic medical needs of peasants.
Compared with urban areas, differentials still exists: in 1985, there were only 0.32 senior
doctors and 1.53 hospital beds per 1,000 population in rural areas, whereas there were
2.15 senior doctors and 4.54 hospital beds per 1000 population in urban areas. The
average per capita health expenditure is about ¥47.37 in the urban areas whereas it is
only ¥11.30 in the rural areas (Shao, 1988).
In 1985, the domestic drug sales was between ¥12-14 billion", of which 40 r;( went to
the TCM sales (brands and herbals). About 32% of the domestic sale goes to the rural
areas while 68% of the total goes to the urban areas, though about 80% of population
is in rural areas (Green Book, 1988). About 90£7. in value of all medical supply are
4 VI:? hillion (Green Book, 19X8); ,'14 billion (WHO, 1988).
supplied by wholesalers to hospitals and less than 10% are sold through retail units
(WHO, 1988). At the manufacturers' prices, the China market for pharmaceuticals was
between ¥12-14 billion in 1985, equivalent to an average spend of¥11.53 per head. This
represents about 1.6% of GDP (Green Book, 1988). The estimated total health care
expenditure in China in 1985 was ¥24.5 billion which accounts for 3.2% of G DP (Shao,
1988). So the cost of medicines is as high as 60% of the total amount spent on health
care in China which is much higher than the ratio of 10% held for the past thirty years
in UK and other developed countries (Scrip, Sept. 18th 1991, No. 1652). This may reflect
the difference in the society's valuation of the role ofmedicines in providing good heal th
between China and the developed countries.
According to the WHO evaluation in 1988, among the three groups of total 104
developing countries, China belongs to the highest grade Group C - the 47 countries
with high medicine coverage.
The situation in China is assessed as follows:
1. 60-90% of the population have regular access to essential drugs;
2. has a national pharmaceutical policy;
3. has a drug regulatory administration but which is not fully functioning;
4. a quality assurance system including a quality control laboratory exists, but does not
function adequately;
5. the provision of information for health workers is semi-organized, and there is no
systematic information for patients;
6. no monitoring mechanisms exists;
7. There is a research capability leading to discovery of New Chemical Entities C\CEs).
8. China pharmaceutical industry is manufacturing type rather than R&D type. ｾｯ patent
protection for pharmaceuticals is one major reason for little R&D in industry.
The UK 5
In UK, as in other western countries, the post war environment promoted the devel-
opment of improved healthcare system, which encouraged an increase in the market for
drug, allowing the pharmaceutical industry to emerge as one of the most successful and
fast growing sectors, relatively free from competition.
The UK pharmaceutical industry of 350 manufacturers includes some of the world' s
largest multinational research based companies (generally known as the seven UK
owned R&D companies); as well as middle sized and smaller specialist companies. Its
gross output in 1989 was around £6 billion.
Britain's place as the world's third largest exporter of pharmaceuticals is reflected in
the fact that in 1989, it exported £2142 million, 32% of the industry's gross output.
Approximately 75% of UK pharmaceutical exports in 1989 went to the "rich" GECD
countries with the US being the single largest customer. These highly competitive
markets are also the principal sources of UK pharmaceutical purchases from abroad
which amounted to £1062 million in 1989. The UK pharmaceutical industry's principal
markets in 1989 are NHS 42% of gross output, exports 32%, household medicines 12%
and other 14%. The net UK balance of trade generated by pharmaceutical in 1989 was
£955 million.
The pharmaceutical industry invested more than £800 million in R&D in 1989. This
sum amounts to more than 10% of all manufacturing industry's R&D expenditure in
UK, representing 18% of total European expenditure on medicines research and 80/c of
the total world pharmaceutical R&D expenditure.
It is currently estimated that the cost of discovering a major innovative medicine has
risen to £ 125 million and it takes between 10 and 12 years before a product reaches the
market.
British pharmaceutical companies make 11 of the world's 50 best selling medicines in
1989.
According to the WHO assessment (1988), the availability of drugs is assured in most
developed countries including the UK. At the manufacturers' prices. the UK market for
5 data in this section is from Britain 1991. and ABPI Pharm Facts and Fiuures 1990.
pharmaceuticals was 3,441 million pounds in 1989, equivalent to an average spend of
60 pounds per head. This represents about 0.7% of GDP and 10% of national healthcare
expenditure.
The quality control system and drug regulatory system function properly. The 1980s
has been characterized by the strengthening of the drug regulatory agencies. the pro-
motion of information for health care professionals and the public, and the development
of post market surveillance. Recently there is a trend for governments of developed
countries to squeeze pharmaceutical companies in attempt to reduce healthcare
expenditure.
Summary on drug situation in China and UK
It is reported that the pharmaceutical prices in China are only 10% of that charged in
the West. Although the drug consumption per capita in China is much lower than the
world average, only 3.1 Pound in China comparing to 60 Pound in the UK in 1989; the
ratio of domestic medicines sale to the GDP in China (1.6% in 1985) is higher than that
in the UK (0.63% in 1985 and steadily rose to 0.70/0 in 1989); and the percentage of
domestic medicine sale against the national health care expenditure in China (around
60% in 1985) is much higher than that in the UK and other developed countries (10%
for the last thirty years). All these may reflect the high valuation given by the Chinese
people to the medicines for providing good health.
China has a pharmaceutical trade volume of $600 million with surplus $200 million in
1985. Of the total export (in value), about 40% are bulk pharmaceuticals and 60% are
from TCM herbal. In 1987, China exported $400 million or V1.5 billion of pharma-
ceuticals (bulk pharmaceutical only) accounting for 10% of the industry gross output
(WM industry).
The UK pharmaceutical industry includes some of the world's largest multinational
research intensive manufacturers. Its export value were two billion pound (or $3.2
billion, for exchange rate see Appendix 2.3) with trade surplus nearly one billion pound
in 1989. The export valued 32 % of UK pharmaceutical industry gross output. UK
continues to be the third largest exporter of pharmaceuticals in the world. The export
capacity of the Chinese pharmaceutical industry (WM) is only about 12.5% of the UK
industry.
The UK ethical pharmaceutical industry has the three major features: their products are
the result of extensive R&D, are patent protected and are available on prescription only.
Britain is one of the top seven investors in pharmaceutical R&D in the world. In 1989.
about eight hundred million pound were spent on R&D by UK pharmaceutical industry.
which account for 18% of total pharmaceutical R&D spending in Europe and 8% in the
world. UK has the most sophisticated drug distribution and legislation system".
On the other hand, there is a developing and expending pharmaceutical industry in China.
It mainly operates in domestic market with 90% self satisfaction. Its products are not
patent protected. It has a small R&D capacity and international marketing capacity
(confined to bulk pharmaceutical intermediates and TCM raw material), and is not
sophisticated in its distribution and legislation system.
3.2 Organization of Medicines Research in the Two Countries
In UK medicines research. there is a strengthening partnership which exists between
the pharmaceutical industry, the academic sector and the National Health Services
(NHS). Although, the division of S&T work among them may not be so clearly and
accurately distinguished, it is generally known that academic institutes are mainly
involved in basic research, NHS researchers mostly concentrate on clinical study, and
the UK pharmaceutical industry is largely responsible for medicines innovations.
The Association of British Pharmaceutical Industry (ABPI) with 117 member companies
includes not only companies with their headquarters in Britain, but also many others
with parent concerns in the USA. Switzerland, Germany, France, Italy and elsewhere.
All are part of the British research based industry, employing S&T staff in the UK, and
also investing in production and domestic and foreign marketing activities. In all more
than half the approximately £700 million UK pharmaceutical R&D expenditure in 1988
came from British owned majors (7 leading companies like Glaxo, ICI, etc.), and just
under half from American, Swiss. and other sources (ABPI British Medicines Research.
1988).
Glaxo Group is the second large pharmaceutical company in the world. It has subsidiary
companies in nearly 50 countries, employing about 30,000 people. of them 2,500 work
6 More detailed discussion on drug regulation and legislation IS in Chapter 7 and Chapter
8.
In the R&D sector in UK (data from the Glaxo Information Division, 19S9). Its
organizational structure is shown in Figure 3.1 & 3.2. The R&D sector is one of the
most important parts of the multinational company.
Research activities in China are mainly found in the following sectors:
1. institutes under the academies; 2. universities and colleges: 3. institutes under the
ministries; 4. provincial and municipal research institutions; 5. defence.
As in the UK, there are three sectors involved in the pharmaceutical field in China- the
industry, the national health system and the national S&T system. (Figure 3.3-3.4)
As far as R&D of pharmaceuticals is concerned, the following ministerial systems
constitute the major "task force" in China:
1. Ministry of Public Health (MPH) system, with 50 pharmaceutical colleges or
departments belonging to medical universities, 411 research institutes. 14 ministerial
R&D labs, 7 national labs and total 4800 S&T staff. The specialized pharmaceutical
institute in MPH is Institute of Material Medical of Chinese Academy of Medical
Sciences with several hundreds of S&T staff.
2. State Commission of Family Planning (CFP) system, with 24 research institutes, two
national labs and several hundreds of S&T staff.
3. State Pharmaceutical Administration ofChina (SPAC) system. SPAC is a government
department at the ministerial level. It is in charge of the overall administration in
pharmaceutical field, covering the production and distribution of pharmaceuticals. It
also runs educational and R&D institutions with 57 research institutes, around two
hundreds large factory based S&T units. There are 7,500 S&T staff in academic sector
and 10,000 S&T staff in industrial sector.
4. State Administration of Traditional Chinese Medicines (SATCM) system (the system
has just become independent from SPAC since 1988), with 60 research institutes and
16,314 S&T staff.
5. Chinese Academy of Sciences (Academia Sinica) system. the life sciences branch
with 27 research institutes, 11 national labs, and 9,000 S&T staff: and the chemistry
branch with 15 institutes and 8000 S&Tstaff. The Shanghai l nstitutc otMaterial Medical
in Academia Sinica with 400 S&T staff is the one of the best institutes in the field in
China. It is also the only specialized pharmaceutical institute in Academia Sinic.i
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6. People's Liberation Army system, with 23 medical research institutes, -+ 1 middle
class labs, and 12 national labs.
Above all, there are 120 academic research institutes in SPAC and SATCM, 236
industrial R&D units plus several dozen pharmaceutical related institutes scattering
among MHP, Academia Sinica, CFP and military system. Those R&D institutions
constitute the major force in medicines research in China. The total pharmaceutical
R&D staff in China totalled 35,000 in 1988 (S&T staff in SPAC and SATCM only).
(National Medicines Exhibition, 1990 July & White Paper, 1990).
In China more than 70% of R&D activities take place in academic institutions while
less then 30% in industry based R&D units. According to the State Science and Tech-
nology Commission (SSTC), in 1986, 55% of national R&D expenditure were spent in
government institutes, 15% in universities and 30% in industry. By comparison, most
of the British national R&D expenditure is in industry (65% of total) while academic
institutions get only a small fraction (35% of total) (White Paper, 1990).
Although the S&T reform starting in China in 1985 is aimed at the effective and quick
S&T transfer from academic laboratory to industrial production, the divorce of research
activities from industrial production is still serious and a radical change will take long
time. The Chinese Government Awards for Innovations in medicines research
(1959-1985) and The New Drugs Approved by the Chinese Authority (1986 - 1987)
may in a sense reflect the status of collaboration between academic institutions and
factories (Table 3.1 and 3.2).
Among the 100-200 pharmaceutical research institutes, and hundreds of medical col-
leges and big hospitals, only 14 institutions got 35 awards out of a total of 43 during the
period of 1959 - 1985, accounting for 81% of the total awards (Green Book, 1988).
These 14 institutions include: Shanghai Institute of Pharmaceutical Industry which
got 9 awards (21 % of total awards); seven institutes from Chinese Academy ofMedical
Sciences which got 13 awards (30% of total); six institutes from Chinese Academy of
Sciences which got 13 awards (30% of total). All these 14 institutes are located in
Shanghai and Beijing.
Among the two hundred pharmaceutical factories with R&D units. the top six have got
14 of the total 43 awards (1959 -19R5). They are the North-East factory which got 3
awards, the Hebei factory (3 awards), the Tianjin factory Ｈ ｾ awards), the Beijing factory
(2 awards), the Shanghai :'\0. 3 factory Ｈ ｾ awards) and the Shanghai XIYI factory (2
awards).
Table 3.1 The Chinese Government Awards to Medicines Research Ｑ Ｙ Ｕ Ｙ Ｍ Ｑ ｬ Ｉ ｾ Ｉ
(Green Book, 1988)
by collaboration
Number of Awards by institutes by factories of factory and
institution
Total 43 21 5 17
New Drugs 25 16 1 8
Technical 18 5
-+ 9
Innovations
*The Chinese Government Awards for Innovations are issued annually to about 5% of total
just finished projects in all S&T fields.
Table 3.2 New Drugs in China 1986-1987
(Chinese Pharmaceutical Affairs, Vo1.2 No.1, 1988)
Total number of Number of new Number of new Number of new
new drugs drugs made drugs made drugs made by col-
by institutes by factories laboration of both
Total of western 21 7 8 6
medicine
Class 1 7 .+ 0 3
Class 2 0 0 0 0
Class 3-5 1.+ 3 8 3
TotalofTCM 9 I 4 .+
Class 1 1 0 0 I
Class ｾ .., 1 0 1
-
6 0 -+ .,Class 3-5
-
The figures mentioned above have shown a very clear distinction between leading
institutions or factories and ordinary ones in S&T capacity. The most advanced phar-
maceutical research mostly takes place at the Institute of Material Medical in Chinese
Academy ofMedical Sciences in MPH, Beijing.; Shanghai Institute ofPharmaceutical
Industry, in SPAC; Shanghai Institute of Material Medical; Beijing Institute of
Microbiology; Shanghai Institute of Biochemistry in Chinese Academy ofSciences.
Table 3.2 shows that of the seven first class western medicines, four were developed by
academic institutes, the remainder three were from the collaboration of academic
institutions and industrial R&D units. Among 14 Class III to Class V western medicines,
however, 8 were from factory based R&D units, 3 from collaboration and only .3 from
academic institutions.
All these indicate that in China, high standard medicines innovations usually take place
in the academic sector rather than in industrial sector. Innovations on TCM show a
similar pattern as well.
The distinction among areas of China in capacity of medicines research is just as sig-
nificant as it is among institutions. The distribution ofGovernment Awards of Medicines
Research Innovations among areas is given in Table 3.3.
Table 3.3 Distribution of Government Awards for Medicines Research among Areas
(Green Book, 1988)
Areas• Rank Number of Awards percentage of total 43
awards
Shanghai 1 21 49
Beijing 2 17 40
Northeast 3 5 12
Guangdong 4 5 12
Sichuan 5 4 9
Wuhan 6 4 9
other" 7 provinces 7 1.3 30
* represented by institutions or factories
** including Tianjin City
Generally, medicines research is concentrated in Beijing., Shanghai, and Tianjin, with
supplement by a handful of other big cities, most of them are the capital cities of the
provinces concerned. Moreover, the biggest state owned phannaceutical factories are
also concentrated in the above ten to twenty big cities of China.
Among those cities, both Shanghai and Guangzhou (the capital of Guangdon province),
have the longest history of marketing and producing Western Medicines dating back to
the 1850s. In the last ten year economic reform, they have benefited more than other
cities from foreign science and technology as well as foreign investment by taking
advantage of their geographically coastal positions.
Summary on medicines research organization in China and UK
In UK pharmaceutical industry, half of total annual R&D expenditure is concentrated
in the 7 largest British companies. The tendency of concentration in pharmaceutical
research also happens in China where 14 of two hundred government institutes and 6
of two hundred industrial R&D divisions have contributed 80% of the highest standard
research of the country.
In the UK, like other advanced countries in the world, the R&D of new drugs has mostly
fallen into the pharmaceutical industry sector due to the high cost, high risk and high
profit.
By comparison, in China the R&D of new drugs has been dominated by a dozen of
biggest government institutions because of the concentration of S&T resources there.
3.3 Status of Medicines Research in the Two Countries
The thousand or so medicinal compounds in current use have been developed from a
few score of prototypes of which only a small proportion were able to meet all clinical
requirements without the need for further development. These prototypes consist of
active principles extracted from plants, mammalian hormones: antibiotics from
microorganisms: and an assortment of synthetic compounds whose therapeutic potential
was mostly revealed by serendipity, a fortunate blend of chance and man's sagacity.
I. CHINA
It is well known that there are two systems of medicines research in China - Western
Medicine (WM) and Traditional Chinese Medicine (TCM). The most distinguished
characteristics of both medicines research and health care in China for the last 40 years
has been the combination and integration of these two medicines systems.
Traditional Chinese Medicine, one of the world's oldest medical sciences, dates back
to 1000 B.C.. It is a great treasure chest with a sophisticated theoretical basis and a
wide therapeutic armamentarium, on a par with Western Medicine. It does not mean
that difficulties in research do not exist, of course. In pharmacology, those Chinese
medicines that are herbal in origin often suffer from the problem of standardization in
ingredients: plants of the same species but growing at various localities differ in detailed
compositions that mayor may not affect therapeutic effectiveness.
The variety ofTCM discovered is huge - more than five thousand different raw medicines
or herbals have been identified in China. So far, only 800 of them have been chemically
and biologically studied and classified. In the industrial sector, about 4000 types ofTCM
preparations or brand products of definite standard compositions have been produced
for the last 40 years. All these TCMs constitute a solid research field to be explored
(TCM 1949-1989).
To achieve the integration of Western Medicine and Traditional Chinese Medicine, it
is necessary to apply western pharmacological knowledge to the TCM study.
So far, basic pharmacological study has been undertaken to 150 out of the total 5000
TCM herbals. Around 500 medicinal active agents have been isolated or extracted from
TCM (TCM 1949- 1989).
In China now, isolating bioactive substances from TCM herbals or other natural sources
and molecular modification or synthesis of bioactive agents chemically similar to
known substances identified from TCM herbals are the most important ways of new
drug development. Since 1949, 150 new drugs have been developed along these two
lines, accounting for more than 50% of the total number of new drugs have ever been
developed in China.
In the 1980s, several Chinese new drugs have attracted world-wide attention and won
international awards. One of the outstanding achievement is the new and effective
antimalarial drug QINGHAOSU (1987)with a chemical structure entirely different from
those based on quinine. Qinghaosu is also the first few China new drugs which have
been underdeveloped through a full R&D process meeting all WHO requirements for
efficacy and safety tests (TCM 1949-1989).
The other important way to develop new drugs in China is molecular modification of
existing western drugs for the enhancement of potency, the enlargement of the spectrum
of activity, and the increase of the therapeutic ratio.
Above all, based on a rich resource of 5000 TCM herbals and several thousand years
of experience in TCM practice, Chinese scientists in some 200 academic institutes and
200 industrial R&D units have been making great efforts to catch up with the advanced
countries in new drug discovery and development for the last four decades.
In the 1950s, China concentrated its smaller S&T resource in R&D of antibiotics, sul-
phonamides, anti-infectives, antipyretics, vitamins and drugs for endemic diseases and
tuberculosis. In the 1960s and 1970s, China started R&D on steroids, cancer drugs,
contraceptives, and cardiovascular drugs. In the 1980s, medicines research in China
have become more sophisticated and mature covering more research areas. China
Pharmaceutical Yearbook 1987 has reviewed the state of art on medicines research in
China. By 1987, major progress have been made in the following areas:
1. TCM herbals identification and classification; revising and translating ancient TCM
literature;
2. Investigation on geographical distribution of TCM herbal resource;
3. Theoretical study on TCM; applying and introducing western pharmacological
science and technology to TCM study; western scientific style pharmacological and
toxicologic test and clinical evaluation are given to many TCM herbals, empirical
preparations and brand products;
4. Identification, isolation, synthesis and molecular modification of active substances
from/in TCM herbals or preparations or brand products;
5. New dosage forms and drug delivery routes research;
6. Pharmacological study has been carried out in all major categories:
hi h rnav enhanc: or moderate the action of naturallv occurring( 1). medicines w ic '" JU
" .neurotransmItters'" ,
(2). medicines which enhance or moderate the action of hormones'
,
(3). medicines which modify the activity of enzymes;
(4). medicines which serve to enhance or moderate the activity of the immune system:
(5). medicines affecting cell growth and/or function;
(6). medicines which serve to destroy alien pathorgans:
7. basic theoretical research on Quantitative Structure Activity Relationship, phanna-
cological receptor hypothesis, etc.:
8. toxicology research;
9. great emphasis on biotechnology;
10. antibiotics research;
11. contraceptive research;
12. chemical pharmaceuticals - design and synthesis: new chemical entities in the fol-
lowing therapeutical areas: cardiovascular, cancer, contraceptive, infective, immune
system etc.;
13. vaccines research;
14. pharmaceutical analysis process, modern techniques have been introduced to
determine that pharmaceuticals conform to specified standards of identity. strength,
quality and purity: they are: ultraviolet spectrophotometry. infra-red spectrophotometry,
chromatography, polarography etc ..
Finally it needs a few more words to describe the progress in Clinical Pharmacologv
in China. To strengthen its export capability in the world pharmaceutical market which
is a new target brought in by the economic reform in the late 1970s, China has to introduce
a full drug R&D process which could meet regulatory requirement" for drug efficacy
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and safety in major countries. Those regulatory requirements, primarily related to human
safety issues, has made toxicologic evaluation and clinical evaluation on a new drug a
more time consuming and costly process. It is reported that clinical pharmacology
become known as a science in the late 1960s and early 1970s in the world (Dukes. 1985).
Generally clinical pharmacology was built up in China some ten years later than in the
world. Since 1978 when the first Chinese clinical pharmacology conference was held,
clinical pharmacology has made great progress in China. In 1980, Clinical Pharmacology
Research Institute was founded in Beijing Medical University which is the first institute
in clinical pharmacology in China. Since then, several dozen of research institutes or
departments in the field have been built up around the country. In 1983. MPH announced
the first batch of 14 national new drug clinical trial hospitals which serve to carry out
clinical evaluation on new drugs applying for product licence in China. In 1985, Chinese
Journal of Clinical Pharmacology (OCP) was first published by Clinical Pharmacology
Research Institute, Beijing Medical University.
II. the UK
It is well known that British medicine innovations have been contributing to the health
of people world-wide, and to the " great treasure chest" of human scientific knowledge.
One example is that five of top 20 best selling medicines in 1987 and 11 of top 50 in
1989 in the world have been innovated by British scientists, and three of them occupied
the top three places (ABPI Annual Report 1987-1988 & Britain 1991).
Since the beginning of the Pharmacological Revolution in Europe in the 1930s, sub-
stantial progress has been made in many areas - such as the control of bacterial infection
and high blood pressure, the new treatments for mental illness, bronchial asthma and
peptic ulcer disease. The ABPI report "British Medicines Research 1988" has sum-
marised 28 therapeutic groups of new drug approaches currently being investigated by
British researchers.
The opportunities open for pharmaceutical researchers in advanced countries like the
UK have in the last decade or so been greatly enhanced. Relevant technical advances
include the increased range of scientific equipment available for conducting analytical
and other measurements, and for observing clinically disease processes in patients: the
increased sophistication of animal models vital for developing new ways to treat human
complaints: the emergence of molecular biology based techniques as powerful new
research tools: and the progressively expanding role of computer based molecular
modelling in pharmaceutical innovation. Britain has been leading in the development
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of molecular graphics, which contribute to the rational design of new drug- through a
computer aided technique for analysing the structures ofcomplicated organic molecules
on a visual display unit.
The advanced process of drug discovery today involves a melding of many disciplines
and interests. Up to 50 major disciplines are required to handle the range of programs
normally found in a major multinational research based pharmaceutical company.
Although there may be the difference in S&T organization among companies, the R&D
procedures for new drugs are similar among all major research based companies. Modem
scientific teamwork, project management and effective communication in this procedure
has been described in detail by Brown (1985).
Step 1. Project definition
The proposal by a scientific or marketing team to embark on the search for a new drug
for a major human disease requires each discipline represented in the project to collect
and evaluate the extant data/information/ knowledge. Sources must include proprietary
stores, published literature and patents. In addition, it is not just the initial retrospective
search but an ongoing commitment that must be made.
Step 2. Discovery
In many R&D projects, assignments in the early stage frequently rest with chemists and
biologists. Activities centre around the collection of compounds and their biological
testing by a defined protocol. The chemist frequently uses a variety of sources for the
test compounds - synthesis, collection from sample/catalogue stores, microbial broths,
plant extracts and molecular modification of known drugs. In recent times, rational drug
design has received more attention. This may stem from hypothesis regarding the
pharmaceutical or enzymatic nature of the disease process - frequently involving an
agonist or antagonist for a known enzyme and its substrate. Molecular modelling, using
three dimensional models has proven stimulating to medicinal chemists.
Whatever the source of the compound, the major goal in this phase is to discover a novel
structure with interesting biological effect as measured in enzyme inhibition, perfused
organ, or whole animal model.
Large volumes of new data are generated by each of the disciplines involved. It is
practical to limit the number of substances that pass this first "Screen" to 1-2"( that is
100 to 200 out of 10,000 testing compounds. It is not just the chemical xvnthesi zcd but
ancillary data that must be collected, evaluated, and recorded. Spectral data are extremely
valuable and form the first recorded indication of a ｾｩｶ･ｮ chemical structure. This
hO
becomes very valuable in patent application or infringement prosecution. For laboratory
records, data and record management protocols need to be followed. These are usually
derived by the proprietary information scientists. Proprietary reports generated by team
scientists must be collected, indexed, and stored for later use.
As the proprietary data is generated and evaluated in the search for a new drug, the
published literature and patents must be combed routinely by information scientists.
Bioassay procedures, new reports of biological activity, and especially quickly pub-
lished foreign patents are reviewed to keep track of competitive activity in the chemical
structure or bioassay areas of interest. Known toxicity for closely related chemical
structures is collected and disseminated to the team members.
Success in this phase is the finding ofone or more structural types that possess interesting
biological activity and offer a chance for novelty (patent protection), and represent a
class of chemicals not usually perceived as toxic. After patents are granted. there is a
peak of scientific publication on medicines research.
So far, the discovery normally takes 3-20 years.
Step 3. Lead development
In this phase, one or more structural types that possess "interesting" biological activity
needs to be exploited further. Efficacy and safety are dominant, but chemical novelty
is very important for patent protection. Systematic structural variation is applied by the
medicinal chemists to determine the chemical attributes that have influence on the
specific biological activity of interest.
On the biological side, it is important to have a whole animal model for pharmacological
study. Biologists provide sufficiently quantifiable data for regression analyses to
determine what quantitative structure activity relationships exist.
It is usually during this phase that a sound basis for patent application is found.
So far, the lead development (i.e. pre-clinical safety) norrnally takes 2-4 years.
Step 4. Drug development
From the last stage a prime candidate is selected for development as a product.
Development chemists prepare bulk chemicals for safety studies. pharmaceutical dosage
forms, and ultimately for clinical studies. Pharmacists initiate studies to determine the
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salt/derivative form, dosage form preparations, and stability studies. Safety assessment
units start studies in the appropriate species to fill out "the Application for Clinical Trial
Certificate" (ACl'C in UK, or "Investigational New Drug Application" (lND) in US).
In preparation for the filling out the AcrC, all major disciplines must search the pro-
prietary literature with the help of information scientists to locate any reports of toxicity
for the candidate or its close relatives.
Clinical studies
At this stage, pharmaceutical companies mmate planning for the clinical phases.
Investigators must be contacted and contracts drawn for the required studies. Claims
targets must be defined vs. patient populations to be studied. Case reports need to be
carefully designed and filed.
During the drug development phase, the original chemical and biological team is now
extending patent coverage, seeking second generation of candidates and preparing
manuscripts for publication (when management feels the patent application are on a
finn footing).
Information scientists responsible for proprietary information must collect, index, store
and retrieve all documents associated with the development. This usually means a new
file is started when the drug candidate is selected.
Application for Product Licence
After the clinical studies, compilation of the "Application for Product Licence" in UK
(or "New Drug Application" (NDA) in US) is the major undertaking, resulting in the
creation ofhundred volumes of information. The final application is frequently delivered
in a truck.
So far, the clinical safety and efficacy normally takes 3-7 years.
Step 5. Market launch
From this stage, the dominant in information work is shifted from S&T information to
business information, drug information, statutory information etc.
Step 6. Post market surveillance
Despite substantial clinical investigation of a new medicine before registration.
unpredictable and rare adverse drug reactions (ADR) may still occur in the
post-marketing phase. At the present time, the only practicable alternatives are large
post-marketing survr illancc studies, or voluntary reporting. In the UK. this is achieved
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through the "yellow card" reporting system operated by the Committee on Safety of
Medicines (CSM). The scheme is based on spontaneous reporting by doctors of sus-
pected ADRs.
After launching a new drug, a pharmaceutical company is responsible for any inquiries
about its product and for monitoring adverse drug reactions (ADR).
Summary on medicines research status in China and UK
In western advanced countries, such as the UK, progress in comprehending the basic
nature of disease and the mechanisms involved in the healthy functioning of the body
is currently taking place faster than ever before. Along with that, since the 1930s there
has been a remarkable revolution in drug discovery that has led to the development of
carefully designed chemical substances.
Chinese medicines research has long been walking on the two legs - Traditional Chinese
Medicine and western medicine. Taking the advantage of several thousand year
experience in using TCM and of several thousand kinds of raw TCM herbals, Chinese
researchers could heavily rely on natural sources for drug development. On the other
hand, applying western science and technology to the development of both TCM and
western medicines; and molecular modification of known Chinese and western drugs
have long been the major target of Chinese pharmaceutical R&D. By the end of the
1980s, China has had a more sophisticated and mature pharmaceutical science and
significant progress has been made in many subject areas even including the most
advanced fields such as Rational Drug Design. Molecular Biology and Molecular
Modeling.
However, in the world-wide competition in pharmaceutical innovation and in innovative
pharmaceutical market, China is still being left behind by the developed countries
including UK. This issue will be discussed in more detail in the next section §3.4 size
ofmedicines research in the two countries.
3.4 Size of Medicines Research in the Two Countries
There are many ways to define the size of medicines research. Lnfortunately. most of
them are harder to quantify than the following four methods- measuring the number of
scientists in existence, the amount of money expended on research, the amount of new
drugs, and the amount of literature published.
I. Scientific Manpower
As described above, the UK pharmaceutical industry is mainly responsible for the
medicines research in Britain, the measurement of S&T manpower in this study will
focus on the industrial sector. On the other hand, the measurement of China's S&T
manpower in pharmaceutical field is to be focused on government research institutes
and industrial R&D units, neglecting the relatively small research force in universities.
The UK pharmaceutical industry has a R&D manpower of sixteen thousand (ABPI
British Medicines Research, 1988). The Chinese pharmaceutical industry has a S&T
manpower of 33,800 (Data from SPAC and SATCM statistics. 1989).
Table 3.4 and 3.5 give the figure of S&T manpower in the UK pharmaceutical research
and in the Chinese pharmaceutical research. The total number of S&T staff employed
by the UK pharmaceutical industry is only 42% of the Chinese counterpart. However,
the proportion of S&T staff to total employees in the UK pharmaceutical industry is as
high as 23% which is 6 times the Chinese figure (3.4%). This is a typical example of
the devastating shortage of S&T manpower in China. For instance, there were 72-1,238
senior doctors in China comparing to 51,300 whole time equivalent medical and dental
staff in hospital and community service and 58,700 medical, dental and optical staff
employed under the auspices of family practitioner committees in the UK (Shao, 1988).
Despite the number of Chinese doctors is seven times the number of British doctors,
the proportion of pharmacists and doctors to the population in China is much less than
that in the UK and other developed countries (Table 3.6).
To measure Britain and China S&T manpower at different work categories and at dif-
ferent levels has proved to be very difficult, because of the different situations in
medicines research and different organization systems in the two countries.
Since the mid 1960s there has been a tendency in the USA and to a loser extent in the
UK to regard a Ph.D degree as the qualification of a practitioner of research (Meadows,
1974). But the situation in China is quite different, because the major R&D force in
China has long been the S&T staff with first degree.
China started post-graduate education much later (in 1977) than its modern inception
of science and technology (in 1910s). At present. of China's S&T manpower higher
degrees holders compose too small proportion to be considered an substantial research
force. The proportion of doctoral degree holders in total S&T manpower is 0,26%, the
proportion of master degree holders is 3.18%. However the proportion of first degree
Table 3.<4 The Employment and S&T Manpower in British Pharmaceutical Industry"
(ABPI facts' 1986 and 1990)
Year 1970 1975 1980 1981 1982 1983 1984 1985 1989
Total Employees 71.0 76.0 74.0 81.1 81.0 80.9 81.4 82.5 71.0
(in thousands)
R&D (in thousands) 7.0 10.0 12.0 13.0 13.0 14.0 14.1 14.2 16.0
R&D in Total (%) 9.9 13.2 16.2 16.0 16.0 17.3 17.3 172 23.0
*All figures include part-time staff
Table 3.5 The Employment and S&T Manpower in Chinese Pharmaceutical Industry
(Green Book, 1988)
Total Employees (in Thousands) 1000
S&T (in Thousands) 33.8
S&T in Total (%) 3.4
* All figures include WM and TCM S&T staff.
Table 3.6 Proportion of Qualified Doctors and Pharmacists to the ｾ ational Population-
comparison among selected countries (Han, 1988)
Country Year Doctors per Phannacists per
1,000 residents 1,000 residents
Japan 1980 1.34 0.99
U. S. A. 1975 1.68 0.68
U. K. 1977 1 -, 0.68.)-
.-
-
W. Gennany 1975 2.0-l O.4S
ＭＭｾＮｾ ｾＭ
China 1986 0.75 0.0)
holders is 46% of total S&T manpower in China which is much higher than the figure
of 33% (degree holders to the total S&T manpower) in the UK (White Paper, 1990 &
Annual Review of Government Founded R&D 1990).
R&D employment in UK pharmaceutical industry was composed of administrative.
clerical staff (29%); technical support staff (33%) and research scientists and engineers
(38%) in 1981 (ABPI, 1985).
If we assume the above ratio (38%) is unchanged, we can estimate there are now six
thousand R&D personnel and ten thousand supporting staff in the UK pharmaceutical
industry.
In the short history of modem S&T in China, there are the following" four generations"
of intellectuals (Table 3.7).
Table 3.7 Four Generation of Chinese University Graduates
generation graduation number of grad- percentage ages in 1990
year uates (%)
(million)
1st 1911-1949 0.22 5 65-80
2nd 1950-1965 1.5 36 50-65
3rd 1966-1979 0.96 23 35-50
4th 1980-1985 1.5 36 30-35
Total 4.18 100
The first generation (1911-1949) of graduates was studying in colleges or universities
before liberation in 1949. Most of them have already retired from work, with only a
few still remaining in university teaching posts. The second generation (1950-1965)
are those who were educated before the Cultural Revolution. Their studies and initial
phase of their research careers were mostly influenced by the Russian Mode. followed
by ten years of unemployment in R&D field during the Cultural Revolution. When in
the early 1980s their scientific work was restored. they found themselves facing a huge
challenge and influence from the western science and technology. Nevertheless. the
second generation is playing the most important role in today' s R&D in China, owning
to their long experience and high reputation in the S&T field. The third generation
(I q66-1(79) is probably the most controversial group of the four in the Chinese S&T
and higher education history. Because of the higher education guide-lines during
Cultural Revolution aimed at training factory workers, peasants and soldiers into
revolutionary experts, the quality of the third generation is questionable. It has been
officially estimated in 1986 that only 25% of the college graduates during the period of
1966-1979 were really qualified graduates (White Paper, 1987). In 1978 China restored
its national higher education system which includes various courses ranging from two
year Diploma to Post graduate course for Master and Doctoral degree. The graduates
since 1980 are labelled the founh generation. Unlike their parents (the second
generation), from the beginning of their higher education the fourth generation has been
studying and working in an information environment with enormous western influence.
After the 1960s and 1970s Cultural Revolution, there has been a serious shortage of
professionals in many fields, especially in the S&T sector. To meet the great demand
for qualified S&T staff, China needs to strengthen its high education system. For the
last ten years, most of Chinese higher degrees graduates have been assigned to lecturing
posts in universities or colleges. A relatively small proportion of them went directly to
R&D posts in academic or industrial sectors.
According to a survey of 294 Master degree holders graduated from 1981 to 1987 in
pharmaceutical sciences in China (China Pharmaceutical Yearbook, 1987). 63.3% of
them have been engaged in university teaching: 20.4% of them were employed by
research institutes, 11.9% of them have undertaken further education for doctor degree,
4.4% have been employed by industrial enterprises, hospitals or other organizations.
That is less than 40% of higher degrees holders are engaged in R&D work.
By comparison, relatively bigger proportion of UK higher degrees holders in pharma-
ceutical sciences has gone into R&D sector, according to the First Destination Survey
by the Department of Education of the UK in 1989. Approximately, of the higher degree
graduates, 86% in Pharmacology, 58% in Biology and 71% in Chemistry started
working in R&D sector. Generally speaking the quality of research staff in UK is higher
than in China.
Up to now, whether one has a first degree or a higher degree is not a criteria for the
grades of research scientists in China. In stead, the hierarchy o/job titles in the Chinese
R&D system divides all S&T staff into four classes or levels, according to both research
experience and professional skill. The hierarchy is described as follow:
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Grade 4 - research assistant, accounting for 30% (40% of total research scientists),
Grade 3 - junior research fellow, accounting for 30C;C (40% of total),
Grade 2 - research fellow,
Grade 1- senior research fellow (the first and second classes accounting for 10% -2017c
of total).'
In practice, the top two classes (Grade I and Grade In of S&T staff are mainly involved
in research and literature produce; while the lower classes of staff (Grade III and Grade
IV) act mainly as supporting workers. In this sense, the ratio of R&D personnel to
supporting personnel is 1 to 4.
To measure S&T manpower at different levels or categories of work enable us to estimate
the number of potential scientific authors and readers.
Generally speaking, it is research scientists who constitute both the potential author
group and the reader group. According to the above estimates (1/3 of UK pharmaceutical
S&T staff and 1/5 of Chinese pharmaceutical S&T staff are regarded as research
scientists), there are about six thousand and seven thousand potential pharmaceutical
authors and readers respectively in the UK and China.
II. Expenditure on R&D of medicines
Over the past 50 years, innovative research within the UK pharmaceutical industry has
been among the most consistently successful of all UK industries with six of the top 15
products in the world originated by the UK companies (Lumley. 1989).This success
has been largely dependent on investment in research and development. A survey of
pharmaceutical companies in the UK has shown that total research and development
expenditure increased by 103% from £331.5 million in 1982 to £672 million in 1987,
with an estimated expenditure of £748.8 million in 1988 and an average yearly change
of 15%. Even after correcting for inflation, the increase from 1982 to 1987 is con-
siderable at 61.7%. Capital expenditure made a significant contribution to this increase,
rising from 14% of total expenditure in 1982 to 24% in 1988. The seven UK owned
companies alone accounted for more than halfof total pharmaceutical R&D expenditure
in 1987 (Lumley, 1(89). The figure quoted above indicate the magnitude of the research
investment in the pharmaceutical industry. It is now estimated that it costs on average
7 the proportion of different classes vary among research institutes .White Paper. 19X7.
19(0).
about £125 million to develop one successful new medicine (ABPI Pharm Facts 1990).
The British pharmaceutical industry expenditure on R&D as a proportion of gross output
(13.4% in 1985) is much higher than the average figure of the whole UK industry (at
1%) (Baker, 1989). Table 3.8 is given to show the growth of R&D expenditure since
1970.
There are no statistics about the expenditure on medicines R&D in China. What we have
got is the official statistics on national S&T expenditure (in government institutes
only) classified into different ministries or provinces (China Economy Statistics
Yearbook 1988). Table 3.9 gives the figure of national S&Texpenditure which includes
the State Council controlled research and the provincial or munici pal controlled research.
Among the State Council controlled research groups, we choose the following five
concerned with medicines R&D: 1. research under the administration of the Ministry
of Public Health (MPH); 2. research under the Commission of Family' Planning (CFP);
3. research under the State Pharmaceutical Administration of China (SPAC); 4. research
under the State Administration ofTraditional Chinese Medicines (SATCM); 5. research
under the Chinese Academy of Sciences (Academia Sinica). These five groups either
entirely or partly involved in medicines research are higher level institutions in China
where R&D expenditure per person is much higher than the average national ratio and
provincial ratio (Table 3.9).
The provincial or municipal controlled R&D expenditure is divided among those lower
level or small scale institutions. The R&D expenditure per person in provincial research
is ¥8,232 which is lower than the average national ratio VIOA03 (Table 3.9). Here it
should be pointed out again that R&D expenditure figures in Table 3.9 only reflect the
situation in academic sector in China.
It must be noted that the expenditure of the above five State Council controlled groups
is not totally allocated to medicines research; and there is a proportion of the provincial
research expenditure spending in medicines research. It is too difficult to get any figure
on total R&D expenditure on medicines in China or any figure on average R&D
expenditure for each new drug in China.
Table 3.8 R&D Expenditure in British Pharmaceutical Industry
(ARPI facts' 1986 and 1990)
Year R&D (£ million) R&D in Gross R&D-
Output (%) per person (£)
1970 30 5.7 4,286
1975 79 7.5 7,900
1980 251 10.3 20,917
1981 296 11.2 22,769
1982 360 11.8 22,692
1983 431 13.2 30,786
1984 483 13.2 34,255
1985 540 13.4 38,028
1986 612 13.8
1987 668 13.3
1988 743 13.0
1989 871 13.8 55,438
*not corrected for inflation
Table 3.9 R&D Expenditure in China in 1987
(China Economic Statistics Year Book 1988)
S&T staff Number of R&D expenditure R&D expendi-
institutions (million ¥)- ture
per person (¥)
National 1,042,675 5,568 10,847 10,403
MPH 20,233 36 255 12,582
CFP 218 1 1.8 8,349
SPAC 2,368 5 39 16,584
SATCM 3,145 8 48 15,179
Academia 66,855 123 886 13,255
Sinica
provincial 454,504 4,490 3,742
8,232
* The exchange rate in 1986 is £ I =¥5.51
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We try to calculate a rough figure by multiplying total S&T staff number in medicines
field by national average R&D expenditure per person in the field:
10,403 (¥)
average national R&D
expenditure per person
in 1987
x 23,800
total R&D staff in
medicines research in
academic sector in
1987
= 2.+7,591 ,400(¥)
total R&D expenditure
in medicines research in
1987
Therefore, it is estimated in 1987 total R&D expenditure on medicines research in
academic sector in China was ¥247.6 million (RMB). This figure does not include R&D
in pharmaceutical industry, because there is no official data on industrial R&D
expenditure available. However, we could roughly estimate the pharmaceutical industry
R&D expenditure according to the share of R&D expenditure among government
institutes (55% of total), universities (15% of total) and industry (30% of total) in 1988
(White Paper, 1990). Therefore the Chinese pharmaceutical industry R&D expenditure
in 1987 is estimated as ¥135 million. In the whole, the annual pharmaceutical R&D
expenditure is estimated as ¥382.6 million in 1987 in China.
The proportion of Chinese R&D expenditure to its pharmaceutical industry gross output
in 1987 is estimated as 1.5% - 2.0%, given China's pharmaceutical industry gross output
in 1987 was ¥21 billion (China Medicines Economic News, No. 39, 1Oct. 1989 & China
Pharmaceutical Yearbook 1987). So the UK pharmaceutical industry's ratio of R&D
expenditure to its gross output (13.4% in 1985 and 14% in 1989) is about 7 times the
China's ratio.
In 1987, the exchange rate was £1 = ¥6.97 (Appendix 2.3). Therefore the Chinese
Pharmaceutical R&D expenditure in 1987 was about £55 million and annual R&D
expenditure per person was between the low level of £ 1,515 ( in CFP) and the high level
of £3,010 (in SPAC). If we compared the whole expenditure (£55 million) and
expenditure per person (£1,500-3,000) with the UK counterparts (£800 million in total
and £54,000 per R&D staff in 1989 see Table 3.8), the UK figures are more than ten
times the Chinese ones.
If we compare the average R&D cost of each NCE in the two countries. the difference
is even more surprising. In the UK in the 1989 the average cost of one succexxful ｾｃｅ
was about £125 million (ASPI Pharm. Facts and Figures. 1990). In China, there were
60 pharmaceutical R& 0 projects with total fund of ,'3 million in 1988 (White Paper.
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1990). If we assume that these 60 project are associated with one new drug, then the
cost of a new drug was about £500,000 (for exchange rate see Appendix 2.3). The R&D
expenditure for each NCE in UK is over 200 times the Chinese figure.
In fact, it is not so valid to compare the two countries' R&D expenditure in absolute
terms of money, because there are two different economy systems in the two countries.
The price system in China is very low comparing to those in UK, USA and other western
countries, only very small amount of R&D expenditure are located on S&T manpower.
Additionally in the domestic market, S&T hardware and software are also comparatively
quite cheap.
For example, the average annual wage in 1989 of a full time UK pharmaceutical industry
employee was £14,452 (ABPI Pharm. Fact 1990), accounting for just under 30% of
average annual R&D expenditure per staff in pharmaceutical industry (£54,4J8 in 1989,
see Table 3.8). By comparison, the average annual earning in 1990 of Chinese employee
was ¥2100 (Peoples' Daily, March 27, 1991) which accounts for 17% of average annual
S&T expenditure per person (¥12,870 in 1990) in China (White Paper, 1990).
Another example is the low price for domestic books and periodicals. In China, in 1990
the regular price for a S&T book was about ¥13 (or £1.3 under the official exchange
rate in 1990) and for a S&T journal the average annual subscribing fee was ¥16.5 in
1990 (or £ 1.65 under the exchange rate in 1990) (Tao, 1991).
By comparison, in 1986 the UK average academic book price was £14 and the USA
book price was £20; the UK average scientific journal price was £60 and the USA figure
was £108 (fletcher, 1987).
If we divide the average wage by the average book/journal price, we have the following
results:
(1) a Chinese employee's annual wage can buy 161 Chinese S&T books or subscribe
127 Chinese S&T journals:
(2) a British (pharmaceutical industry) employee's annual wage can buy 723 British or
American academic books or subscribe 134 British or American academic journals.
It is also said that the price of domestic made S&T equipment is also very low in a sense
that ¥ 1 of spending on equipment in China market is equal to 11 of spending on
equipment in the II K market (Ma, 1990).
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Having said all that, one must also notice the obvious financial constraint in China R&D
sector.
China has to rely on the import of high technology equipment and S&T documentation
expensively from the western countries. This part ofexpenditure accounts for the largest
part of S&T expenditure in China.
In 1987, the Shanghai Institute of Pharmaceutical Industry, one of the largest institution
in the field in China, spent about V200,000 on information acquisition. By dividing the
annual documentation expenditure by its 1,000 S&T staff, the average annual docu-
mentation expenditure was ¥200 or just under £30 per staff (according to the Shanghai
Institute of Pharmaceutical Industry statistics in 1989).
According to ICI Pharmaceutical Division, in 1985 its journal subscriptions was 38%
of the library materials budget, others include online/SDI 26%. monograph 29%,
BLOSC loan 3% and patent 4%. Over recent years it has subscribed average 1,400 serial
titles. Given that ICI mainly purchase British and American journals and the average
UK journal price was £60 per year (US price is higher than that), then one could roughly
estimate that ICI spent £84,000 on journals or £221 ,000 on information (including 26%
in SOl/online) each year.
According to ABPI Fact 1986, 17% of employees in UK pharmaceutical industry are
in R&D sector. Since there are 4000 employees in ICI pharmaceutical division (Jackson,
1987), it is estimated that there are some 680 R&D staff in ICI pharmaceutical division.
By dividing ICI annual information expenditure of £221 ,000 by 680 R&D staff, annual
information expenditure was £325 per staff, which is almost ten times the Chinese figure.
Because China has to rely greatly on importing documentation from the Western
countries, the existing R&D budget is far too limited. The Shanghai Institute of Phar-
maceutical Industry only subscribes some 600 foreign journals each year. whereas ICI
pharmaceutical division subscribes about 1,400 titles of current journals.
III. New Drugs
In the West, industrial researchers usually adopt "new chemical entity " ＨｾｃｅＩ as the
quantitative measure of pharmaceutical innovation. A new chemical entity is defined
as" a new chemical or biological compound, not previously tested in man fortherapeutic
purposes. excluding new salts and esters unless they confer some major therapeutic
advantage" (Walker. 1988).
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Data on the number of NCEs do not give any indication of the quality or relevance of
the pharmaceutical R&D. The FDA in USA and Barral in France have developed a
classification on the 508 NCEs marketed in the world during the period of 1975-1984.
It reported that 35 NCEs (6.9% of total) are in the group A "new structure " therapeutic
improvement;", 115 NCEs (22.6%) in the group B "well known structure; therapeutic
improvement;", 75 NCEs (14.8%) in the group C "new structure, no therapeutic
improvement;" and 283 NCEs in the group D "well known structure; no therapeutic
improvement" (WHO, 1988).
Throughout the 1960s and 1970s, and in the early 1980s, only five countries in the world
have dominated the world pharmaceutical industry in terms of NCEs and of R&D
expenditure - they are the UK, France, West Germany, Switzerland and the USA. Since
the early 1980s, Japan has become one of the leading countries in the world pharrna-
ceutical industry (WHO, 1988).
The number of NCEs investigated by the UK owned research based companies was 319
from 1964 to 1985. There was an increase in the number of NCEs investigated each
year in man - doubling from an average of 12 per year (1964-1980) to over 20 per year
(1981-1985) (Walker, 1988).
From 1969 to 1989, the annual number of NCEs launched by UK pharmaceutical
companies has fluctuated between 12 and 28. The annual number of UK companies
involved in NCE launching has fluctuated between 12 and 24 (ABPI Phann. Fact 1990).
From 1980 to 1989, European pharmaceutical companies were responsible for orig-
inating 42% of the NCEs reaching one of the 20 key countries' market (16 European
countries and USA, Canada, Japan, or Australia), while US accounting for 27% and
Japan for 31%. UK holds 14% of NCEs introduced onto the 20 countries' market and
27.6% of the top 50 products marketed world-wide with respect to the patent holders
(CMR news, Vol 8 No.4, 1990).
China has a definition and classification system of new drugs which is different from
the NCEs system applied in other countries, in the sense that the Chinese new drugs
include - western medicines (WM) and traditional Chinese medicines (TC\1). TCM
new drugs are not comparable with the NCEs defined above.
The Medicine Act introduced into China in 1985 defines and classifies a new drug as:
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Class I.
Class II.
Class III.
TCM
1. man made substitute for a TCM herbal or
2. newly found TCM herbal or
3. new medicinal part of a known TCM herbal
WM
1. a new chemical or biological compound and its preparation or formulation
which has not been tested in man in the world or
2. a new chemical or biological compound and its preparation or formulation
which has not been granted product licence in any foreign country
TCM
1. new preparation or formulation which change traditional delivery routes
or
2. isolated substances (not a single compound) and associated preparation
or form ulation
WM
1.new compound and associated preparation or formulation which has been
granted product licence in foreign country but not been indexed in phar-
macopoeia in any foreign country or
TCM
1. new preparation or formulation of traditional Chinese medicine (ancient
formulation, empirical formulation, etc ..)
WM
1. new combine WM formulation or preparation; or TCM formulation or
preparation
Class IV. TCM
1. new dosage form of TCM which does not change traditional delivery
route
WM
1. synthesis of known compound existing in natural sources
2. new compound which has been granted product licence and indexed in
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pharmacopoeia in foreign countries
3. new dosage form
4. new formulation which changes previous delivery routes
Class V. TCM
1. existing drug which has a new therapeutical function
WM
1. existing drug which has a new therapeutical function
Generally, the Chinese new drugs in the western medicine group are the equivalent of
NCEs defined elsewhere in the world.
There are no official statistics on the number of new drugs developed by Chinese
Scientists before 1985. One estimated number is three hundred or so during the period
of 1949 - 1988 (TCM 1949-1989), an average of 8 new drugs per year.
There have been 25 medicines being given the Government Innovation Award from
1959 to 1985. These awards reflect the highest standard R&D achievements in drug
discovery and development in China for the period. Table 3.10 is the distribution of the
awards over the years (Green Book, 1988).
Table 3.10 The Government Awards for Innovations in Medicine Research (Green
Book, 1988)
Year 1960 1965 1979 1980 1981 1982 1983 1984 1985 total
Number 1 1 1 2 3 4 6 4 3 25
After 35 years of disperse administration on pharmaceuticals, the first Medicine Act
was introduced into China in 1985.
Since then the new drug approval process in China has been under the full control of
the Chinese central government and has been continuously improved to become
compatible with the new drug approval process in the major countries in the world.
In 1987.32 WMs and II TCMs developed by Chinese researchers have been approved
for industrial production and marketing and granted Product Licence. Among the ＴＮｾ
new drugs. there were 32 'CEs (Chinese Pharmaceutical Affairs. Vol. 2 '0. 2. 1988
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& China Pharmaceutical Yearbook 1987). Comparing with average 20 ｾｃｅｳ being
launched by UK companies each year, China is not out of line with UK in term s of \ CEs
launched per year.
However, these Chinese NCEs are not generally recognized by the world pharmaceutical
industry, neither in the form of patent nor in the sale volume at the world market.
IV. S&T literature productivity
When talking about literature productivity in a specific field, a more acceptable measure
is to count entries in the most comprehensive bibliographies or abstracting journals in
that field. Table 3.11 and 3.12 show the results of several countries' contribution
towards the world literature by measuring their entries in Chemical Abstracts (CA).
Both in general and in pharmaceutical field, China accounts for very small fraction of
the world literature. In pharmacology, toxicology, pharmaceuticals and pharmaceutical
analysis, China accounts for 1.4%,0.8%, 1.8% and 0.4% of world literature in the field
respectively while correspondingly UK is 7.1%, 6.1%, 5.5% and 2.4% in these fields.
In these areas in 1988, China produced total 517 papers (as indexed in CA) while UK
produced 3377 papers (in CA). China's productivity is only 1/6 of the UK.
Though CA is much more comprehensive in covering S&T literature not in English and
literature by smaller scientific nations than other international abstracting services
(Boxenbaum, 1981), the above counts of Chinese papers appearing in CA can only
reflect a small fraction of and the best part of total Chinese S&T literature in the fields.
Table 3.13 compares the entries in CA and in "China Pharmaceutical Abstracts (CPA)"
which is the most comprehensive Chinese abstracting journal in the field. The results
show that total entries in pharmacology, toxicology, pharmaceuticals and pharma-
ceutical analysis in CA is equal to 15% of entries in CPA in the same fields. So in a
catch all measure, China produces about 3,000 papers per year in pharmacology,
toxicology, pharmaceuticals and pharmaceutical analysis; which is similar to the UK
annual literature production.
Having said all that, we have to emphasise that almost all papers abstracted in CPA are
written in Chinese and about 98% of the Chinese papers in CA are in Chinese (Jhaveri,
1989). In world-wide scientific communication, these non-English papers have only
little impact.
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Table 3.11 National Productivity of S&T Literature
Under the Measure of CA Entries in 1988 (Jhevari,1989)
journal papers % of journal patents in CA % of patents
in CA paper in CA in CA
World 389,685 100 80,795 100
USA 106,774 27.4 5,575 6.9
USSR 50,659 13.0 5,332 6.6
Japan 44,814 11.5 43,468 53.8
UK 21,822 5.6 - -
W. & E. Germany 29,226 7.5 - -
India 12,080 1.3 - -
China 13,639 3.5 1293 1.6
Table 3.12 Pharmaceutical Literature Entries in CA in 1988
- comparison between UK and China'
Pharmacology Toxicology Pharmaceuticals Pharmaceutical
(SCI) (SC4) (SC63) Analysis (SC64)
world 20445 (1()()%) 12353 7165 (100%) 1371 (1()()%)
(100%)
UK 1446 (7.1 %) 752 (6.1 %) 394 (5.5%) 33 (2.4%)
China 287 (1.4%) 99 (0.8%) 126 (1.8%) 5 (0.4%)
* the results are from the online searching counducted by information officer in the City
University Library in Oct. 1990 through STN CARLE
Table 3.13 Chinese Pharmaceutical Literature Productivity
_entries in Chemical Abstracts (1988) and in China Pharmaceutical Abstracts (1989)
CA section No. entries in CA CPA section No. entries in CPA
pharmacology & SCI & SC4 386 06& 07 1479
toxicology
pharmaceutcals SC63 126 03 & 04 1258
&05
pharmaceutical SC64 5 08 745
analysis
total 517 3482
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Summary and discussion on the size of medicines research in China and L K
Both China and the UK has a large number of S&T staff in medicines research - about
33,800 in China (including those working in WM and TCM), and 16,000 in the UK
pharmaceutical industry. The estimated pharmaceutical R&D staff numbers are six
thousand in the UK and seven thousand in China.
It is not valid to compare R&D expenditure in UK and China in the absolute terms of
money, because of the different price systems in the two countries. In the West, the
R&D cost of a new drug has reached £125 million in 1989. However, in China in 1988
the R&D budget for a new drug was estimated at the level of £500,000. The British
pharmaceutical industry R&D expenditure has amounted to £800 million in 1989.
accounting for 14% of the gross output of the industry. By comparison, it is estimated
that in 1987 China has spent about ¥382 million (or £55 million) in pharmaceutical R&D
accounting for only 2% of the industrial gross output.
However, as far as the import of high-technology and S&T documentation is concerned,
the situation in China is very serious due to the shortage of hard currency. The annual
information expenditure in ICI pharmaceutical division is about £300 per R&D staff,
while the money spent on per Chinese S&T staff in pharmaceutical field is only £30 -
a difference of ten times.
Although China has a R&D manpower in pharmaceutical industry as large as the UK,
in terms of pharmaceutical R&D money input, it is obviously left behind by the UK.
Lack of funds has had serious impacts on the output of pharmaceutical R&D in China.
The annual productivity of literature in pharmaceutical sciences (pharmacology, toxi-
cology, pharmaceuticals and pharmaceutical analysis) is between two to three thousand
in the UK (CA, 1988). The productivity in the same subject areas by China is between
three and four thousands per year (CPA. 1989). However only 15% of Chinese papers
are abstracted in CA. So China has a scientific productivity similar to UK in pharma-
ceuticalliterature. But in terms ofliterature disseminated into the world (i.e. the amount
of papers being indexed in CA), China' capacity is only 1/6 of the UK. Furthermore
only 4% or so Chinese S&T literature is published outside China and in English (see
Chapter 6). That means only very small proportion of Chinese literature are accessible
to foreign scientists without a language barrier.
By now. although the annual number of NCEs launched by China is not out of the line
comparing with C K: in the world-wide competition in pharmaceutical innovation and
in innovative phannaceutical market, China is still being left behind by the developed
countries incl uding UK.
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Firstly, the Chinese new drugs both TCM and WM are not world-wide recognized.
China has no international market share of ethical pharmaceuticals.
Secondly, China's pharmaceutical export are almost confined to TCM raw materials
and WM bulk chemicals.
On the other hand, UK is one of the seven "superpowers" in the world pharmaceutical
industry. In terms of R&D expenditure - UK accounts for 8% ofthe world pharmaceutical
expenditure in 1989; in terms of productivity of NCEs - UK accounts for 14% of world
NCEs launched to 20 key countries during 1980-1989; and in terms of sales volume in
world market - UK accounts for 31% of world prescription sale of £95 billion in 1989.
The UK industry has its products that are results ofextensive R&D, are patent protected,
are available on prescription only and have a significant share of the world market.
The main reasons for the above differences include:
1. NCEs developed in China do not usually have patent protection both at home and
abroad (see Chapter 8), therefore Chinese NCEs are less competitive in the home market
and the world market.
2. The Chinese new drug registry system was just established in 1985 and not compatible
with those sophisticated systems in the developed countries (see Chapter 8). So far, few
Chinese NCEs could meet those complex regulatory requirements in the major counties
in the world.
3. Chinese pharmaceutical industry mainly is the manufacturing type of industry rather
than the R&D type of industry. Most of pharmaceutical innovations are taken place in
government research institutes rather than inside the industry. The divorce of R&D
activities from industrial manufacture has resulted in the following problems:
(1) Because there is no direct link between the pharmaceutical innovation
and the profit of the pharmaceutical industry. the R&D investment from the
industry has been prevented".
HOther factors preventing the Chinese pharmaceutical industry from large R&D investment
include the general low price for pharmaceuticals in the domestic market and no patent
protcction in China.
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(2) The low R&D investment has resulted in that most of Chinese new drugs
could not meet the regulatory requirements of foreign countries without
undertaking a full R&D procedure as that being implemented in the West.
This procedure is a very expensive one which takes 3-20 years for discovery.
2-4 years for lead development, 3-7 years for development and costs £1ｾＵ
million for a new drug to reach the market.
(3) Failing to meet international standards. most of Chinese new drugs are
not able to be launched in the world market. This further weakens the foreign
currency income of the Chinese pharmaceutical industry, while the hard
currency is greatly needed for purchasing high technology and documen-
tation from the West.
3.5 Concluding Notes
The drug situation and the pharmaceutical industry are significantly different in China
and the UK.
China is a developing country with an essential drug policy. Although the drug con-
sumption per capita is very small (£3.1 in China comparing to £60 in UK in 1989), the
average pharmaceutical price in China is only 10% of that charged in the West.
Furthermore, the Chinese society has given medicines higher value in terms of domestic
drug sales vs. GDP (1.6% in China comparing to 0.7% in the UK) and of domestic drug
sales vs. national health expenditure ( 60% in China vs. 10% in the UK and other
developed countries). China, a country with 1/5 of world population, has reached the
stage of 90% self sufficient in drug supply.
As a developing country China still faces problems in the legislation and quality
assurance systems, drug information supply for professional and the public. ADR
monitoring, and patent protection.
For the past 12 years the Chinese pharmaceutical industry has grown at a rate of over
10% per year. However. the role of the Chinese pharmaceutical industry is not so sig-
nificant in terms of world pharmaceutical trading. Its bulk pharmaceutical export in
1987 accounts for 10% of the Chinese pharmaceutical industry gross output (Western
medicine industry only); comparing to the UK figure of 32lJc in 1989. Its world trade
volume ($400 million in 19X7) is only 12.5lk of the UK figure Ｈ ｓ ｟ ｾ Ｎ Ｒ billion in 19X9).
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Furthermore, China's pharmaceutical export are almost confined to TCM raw materials
and WM bulk chemicals. Its new drugs are not generally recognized by the world. Its
international marketing capacity of ethical drugs is very small.
The fundamental difference between the Chinese pharmaceutical industry and the UK
pharmaceutical industry are in the pharmaceutical R&D, in patent protection and
international market share. To narrow the distance between China and the West in the
world-wide competition for pharmaceutical market, and to increase the national capacity
of pharmaceutical innovation to serve the Chinese people, the following goals for
development and transition have been set up by the Chinese government recently (China
S&T Daily, July 18 1990):
1. From simply molecular modification of existing drugs to discovery of
new drugs, that is to implement a full drug R&D procedure which will
meet all regulatory requirements of the Chinese government in the first
place, and meet all requirements in some major countries (markets) in the
future.
2. From exporting intermediary chemicals (bulk pharmaceuticals) to
exporting ethical products.
3. Fully introducing into Chinese pharmaceutical industry the Good
Manufacturing Practice and other international standards to improve
product quality and to promote the international marketing capacity of
the Chinese pharmaceutical industry.
Above all, there is a long way for the Chinese pharmaceutical industry to transfer into
a R&D industry. Such a development is bound to happen in the modernization process
of the country. Such a development or transition will inevitably have impacts on the
pharmaceutical information flow in China.
The most recent trend in the Chinese pharmaceutical industry is that early in 1992, the
Chinese government agreed to introduce patent protection for pharmaceuticals in China.
The implications include:
1. Chinese pharmaceutical manufacturers and foreign manufacturers have their ethical
products protected by Chinese law;
2. Encouragement on pharmaceutical industry R&D and ､ ｩ ｳ ｣ ｯ ｵ ｲ ｡ ｾ ｣ ｭ ･ ｮ ｴ on copying
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drug products "me too" drugs in China;
3. Market competition among Chinese and foreign companies in the Chinese market.
Since the Chinese pharmaceutical industry is moving towards modernization, an R&D
based and ethical pharmaceutical industry is bound to emerge in China. In the mean
time, other sectors of Chinese pharmaceutical activity- quality control, legislation,
distribution, ADR monitoring and information provision- are also experiencing mod-
ernization. This means that studying the advanced UK pharmaceutical information flow
model is very necessary for the future information flow system in China.
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Chapter 4 The Growth of Science
To measure the performance of S&T information flow is difficult. Since the 1960s, there
have been some studies that try to measure the worldwide scientific growth in manpower.
expenditure and literature.
In this chapter, the growth of science in the world, the UK and China in the current century
will be studied; the impact of the growth on Chinese scientific communication will be
discussed.
Perhaps no one but Derek J. De S. Price has won such a high reputation in the field of
measuring the growth in science. In the early 1960s, he stated:
"All of these [empirical statistical evidences] shows with impressive consistency and
regularity that if any sufficiently large segment of science is measured in any reasonable
way, the normal mode of growth of science is exponential.
"One of the important features of the growth of science is that it is surprisingly rapid however
it is measured.
"Now, depending on what one measures and how, the crude size of science in manpower
or in publications tends to double within a period of 10 to 15 years.
"The 10-year period emerges from those catch-all measures that do not distinguish low-
grade work from high but adopt a basic, minimal definition of science; the IS-year period
results when one is more selective, counting only some more stringent definition of
published scientific work and those who produce it. If this stringency is increased so that
only scientific work of very high quality is counted, then the doubling period is drawn out
so that it approaches about 20 years". (Price, 1963)
However, in the real world things do not grow and grow until they reach infinity. According
to Price, the growth of scientific manpower and publications follows a "normal" logistic
growth curve (Figure 4.1). This is characterized by early exponential growth followed by
a decline in growth toward a ceiling beyond which it cannot grow in its accustomed fashion.
In 1961, Price estimated that science in the USA was approximately entering the mid-region
near the inflection. He predicted" 30 to 45 years will elapse before the exact midpoint
between floor and ceiling is reached. An equal period thereafter, the curve will effectively
have reached its limit". (Price. 1963)
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No matter whether Price's prediction is right or not, the world has seen that the growth of
science has been slowed down during last 20 years. Along Price's line, A. G. Henderson
has monitored the growth during 1900-1988. He argued that most of the developed countries
like USA, Japan, UK are already facing or fast approaching stagnation in science under
present circumstances. (Henderson, 1988)
Compared with the growth pattern in the world and in the UK, what is China' s pattern
during the last four decades?
4.1 The Growth in Scientific Manpower
The patterns of evolution of science vary significantly among continents as well as
nations. As Price estimated, the USA has undergone the exponential expansion in science
at a considerably higher rate than Europe. Later came the economic and scientific rise
of the USSR and China with even higher expanding rate - the scientific manpower
doubling period in the USSR is seven years while in China it is three to five years.
(Figure 4.2)
Of many indicators Price has used to demonstrate the USA scientific manpower growth,
the number of entries in the biographical directory "American Men of Science" (AMS)
(lst. Edition of 1906 -- 10th edition of 1960) is one of the more accessible. A. G.
Henderson studied the latest 6 editions (11th of 1967 -- 16th of 1986) which has changed
its name to "American Men and Women of Science" (AMWS) ever since. Figure 4.3
shows that the US scientific manpower reached the peak in the late 1960s and started
to decline afterwards. For the period of 1900-1960, USA S&T manpower doubled every
12.5 years (Price, 1963).
For an exponential growth, the average annual growth rate (R) and the doubling time
(T) are calculated as follows:
Given Yo is the value of the initial year, YI is the value of the year which is t years after
the initial year, t = 1,2,3,4... ; Then the relationship of Y I and Yo is:
Y, = Yo(l +R)'
Here R represents the average annual growth rate.
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Therefore
When YT= 2Yo, T is defined as "doubling time".
So T= Log 2
Log(l +R)
For the number of US scientists represented by the entries in the AMS and AMWS, the
calculation according to the above formula gives the following average annual growth
rates and doubling times for different periods between 1906 and 1988.
Period annual growth rate doubling time (years)
1906-1927 5.8% 13
1928-1949 5.9% 13
1950-1973 4.5% 16
1974-1986 decline n/a
The above results have confirmed that the accustomed exponential growth in S&T
manpower in USA has not been able to continue since the 1970s.
Henderson used the membership figures of the Royal Society of Chemistry (RSC) as
an indicator of scientific manpower growth in the UK during 1900 and 1987.(Figure
4.4)
A substantial increase in membership after 1972 is due to the inclusion of the Royal
Society for Analytical Chemistry and the Faraday Society since then. So the growth rate
from 1970 to 1980 is replaced by the rate of 1972-1987. For the UK scientists represented
by the RSC membership, the average annual growth rates for different periods between
1900 and 1987 are summarised as follows:
Period
1900-1910
1910-1920
annual growth rate
Y7r
1.9%
1920-1930 0.3%
1930-1940 decline
1940-1950 8.5%
1950-1960 2.7%
1960-1970 4.4%
1972-1987 0
It is clear that in the 1940s, there was a rapid increase in the UK scientific manpower.
followed by a slow down in the 1950s, then a rise in growth rate was found in the 1960s.
Since 1972, there has been no growth in the number of RSC members.
The UK doubling time for the period 1900-1960 is about 27 years which is much longer
than the USA figure( 12.5 years) for the same period. One of the reasons for that may
be due to the difference in the grades of the two sample groups of scientists. The RSC
members might be more eminent than those in AMS and AMWS- this is only a guess.
The other reason may be the difference in the growth rates of the two countries.
The Cabinet Office published an Annual Review of Government Funded R&D in 1990
which provides the most comprehensive statistic source on UK R&D development in
the 1980s. In 1988-89, the total R&D employment in government was 43,685, of which
14,405 were at degree level. In 1988-89, the UK industrial R&D employment was
183,000 which was 4 times the government R&D manpower.
The government R&D employment (either in terms of civil R&D or total R&D) has
been decreased slightly since 1987, this trend is estimated to be maintained until 1992.
The UK industrial R&D manpower has fluctuated during the 1980s, with 195,000 in
1981, 186,000 in 1983, 173,000 in 1985, 188,000 in 1986, 185,000 in 1987 and 183,000
in 1988. Against the overall trend of stagnation in UK R&D manpower growth, the UK
pharmaceutical industry R&D manpower has kept growing in the 1980s.
It is reported that the UK pharmaceutical industry employment has fallen steadily since
1985 at an average rate of 3.7% per year. However. R&D employment in UK phar-
maceutical industry continues to expand. growing from around 12.300 in 1980 to 16,300
in 1989 with an average rate of 3.5% per year. In relation to the overall labour force of
the industry, these figures corresponding to a rise from 150'(' to 23C7r during 1980-1989.
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Since its modem inception in the early 1900s in China, S&T had grown slowly until P.
R. China establishment in 1949. From 1950 to 1964 there was the first "golden period"
of S&T during which China had produced its second generation of university graduates
of one and half million which is seven times the total number of the first generation
graduates (1911-1949), and built up thousands of S&T research institutions and a
national S&T infrastructure which embraces most of important sciences or subjects in
the world. The Cultural Revolution (1966-1976) had a devastating effect on China's
science and technology. During this period, scientific work and university education
came to a halt, only during 1972-1976 there were some two year courses in universities
for training peasants, workers and soldiers. After that, China began rebuilding slowly,
research capabilities were established again in the government. industry. and university
sectors. Higher education was also restored with first enrolment of first degrees students
in 1977, of master degrees students in 1978 and of doctoral degrees students in 1981
(Infor. China, 1989).
China official statistics on university students enrolment and graduates productivity
enables us to draw lines showing the growth pattern of various degrees graduates
representing the Chinese S&T manpower growth to some extent (Figure 4.5 a&b).
Forcomparison, the growth of UK degrees graduates is shown in Figure 4.5c. In general,
the UK growth pattern is a smooth and stable one with a relatively lower annual growth
rate- 1.96% for first degree and 3.950/0 for higher degree during the recent 13-years
period of 1975-1988.
In contrast, the Chinese growth pattern is an erratic and unstable one with a relatively
higher average annual growth rate - 150/0 during the recent period of 1977-1985 for
first degree graduates; 14.5 % for the master degrees during 1978-1987; 43 % for the
doctoral degrees during 1981-1987.
Today the annual productivity of first degree graduates (over .300,(00) in China is more
than four times the figure in the UK (73,600), the annual productivity of higher degrees
graduates in China (nearly 40,(00) is 1.5 times the UK figure Ｈ Ｒ ｾ Ｎ Ｗ Ｐ Ｐ Ｉ Ｎ
To view the growth in S&T employment in China is very difficult because of no annual
statistics available before 1986. In 1986, China launched its first attempt to develop a
science indicators database by conducting a national survey of S&T capabilities of
government research institutions and by publishing a White Paper describing national
S&T accomplishments and aspirations. Unfortunately, there are only figures for 1949,
1965 and 1985 available in the first national S&T White Paper (1987).
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According to the White Paper of the State S&T Commission (1987), there were 50.000
S&Tstaffin 1949,2.5 million in 1965 and 7.81 million in 1985. From 1949 to llJ65.
the growth is much quicker with a doubling time of 3 years. After the Cultural Rev-
olution, from 1978 to 1985 the growth is restored with an average rate of9.4% per year
or a doubling time of 8 years.
If we compare R&D manpower growth in USA and UK during the period of 1900-1960
with the manpower growth in China during the period of 1949-1985, then the fastest
growth is in China with a doubling time of 3-8 years, the modest growth in USA with
a doubling time of 12 years, the slowest growth in UK with a doubling time of 27 years.
In the 1970s and 1980s, there has been a stagnation in R&D manpower growth in UK
and USA, comparing to a rapid growth in China with an average growth rate of 9A%
per year.
One may argue that to compare with the US scientists cited in the AMS and AMWS
and with the UK scientists belonging to RSC, a more stringent measure is needed in
choosing the same class of Chinese scientists rather than the total S&T manpower in
China. The Academia Sinica (the Chinese Academy of Science) and several other special
Academies, for example the Academy of Medical Sciences, the Academy of Agriculture
etc., are ranked the first class research institutions in China. It is believed that the senior
research scientists (e.g. those scientists at the grade I & II within the Chinese job hier-
archy) in those academies are at the same class as the US scientists in the A\1S and
AMWS and the UK scientists in the RSC.
The number of senior Chinese scientists in the Academia Sinica rose from 200 in 1949
to 3000 in 1985 and 10,000 in 1989 (White Paper. 1990). which means a doubling time
of 7 years and annual growth rate of 10.3% for the 40-year period. Even after choosing
higher grade of Chinese scientists. the growth is still quite faster than the growth in the
USA and much faster than the growth in the UK - with 12.5 year and 27 year of doubling
time respectively (for the period 1900-1960).
4.2 The Growth in Scientific Literature
The Chemical Abstracts (CA) has been used by many bibliometric researchers for
monitoring the world-wide literature growth. because of its comprehensive coverage in
countries and in languages: and of its growth in proportion to the world literature. Figure
4.6 and ｾ Ｎ 7 show the growth of CA literature in the world. as v.ell as in the l'S:\ and
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the UK. It is clear that after the War II, the world literature and the USA literature have
grown very rapidly, followed by the stagnating period since the late 1970s. The LK
literature in CA has grown at a relatively small rate after the War II, and seems also
facing the stagnation since 1980.
Figure 4.8 shows the average annual growth rates for different periods for the four
leading scientific nations- USA, USSR, Japan, and UK. All the countries except Japan
have experienced the decline in literature growth since 1980.
Above all, the average annual growth rates and the doubling times for the four countries
for the period of 1907-1988 are as follows:
World 5.0% 16 years
USA 5.0% 15 years
USSR 7.6% 10 years
Japan 8.2% 9 years
UK 3.6% 20 years
To monitor the growth of literature in China needs a Chinese abstracting or indexing
journal equivalent to CA in terms of comprehensiveness. "China S&T Documentation
Index" (CSTDI) published by ISTIC is regarded as the most comprehensive index journal
in China. The growth of entries in Chinese Pharmaceutical Science in CSTDI for the
period of 1983-1990 has been recorded in Table -l.I: which gives an average annual
growth rate of 9% and doubling time of 8 years.
Table 4.1 Growth in Chinese Pharmaceutical Literature
-Entries in China S&T Documentation Index (1983-1990)
Year 1983 1984 1985 1986 1987 1988 1989 1990
Papers 3102 4342 3822 4630 4765 5156 4551 5212
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In response to the restoration and growth in S&T in China after the Cultural Revolution,
CA has increased the proportion of Chinese literature significantly since 1980 (Figure
4.9). In CA, the Chinese literature has grown at an average annual rate of 21.6% from
1980-1988, or has a doubling time of 4 years; comparing to the decline in literature
growth in most developed countries in the 1980s.
Like CSTDI, CA mainly reflects the S&T literature growth in China, because 98% of
the Chinese entries in CA are in Chinese (Jhaveri, 1989). To measure Chinese literature
in non-Chinese languages especially in English will show China's contribution to the
world literature.
In 1986, there were 4566 Chinese S&T papers published abroad mainly in English which
accounts for 9% of total Chinese S&T journal literature (White Paper, 1988). In 1988,
the figure rose to 6647 which accounts for 12.9% of total Chinese journal literature in
the year (White Paper, 1990). (The above figures include only S&T journal papers
published by Chinese scientists in government institutes.)
Frame et al studied the growth of Chinese S&T literature in the world core journals
covered by Science Citation Index (SCI) from 1973 to 1984. By using the constant set
of 2300 world core S&T journals indexed in SCI since 1973 (less than one tenth of the
total world journals), Frame had monitored the growth from only one Chinese paper in
1973 to 1()()() in 1984. An exponential growth at an average rate of 87.... % per year and
a doubling time of one year (Frame, 1987).
Along this line, ISTIC has monitored the growth for the period of 1983-1989 (Zhang,
1990). Table 4.2 shows the growth of all the Chinese papers (including Chinese authors
as first authors and co-authors) appearing in the 1980s SCI journals. The figures show
that in 1980s, Chinese S&T papers in SCI has kept growing at a high speed of 12%
p.a.. More significantly the number of Chinese papers appearing in foreign journals has
grown even faster at an average annual rate of 17.6%.
Table 4.2 Chinese Papers in SCI (1981-1989)"
Year 1983 1984 1985 1986 1987 1988 1989
No. of papers 3475 3714 3788 4349 4800 5590 6776
papers in ten Chinese 43% 41% 26% 26% 24% 21% 22%
journals in SCI
papers in three thou- 57% 59% 74% 74% 76% 79% 78%
sands SCI non- Chi-
nese journals
* In 1980s, SCI had increased its coverage of world core journals from two thousands
in the 1970s to some what three thousands. Among the three thousands journals. there
are apparently ten Chinese published English journals.
4.3 The Growth of Expenditure on Science
It is noticed that the significant growth in R&D expenditure as a fraction of the total
GDP since the War II has commonly occurred in all the technologically advanced
countries - USA, UK, USSR, France etc. For example. the figure in the USA rose from
0.3% GDP in 1940 to over 3% in 1964. So, of course, has the total amount of annual
expenditure. Also taking the USA example, the total R&D expenditure rose from $0.5
billion in 1938 to $12 billion in 1962 (at constant price, using 1940s as a baseline).
(Meadows, 1974)
In terms of R&D expenditure as a fraction of the total GDP, the USA reached the peak
in 1964 at about 3.15 % and then declined steadily until 1978 at 2.4 0/0. The UK reached
its peak in 1966 at about 2.4% then declined until 1975 at 2.1 % (Fig. 4.10).
Because of the growth of GDP in the two countries over the period of 1966-1975, the
R&D expenditure still increased in real term of money. For example, the UK R&D
expenditure in 1966 was about £5.73 billion which rose to £6.20 billion in 197 ｾ at
constant price (using 1985 as a baseline). (International Monetary Found, 19H9) That
means an average annual growth rate of 0.9% during 1966 and 1975.
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Since 1976, the UK has gradually speeded up the growth rate of R&D expenditure. The
USA followed suit since 1979. For example in the UK, the R&D as a fraction of GDP
rose from the bottom 2.1 % in 1975 to 2.2% in 1978 (Fig. 4.10); then rose to 2.3% in
1981 which has been kept until 1987. The growth in the UK R&D expenditure over the
period of 1981-1987 is summarised in Table 4.3:
Table 4.3 R&D Expenditure in the UK (Britain 1980-1990)
Year R&D (£) million R&D (£) million at 1985 price ClcGDP
1981 5800 7334 2.3
1983 6700 8719 2.6
1985 7900 7900 2.2
1986 8800 8423 2.3
1987 9500 8785 2.3
The UK R&D expenditure has grown at an average annual rate of 2.9% from 1975 to
1987. (at constant price, using 1985 as a baseline)
About 50% of UK R&D expenditure was provided by industry, 39% by the government
(Britain 1990). The British Pharmaceutical Industry is a leading industry in the country
and in the world with the largest R&D investment. In 1989, its R&D expenditure was
over £800 million, amounting to more than 10% of all manufacturing industry R&D
spending in UK (Britain 1991). The R&D expenditure has increased by 61.7% during
the 5-year period of 1982-1987 in real term; comparing to the increase of 36% in the
whole UK industry for the same period (Annual Review on Government Founded R&D
1990). That also means an average annual growth rate of 10% in UK pharmaceutical
R&D investment (Lumley, 1989).
According to the White Paper of the State Science and Technology Commission in 1986,
R&D expenditure in China has been grown substantially since 19-19. The total amount
was ¥ 1437 million during the period of first five year plan (1953-1957), reached ¥33278
million during the period of sixth five year plan (1979-1983), increasing by 23 times.
Or in real term it increased by 18 times (using 1985 as a baseline). Table ｾ ａ shows the
growth in R&D expenditure in China (1953-1983).
From 1953 to 1983, China has managed to maintain its R&D expenditure as a certain
proportion of the National Income (N!) at over 1.61 Cir,except fort he period of 1966-1970
(at 1.36%). China has had a golden period for science and technology during 1977- 19X-l.
Table ｾ Ｎ ｓ and Table 4.6 show the growth in R&D expenditure in China (1977 -1988).
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Table 4.4 R&D Expenditure in China (1953-1983)- (White Paper. 1986 & International
Monetary Found. 1989)
Period R&D (¥) in million N( (¥) in million % xr:
1953-1957 1437
1958-1962 9742
1963-1965 7005 335.3 1.97
1966-1970 10.932 803.1 1.36
1971-1975 18.333 1138.2 1.61
1976-1980 26.050 1511.9 1.72
1979-1983 33,278 1996.9 1.67
* not correcting for inflation
** figures only include R&D expenditure in government institutes.
Table 4.5 R&D Expenditure in China (1977-1988)- (White Paper. 1987-1990 & Interna-
tional Monetary Found, 1989)
year R&D (¥) million growth rate Nf (¥) billion %N"·
per year
1977 4148 264.4 1.57
1978 5289 27.5% 301.0 1.76
1979 6229 17.8% 335.0 1.86
1980 6459 3.7% 368.8 1.75
1981 6158 -5% 394.0 1.56
1982 6529 6% 426.1 1.53
1983 7903 21% 473.0 1.67
1984 9501 20% 565.0 1.68
1985 n/a
1986 11150 788.7 1.41
1987 10847 -3% 932.1 1.17
1988 13324 22.8% 1254 1.06
* not correcting for inflation
** figures only include R&D expenditure in government institutes
Table 4.6 The Growth Rate of R&D Expenditure and the Inflation Rate in China for
1978-1988
Year 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988
growth rate % 27.5 17.8 3.7 -5 6 21 20 -3 22.8
inflation rate 0/0 0.7 1.9 7.5 2.5 2 ') 2.7 11.9 7 8.8 27
*(Hartland-Thunberg. 1990)
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The average growth rate of Chinese R&D expenditure for the period of 1977-Il)X"+ is
13% per year. After correcting for inflation rate (average rate for the same period is
2.7% per year (International Monetary Found, 1989 & Hartland-Thunberg, 1990»), the
real growth rate for Chinese S&T expenditure is 10.3% per year. It is quite rapid,
comparing to the UK rate of 2.9% during 1975-1987( in real term, using 1985 as a
baseline).
However, since 1985, the growth of Chinese S&T expenditure has been greatly held
back. In 1987, the annual reduce of S&T expenditure was 3%. After correcting for
inflation, the annual decrease was 11.8%. In 1988, the annual growth was 22.8%. After
correcting for inflation, it decreased by 4.2%.
From Table 4.5, it can also be found that since 1984, the ratio of S&T expenditure to
National Income (NI) has declined steadily from 1.68% in 1984 to 1.06% in 1988. On
the whole, Chinese S&T finance situation is under severe constraints now.
4.4 Impacts on the Chinese Scientific Communication
Science and its communication are always inextricably bound together, so that the
production and the dissemination of the results of research go hand in hand. The rapid
growth of science for the last three centuries has on one hand greatly accelerated the
development and enhancement of the complex of information channels and sources,
and on the other hand has been changing scientists' communication behaviour.
4.4.1 Impact on Formal Scientific Communication
Today scientific communication formally go through learned journals, books,
reports, and patents etc..
Currently one of major impacts of scientific growth on scientific communication in
the developed countries comes from the fast increasing amount of scientific literature
in the developing countries and the difficulty in accessing them because of the
language barrier (1haveri, 1989). Although certain proportion of pharmaceutical
scientists in Britain are aware of the value of foreign information and the language
barrier, what they have noticed is the existence of S&T information in German.
French. Japanese (Thorp, 1987). There is little doubt that the scientists in the
developed countries like UK have difficulty in getting aware of and access to the
Chinese S&T information, since of which only ..+% are in English, only 15% are
covered by CA (See Chapters] and 6).
10]
The world-wide exponential growth of science mainly has impacts on scientific
communication in China.
Firstly, like many developing countries China has very limited hard currency to
purchase foreign S&T journals. Today there are as many as 850,000 S&T papers per
year adding into the world literature pool (Price, 1986 & Martyn, 1979). The estimate
of the number of current journals in the world, based on the holdings and the titles
on order at National Lending Library in UK in December 1965, was 26,000 (Martyn,
1979). This number has risen to 55,000 by 1990 (BLDSC Figures, 1989-1990).
Facing such an "information explosion", the S&T information system in China has
some problems in collecting and disseminating the world S&T literature effectively
to its 7.8 million S&T manpower. When China opened the door to the world in the
late 1970s, it found itself facing a very expensive world information market and the
ever increasing prices of the world S&T literature.
From 1974 to 1979, the average journal price rose by 120% in UK (Royal Society,
1981). From 1980 to 1990, the world scientific journal price rose by 245% (Enright,
1990). The combination of the proliferation of journals and the inflation of journal
price world-wide has greatly limited the S&T information reserve in China.
Secondly, because of the last four decades exponential growth in S&T manpower,
there are not enough S&T journals for scientists to publish papers in China. Unlike
in the western countries, there are no commercial S&T journal publishers in China,
because of very low or no profit in S&T journal publishing. About 30% of journals
are published by universities, 24.5% by learned societies, 35.6% by government
departments, and 6.8% by Chinese Academy of Science (White Paper, 1987). Partly
due to the above reason, there are not enough journals for millions of Chinese
scientific and technological workers to publish papers. There are only some 3000
S&T journals in China against 7.8 million S&T workers; by comparison there are
some 4,000 scientific journals in UK against 0.2 million S&T workers (see Chapter
6).
Additionally, mainly owing to language barrier, China has had difficulty in dis-
seminating Chinese S&T information into the world through its very small number
of English language journals (less than 70 titles, according to lnfor China, 1989).
Furthermore, the existing Chinese national secondary publication system is not
comprehensive to cover the ever increasing Chinese S&T literature. All these
problems will be further discussed in Chapter 8.
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4.4.2 The Changing Informal Communication Pattern
Studies of UK and USA scientific communication pattern suggest that urgent dis-
semination usually pass through informal or less formal channels, such as "invisible
colleges" and conferences etc.. (Garvey, 1972 & Royal Society, 1981).
The discussion about invisible colleges in science or informal scientific communi-
cation has been lasting for thirty years. Derek Price (1963) has estimated the number
of people with whom a good scientist can exchange reprints. preprints and
professional correspondence, and with whom he can perhaps collaborate at a rea-
sonable and comprehensive level. His guess is that there are a few hundred colleagues
for every worker. In his book" Little Science, Big Science", Price described:
"The first noteworthy phenomenon of human engineering is that new groups of
scientists emerge, groups composedofour maximaIIOOco/leagues./n the beginning,
when no more than this number existed in a country, [hey could compose themselves
as the RoyaL Society or the American Philosophical Society. At a later stage, they
couLd split into specialist societies of this size. Now, even the smallest branches of
subject matter tend to exceed such membership, and the major groups contain tens
and hundreds of thousands. In a group ofsuch size, by our previous analysis, there
are likely to be a few groups ofmagnitude 100, each containing a set of interacting
Leaders".
Price suggested "such groups constitute an invisible college".
Such an invisible college can effectively solve a communication crisis by reducing
a large group to a small select one of the maximum size that can be handled by
interpersonal relationships - exchange of preprints and reprints, personal contacts
and conferences. In the West. it is said that the above "invisible college" has a history
of three hundred years and has changed little ever since.
Garvey has described S&T communication through conferences as follows:
"As the process of scientific communication has grown longer and more complicated
in recent years. the national meeting has developed a distinct and increasingly
important function in the overall communication process. \owadays the national
meeting integrates into this total process in such a way as to usually constitute both
the first major occasion for early dissemination of scientific work and the last major
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informal medium before such work becomes temporarily obscured from the public
during the relatively long period between first submission of manuscripts and their
eventual journal publication.
"Much of the scientific information exchange behaviour is intrinsically exploratory-
i.e. few participants attend meetings with a plan of what information they will seek
there or of how they will go about assimilating information there.
"Especially younger scientists rely heavily on the national meeting to obtain new
information from the informal networks. More experienced scientists, because of
their prominence in the field, find this new information readily accessible to them"
(Garvey, 1972).
Price and Garvey had described informal communication based on the USA situation.
We may assume that the description also applies to UK since the two countries both
belong to the most advanced scientific nations in the world. both have a common
cultural origin and use the same language.
Whether there is a similar informal communication pattern existing in China has not
been much studied. Since many users studies suggest that 907c of Chinese scientists
greatly rely on foreign literature and most senior Chinese scientists mainly use foreign
S&T information in their research work (please see the next chapter); we feel that it
is more important to ask whether and to what extent Chinese scientists take part in
informal communication network internationally.
Chinese scientists face two kinds of information communication circuits - native
language communication circuit and foreign language communication circuit. A
scientist is spontaneously at his native language communication circuit. However,
he might or might not be involved in foreign language communication circuits,
depending on current communication relationship between China and other countries
and on his language ability as well.
In 1890, first big group of 120 Chinese students were sent abroad to study modem
S&T by the last feudal empire "Qing". Since then until 1949. there had been a certain
number of Chinese scholars being educated abroad. About one thousand of them
return back to China in the early 1950s. They constitute the "first generation" of
overseas Chinese scholars. Today some of them at their seventies are still actively
involved in Chinese S&T activities and higher degrees education. (Chinese Scholar
Abroad. No. 1 1991)
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Since 1949 along with the rapid growth in S&T nationwide, China has experienced
an uneven progress in international scientific communication- from the 1950s'
scientific communication mainly with Soviet Union and some Eastern European
countries, followed by the 1960s' and 1970s' isolation from the outside world, to
today's proliferation ofinternational communication acti vities with most of the world
developed countries. From 1950 to 1965, China has sent some 10,000 university
students and postgraduate students to East Europe, among them 80% went to Soviet
Union. About 95% of the students returned back to China after the education abroad.
From 1978 to 1990, some 40,000 postgraduate students and visiting scholars have
returned to China after their education abroad. By 1990, there are other 60,000
students and scholars studying abroad and being sponsored by the government;
while the number of mainland students and scholars abroad in 1985 was 30,000
(Chinese Scholars Abroad, No.1, 1991 & Howe, 1987). The number of overseas
students and scholars from mainland China has doubled during five years.
Here we use the example of Chinese Academy of Sciences to demonstrate the
progress in international scientific communication.
From 1979 to 1988, the total number of exchange scholars in Academia Sinica was
36,000- half are Chinese outflowing and half are foreigners flowing into China. A
growth from 1860 in 1979, to 2520 in 1984, and to 6800 in 1988. Apart from the
above exchanges for short time communication, there have been 3,000 senior
research scientists or engineers from Academia Sinica working in academic
institutions in many advanced countries for longer term (six months or more). These
three thousand people account for one third of total senior S&T staff with first or
second job grade (see §3.3) in Academia Sinica.
From 1978 to 1988 Academia Sinica alone has sent out 6,300 visiting scholars and
postgraduate students to study abroad which almost totalled the national number of
overseas Chinese students sent out by the government for the previous thirty years
(1949-1977) (Bureau of International Cooperation in Academia Sinica, 1989).
The number of Chinese scientists attending international meetings and conferences
has also increased greatly. In Index of Scientific and Technological Proceedings
(lSTP) , Chinese scientists' papers has increased from 918 in 1985 to 2139 in 1989.
The figure doubled in five year time. The figures from 1985-1989 are: 918, 1617.
2278,3214,2139 (Zhang, 1990). For Academia Sinica alone, the number of Chinese
scientists attending international meetings abroad rose from 2XO in 1979. to 580 in
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1984, to 1()()() in 1988. Furthermore, for the past ten years, Academia Sinica has held
around one hundred international meetings in China. In 1987 alone, Academia Sinica
held 30 such meetings (Bureau of International Cooperation in Academia Sinica.
1989).
Nowadays, the world scientific community started to see more and more Chinese
scientists joining S&T performance and playing more and more important roles in
the world stage. Twenty scientists from Academia Sinica have been elected as major
leaders in international academic organizations. One hundred scientists from
Academia Sinica have been invited as visiting professors or awarded honour S&T
titles by academic institutions in other countries (Bureau ofIntemational Cooperation
in Academia Sinica, 1989).
There have been two major trends in the growth of science in China since 1978 - the
high tide of scholars and students going abroad for education: and the massive inflow
of foreign scientists both for communication and lecturing.
All the above facts and figures have shown that today Chinese scientists have taken
part in informal communication world-wide much more than ever before; though
their impact on the world is still quite small (see Chapter 6), though few of them are
regarded as leaders in the world "invisible colleges".
Bearing in mind that there have already been 40,000 scholars finished their education
abroad and returned back to China for the last ten years, and that there are apparently
60,000 studying in the developed countries, within years, they will enter the front
of the world S&T. This new generation of Chinese scientists will greatly change
scientific communication pattern in the world byincreasing the proportion ofChinese
papers in the world journals and by adding more Chinese scientists into the world
"invisible colleges" and the world scientific conferences.
4.5 Concluding Notes
The S&T manpower in USA has grown at an average rate of 6% p.a. with a doubling
time of 12 years for 1900-1960. Since the late 1960s stagnation has been reached and
maintained until now. The S&T manpower in UK has grown at a relatively low speed
for 1900-1960 with a doubling time of 27 years. Also stagnation has been found in the
early 1970s and kept until now.
Although modern S&T was introduced into China late in the first half of the (Lntury.
its boom had not started until 1950. From 1949 to 1989. S&T manpower in China has
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been growing at an average rate of some 10% p.a. with a doubling time of 7 years.
As a result of the growth in S&T manpower, by 1987 China has an annual productivity
of 300,000 first degree graduates, which is 4 times the UK figure: of 40,000 higher
degrees graduates which is 1.5 times the UK figure. By 1985, there are 7.8 million S&T
manpower in China with degree holders or equivalents accounting for 40% of total. In
1988, there is a S&T manpower of 227,000 in UK with degree holders and equivalents
accounting for one third.
In contrast to the overall decline trend or stagnation in R&D employment in the 1980s
in the UK, the British pharmaceutical industry has maintained a substantial growth in
R&D employment at an average rate of 3.5% p.a. and has risen the R&D proportion in
its whole labour force from 15% in 1980 to 23% in 1989.
Referring to CA, after the World War II, the US literature has grown rapidly followed
by a stagnation since the late 1970s. The doubling time for US literature is 15 years for
1907-1988. After the World War II, the UK literature has grown at a relatively low
speed, and seemed also facing stagnation since 1980. The doubling time for UK literature
is 20 years for 1907-1988.
After the Cultural Revolution (1966-1976), S&T literature in China has experienced a
rapid growth. Pharmaceutical literature as indexed in CSTDI, for example, has grown
at an average rate of 9% p.a. or a double time of 7 years for the period of 1983-1990.
Perhaps more significant growth in Chinese S&T literature in the 1980s have been
recorded in CA, SCI and other international secondary publications. In CA, the Chinese
literature has grown at an average rate of 21.6% p.a. for 1980-1988. That has risen the
Chinese proportion of the world literature from 0.7% in 1980 to 3.5% in 1988; comparing
to the reduce trend in UK ratio from 5.9% in 1980 to 5.6% in 1988.
Using SCI to monitor Chinese literature growth in the three thousand of the world core
journals, a rapid growth was found from one Chinese paper in 1973 to 1000 papers in
1984 with an average growth rate of 88% p.a. Following that rapid growth. from 1983
to 1989, Chinese literature in the world core journals continues to grow with an average
rate of 12% p.a.
It is noticed that the significant growth in R&D expenditure as a fraction of GOP since
the World War II has commonly occurred in all developed countries from less than 1%
before the war to some 2-3'7(' by the mid 1960s. After this rapid increase in R&D
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expenditure, there has been a stagnation in the growth of R&D as proportion of GOP
in UK and other developed countries. In UK the R&D as the proportion of GOP has
been fluctuating between 2.1% and 2.3% since the mid 1960s.
In real terms, the UK R&D expenditure has grown at an average rate of 2.9% p.a. from
1975 to 1987. The UK pharmaceutical industry is a leading industry with the most heavy
R&D investment in the UK and in the world. The UK pharmaceutical industry R&D
expenditure has increased by 61.7% for 1982-1987 while the increase in the whole UK
industry for the same period is 36%. The UK pharmaceutical industry R&D expenditure
has grown at an average rate of 10% p.a. in the 1980s, comparing to 2.9% p.a. in the
whole UK R&D expenditure in the 1980s.
From 1953 to 1983, the R&D expenditure in China has increased by 18 times in real
term. During the period, China has maintained its R&D as a proportion of National
Income at the level of 1.61%.
From 1977 to 1984, a growth in R&D in China has been made with an average rate of
10.3% p.a. in real term; comparing to 2.9% p.a. in UK for 1975-1987.
However, since 1985, a stagnation in R&D expenditure has been found in China. In
1987 and 1988, the R&D expenditure has fallen by 11.8% and 4.2% respectively in real
term.
Moreover, since 1984, the R&D ratio as proportion of National Income (NI) in China
has declined steadily from 1.68% in 1984 to 1.06% in 1988.
It is noted that UK pharmaceutical industry has maintained a steady growth in R&D
manpower and expenditure against the overall stagnation in UK in the 1980s and in
China since 1985. The implications include:
1. The growth of science (or R&D) depends on the economic capacity of a country or
an industry.
2. The worldwide scientific growth has a positive impact on Chinese scientific com-
munication by increasing the proportion of Chinese papers in the world, and hy adding
more Chinese scientists into the world scientific communication.
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3. The worldwide scientific growth has a negative impact on Chinese scientific com-
munication through costs and information inflation, by increasing the dependence of
China on foreign S&T information which is greatly obstructed by language barriers and
foreign currency shortages.
4. In China, the growth of scientific manpower should be parallelled by the growth in
the Chinese publishing industry and secondary information services.
III
Chapter 5 Scientists' Information Xeeds Searching
and Accessing Ability
5.1 Introduction
Information user satisfaction is subjective and hard to define, but the attitudes of the
users to an information system is always of primary importance in "measuring" the
performance of scientific information flow in a country. This information users' study
will provide some evidences for planning the reform of the Chinese S&T information
flow in Chapter 9.
Results from six surveys are analysed to compare the situation in the UK and China.
Although the six surveys were conducted in different period of the 1980s and were using
different sampling methods, they all looked at scientists' information needs, searching
and acquiring habits with the following common features:
1. Good coverage of the area; of the six surveys, two are British nationwide surveys and
one is the Chinese national survey;
2. Good coverage of the pharmaceutical subject; four of the six surveys are with particular
concern on pharmaceutical sciences;
3. Representative of various kinds of scientists; the British surveys distinguish between
academic, industrial and government scientists whereas the Chinese surveys focus on
scientists in academic institutes where most of high standard R&D take place; because
65% of R&D is performed in industry in the UK whereas 709r of R&D is in academic
institutions in China (see Chapter 3).
A summary of the six surveys is given as follows:
Survey 1. A Study of the Scientific Information System in the UK (nationwide survey)
conducted by - Royal Society
period covered - 19X 1
subjects - scientists from a range of subjects and types of employers
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responses - 592 (rate: 63%)
sampling method - An attitude questionnaire was sent to four groups of scientists:
biological scientists in research institutes and university departments in Aberdeen;
physical scientists in the University of Oxford; physical scientists at the National
Physical Laboratory; and biologists, biochemists and chemists at ICI pharmaceutical
division.
Comment - There is very good reason to believe that the survey reflected reasonably
representative of pure scientists' view in the early 1980s in the UK. The survey is
extremely valuable in that it included a case survey on pharmaceutical scientists at ICI
pharmaceutical division. In the following study, only data on Oxford chemists and ICI
chemists will be used.
Survey 2. Literature Searching Habits and Attitudes of Research Scientists
(nationwide survey)
conducted by - John Martyn, Aslib
period covered - 1986
subject - academic, industrial and government scientists in the UK.
responses - 266 (rate: 35%)
sampling method - 450 academic scientists were drawn from the "Research in British
Universities. Polytechnics and Colleges", and 183 responded (rate: 41%). 100 gov-
ernment scientists and 200 industrial scientists were selected from SCI 1985 edition, 30
responses from government (rate: 30%) and 53 from industry (rate: 26.5%).
comment - This is a national survey of scientists' searching habits and attitudes. Since
the early 1980s, there have been many changes in the information sector, including the
popularization of online searching, large scale automation of library and information
service. e-mail. viewdata etc .. the survey of 1986 with supplement of the other latest
ones (Howorth, 1988; Byway, 1988) may reflect the changes in searching behaviour
along with the changes in the information environment during 1980s.
1 ｬＮｾ
Survey 3. The Foreign Language Barrier: a study among pharmaceutical research
workers
conducted by - R G Thorp et al.
Period covered - 1987
subjects - all research scientists requiring information in Pfizer pharmaceutical company
(UK)
responses - 58 (rate: 94%)
sampling method - A questionnaire was sent out to all scientists requesting literature
searches or similar services during a week period at Pfizer Central Research (UK). A
total of 62 forms was handed out, of which 58 were returned. This represents about a
quarter of the research scientists at Pfizer.
Comment - It was noticed in the Royal Society survey (1981) that the greater attention
to foreign language information by chemists at ICI than by other groups of scientists.
The latest survey gives a more clear picture of pharmaceutical scientists' performance
in foreign language information communication.
Survey 4. A National Survey of Scientists' Information Needs and Uses in China
conducted by - ISTIC
period covered - 1981
subjects - scientists from a wide range of subjects in China
responses - 1840 (rate: 23%)
sampling method - 8,000 questionnaire forms were sent out to scientists at .t.t() academic
institutions in ｾＨＩ prov inces of China. 1840 returned (rate: 23%).
comment - It is the most comprehensive survey which has ever been conducted in China.
However it has the weakness of not distinguishing between subject areas.
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Survey 5. A Survey of Medical and Pharmaceutical Scientists' Information Needs and
Usage in the Tianjin City
conducted by - Tianjin Medical Information Institute
period covered - 1988
subjects - medical and pharmaceutical scientists in the Tianjin City
responses - 182 (rate: 61%)
sampling method - 300 forms were sent out to scientists at 29 medical and pharmaceutical
research institutes in the Tianjin City. 182 were returned (rate: 61%).
comment - The Tianjin City is one of the three large municipalities in China and is also
one of the most important pharmaceutical R&D bases in the country. It is felt that where
all these scientists agree, we may regard their view as reasonably representative of
scientists in pharmaceutical sciences in big cities in China.
Survey 6. A Survey of Pharmaceutical Scientists' Information Needs and Usage in
Beijing and Shanghai"
conducted by - B. Chen
period covered - 1989
subjects - pharmaceutical scientists in Beijing and Shanghai
responses - 56 (rate: 56%)
sampling method - 100 forms were distributed to scientists who were searching for
information at four pharmaceutical research institute libraries (two in Beijing and two
in Shanghai) during one week period. 56 returned (rate: 56%).
9 A sample of the questionnaire used in this survey is in Appendix 5.3.
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comment - Together with the survey of the Tianjin City, this latest survey try to draw
a picture ofinfonnation needs and usage by pharmaceutical scientists in the three biggest
cities (municipalities) in China. Because of the small sample size of this survey, no
claim is made for statistical significance and the findings can only be indicative.
Questionnaire survey was not widely used in China until the late 1980s. Chinese
scientists tend to give low response in surveys. Being aware of that, the author distributed
all forms in person in order to get a better response.
5.2 Information Needs and Need Satisfaction
From an information scien tist' s point ofview, scientific research is Ii ke a spiral procedure
of stimulating information needs, searching for information, older information needs
being satisfied and new information needs being generated, then a new information
searching cycle starting, and so on and so forth. This spiral procedure is not repeating
at the same level of information needs but rising from lower level to higher level all the
time. In other words, as the spiral procedure continues, scientist's information needs
change from general status to more specific status, from am biguous to clearer. Gradually,
the more cycles a scientist processes, the higher level of information needs get satisfied,
the nearer he is approaching the goal of his research work.
As a scientist is seeking to maintain his work at the cutting edge of science, he constantly
seeks new, viable information- namely, information which he needs to place his work
in context with similar work recently completed- so his own work will not be passe' by
the time it is completed.
Generally, scientific information needs fall essentially into three categories:
1. Current awareness of ongoing R&D projects,
2. Retrospective searching for accomplished projects,
3. Day to day data or factual information consulting.
During the early stages of any research, the scientist especially needs information to aid
in perception of his problem and in formulation of procedures appropriate to his inquiry.
Here both current awareness and retrospective searching are needed.
In the intennediate stages, his information needs become more specific, for example,
details of techniques and methods, day to day information consulting are needed.
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In the final stages his needs shift to the general body of knowledge as he seeks to fully
interpret his data and integrate his findings into the current state of knowledge.
Above all, the spiral procedure of information need/satisfaction is an essential part of
scientific research. Whether or not such an information spiral procedure can be built up
properly in a scientific research will determine the success and the quality of the work.
5.3 Scientists' Information Searching and Accessing Ability
5.3.1 How do scientists keep aware of current progress in their
fields
Before initiating a R&D project, research scientists need to know what is happening
in their relevant fields or specialities, where are things happening, and conducted by
whom?
Throughout all stages of R&D, they also constantly seek new, viable information,
so their work will be in proper context with other current work in the fields.
To avoid unwarranted duplication of research effort is another reason for scientists
to keep aware of current progress. However to keep aware ofcurrent progress is very
difficult for ordinary scientists especially those in the developing countries.
A scientist discusses his work rarely in the first one or two years. After he has reached
the stage at which he feels prepared to give acomplete report, he begins disseminating
his findings within his immediate environment and to a very small group of outside
workers normally those prominent scientists in the fields. So far, for all practical
purposes, information about the early stages of a R&D work is inaccessible to the
public scientific community. Being aware of current progress in the earlier stages is
a privilege of very few prominent scientists or leaders in "invisible colleges". For
ordinary scientists, there are three channels through which they could get the current
progress information.
The first channel is current research information system.
"The current research information is characterized as a standardized set ofscieniific,
technical and administrative data which describe research projects about to be
initiated, actually in progress. or recently completed.
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'The general survey conducted by UNESCO and SSIE showed that there had been
an increasing interest in the field of transfer of information on ongoing research.
"By 1982, there were already 230 planned, pilot and operational systems in 67
countries in the world" (Lei, 1988).
The most known systems includes SSIE (1949-) in USA which annually registers
150,000 projects by 1300 governmental or non-governmental organizations; and
Current Research in Britain (1985- ) which is the national register of current research
being carried out in universities and other institutions in UK.
This sort of current information systems, however, has the difficulty in control of
non-governmental information source especially industrial source. Because of the
need of intellectual property protection, in pharmaceutical R&D, the first chance for
scientists to publish their findings is after new chemical compounds having been
protected by paten t.
Unfortunately, so far, this sort of information system is not available
in China (Lei, 1988 & Academia Sinica, 1991).
The second channel for current progress information is via conferences, where the
participants exchange information personally. How do British scientists view con-
ferences as a source of current progress information? Table 5.1 is from the Royal
Society Survey in 1981.
Table 5.1 Conferences as An Information Source
Royal Society survey in 1981. responses: 149 from Oxford (rate: 6Y7c)
and 80 from leI (rate: 52%)
Oxford Oxford Oxford ICI ICI
overall physics chemistry overall chemistry
needs more effort to extend 13% 8% 17% 23% 13%
this resource
present effort in organi- 53% 51% 52% 59% 60lk·
zing them is about right
too many conferences have 34% 41%
-'Ilk 1RC1r 17 Cy
been around
11H
There is a slight difference in view on conferences between industrial scientists and
academic scientists in UK. The survey showed that industrial scientists at ICI
favoured greater expenditure and effort on conferences than favoured less, although
academic scientists at Oxford favoured the status of conferences at that time.
One plausible reason may be that the heavy competition in industrial research
prevents both informal communication and current research information systems
from covering industrial R&D activities at early stages. Therefore conferences
become more important to industrial scientists for the purpose of current awareness.
In Chen's survey on Chinese pharmaceutical scientists information needs and sat-
isfaction in 1989, no respondents regard conference as an effective channel for current
awareness, because there are not enough conferences for them. It was reported in
1987, there were 30 regional and national pharmaceutical conferences in China with
about 4,000 attendants (China Pharmaceutical Year Book 1987). Given there are
35,000 S&T workers in the field, on average each Chinese scientist could attend
such a conference every 7 year; which is much out of the line in comparison with
the western figure of 1-2 conference per scientist per year (Meadows, 1974).
Because of the great importance of foreign S&T information to Chinese R&D,
international conference is one of the most valuable current information source for
Chinese scientists.
However, only very small fraction of Chinese scientists have the chance to attend
international conference. In 1987, China held four international pharmaceutical
meetings or conferences with 370 foreign attendants and 400 Chinese attendants,
accounting for 1% of the 35,000 Chinese S&Tworkers in the field. In the same year,
thirty Chinese scientists attended six international pharmaceutical meetings or
conferences abroad. They account for only 0.1 % of the 35,000 S&T workers in the
field (China Pharmaceutical Yearbook 1987).
The third channel for current progress information is via primary and secondary
literature.
The rank of information searching activities for current awareness purpose by the
two countries' scientists are shown in Table 5.2 and 5.3. In Chen' s questionnaire.
two activities were omitted: using SOl, reading patent specifications. The reasons
for doing that arc as follows.
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-Table 5.2 Mean Rank of Activities in Searching Current Information
by British Scientists
Royal Society survey in 1981, responses;.l12. from Oxford ｾ 63%),
illld.8Q from llJ (rate:52%)
Oxford Oxford Oxford lei leI
overall physics chemistry overall chemistry
l.scanning journals 1.35 1.35 1.17 1.86 1.76
2.scanning "Current Contents" 3.24 3.33 3.28 3 4.90
3.colleagues recommending 2.23 2.02 2.62 3.72 4.21
papers
4.scanning abstract journals 3.01 3.17 3.16 3.64 3.47
5.reading reviews 3.34 3.18 2.92 4.34 4.24
6.SDI 4.64 5.08 4.42 1.89 2.26
7.reading patent specifications - - · 5.91 5.04
8.using NEW DRUG - - · 3.95 3.19
BULLETIN*
9.using PATENTS BULLE- - - · 4.56 2.58
TIN*
IO.using MIDAS* - - · 5.21 5.41
* ICI inhouse indexes
Table 5.3 Activities of Searching Current Information by Chinese Scientists
Chen's survey in 1989. responses; ｾ from phannaceutical scientists in ｂ･ｩｪｩｮｾ and
Shanghai ｾ 56%),
Activities rank order no of persons
Scanning journals 1 46
Scanning abstract journals 2 33
reading reviews 3 31
using inhouse bulletin 4 16
scanning "Current Contents" 5 4
colleagues recommending papers 6 0
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1. Selective Dissemination of Information (SOl) is still a very rarely used service in
China. It was not available in Chinese medical and phannaceutical fields until 1987
when the China Medlars retrieval centre was set up in Beijing. Currently, the national
centre provides just over 500 SOl services whereas there are about 7000 R&D
projects in the field in China each year (Wu, 1989 & White Paper, 1991).
2. The Chinese survey does not distinguish scientists by subjects such as chemistry,
physics etc.. Because patent information is generally regarded as chemistry related
in pharmaceutical sciences, therefore the Chinese survey on patent information
would not be comparable with the Royal Society survey which emphasised chemists'
patent information needs and uses.
From Table 5.2 and Table 5.3 we could get the following results.
Both British and Chinese scientists mainly rely on the traditional mean of scanning
journals - it is the first rank in the UK survey and Chinese survey. The effectiveness
of such a searching activity would greatly depend on the journal collection in
scientists' institution library and local S&T libraries.
SOl was rated as the second most frequently used activity by chemists at ICI; whereas,
Oxford chemists gave it the 6th rank. As one might expect, because of the high cost
of SOl in terms of manpower and/or technology, only industrial scientists can afford
this service.
The usage of SDI by academic scientists has been improved little since then. In
Martyn's survey in 1986, the use of SOl by British academic scientists still remained
very low rank- the 11th of the total twelve searching ways (Table 5.8).
British academic and industry scientists rank scanning abstract journal at a similar
level - the 4th by the former and the 5th by the latter.
It is clear that academic chemical scientists at Oxford rely on colleagues recom-
mendation and reviews for current information more than industrial scientists at ICI.
ICI chemists rely on SOL inhouse patent bulletins more than academic scientists.
This reflects that there are better information services in pharmaceutical industry
than in academic institutions, whereas UK academic scientists are still in favour of
traditional ways such as personal contacts, reviews for current awareness which are
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greatly self supported. The nature of heavy market competition means UK phar-
maceutical companies could not afford missing of information and delay in getting
information,
Chinese scientists ranked abstracting journals at the 2nd, reviews at the 3rd, inhouse
bulletin at the 4th and Current Contents at the 5th. There are no report on colleagues
recommending paper by Chinese scientists.
UK academic scientists ranked colleague recommending paper at Znd, reviews at
the 3rd, abstracting journal at the 4th and Current Contents at 5th.
UK industrial scientists ranked SDI at the 2nd, inhouse bulletins at the 3rd & 4th,
abstracting journal at the 5th, colleagues recommending papers at 6th and reviews
at the 7th.
Both Chinese scientists and British academic scientists rank abstracting journal and
review as frequently used methods. But British academic scientists show much more
use of colleagues recommending papers than Chinese scientists. British academic
scientists rank review higher than abstracting journal whereas Chinese give the
opposite rank.
Comparing to British industrial scientists, Chinese scientists rank abstracting journal
and reviews relatively high in their index. British industrial scientists rank SOl,
inhouse bulletins and colleagues recommending papers relatively high in their index.
In China, each big research institute usually has a library and an information
department. The latter is responsible for compiling inhouse information bulletins.
This is similar to the situation in the UK pharmaceutical industry. So ICI chemists
rank inhouse bulletins at the 3rd of total 10 searching activities whereas Chinese
scientists also reponed certain use of such information service for current awareness.
5.3.2 How do scientists trace accomplished work in a particular
area
In tracing what has been accomplished already in a particular area. how do scientists
proceed?
Table 5...1 and 5.5 show the retrospective searching activities favoured by British
and Chinese scientists respectively.
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Table 5.4 Mean Rank of Activities in Retrospective Search by British Scientists
Royal Society survey in .l.2.8.L responses: ill.from Oxford ｾ 63%),
and.8Q from .ra (rate:52%)
Oxford Oxford Oxford ICI leI
overall physics chemistry overall chemistry
following up references 1.50 1.39 1.71 2.01 2.46
cited in relevant papers
online searching 3.52 3.25 3.67 2.15 2.16
following up references 1.94 1.82 1.88 2.27 2.37
cited in reviews or books
searching through 2.26 2.31 1.93 2.63 2.09
abstracts journals
searching SCI 3.19 3.31 3.14 3.32 3.45
searching New Drug - -
- 3.94 2.75
Bulletin*
searching MIDAS* - - - 4.56 4.67
searching Patents 4.74 2.78
Bulletin*
* ICI inhouse bulletin
Table 5.5 Activities of Retrospective Search by Chinese Scientists
ｾ survey in 1989. responses: i6 from phannaceutical scientists
in ｂ･ｩｩｩｮｾ and ｓＮｨ｡ｮｾｨ｡ｩ (rate: 56%),
Activities Rank Order No of person
Searching through abstract 1 56
uournals
following up references cited 2 37
in relevant papers & reviews
searching inhouse bulletins 3 19
searching computerized data- 4 10
bases
searching SCI 5 1
ＡＮｾｊ
British academic scientists (Oxford chemists) rank following up references at the
1st, abstracting journal at the 2nd, SCI at the 3rd and online at the 4th.
British industrial scientists (lCI chemists) rank abstracting journal the 1st, online
2nd, following up references the 3rd, inhouse bulletin the 4th, and SCI the 5th.
Chinese scientists rank abstracting journal the 1st, following up references the 2nd,
inhouse bulletins the 3rd, computerized databases the 4th and SCI the 5th.
The domination of the traditional methods offollowing up references ci ted in relevant
papers or reviews is striking in the British academic sector. However, ICI chemical
scientists regarded this as less important than searching online or searching through
abstract journal. This reflects the combination of high online application in phar-
maceutical company and good bibliographical control by CA and databases in
chemical field.
Chinese scientists regarded following up references as less important than searching
abstractingjournal. The main reason may be that Chinese scientists feel less confident
in their ability of obtaining or accessing literature comprehensively in their field.
It is clear, in the early 1980s British industrial scientists relied on online searching
much more than their academic counterparts. In 1981, online was ranked the second
by ICI scientists but the 4th by Oxford scientists.
By 1986, when Martyn conducted the national survey for Aslib, online searching by
academic scientists was reported as still in low usage - the 9th searching activity of
total 12, comparing to the 3rd rank in the industrial scientists index (Table 5.8).
Computerized information technology (or IT) was introduced into China only in the
early 1980s, it has been mainly concentrated in the big cities. Ten of the 56
respondents in Beijing and Shanghai pharmaceutical research institutes have used
some kind of computerized information retrieval.
It seems that in house bulletins are regarded as useful for retrospective searching-
by ICI scientists and Chinese scientists.
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How often do scientists have to trace literature back to decades ago?
Differences in using literature from various periods usually exists between disci-
plines. This study shows that a difference also exists between the two nations (Table
5.6 & 5.7).
Table 5.6 Tracing Back Literature by British Scientists
Royal Society survey in.l2B.L responses: H2 from Oxford ｾ 63%),
and ao fmm 1Cl (rate:52%)
Oxford Oxford Oxford leI lei
overall physics chemistry overall chemistry
19th century
never use 64 79 47 50 25
occasional use 32 21 49 45 65
regular use 4 0 4 5 10
1900-1940
never 28 39 13 25 10
occasional 64 59 76 58 60
regular 8 2 11 17 30
1940-1960
never 2 3 0 6 .3
occasional 49 68 33 45 25
regular 49 29 67 49 72
1960-1970
never 0 0 0 0 0
occasional 5 7 0 10 11
regular 95 93 100 90 89
1970-1979
never - - - 0 -
occasional - - - 1 -
regular - - - 99 -
Table 5.7 Tracing Back Literature By Chinese Scientists
Jianiin survey in 1988. responses: ill from ｾ and pharmaceutical scientists
in Iianjin (rate: 61%),
before 1960 1960s 1970s 1980s
never use 97% 92% 63% 0
use 3% 8% 37% 100%
As we would expect, the older the literature, the less it is consulted. Chemists (at
both Oxford and ICI) used the older literature far more than physicists, probably for
preparative details of compounds.
The immediacy in using literature by Chinese medical and pharmaceutical scientists
is striking. Less than 40% of them use literature of ten years old, comparing to 100%
British scientists; less than 10% of them use literature of 20 years old, comparing to
more than ninety percent of British scientists; the Chinese figure of using literature
of more than 30 years old is very small- only 3% of Chinese scientists in comparison
with 60% of British.
The immediacy in using literature usually happens in new subject fields or sciences.
It is also more likely to happen in developing countries where most scientific
disciplines are very young. The immediacy may also reflect the difficulty for Chinese
scientists to obtain older scientific literature or more precisely "older foreign lan-
guage literature".
5.3.3 How do scientists search for information in general
In theory, scientists' information needs can be divided into three categories- current
awareness, retrospective searching and day to day consulting. However, in practice,
the above needs and searching may not be distinguished so clearly as black and white.
A scientist going to do a retrospective retrieval may also want to satisfy some of his
current awareness needs. On the other hand, one seeking current progress information
may start retrospective retrieval at any time when he finds any striking traces.
Therefore. sometimes information scientists do not bother to ask the real purpose
for a search activity. but directly compare all kinds of searching together.
Table 5.8 & 5.9 & 5.10 generally show searching activities favoured by British and
Chinese scientists. The lower rates in Tianjin survey (Table S.'l0) than ISTIC (Table
12h
Table 5.8 Information Searching Activities by British Scientists
Martyn's survey in ｊｾ responses; .2.QQ from ｮ｡ｴｩｯｮｷｩ､ｾ scientists
in all subjects (rate: 38%),
academic Indus.& gover. all
action value action value action value
follow up references cited 1 1 1 1 1 1
in relevant papers
keep up with the literature 2 2 2 2 2 2
by reading current papers
search through 3 6 3 7 3 6
abstracts journals
do an online search or 9 8 3 6 8 7
have one done for you
rely on another member of your 8 9 12 11 9 9
team to collect information
collect references from 5 5 5 4 5 4
other colleagues
use a personal index or other 7 7 7 3 6 5
personal record of S& T data
use library indexes or catalogue 10 12 10 12 10 12
ask a librarian do a search for you 12 11 9 8 11 11
use standard textbook or mono- 3 10 5 10 4 10
graph
use SDI 11 3 11 9 12 8
try to get unpublished material or 6 3 8 5 6 3
pre-print from other workers
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Table 5.9 Information Searching Activities by Chinese Scientists
lS.IlC survey in .l.2..8l. responses: l8..4Q from natjQnwidt scientists
in all subjects ｾ 23%),
Rank Activities % of total respondents
1 scanning journals 98
2 searching through abstracts journals 93
3 following up references cited in relevant papers 87
4 use library indexes and catalogue 87
5 attending conferences 75
6 use inhouse bulletins 72
7 personal contact 58
8 ask a librarian to search for you 30
Table 5.10 Information Searching Activities by Medical and Pharmaceutical Scientists in
Tianjin
Tianjin survey in 1988. responses; ill from medical .a.o..d phannaceutical scientists in
Tianiin (rate: 61 %t
.
Rank Activities % of total respondents
1 scanning journals 76
2 searching through abstracts journals 75
3 following up references cited in 59
relevant papers
4 using library index or catalogue 54
5 asking a librarian searching for you 5
6 personal contact 3
- ,
5.9) may reflect the different attitudes between ordinary scientists in Tianjin survey
(higher response 61 %) and the frequent library users in ISTIC survey (lower response
23%).
For British scientists, it is clear that the most used searching ways are: first, following
up references; second, reading current papers and third searching abstracting
journals.
For Chinese scientists, the fITSt place of most used searching methods is scanning
journals or reading current papers, searching abstract journal at the second.
while following up references in the third place.
The results suggest that scanning journals still is the most popular method for
information searching in the two countries.
Unlike British scientists, Chinese scientists regarded following up references as
either less important or a more difficult searching method. The explanation is that
they face greater difficulty in getting access to and hold of most of relevant papers
in the world.
The results also indicate that Chinese scientists quite firmly believe in the abstract
journal for timely and comprehensive information searching. They seem to be more
happy with the current situation in bibliographic control by secondary publication
than with the situation in document supply (document supply in China will be further
discussed in the later part of this chapter).
British scientists view personal contacts (including collecting references from other
colleagues, getting unpublished or pre-printed material from other workers) as
valuable channels. They rank them at the 5th and 6th of total 12 activities.
By comparison, Chinese scientists regarded personal contacts as the least used
method for information searching and gathering. This reflects the generally bad
communication condition inside China. As far as communication between Chinese
scientists and foreign scientists is concerned, language barrier, geographical barrier
etc. constitute the major influential factors.
By 1986, British academic scientists still did not use online searching very much,
probably for financial constraint reason. Academic scientists ranked it the 9th of total
12 activities; whereas industrial and government scientists use it more frequently in
the third place.
Because online searching is still in its infancy stage in China, neither the ISTIC
survey in 1981 nor Tianjin survey in 1988 include it as a searching method.
For British scientists, using library index or catalogue and asking librarian to
search for oneself are not frequently used; ranked at 10th and 11th of total 12
activities. This may reflect that UK scientists do not regard library catalogue and
collection as the major source for information searching. Instead, they search
scientific literature mainly through secondary publications, computerized databases
and informal communication. They do not have to worry about document supply.
They assume most of scientific literature which they have traced would be available
either from local library or the national library document supply centre (BLOSe).
Chinese scientists rank asking librarian to search at the last. But they seem to be
strongly in favour of using library index or catalogue ranking at 4th of total 8
activities. About 87% ofISTIC respondents and 54% ofTianjin respondents reported
frequently usage. This reflects that Chinese scientists still regard library catalogue
as major source for information searching and that Chinese scientists have to greatly
rely on local libraries' collection, since there is no national or regional interloan
systems available.
A interesting finding in Martyn's survey in 1986 is the least frequently use of SOl
by both UK industrial and academic scientists at rank 12th. This is different from
the Royal Society result that ICI scientists rank SDI at the second place. This may
reflect the difference in IT application between pharmaceutical industry and other
industries in UK.
In China there has been a tradition for information officers to compile inhouse
information bulletins regularly or occasionally. In ISTIC national survey in 1981.
72% of Chinese scientists reported use of this information source.
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5.3.4 Foreign language barriers in S&T information searching
Scientists' ability ofreading literature in foreign language
It seems that in general British scientists' ability in French language is similar to
Chinese scientists' ability in English language; while the proportion of British
mastering German is much higher than the ratio of Chinese mastering Japanese
(Table 5.11 - 5.14). Only some old Chinese scientists (the second generation) can
read Russian literature. Nowadays, almost all Chinese universities teach English as
first foreign language with mostly Japanese or sometime German as secondary
foreign language.
Whether all worthwhile work would be published in English?
In the Royal Society survey (1981), to the question "do you think that a researcher
can safely confine himself to the English language literature without risk of missing
much important material?", 41% of ICI respondents said "yes", whereas 59% "no".
In the survey at Pfizer (Thorp, 1987), to the question "whether all worthwhile work
would be published (or re-published) in English?", 69% said "yes", 26% "no" and
5% were unsure. Although the two results differ from each other - the leI result
shows a dominant belief of importance of foreign scientific literature, whereas the
Pfizer shows the opposite dominance; they all indicate that a significant proportion
of British pharmaceutical scientists admitting the existence of foreign language
barrier.
Table 5.11 Ability in Reading Foreign Language Literature
by Pharmaceutical Scientists at Pfizer
Thorp's survey in 1987. responses: .i8 pharmaceutical scientists at Pfizer ira:
te:94%).
French German Russian Japanese
good 10% 9% 0 0
fair 36% 12% 0 0
laborious 41% 41% VI( 0
Nil 10% 36% 97Cfr 100%
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Table 5.12 Ability in Reading Foreign Language Literature
by Pharmaceutical Scientists At ICI
Royal Society survey in.l2.8.L responses: .an fmm liJ (rate:52%)
French German Russian other
ICIoverall 76% 52.5% 1.3% 6.3%
ICI chemistry 82.5% 70% 0 5%
Table 5.13 Ability in Reading Foreign Language Literature
by Pharmaceutical Scientists in Beijing and Shanghai
Chen's survey in 1989. responses: ｾ fum1 pharmaceutical scientists
in ｂ･ｩｪｩｮｾ and ＮｳＮＮｨ｡ｮｾｨ｡ｩ ｾ 56%),
English German Japanese Russian French
can read 100% 11% 22% 9% 9%
Table 5.14 Ability in Reading Foreign Language Literature
by Pharmaceutical Scientists in Tianjin
Iianjin survey in ｾ responses: ill frQm ｾ and Dbannaceutical
scientists in Iianjin ｾ 61%),
English German Japanese Russian French
can read 88.5% 1.6% 27.5% 3.3% 2.2%
To the question "Do you often discover references to materials published in foreign
language?", in the Royal Society survey (1981),43% of respondents at ICI reponed
regular discovery, 56% reponed occasional discovery.
By comparison, more than 90% ofChinese scientists reponed that they regard foreign
language literature very important to their R&D activities. Moreover, ｉ Ｍ ｆ ｾ Ｈ of them
(those senior research scientists) confirmed relying on foreign literature more
than relying on Chinese literature (lSTIC, 1982).
In the ISTI C national survey in 1981 ,it was reponed that apart from reading Chinese
literature, 59% of them mainly rely on English language literature for scientific
infonnation, 23% mainly rely on Japanese for information, }4% mainly rely on
Russian, 4% mainly rely on German and French.
In 1989 Chen's survey on Chinese pharmaceutical scientists, all 56 respondents
reported relying on foreign literature more than on Chinese literature. All the .56
respondents reported mainly using English, 22% mainly using Japanese, 11 % mainly
using German, 9% French and 9% Russian.
What do you do when you find literature in foreign language?
The actions that respondents from ICI and Pfizer suggested they would take when
confronted by a foreign language literature are given below (Table 5.15 & 5.16 &
5.17).
If a scientist had a knowledge of the foreign language, he would read it in its original
language. Otherwise finding an English abstract is a popular choice for all languages.
Identifying or commissioning a translation is not a highly favoured option. Ignoring
a foreign literature is always the least choice.
How do Chinese scientists do whenfacing literature inforeign languages unreadable
In ISTIC 1981 survey, 10% of respondents reported that they would commission
translation. The figure in Chen's survey in 1989 was 6%. Comparing to the UK
figures in Pfizer (Table 5.16), Chinese scientists regarded getting translation as
less important than British scientists.
Because in China today more than 90% foreign literature imported is in English
(ISTIC, 1986), and 90% of Chinese scientists could read English papers, Chinese
scientists tend to mainly rely on English language literature and to ignore literature
in other languages.
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Table 5.15 Reactions to Foreign Language Literature by Pharmaceutical Scientists at leI
Royal Society survey in 198 t responses: .8Q from Ia (rate:52%)
Mean Actions
Rank
1.66 Reading English abstract if there is one
1.67 try to read it in the original language
2.65 try to find existing translation
2.35 get it translated
4.09 ignore it
Table 5.16 Reactions to Foreign Language Literature
by Pharmaceutical Scientists at Pfizer
Jhorp's survey in 1987. responses: ｾ pharmaceutical scientists ill Pfizer (rate:94%),
Actions French German Russian Japan
read or translate by oneself 47 26 2 0
get help from colleague 15 31 3 0
find English abstract 25 34 41 43
find existing translation 9 13 21 20
get it translated 8 11 19 22
ignore it 4 6 16 17
Table 5.17 Reasons for Ignoring Foreign Language Literature
by scientists at Pfizer
Thorp's survey in 1987. responses: ｾ phannaceutical scientisis at Pfizer (rate:94%),
Reasons French German Russian Japanese
time to acquire literature 6 6 11 10
time to deal with literature 11 13 23 23
cost of translating literature 6 8 17 18
unsure how to deal with it 6 6 11 11
5.3.5 How do scientists assess S&T information services
Do you have problem in tracing information
In general, British scientists enjoy better library information services than Chinese
scientists. Over 95% of them have access to relevant abstracting journals and 78%
to online searching at their working places, according to Martyn's survey in 1986.
By the end of the 1980s, it is estimated that over 90% of scientists in the UK could
use online searching at their working place. Therefore, to the question "Do you have
problem in tracing information? ", the majority (over 70%) of British scientists'
answer is "no".
In Martyn's national survey in 1986, 25.6% of the academic scientists, 21.Y7r of
industrial scientists and 30.4% of the government scientists have discovered some
literature which they wish they had seen earlier in their projects. Those are so-called
"later-finders".
The reasons for late finding include:
1. Failure to make a systematic approach to literature (11% of later finders);
2. Literature were published in unexpected place (16% of later finders);
3. Literature were not indexed as expected (15%).
Therefore, 42% of later finds are caused by searching difficulties, or in other words,
only 11% of total 266 respondents did have problem in tracing information.
Information searching difficulty is a problem in China, partly owing to the inability
for many middle and small S&T libraries to hold an adequate collection of relevant
foreign abstracting journals, partly due to the lack of user education on how to use
existing secondary publications. It was reported by ISTIC survey in 1981, that 64%
of Chinese scientists have some kind of searching difficulty.
In another survey on a provincial teaching hospital. 88% of respondent medical and
pharmaceutical staff reported searching difficulty (Wuhan Hospital. 19H5).
During the Cultural Revolution in 1960s and 1970s. most scientific and technological
professionals ceased R&D practice. So when China resumed S&T undertaking in
the early 1980s. most of Chinese scientists were not familiar with international
secondary journals. It seems that scientists' searching ability through abstracting
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journal has been greatly improved since then. Fewer scientists in Beijing and
Shanghai have problems in searching - only 149t- of respondents in Chen's survey
in 1989.
How do scientists searching through abstracting journals and online systems?
Table 5.18 shows the general good view of abstracting journals by British scientists.
Table 5.18 Is your field is adequately covered by abstracts journals?
Royal Society survey in .l.2.8.L responses:
li2 from Oxforq (rate: 63%), iilll ｾ from lCl (rate: 52%)
Oxford Oxford Oxford ICI ICI
overall physics chemistry overall chemistry
too many 1% 0 20/0 5% 0
adequate 77% 78% 89% 80% 90%
not enough 4% 0 2% 5% 5%
.. 18% 22% 70/0 10% 5%no OpInIOn
Nowadays, although online searching are available in all the UK universities,
governmental research institutions and big industrial R&D departments, impact of
online on hard copy abstracting journals subscription is still very small (Howorth,
1988). It seems that UK university libraries and other S&T libraries will continue to
subscribe to the major and well-used printed sources to allow simultaneously access
to hard copy by majority users.
Today Chinese scientists regard searching through abstracting journals as the
second most important searching method, after the method of scanning current
journal. This reflects that they are satisfied with this information searching channel
generally.
In the Royal Society survey in 1981,66% of ICI respondents had performed an online
search in comparison with only 34% of Oxford scientists.
However, by the end of 1980s, online has become a relatively mature tool and
technique of information retrieval, despite differences in usage do exist between
academic scientists and industrial scientists.
G. B. Howorth in 1988 conducted a survey of all university libraries in the UK on
their online services (TCU Msc thesis, 1988). By 1988, 100% of UK university
libraries offer online searching services. Of them, 75% reported that the annual
number of searches had risen during last two years, only 11% had fallen.
Another nationwide survey of 58 UK chemical companies' online searching per-
fonnance has been conducted by S. Byway in 1988 (TCU MSc Thesis, 1988). About
56% of the companies had gone further to train users for end-user online searching.
Among the five companies Byway interviewed, company (1) and (2) each has a
information department of 7 staff conducting 1,000 online searches per annum;
company (3) has 16 information staff and annual online searches of 2.000; company
(4) has 30 information staff and annual online searches of 1,500; company (5) has
85 information staff and conducts more than 4,000 online searches annually.
By the end of 1986, 60 online searching terminals connecting with European and
North American hosts have been established in 27 big cities of China. The biggest
international online searching centre is at ISTIC headquarter in Beijing with an annual
volume of online searching of $34,600 in 1986 accounting for 15% of the British
Library SRIS online expenditure in 1986/87. In 1988, China conducted some 20,000
international online searches accounting for 0.1% of the world figure (see Chapter
2).
According to Chen's survey of 56 pharmaceutical scientists in Beijing and Shanghai
in 1989,8 of them (16%) had used computerized databases. The eight users were all
satisfied with the retrieval technique. However, they all reported the inaccessibility
to a considerable proportion of literature which have been hit.
According to an ISTIC random survey of 23 searches done in a week in 1986, of a
total of 679 journal papers hit, about 17% are not available in China: of total 225
conference proceedings hit, about 73% are not available in Beijing; of total 298
reports hit, about 45% are not available in Beijing; and finally none of total IRtheses
hit are available in Beijing (Zhou, 1987). The above results indicate that although
online searching is not widely used in China, it seems not to be the major problem
for Chinese scientists. The major problem is the limited literature resource and the
low satisfaction rate in document supply in China.
How do ",den/ists trace information from reviews?
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Apart from secondary publications and the computerized versions, reviews provide
another tool for information searching.
There are reasons to believe that for many scientists reviews form an important
information source for gathering information. Table 5.19-5.21 are drawn from the
Royal Society survey which confirms the high regard in which British scientists hold
reviews. It also shows that reviews are regarded as adequate in both quality and
quantity in various different fields.
In China, a significant proportion of reviews are written by information officers
rather than by scientific researchers. The reviews are so-called "foreign information
analysis and research" reports or reviews.
To the question "are the reviews by Chinese information officers ofadequate quality
in general?" in the ISTIC national survey in 1981, 32% of respondents reported
"good" quality, 18% "adequate", and 50% claimed the reviews are "not good enough" .
There is a contrariety in the assessment. This kind of reviews are normally written
by professional translating staff who do not necessarily have a scientific background.
Inevitably the contrariety happens - on one hand some Chinese scientists with less
systematic searching skill and less ability of some foreign languages often request
this kind of reviews; on the other hand, this sort of reviews is lack of adequate value
from professional scientists' viewpoint.
How do scientists assess library document supply service
British scientists generally enjoy better document supply service than Chinese.
Although funds for academic libraries have been reduced in real term and show signs
of continuing to be reduced; although there has been a continuous cut in scholarly
acquisitions, interloan and national reference services can be called upon to help out
in this event.
In Martyn's national survey in 1986, 98% of respondents claimed availability of
library of current journals, 94% with the availability of relevant abstracting journals
and document delivery service.
The availability of obtaining documents not held locally is said to be almost certainly
understated, given the ubiquity of British Library Document Supply Centre (BLSDC)
service. The annual satisfactory rate of interlibrary loan requests in BLSDC has been
maintained at the level of 9()l(;. for long time. In 1989. the rate IS 92.3Ck (BLOSe
Figun's 1989/1990).
Table 5.19 Do you regard reviews as especially valuable information?
Royal Society survey in 1981, responses: JA2 from Oxford ｾ 63%),
illld.BQ from IQ (rate:52%)
Oxford Oxford Oxford ICI ICI
overall physics chemistry overall chemistry
yes 86% 86% 98% 88% 93%
no 14% 14% 2% 12% 7%
Table 5.20 Are there enough reviews in your field?
Royal Society survey in 1981, responses: .H2.from Oxford ｾ 63%),
and.8..Q from IQ (rate:52%)
Oxford Oxford Oxford ICI ICI
overall physics chemistry overall chemistry
too many 5% 4% 7% 9% 5%
enough 79% 84% 84% 79% 80%
not enough 16% 12% 9% 12% 15%
Table 5.21 Are the reviews in your field of adequate quality in general?
Royal Society survey in 1981, responses: l42 from Oxford ｾ 63%),
ill1d.8.Q from ICl (rate:52%)
Oxford Oxford Oxford leI leI
overall physics chemistry overall chemistry
good TF70 78% 89% R7c;;, 88%
adequate 22% 19% 11% 9';;, 12%
not good 6c;t 3% 0 4% 0
enough
-
ｾＬｽＹ
(]
In China, however, obtaining a relevant document may be more difficult than tracing
it. In ISTIC survey in 1981, 64% of Chinese scientists reported searching difficulty
while 69% with obtaining difficulty. According to Chen's survey in 1989, to 56
pharmaceutical scientists in Beijing and Shanghai, 42 of them (75%) claimed
obtaining difficulty in comparison with 8 of them having searching difficulty.
In 1990, Academia Sinica conducted a survey on the users satisfaction with the
document supply. A sample of just under 3,000 scientists from total 50,000 S&T
staff in 124 research institutes of Academia Sinica were asked "Does the document
supply by your institute library and the existing library networks satisfy your
information needs?".
About 60% of scientists reported that they do not satisfy with the document supply
because less than 75% of their information needs can be met. There are difference
in the unsatisfactory rate among different regions. About 50% of 720 scientists in
Belling, 55% of 300 scientists in North East China, 46% of 604 scientists in East
China (including Shanghai), 63% of 369 scientists in Middle South China, 800'(' of
330 scientists in South West China and 65% of 512 scientists in North West China
reported not satisfying with the situation of document supply.
In Chen's survey on pharmaceutical scientists in Beijing and Shanghai in 1989, a
similar proportion (600/0) of users reported unsatisfactory with document supply: 34
of 56 respondents reported less than 50% of their needs could be satisfied by current
document supply services. Only 17 of 56 respondents (30% of them) could get over
50% of document they need and only 9% of them could get over 80% of document
they need.
According to an ISTIC random survey of 23 searches done in a week in 1986, of
total 679 journal papers hit, about 17% are not available in China; of total 225
conference proceedings hit, about 73% are not available in Beijing; of total 298
reports hit, about 45% are not available in Beijing; and finally none of total 1Xtheses
hit are available in Beijing (Zhou, 1987).
The obtaining difficulty is certainly caused by poor library collection locally and no
interlibrary loan services available at all. given the relatively poor transport, postal
and telecommunication services in China.
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In 1984, the Hubei provincial Academy of Medical Sciences conducted a survey on
500 medical and pharmaceutical scientists in the province, with 356 respondents.
The results showed that a significant fraction of Hubei scientists (44%) would only
use the institution library collection; 27% would try other institution libraries within
the province for unsatisfied information needs; 24% would go further to use library
collections in other provincial capitals or the three municipalities; 6.6% of them
would try foreign contacts for reprints (Hubei Academy of Medical Sciences, 1986).
Under the circumstance of today's "information explosion", no single S&T library
(even those libraries in developed countries) could claim to be comprehensive in
collection. The general limited information resource in Chinese S&T libraries and
information centres are eminent (see Chapter 8). However, most of Chinese scientists
have been restricted to very limited information collection and resource in their area.
Share of the national information resource is still far from reality in China.
Hubei is about three quarterof the size ofBritain. It is the 9th most populated province
in the total 26 provinces of China; having a similar rank in its industrial, agriculture.
as well as scientific and educational productivity. The above results therefore could
reflect the backwardness in document supply and interloan system in China.
There is little doubt that in China today the most serious crisis is the inadequate
resources of primary literature, especially in foreign information. The combination
of rapid inflation at home and in the world scientific literature market has made the
situation intolerable.
When a professor in the Shanghai Biochemical Research Institute of Academia Sinica
was interviewed by the author in 1989, he gave the following assessment.
"Because of the financial problem, many S&T libraries and information institutes
cancel their already limited journals subscription and books acquisition.
"The situation is becoming worse for the current 3-5 years, when even some biggest
S&T libraries or information institutes greatly cut their acquisitions. for example the
Shanghai S&T information institute, the Shanghai library of Academia Sinica, and
Guangzhou S&T library.
l..t I
"To improve other information services, such as online searching, SDI, foreign
literature translation etc. is definitely needed. However, without sufficient resources
of primary literature and secondary publications, those services will inevitably
become unwarranted decoration to the poor information system.
"Without a stable and rich S&T literature resource, one cannot think of any Chinese
R&D work being able to be up to the world standard".
His assessment has been currently supported by the investigation conducted in S&T
information system in Academia Sinica. "Due to the rapid inflation in domestic and
foreign S&T literature for the last ten years, a substantial cancellation of every kind
of literature has happened in almost all S&T libraries. In the Library of Academia
Sinica in Beijing alone, from 1985 to 1989, the number of foreign journals have been
reduced by 50%." (Academia Sinica, 1991). Even the national S&T libraries have
received substantial cut in their foreign journal subscription.
Since the early 1980s, many UK academic libraries have been under a finance
constraint and reduced their subscription of learned journals and books. However
the above cut in subscription is made under the assumption that British Library
Document Supply Centre would function as a back up service to the academic
libraries (Line, 1990). So the current constraints in UK academic libraries. although
considerable, is nothing like the serious situation in Chinese S&T libraries and
information centres.
5.4 Concluding Notes
5.4.1 Value of Foreign Language Information
Although a significant proportion of British pharmaceutical scientists admits the
existence of foreign language barrier, up to 70% of them think all worthwhile work
would be published in English.
Bycomparison, more than 90% ofChinese scientists reported that they regard foreign
language literature very important to their R&D activities. Moreover. 14% of them
(those senior research scientists) confirmed relying on foreign literature more than
relying on Chinese literature.
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5.4.2 Scientists' Information Accessing Ability
In general it is perceived that scientists in UK have higher information accessing
ability than scientists in China. British scientists generally enjoy better document
supply service than Chinese. Although funds for academic libraries have been
reduced in real terms and show signs of continuing to be reduced; interloan and
national reference services can be called upon to help out in this event.
About 60% of Chinese scientists do not satisfy with the situation ofdocument supply
by their institute library or existing library networks, because less than 75% of their
information needs can not be met. The unsatisfactory is reported by 50% of scientists
in Beijing and Shanghai and by 80% of scientists in remote areas.
Under the circumstance of today's "information explosion", no single S&T library
could claim to be comprehensive in collection. However, most of Chinese scientists
have been restricted to very limited information collection and resource in their area,
because of the poor communication and transport condition. Share of national
information resource is still far from reality in China, without national or regional
interloan system or document supply system available.
5.4.3 Scientists' Information Searching Ability
1 Generally, because the several large world secondary publications provide
comprehensive coverage over chemistry and life science literature in the world, both
British and Chinese scientists have little problems in literature searching. In
China the national secondary publication system now produces 250,000 biblio-
graphic records per year covering about 50% of Chinese literature (see Chapter 8).
Generally Chinese scientists are also satisfied with the situation in searching domestic
literature.
However, there are differences in scientists' information searching ability between
the two countries. The common features and differences are summarized as follows:
2 Both British and Chinese scientists mainly rely on the traditional mean of scanning
journals for current awareness - it is the first rank in the UK survey and the Chinese
survey. The effectiveness of such a searching activity would greatly depend on the
journal collection in scientists' institution library and local S&T libraries.
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3 SDI service for current awareness is the second most used searching method by
ICI chemical scientists. However, it is much less used by British academic chemical
scientists and by Chinese scientists.
4 That ICI chemists rely on SDI, inhouse patent bulletins more than academic
chemical scientists reflects that there are better information services in pharma-
ceutical industry than in academic libraries, whereas UK academic scientists are still
in favour of traditional ways such as personal contacts, reviews for current awareness
which are greatly self supported.
5 Both Chinese scientists and British academic scientists rank abstracting journal
and review as frequently used methods. But British academic scientists show much
more use of colleagues recommending papers than Chinese scientists. British rank
review higher than abstracting journal whereas Chinese give the opposite rank.
6 Comparing to British industrial scientists, Chinese scientists rank abstracting
journal and reviews relatively high in their index. British industrial scientists rank
SDI, inhouse bulletins and colleagues recommending papers relatively high in their
index.
7 In China, each big research institute usually has a library and an information
department. The latter is responsible for compiling inhouse information bulletins.
This is similar to the situation in the UK pharmaceutical industry. ICI chemists rank
inhouse bulletins at the 3rd of total 10 searching activities whereas Chinese scientists
also reported certain use of such information service for current awareness.
8 Unlike British scientists, Chinese scientists regarded following up references as
either less important or more difficult searching method. The explanation is that they
face greater difficulty in accessing to relevant papers in the world.
9 Chinese scientists quite firmly believe in abstract journal for timely and com-
prehensive information searching. They seem to be more confident in their ability
in information searching than in obtaining literature (i.e. accessing to information).
10 UK scientists do not regard library catalogue and collection as the major source
for infonnation searching. Instead, they search scientific literature mainly through
secondary publications. computerized databases and informal communication. They
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do not have to worry about document supply. They assume most of scientific lit-
erature which they have traced would be available either by local library or the
national library document supply centre (BLDSC).
By comparison, Chinese scientists still regard library catalogue as major source for
information searching. And Chinese scientists have to greatly rely on local libraries '
collection, since there is no national or regional interloan systems available.
5.4.4 Informal Scientific Communication
Personal contact (colleague recommending papers, exchange preprint and reprint
etc.) is not a frequently used channel in China as in the UK. The poor communication
and transport condition in China and the weak link between Chinese scientists and
the world scientific community may be the major causes. The informal communi-
cation between Chinese scientists and foreign scientists is at a low level today- most
of Chinese scientists are going abroad to study whereas most of foreign scientists
are coming to China for lecturing.
Conference is one of informal channels for scientists to get aware ofcurrent research
work. In general British scientists are satisfied with the status of conference as a
communication channel. On average each British scientist attends 1-2 conferences
per year.
There are not enough conferences for Chinese scientists. Conference is not a fre-
quently used information channel for current awareness in China. On average each
Chinese S&T worker attends conference every 7 year. The great importance of
foreign S&T information to Chinese R&D have made international conference one
of the most valuable information source for Chinese scientists. However each year,
only 1% of Chinese pharmaceutical scientists could attend international conferences
in China and only 0.1 % of Chinese pharmaceutical scientists have chance to attend
international conferences abroad.
5.4.5 Enhanced Searching Ability bv Online
It is clear, in the early 1980s British industrial scientists relied on online searching
much more than their academic counterparts. In 1981. online was ranked the second
by leI scientists but the fifth by Oxford scientists. During the period of the 1980s.
online service s have been widely spread in the whole research community in the
UK.
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By 1988, 100% of UK university libraries offer online searching services. Of them,
75% reported annual number of searches has risen during last two years. However,
British academic scientists still use online less frequently (9th rank) than industrial
scientists (3rd rank).
By the end of the 1980s, IT application has been further improved in UK industrial
R&D sector. About 56% of UK chemical companies have started end user searching
in 1988. In 1988, the online volume in a middle sized pharmaceutical company Pfizer
UK is ten times the average figure in a UK academic or public library.
Computerized information technology (or In was introduced into China in the early
1980s, it has been mainly concentrated in the big cities.
By the end of 1986, 60 online searching terminals connecting with European and
North American hosts have been established in 27 big cities of China. The biggest
international online searching centre is at ISTIC headquarters in Beijing with an
annual volume of online searching of $34,600 in 1986 accounting for 15% of the
British Library SRIS online expenditure in 1986/87. In 1988. China conducted some
20,000 international online searches accounting for 0.1% of the world figure and
being only 4 times the online volume in a large UK pharmaceutical company Glaxo.
The average online volume in the 60 Chinese online searching centres is 2-300
searches per year, which is similar to that in a medium sized British academic library.
The current status of online searching in China is similar to that in Europe in the
early 1970s.
Generally, Chinese scientists are satisfied with online searching results but not with
the document supply service later on. About 17% of journal papers, 73% of con-
ference papers, 45% of reports and 100% of theses hit are not available in
Chapter 6 Scientists' Information Using Disseminating Ability
In Chapter 5, British and Chinese scientists' information needs, searching and acquiring,
or in short their "information accessing searching ability" have been compared and
studied. In this chapter, let us look at their information activities on the production side of
scientific communication. The aims in this chapter are to analyse and "measure" the two
nations' scientists "information using and disseminating ability". Such a measurement
will provide some data and evidences for planning the reform of Chinese S&T information
flow system in Chapter 9.
6.1 Scientific Literature Production and Scientist's Information Abil-
ity
In the practice of science, there are four important characteristics which mostly concern
us here.
First, a scientist must read the papers and books by other workers. except the man who
is the sole practitioner in the field and therefore can read nothing beside his own papers.
He has to practice scientific research on the base of previous work in the field. As Newton
said" If I have seen further, it is by standing on the shoulders of giants".
Secondly, a scientist must cite other workers' papers in his publications if his work is
related to or based on them. In the practice of scientific research a scientist must draw
on others' experiences and findings because science is regarded as a process of con-
tinuous renewal and cumulation. As a result. in scientific literature, papers beget papers:
a scientist will read and assimilate the work of his precursors and peers and use their
experience as a catalyst and stimulant to his 0\1./0 activity. Their papers will act as a
platform and a springbank for his published work and they will be cited in his paper.
His own published works will be sequentially cited by his peers and heirs and so the
fabric of the literature will be worked.
Thirdly, a scientist must publish or perish in his subject field. except for those whose
work are not allowed to published by the employer for confidential reasons. There are
always competition and urge to publish within a scientific community. though this
publish or perish does not apply to scientists in industry.
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Fourthly, a scientist must get his work approved by the refereeing system of scientific
journals. New contributions for publication are customarily examined for acceptability
by the refereeing system which acts as a filter to remove unworthy contributions.
After all, while a scientist writes papers to contribute to scientific knowledge, he is
involved in an information processing procedure including using, generating and dis-
seminating activities.
In this chapter, scientists' information disseminating ability in the two countries is to
be compared (§6.2 and §6.3).
A scientist's or a group of scientists' information using ability is a subjective term and
is difficult to define.
To a looser extent, we may define it as "when a scientist (or a group of scientists) is
exposed to an information environment, his ability (or the group's ability) to integrate
others' knowledge and experience into his (or its) own work".
Obviously it depends on the scientist's or the group of scientists' intelligence, foreign
language ability and scientific training. It is further conditioned by their information
environment, their information accessing ability, the academic level of their research
work and many other influences. Since this study is only interested in the comparison
of the two nations' scientists, we may assume that the intelligence, foreign language
ability and scientific training as ceteris paribus. Therefore major influences on the two
nation scientists' information using ability would be their information accessing ability
and the academic level of their research work.
A convenient indicator system for "information using ability" is citing behaviour in
scientific literature production. In §6.4 and §6.5 we are to study the two nation scientists'
citing behaviour.
To study scientific literature production, there are some quantitative methods in the
information science namely bibliometric studies. Among the bibliometric studies.
Bradford's law is about the concentration and dispersion of papers in journals: Latka's
law is about the concentration of scholarly productivity; the aging of literature is about
the utility of literature over time; the citation analysis studies the relationship between
citing papers/authors/journals and cited papers/authors/journals. In this chapter, the
bibliometric methods are to be applied to compare the scientific literature production
by the two l'ountries' scientists.
6.2 Scientists' Ability in Disseminating R&D Information
6.2.1 Journals' Publishing Capacity
Within science, the primary journal fulfils four functions: quality control, assignment
ofpriority to authors, dissemination ofinformation and permanent archive. Although
China has a short history of scientific journal publication less than seventy years.
the Chinese system is quite similar to the systems in scientific advanced western
countries. In each subject journals receive papers from authors and send them to
other scientists who act as referees. With the referees' reports to help him. the editor
decides whether or not to publish. Often a paper is returned to the author for revision
in the light of the referee's report. Finally, if a paper is accepted. it is sent to the
printers and eventually appears in print, usually 6-12 months after the initial sub-
mission to the British journals (Royal Society, 1981) or 12-18 months after the initial
submission to the Chinese journals (Wu, 1988).
That the average editing time for submitted journal paper in China is 1.5-2 times the
length in UK may in a sense reflect a relatively smaller dissemination capacity by
Chinese journal than British journal.
In 1979, there were about 1500 scientific learned journals in UK, excluding social
science, engineering and clinical medicine (Royal Society. 1981). Another estimate
is that there are some 4,000 S&T learned journals being currently published in UK
(Vickery, 1987). By comparison, in 1988, China published around 3000 scientific
and technical journals (Zhong, 1990).
There are some 220,000 scientific and technological workers in UK (Annual Review
of Government funded R&D, 1990) comparing to 7.8 million in China (White Paper,
1987). If the factor that China has a S&Tmanpower which is 35 times the UK whereas
China has a number of S&T journals similar to UK is taken into account; then the
number of journal per S&T worker in China is far too lower than in UK. In other
words, China has a much smaller journal publishing capacity for disseminating
its R& D results than the UK.
Moreover. Chinese journal has a smaller productivity than the world journal in terms
of average publications per journal per year. By the late 19XOs. the average publi-
cation rate of Chinese journals was reponed as 100 papers per journal per year (Yan,
1988, Zhang, 1988 and Li, 1988). The Chinese rate in the late 19805 is more or less
equal to the average rate in the late 19605' USA which was reported as 110 papers
per journal per year (Wooster, 1979).
Since the 1960s, the size of world scientific journal in terms of the number of papers
or the number of pages has been growing slightly and steadily (Royal Society, 1981).
A random survey on 35 British scientific journals in SCI (1988), by choosing the
journals with "British" in the beginning of their titles, showed that the average
publication rate was 171 papers per journal per year in 1988.
Perhaps, Chinese scientific journal is the one of the most competitive publication
system in the world. It is reported that there are somewhat five hundred medical
and pharmaceutical learned journals against 4.5 million S&T professionals in the
field in China (Wu, 1988). That is one journal for every 10,000 potential scientific
authors on average.
The lack of journals for disseminating R&D results in China has forced many junior
research workers out of scientific publication (Wu,1988). If we adopt the Chinese
scientific job hierarchy and assume the senior research scientists as potential
authors conservatively, there are about seven thousands of such potential authors
in Chinese pharmaceutical areas (seeing Chapter 3). It is estimated that there are
60-80 learned journals in Chinese pharmaceutical areas (China Pharmaceutical
Yearbook 1987 & China Pharmaceutical Abstracts, 1989). Under that circumstance,
there will be 100 potential authors for each journal in the field. Given that each
Chinese journal publishes 100 paper each year. then one can roughly deduce that the
average publication rate of Chinese pharmaceutical scientists is one paper per person
per year.
One old survey on the number of publications produced by staff members of the UK
university chemistry departments in 1969 reported an average productivity of 236
papers per staff annually (Baglow, 1979). School of Pharmacy in University of
London reported an average productivity of 3 papers per staff among its 61 academic
staff in 1987-88 ( School of Pharmacy Annual Report 1987- XX).
Though there is no similar survey conducted in China. according to the above estimate
of one paper per research scientist annually in Chinese pharmaceutical areas. we
could estimate that a Chinese scientist annual publication capacity is only about 1/'2
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or 1/3 that of a British scientist. This may have been resulted from the lower S&T
journal capacity in disseminating the nation's R&D results in China in comparison
with the situation in the UK.
It has been recently highlighted that there is difficulty in journal publication for
ordinary Chinese scientists. "There are several problems facing today's scientific
journal publishing industry in China. Firstly, there are not enough journals for
scientists to publish their work which results in the very high rejection rate in all
grades ofjournals. Secondly, there are not enough editors for each journal- the
average number ofeditors for each journal is 2,. which is lower than the government
guide-line: 3 for Quarterly journal, 5 for bimonthly journal, and 8 for monthly
journal. The lack of resource for journal publishing has inevitably prevented the
growth in the size ofjournal and the improvement in publishing speed. Thirdly, there
is longer delay for journal paper publishing which is 50% or 100% longer than the
world speed, in terms of the time requested for refereeing, editorial alld priming
work". (Wu, 1988)
By comparison, Royal Society's survey in 1981 showed that only 10;-· of British
scientists thought the journals in their fields were not enough. About 25% of British
scientists even thought there were too many journals while the majority 72% thought
there were about enough journals (Royal Society, 1981).
6.2.2 Scientists' Information Disseminating Ability
So far, China has reached a scientific literature production of 200,000·400,000 papers
per year. One estimate is from the items being indexed in Chinese secondary
publications (abstract or index journals) which total 200,000 entries each year,
includingjournal papers andotherdocuments (White Paper, 1987).Anotherestimate
is from the latest S&T survey by the State S&T Commission (White Paper, 1990).
In 1988, there were 52,000 S&T journal papers and 470 million words of S&T
monographs published by government scientists. and 112JXX) S&T journal papers
and 15(X) million words of monographs by university researchers. Given that 8000
words1o of monographs equal to one journal paper. the total number of S&T papers
published by Chinese scientists were 400,000 in 1988.
10 The average number of words in each journal paper is S(XX). according to the survey on
CJCP (1985-1987).
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In the world, despite Chinese scientific literature has grown relatively quickly since
the late 1970s, from 0.7% of total CA items in 1980 to 3.5% in 1988 which made
a total of 13,639 Chinese records in that year (Jhaveri, 1989), China is still a very
small scientific nation contributing to the world science. Table 6.2.1 shows the
contribution made by China to world phannaceuticalliterature is still at a small scale
comparing with the UK.
Table 6.2.1 Contributions by China and UK to Pharmaceutical Literature
as percentage of total papers in CA
Source from Sec. 1 Phannocology, Sec.4 Toxicology, Sec. 63 Pharmaceuticals and
Sec.64 Pharmaceutical analysis in CA •
1972 1988
UK China UK China
SEC1 6.5 1.4 7.1 1...+
SEC4 4.6 0.6 6.1 0.8
SEC63 4.1 1.3 5.5 1.8
SEC64 3.6 1.9 2.4 0.4
* the result is from an online search conducted in STN CA FILE(1967, 1-1990, 10)
in Oct., 1990.
There is a contradictory situation in Chinese scientific literature production. On one
hand, China produces a great number of scientific papers each year- somewhat
200,000 - 400,000. On the other hand, only a very small proportion (no more than
10%) of the Chinese scientific literature could disseminate to the world by means of
international secondary publication services.
There is a hierarchy of different grades of papers and authors:
At the top of the hierarchy is the group of papers being published in foreign or
international journals in English lor sometimes in other foreign languages) by
Chinese scientists. The total number of this group of papers was about 16,486 in all
subjects in 198X (including government scientists and university researchers) (White
Paper. 1990).
At the second level, there are papers published in the high quality Chinese journals
and sequentially being indexed in the big international abstracting journals such as
CA, BA, SA, 1M etc. It was reported, in 1988 total of 13,091 papers with the first
authors' addresses in China have been covered by CA accounting for 3.7% ofjournal
papers in CA (Jhaveri, 1989). These 13,000 papers account for at least one third of
the total Chinese papers abstracted by international secondary publication services,
according to the following estimation.
It was reported that in 1988, SCI covered 10 Chinese journals accounting for 0.3%
of total journals in it. EI covered 40 Chinese journals accounting for 1.2% of total
journals in it. CA covered 281 Chinese journals accounting for 2% of total journals
in it. In USSR, "S&T Abstracts" covered 131 Chinese journals accounting for 0.6%
of its journal coverage. In Japan, "S&T Abstracts" covered 40 Chinese journals
accounting for 0.3% of its journal coverage. In UK, Science Abstracts covered 62
Chinese journals accounting for 2.2% of its journal coverage. Among the above six
world leading secondary publications, Chinese journal coverage in CA accounts for
50% of the total. On this base, one may estimate the number of Chinese papers
covered by CA accounts for at least one third of total Chinese papers covered by
world secondary publications.
In other words, about 39,000 Chinese papers or 10% of total 400,000 Chinese
scientific literature are covered by international secondary publications.
In Chapter 3, the ratio of Chinese phannaceuticalliterature being abstracted in CA
and in China Pharmaceutical Abstracts was estimated as 1 to 7 (Table 3.13).
This also supports the finding that around 10\;( of Chinese papers are indexed by
international secondary publications.
At the third level, there are 200,000 Chinese scientific papers (half journal papers
and half other documents) annually being indexed and abstracted by 219 Chinese
abstracting journals. The 200,000 papers are reponed accounting for 50% of total
Chinese scientific literature (Huang, 1986).
The other half scientific literature which is not indexed by any secondary publications
make up the fourth level of the hierarchy.
The Chinese sl'ientific literature has been lrystallilcd into a "triangle" structure as
shown in Figurl' 6.2.1.
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Figure 6.2.1 Triangle Structure of Chinese Scientific Literature
Because British scientists use the English language which has been the world
scientific language for more than half a century, it is safe to say that all journal papers
by British scientists are disseminated on the world communication circuit. Here it
must note that 4% of Chinese papers in world journals and 10% of Chinese papers
in world secondary publications do not indicate that only such proportion of Chinese
literature are at the same academic level as all British journal papers. It only indicates
that Chinese scientists have a much smaller capacity in disseminating infor-
mation to the world than British scientists.
6.3 The Concentration of Scholarly Productivity
There is a well known effect in scientific communication that is the concentration and
dispersion of scholarly productivity.
Lotka 's Law provides a measure on the concentration of scientific productivity. It counts
the number of items under each author's name in the cumulative index of a journal. The
number of authors making N contributions is about 1{N2 of those making one; and the
proportion of all contributors that make a single contribution is about 60% (Potter, 1981).
The following case is chosen from the cumulative index of a Chinese leading journal
"Chinese Journal of Pharmaceutical Science" (YAO XU xi: BAO, 19)3-19HS)"
(Pharmaceutical Sciences Journal). (Table 6.3.1) "Chinese Journal of Pharmaceutical
Science" is the most reputable learned journal in Chinese pharmaceutical field.
Table 6.3.1 Authors' Contribution in Chinese Journal of Pharmaceutical Science
(1953-1985)
actual data Latka's prediction
papers per author authors paper per author authors
1-9 2954 1 1811
2-9 976
10-29 58 10-29 129
30 2 30-35 10.5
33 3
36 1 36-40 6.3
40 1
Total 3019 ... ...
It seems that the above Chinese data do not confirm Lotka's law very well. Especially
the number of productive authors (those produce more than 10 papers) is only half
of the Lotka's prediction. Perhaps we should not be too surprised at this. Coile (1977)
has shown in an extensive study of author productivity that few data sets do conform
to Lotka's Law.
According to Coile's hypothesis, there are three possible causes for the deviation in
Chinese Journal of Pharmaceutical Science.
Firstly, the community of authors may not be broad enough. Secondly, although the
total time span is more than ten years (1953-1985), there is a long period of disturbance
(The Cultural Revolution) in the journal publication during 1964-1977. Thirdly. it is
possible that the productivity of Chinese eminent scientists is lower than that being
predicted by Lotka.
Nevertheless. Table 6.3.1 shows that there is a concentration and dispersion of scholarly
production in Chinese pharmaceutical science. Among the overall three thousands of
scientific authors in the journal, only 65 person (or 2 '7c of the total) have published more
than ten papers for the thirty years (1953-19H5). Therefore one could say the eminence
of Chinese scientists is 2lJe.
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To study the eminence in the young generation of Chinese scientists, we use a sample
of23 eminent scientists in Academia Sinica. Data is drawn from a biography book edited
by Academia Sinica (1987).
In 1986, the average age of the 23 scientists was 44 and they mainly graduated from
university just before the start of the Cultural Revolution in 1965. Soon after the Cultural
Revolution in the early 1980s, all the 23 had been sent to study abroad for some time
ranging from several months to several years.
All 23 scientists give the number of their publications for a self-defined publishingpeak
period during 1977-1986.
Since the sample group of scientists graduated soon after the start of the Cultural
Revolution and were without work because of the nationwide cease in scientific practice
during that period; we could safely say that the publishing peak period represent the
first peak in their career. Table 6.3.2 shows the pattern of the 23 Chinese eminent
scientists productivity.
The average time span of self-defined peak is 4 years for the period of 1977- 1986.
All the scientists have their peak publishing period starting from their work abroad.
The plausible reasons for that are as follows:
1. Good work conditions abroad, including library information services and laboratory
facilities:
2. Good collaboration with other countries' scientists and sometimes with eminent
scientists in the world;
3. Good access to word processing facilities and journal publication system;
4. Improved personal foreign language ability and research skill.
During their scIf-defined peak period. the average publication rate is 4 papers per person
r (l' ncluding puhlication inside and outside China).per yea '-
Table 6.3.2 Eminent Chinese Scientists Productivity
during their first peak period after the Cultural Revolution
author subject first peak total total non- papers non-Chinese
case no. years papers Chinese papers per year papers per year
1 computer 6 60 17 10 3
2 toxicology 5 38 8
3 mathematic 6 20 20 4 4
4 physics 2 7 7 4 4
5 physics 1 3 3 3 3
6 chemistry 7 12 6 2 I
7 physics 2 8 8 4 4
8 biology 1 4 4 4 4
9 physics I 6 6 6 6
10 chemistry 2 2 2 1 1
11 physics 4 7 7 2 2
12 computer 6 30 5
13 mathmatic 2 5 5 3 3
14 computer 8 20 3
15 physics 4 20 20 5 5
16 mathmatics 9 40 4
17 chemistry 2.5 8 8 4 4
18 physics 8 40 5
19 computer 3 10 10 3 3
20 physics 2 3 3 1.5 1.5
21 computer 4 20 20 5 5
22 biology 2 8 8 4
4
23 chemistry 2 2 2
1 1
Average 4
4 3
}57
All of the 23 scientists had published papers in foreign or international journals in
non-Chinese languages. During their self-defined peak period, the average publication
rate is 3 non-Chinese papers per person per year.
After returning back to China, 12 of the 23 scientists had been continuing to publish in
foreign journals and Chinese journals at a similar speed as when they were abroad.
Today the major differences between the ordinary and eminent Chinese scientists include
1. An eminent scientist publish 4 papers per year while an ordinary senior scientist
publish one paper per year.
2. An eminent scientist is able to publish in foreign journals with a speed of 3 papers
per year while an ordinary senior scientist mainly publish in Chinese journals.
If we want to know how many eminent scientists there are in China today. we could
estimate from the figure of Chinese Academy of Sciences. Those 23 eminent scientists
were drawn from 4,000 scientists had been studied abroad and returned back to Chinese
Academy of Science in the first half of 1980s. The eminence is therefore estimated as
0.6% of the 4,000 Academia Sinica scientists trained abroad or 0.23% of the 10,000
senior research scientists in Academia Sinica.
By 1990, in the whole China, there were 40,000 Chinese scientists had completed their
study/work abroad and returned back, if the above 0.6£7(' of eminence still hold, there
would be 200-300 prominent scientists in China.
One may disagree with the above standard of "eminence" which requires the eminent
Chinese scientist publishing 3-4 non-Chinese papers in world journals in one year.
Nevertheless, it seems to be acceptable in practice. For example. ISTIC also adopted
this standard in its study on Chinese authors' productivity. In 1989. there were about
six thousand Chinese S&T authors (both first and co-authors) being indexed in SCI.
of whom the top 50 authors had more than ｾ papers published in world core journals
(78% in foreign journals and 22% in Chinese published Englishjournals) (Zhang, 1990).
Given SCI covering less than one tenth of v.. orld S&T journals. one could roughly
estimate that the number of so-called "eminent" Chinese scientists may be ten times the
50 authors. Therefore there are around five hundred eminent scientists in today' s China.
Generally, there is a hierarchy of S&T authors corresponding to the triangle structure
of S&T literature production (Figure 6.2.1). Overall, there are about '+00,000 scientific
authors in China.
The most prestigious of the UK learned societies is the Royal Society with 1000 fellows
currently. Those scientists elected Fellows of the Royal Society (FRS) are regarded as
the most eminent scientists in the UK. They account for 0.4% of total 220,000 S&T
workers in the UK.
The eminence in China is several hundred scientists accounting for 0.1% of 400,000
scientific authors or 0.005% of total 7.8 million S&T workers; comparing to the emi-
nence of one thousand scientists accounting for 0.4% of total 220,000 S&T workers in
the UK.
To compare the productivity of Chinese and foreign eminent scientists is very difficult,
because there are few studies on Chinese scientists life productivity. Nevertheless, the
following figures may shed some light on the comparison.
Dennis (1954) had looked at the productivity of members of the US National Academy
of Sciences and found that his sample had a life time publication range of 27 to 768
papers with a median volume of 145. In Britain. those chemists elected Fellows of the
Royal Society are regarded as the country's most eminent chemists, so Baglow and
Bottle (1979) studied their life time productivity. The study showed an average life time
productivity of 144 publication for FRS chemists. The study also showed that the first
publication age appeared in 24 and the average life time is 72 for the FRS chemists.
Therefore, the average publishing time is 72-2.+=-+X years for the FRS chemists. Dividing
144 papers by 48 years. the average productivity for FRS chemists is 3 papers per person
per year. From the same study one could also deduce the average productivity for FRS
medical scientists is 2.7.
From the 23 eminent Chinese scientists in Academia Sinica, and the 50 eminent Chinese
scientists in the SCI 1989 survey; one could see that the average productivity of Eminent
Chinese scientists is ＳＭｾ papers in world journals per person per year.
The productivity of eminent scientists in UK and China seems to compare well.
6.4 Scientists' Citing Behaviours
A citation is the acknowledgement that one document receives from another. In general,
a citation implies a relationship between a part or the whole of the cited docu-
ments/authors/journals and a part or the whole of the citing documents/authors/journals.
Citation analysis is that area of bibliometrics which deals with the study of these
relationships.
6.4.1 Citation Analysis & Bradford Distribution
in Pharmaceutical Area
Bradford's law is characterized by both concentration and dispersion of specific
items of information over different sources of information, which constitute an
important feature of scientific literature production. To put it another way, for a
search on some specific topic, a large number of the relevant articles will be con-
centrated in a small number ofjournal titles. The remaining articles will be dispersed
over a large numberofjournal titles. For such an effect there are three obvious causes:
1. Subject width of journal - those journals with more narrow subject coverage and
those specialist journals are more likely to become "core" in the field;
2. Standard and quality of journal - those higher standard journals in a subject are
more likely to become "core" in the field;
3. Journal capacity in terms of the number of papers per year - those journals with
larger number of papers published per year are more likely to become "core" in the
field.
The most profound impact on the theoretical foundation of Bradford's law has come
from the efforts of B.C. Brookes. He described the law in two parts:
Rin i>« x n" (1 ｾｮ s c)
R (11) =.\ x ｉｏｾ［ ) (c ｾ 11 ｾＮ｜Ｉ
These two equations refer to the rising curve and the linear curve of the whole graph
1b()
which is named "bibliograph" by Brookes (Figure 6.4.1).
n is the rank order of periodicals arranged in decreasing order of the number of
articles they contribute to a specified subject;
R(n) is the cumulative sum of articles contributed by all periodicals of rank 1 to n :
a is the number of articles contributed by the most productive periodical ( i.e. the
periodical of rank 1);
b is the constant if the publications considered cover only a short time-span. Its value
is always less than 1;
N is the total number of periodical title that would be expected to publish paper on
the subject;
c is the value of n at the point C where the curve runs smoothly into the straight line.
Periodicals ranked 1 - C constitute the "nucleus" of periodicals publishing papers on
the given subject;
s is the value of n at the intersection of the straight line with the log(n) axis.
For strict conformity with Bradford's law. certain conditions have to be imposed on
the bibliography. They are: (I) the subject of the bibliography must be well defined,'
(2) the bibliography must be complete, that is, all relevant papers and periodicals
must he listed,' (3) the hibliography must be of limited time-span so that all con-
tributing periodicals have the same opportunity of contributing papers.
However, it is found that the form of the graph is surprisingly stable even when these
conditions are not fully satisfied (Brookes, 1969).
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To apply Bradford's law to the pharmaceutical sciences area, we choose the following
four bibliographies:
(1) 1635 citations from 614 source papers published in a Chinese journal "Phar-
maceutical Analysis" (1984-1987); with an average citing rate of 2.7 citations per
paper. Citations are from 125 Chinese source journals and 215 foreign source
journals. That are from total 340 source journals.
(2) 1070 citations from 124 source papers published in "Chinese Journal of Clinical
Pharmacology (1985-1987) " (DCP); with average citing rate of 8.6. Citations are
from 76 Chinese journals and 224 foreign journals. That are from 300 source journals.
(3) 1930 citations from 106 source papers published in "British Journal of Clinical
Pharmacology (Jan. - June, 1984)" (BJCP); with average citing rate of 18.2. Citations
are from 306 source journals.
(4) 9501 references from 90 source papers of the American "Annual Review of
Pharmacology (1968-1970)" with average citing rate of 106 (source from Segupta,
1974). Citations are from 779 source journals.
For the four bibliographies, the Bradford's distribution of papers over journals are
presented in Appendix 6.4.1 - 6.4.9. Figure 6.4.2-6.4.5 show the actual and estimated
"complete" bibliographs of (1) citations in Chinese journal "Pharmaceutical
Analysis" (Fig. 6.4.2); (2) citations in DCP and BJCP (Fig. 6.4.3); (3) citations in
CJCP and references in American journal "Annual Reviews of Pharmacology" (Fig.
6.4.4); and (4) Chinese citations and English citations in CJCP (Fig. 6.4.5).
RESULTS AND DISCUSSION
All the figures show good conformity with Bradford distribution. Only Annual
Review of Pharmacology bibliograph (Fig. 6.4.4) shows a significant drop in N
Which is the total number of periodical title that would be expected to publish paper
on the subject. There is expected to be 2193 source journals contributing to the
pharmacology field and 14390 papers in a complete bibliography. In fact, the Annual
Review of Pharmacology bibliography only covers 779 source journals and 9501
papers. This difference may be caused by the highly selective nature of the Annual
Review of Pharmacolouv which eliminates many relevant papers that the Review
'- .
believes lack of value.
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All the bibliographs demonstrate the "core" journal and "peripheral" journal effect
in pharmaceutical areas. Pharmaceutical Analysis has a core of 3journals (Fig. 6.4.2).
CJCP has a core of 18journals (Fig. 6.4.3). BJCP has a core of 7 journals (Fig. 6.4.3).
Annual Review of Pharmacology has a core of 15 journals (Fig. 6.4.4).
To explain the difference in "core" effect among the four bibliographies (Fig.
6.4.2-6.4.5), we quote Brookes' theory first:
" The mechanism underlying the generation of a Bradford distribution seems to
consist of two competing processes. The primary process is a bandwagon effect:
authors would in general prefer to publish their papers in the core journals which
correspond to the sources on the curved part of the bibliograph. But these journals
receive more than they can publish. So their standards ofacceptance are high and
this secondary restrictive process then pushes some papers out into the peripheral
journals.
"The Bradford distribution follows: it represents an overall bandwagon effect which
is modified by a restrictive effect over the sources at the core.
" On the other hand, when there is no competition or other form ofrestriction, there
is no core."(Brookes, 1973)
Chinese Journal of Clinical Pharmacology (CJCP) and British Journal of Clinical
Pharmacology (BlCP) have the similar subject area, therefore the two bibliographs
are compared in Fig. 6.4.3. In general, BlCP has much bigger annual production of
papers (293 in 1984) than C1CP (41 papers per year for 1985-1987). So the citations
bibliography of BlCP is chosen from the 106 source papers in the first half 1984 to
be compared with the citations bibliography of OCP from 124 source papers for
19R5-19R7.
As we have already mentioned BlCP authors generally cite more than CJCP authors.
The average citing rate in each BlCP source paper is 18.2 while the rate in OCP is
8.6. Therefore, from Fig. 6.4.3, one could find that the B1CP graph is higher above
the CJCP graph. Comparing to 394 citations to 18 "core" journals in CJCP, there are
721 citations to 7 "core" journals in BJCP.
Fig. 6.4.3 also shows that a bigger "core" in CJCP with 18 journals accounting
for 37% ofcitation comparing a smaller" core" in BJCP with 7 journals accounting
for 37c!c of citation. The effect may reflect the difference in subject width covered
16R
by BJCP and CJCP which is to be discussed later.
In the case of "Annual Reviews of Pharmacology" (Fig. 6.4.4), the bibliography is
more comprehensive than the other three journals in the number of both source
journals and citations. There is a relatively big core of 15 journals comparing to
CJCP (18 cores), BJCP (7 cores) and Pharmaceutical Analysis (3 cores). The big
core also reflects the fact that there is a wide subject coverage in the Annual Review
of Pharmacology,
Like "Pharmaceutical Analysis", CJCP also is a Chinese scientific journal. However,
the CJCP bibliographs (Fig. 6.4.3 & Fig. 6.4.5) have bigger "cores" whereas the
"Pharmaceutical Analysis" bibliograph (Fig. 6.4.2) have smaller one. Here, the
difference may also rise from the different subject width covered by the two journals.
According to Brookes' theory, parameter ss l is for only narrow scientific subjects,
as the subject widens, so does s. A bibliograph in a wider subject area is likely to
have a bigger core than a bibliograph in a less wide subject area.
It is generally understand that the pharmacology has the widest subject. clinical
pharmacology has the second wide subject and pharmaceutical analysis has the
narrow subject, so Annual Review ofPhannaco logy has the biggest subject parameter
(s=3.1) and biggest core (15 cores), the BJCP has the modest subject parameter
(s=O.86) and the modest core (7 cores) and Pharmaceutical Analysis has the smallest
subject parameter and core (s= 0.8 and 3 cores).
However, it comes the problem that how to explain CJCP has a bigger subject
parameter (s=4.0) and a bigger core (core 18) than Annual Review of Pharmacology
( s= 3.1 & Core 15), BJCP (s= 0.86 & core 7) and Pharmaceutical Analysis (s= 0.8
& core 3).
The explanation could come only from the subject width of CJCP, BJCP and Annual
Review of Pharmacology. The width of a subject is different to different nation's
scientists. The hypothesis is that ifa subject is well developed and the academic level
of research work is high in a country. the nation's scientists will make focused
information use over subject width.
Figure 6.4.3 and 6.4.4 show that CJCP has a subject parameter s=4.0, with BJCP
s=O.R6 and Annual Review of Pharrnacology s=3.1. The figures indicate that
although CJCP is a specialist journal in clinical pharmacology, its bibliography of
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citations are from a much wider subject area. It reflects a relatively diffuse infor-
mation using and citing behaviour by Chinese clinical pharmacological scientists
compared with British pharmacologists and clinical pharmacologists.
Clinical Pharmacology is a relatively "young" subject area in China which formally
started in the 1979 while in the western countries it started in the late 1960s (see
Chapter 3). The younger a subject area is and the lower the academic level is; the
broader the scientists' interest might be and the more diffuse information use will
happen, because there is no sophisticated framework being widely accepted and
adopted in the subject area.
Further analysis also explains a bigger core in CJCP (18 cores) vs. a smaller core in
Pharmaceutical Analysis (3 cores). The two journals are all Chinese leading journals
in their fields. Apart from the obvious reason that clinical pharmacology is wider
than pharmaceutical analysis, the hidden reason may also come from different
information using and citing behaviour between Chinese clinical pharmacologists
and pharmaceutical analysists. Clinical pharmacology has a shorter history of less
than 8 years in China whereas pharmaceutical analysis has a longer history of more
than 60 years in China.
Pharmaceutical analysis has already been a sophisticated and mature area in China.
The relatively mature status in Chinese pharmaceutical analysis seems to have made
the citing behaviour of Chinese pharmaceutical analysists quite different from that
of Chinese clinical pharmacologists. It is observed that pharmaceutical analysists
cite more Chinese papers than foreign papers comparing to clinical pharmacologists
cite more foreign papers than cite Chinese papers. In Pharmaceutical Analysis, 40%
ofcited journals are Chinese journals; comparing to 24% in CJCP. In Pharmaceutical
Analysis. 50% of citations are Chinese papers: comparing to 26% in CJCP.
We may conclude that Chinese clinical pharmacological scientists show more
diffuse information use (over subject width) than their British colleagues as well
as than their Chinese colleagues in pharmaceutical analysis field, may be caused
by the premature status of the clinical pharmacology in China.
The above discussion implies that a nation scientists' information using ability
(as reflected from citing behaviour] may be influenced bv the academic level or
the status of research in the subject field in the country. Lower academic level
and premature research status may result in diffuse information using b)'
Chinese clinical pharmacological scientists.
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Perhaps a more straightforward demonstration of the concentration and dispersion
effect of papers in journals is to show the number of periodicals required to cover a
specified fraction (p) of total papers of a subject. Table 6.4.1-6.4.3. give the results
of "journal coverage of specified fraction of papers" from "Pharmaceutical
Analysis" Chinese bibliography and English bibliography, from OCP Chinese
bibliography and English bibliography, and from "Annual Reviews of Pharmacol-
ogy" bibliography.
From the above tables, we can see that in the "Pharmaceutical Analysis" bibli-
ographies and "Ann. Rev. Pharmacology" bibliography, 2%-4% of source journals
contribute 40% of total papers in the fields, and 80% of total papers are contributed
by 26-31 % of journals. In the case of CJCP, the concentration and dispersion is not
as extreme as in the other two cases ("Pharm. Anal." and "Ann. Rev. Pharmacology"):
80% of Chinese papers are contributed by 49% Chinese journals and 80% of English
papers by 43% of English journals.
To compare the third column of Chinese citations covered by % of source journals
and the sixth column of English citations covered by % of source journals in Table
6.4.1 ("Pharmaceutical Analysis"), one could find the relative percentages of source
journals covering certain percentages of citations in the two columns with a rea-
sonable degree of unanimity. The same unanimity can also be seen in Table 6.4.2 in
the case of CJCP.
The results seems to indicate that major influence on a Bradford's distribution pattern
ofa specific bibliography is subject related rather than language related. In a Bradford
distribution pattern, Chinese scientists from the same subject area cite and use
Chinese papers in a pattern similar to that when they cite and use English papers.
6.4.2 Average Number of Citations in Each Paper
Generally. Chinese scientists cite far fewer in each periodical paper than their British
and western colleagues. According to the study on 1227 Chinese S&T journals, the
average number of citations made by each periodical paper in 1989 is 5A and in
medical and pharmaceutical field the average number of citations is 8.7 (Zhang.
1990). By comparison with the world figure, using "Source Data Listing" of SCI
in 1987. the average citations made by each papers in the three thousands source
journals is 20.8.
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Table 6.4.1 Source Journal Coverage By Percentage -in bibliographies
of "Pharmaceutical Analysis"
Chinese citation bibliography English citation bibliography
%of no. of %of % of no. of %of
papers sources sources papers sources sources
100 145 100 100 130 100
80 38 26 80 40 31
60 12 8 60 17 13
40 3 2.1 40 5 4
20 0.85 0.6 20 1.8 1.4
Table 6.4.2 Source Journal Coverage By Percentage - in bibliographies of ClCP
Chinese citation bibliography English citation bibliography
%of no. of % of %of no. of %of
papers sources sources papers sources sources
100 71 100 100 215 100
80 35 49 80 92 43
60 18 25 60 39 18
40 9 13 40 17 8
20 4 6 20 7 3
Table 6.4.3 Source Journal Coverage By Percentage - in bibliography
of "Annual Review of Pharmacology"
% of papers no. of sources % of sources
100 2193 100
80 594 27
60 160 7
40 43 2
20 12 0.5
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Another example is the comparison of Chinese Journal of Clinical Pharmacology
(CJCP) and British Journal of Clinical Pharmacology (BJCP).
106 source papers in first half year of BJCP in 1984 had cited 1930 papers, with an
average citing rate of 18.2 citations in each source paper.
By comparison, 124 source papers in CJCP (1985-1987) had cited 1070 papers, with
an average citing rate of 8.6 citations in each source paper.
The reasons for less citations by Chinese papers are complex. One possible influence
may be the lower information accessing ability to world S&T information, comparing
to the situation in UK and developed countries. Other reasons may include the
difference in scientists' citing habits and the difference in the academic level of
research between the two countries.
6.4.3 Language of Citations
It is not surprising that because English is the world scientific language, British and
American authors would mostly cite papers in their native language, Chinese authors
have to read and cite more English language papers than their own language papers.
For example, 106 source papers in BJCP (Jan. - June, 1984) had cited 1930 citations,
of which more than 90% are English language citations. By comparison, there are
1070 citations from 124 source papers in CJCP (1985-1987), of these citations 72%
are in English and 26% in Chinese.
However, the ratio of Chinese citations vs. foreign language citations by Chinese
journals varies accordingly.
According to ISTIC survey on 2870 papers published in Chinese pharmaceutical
journal in 1989, the average citation number in each paper is 8, of which 3.8 are
Chinese citations and 4.2 are foreign language citations (Zhang, 1990).
The figures show a balanced citation pattern between Chinese and foreign language.
In Pharmaceutical Analysis. as being described above. 50% of citations are Chinese
papers: comparing to 26% of citations arc Chinese citations in CJCP.
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Above all, that Chinese scientists have to use over 50% of literature in foreign
language whereas British scientist use over 90% of literature in the nati ve language
may reflect the difference in the S&T position and the S&T impact in the world
between the two countries.
6.4.4 Highly Cited Authors
Although there is no guarantee that the less productive authors are nonentities and
the more productive authors are distinguished scientists, there is a strong correlation
between productive authors and highly cited authors. Forexample, one study reported
that among the top 30 highly productive authors, 11 of them are also found to be at
the top 30 highly cited authors in that field (Pharmaceutical Analysis in China) (Yuan,
1989).
It is generally believed that Chinese "star" authors mainly have great impact on
Chinese scientific society rather than on the world scientific society. Table 6.4.4
shows how is the impact from Chinese authors on Chinese scientists.
Table 6.4.4 28 "Star" Chinese Authors' Impact on Chinese Scientists
(in Chinese journal "Pharmaceutical Analysis" 1981-1987)
citations received by 26 19 15 13 12 11 10 9 8 7
one author
No. of cited authors I 1 2 I I 2 I 5 6 8
*total 28 "star" authors
On searching for those 28 "star" authors in SCI 1987 edition, we find that only three
of them have been cited in that year. one has been cited 7 times, the second twice.
and the third once. This implies that Chinese authors have little impact on the world.
On the contrary. British scientists generally have much more impact on the world
scientific society than Chinese scientists. We chose 8 leading British scientists in
the same field (Pharmaceutical Analysis) as the above 28 Chinese authors (Liu,
19(0). Using SCI 1987 edition. we search for the 8 British "star" authors and list the
number of citations they have received in 1987 from the world 3200 major journals
(Tahlt.' 6.4.5).
ｬＷｾ
Table 6.4.5 Eight British "Star" Authors' Impact on World Scientists in SCI 1987
citations received by 72 68 63 47 28 13 10 4
one author
No. of cited authors 1 1 1 1 1 1 1 1
It is clear that British scientists, with the top author getting 72 citations in 1987, have
much greater impact in the world scientific society than Chinese scientists among
whom the top author gets only 7 citations in 1987.
In all Chinese S&T fields, Shanghai Institute of Biochemistry of Academia Sinica,
and Shanghai Institute of Material Medical of Academia Sinica are ranked at the
first and the sixth highly cited Chinese research institutes, according to SCI citations
to their work during the period of 1985-1987 (Zhang, 1990).
Compared with the world leading pharmaceutical companies, however, the top two
Chinese pharmaceutical institutes have produced far fewer world class papers and
received far fewer citations from worldjournals(Table 6.4.6 a & b).
The above facts may reflect that the academic level of research in China is relatively
low comparing to that in the UK.
6.4.5 Highly Cited Journals
Now let us look at another feature of scientific journal literature - the quantity vs.
the quality.
"We have now a world list of some 50,000 scientific periodicals that have been
published: these have produced a world total ofabout six million scientific papers,
and an incrcase at the approximate rate of at least half a million a year" (Price,
1963).
The exponential growth in S&T literature has inevitably brought in the problem on
quality control of journal papers. According to ISTIC survey in 1990, only 12'27 of
the total three thousand Chinese journals are up to the national editing standards.
Only H2(i; of total Chinese journals have paper title in English, 6H% of journals have
English abstracts. and only 56Cfr of journals give full description of citations or
references ｾ ｚ ｨ ｡ ｮ ｾ Ｎ 1(90).
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Table 6.4.6a Leading Chinese Pharmaceutical Institutes"
-papers published in SCI world journals and citations received in SCI (1985-1987)
rank by no. of R&D institute no. of rank by
papers published papers citations citations in SCI
1 275 Shanghai Institute 121 1
of Biochemistry
6 109 Shanghai Institute 47 6
of Materia Medica
*The institutes at 2nd, 3rd, 4th, and 5th are non pharmaceutical institutes.
Table 6.4.6b International Pharmaceutical Companies Ranked by Articles and Citations
(SCI 1970-1974)
Source: (Koenig, 1983)
rank company papers rank company citations
1 Roche 1732 1 Roche 4736
2 Lilly 1051 2 Lilly 1980
3 Upjohn 950 3 Upjohn 1605
4 Merck 785 4 Merck 1491
5 Warner L. 646 5 Abbott 1106
6 Smith K. 498 6 WarnerL. 846
7 Abbott 455 7 Smith K. 802
8 Pfizer 451 8 Searle 757
9 Searle 399 9 Pfizer 640
10 Schering 325 10 Syntex 605
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In general, the refereeing technique, which has been adopted in scientific community
in the world for long time, measures the quality of scientific work, not just on a
binary good or bad scale, but on a graduated scale from publication in one of the
best journals down to publication in non-refereeing journals and finally to outright
rejection. It is generally accepted that there is a "pecking order" of journals within
any given subject area (Garfield, 1972). Generally, the distribution of a nation's
scientific journals in the world journal "pecking order" reflects the nature of
quality vs. quantity in the nation's scientific literature.
If a journal is relatively highly cited by scientists in the subject area, it is considered
having greater impact in the field. SCI defines the following "impact factor" of a
journal:
"Impact factor is a measure of frequency with which the" average article" in
a journal has been cited in a particular year. Thus the 1988 impact factor of
journal X would be calculated by dividing the number ofall SCI sourcejournals'
1988 citations of articles journal X published in 1986 and 1987 by the number
of source items it published in 1986 and 1987 (SCI Vol. 19, 1988)."
Since 1973 when SCI introduced the Journal Citation Reports (JCR) which includes
ranking of 3200 its sources journals and one thousand non-source journals by cita-
tions and by impact factors; it has provided a more convenient tool for evaluating
scientific journals in the world, particularly in the English language world.
Unfortunately, so far. due to the language barrier, SCI has only covered ten Chinese
published English language journals. Among them two are pharmaceutical relevant,
they are: ACfA Pharmacologica Sinica (APS) and Scientia Sinica B (SSB).
To compare with the two Chinese leading journals in the field, we choose five major
western journals:
I. Clinical Pharmacology and Therapeutics (CPT) ,
2. British Journal of Clinical Pharmacology (BJCP),
3. European Journal of Clinical Pharmacology (EJCP),
4. Journal of Clinical Pharmacology OCP),
5. International Journal of Clinical Pharmacology and Therapy (IJCP1).
LJ sing the Journal Citation Reports (JCR) 19HH edition, we have the two Chinese
journals and five western journals ranked by times cited in 1988 SCI (Table 6.4.7).
The above results show that Chinese journals have received less citations and have
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less impact than their western counterparts. The implication is that the academic
level of research in China is relatively low comparing to that in the UK and other
western developed countries.
Table 6.4.7 Journals Ranked by Times Cited in 1988 SCI
rank journal citations in 1988 citations in 1988 source items impact
to all years to 1987+1986 In factor
1987+1986
174 CPT 8098 1176 372 3.161
257 BJCP 6063 1317 523 2.518
395 EJCP 3952 833 548 1.520
970 JCP 1438 355 292 1.147
1609 I1CPT 675 112 275 0.407
2807 APS 211 42 302 0.139
3015 SSB 166 42 267 0.157
lie the total rank in JCR 1988 is 4375.
On the other hand, it is clear that the most important journals in the world also have
great impact in China. Table 6.4.8 and 6.4.9 show the top 30 and the top 20 highly
cited journals in Chinese Journal of Clinical Pharmacology (CJCP) and in BJCP
respectively.
Among the top 30 high cited journals in CJCP, there are 6 Chinese journals, 3 British
journals and the others being mainly American journals.
Among the top 20 high cited journals in BJCP, there are 6 British journals and none
Chinese journals. The largest proportion of journals is from American.
There are five important western journals have been highly cited among the top ten
bv both C.lCP and BJCP.
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Table 6.4.8 Journals Ranked by Citations Received during 1985-1987 in ocp
rank in rank in journal citations SCI-JCR SCI-JCR
OCP BICP received impact rank by
in 1985-1987 factor impact
in CJCP factors
1 2 CLIN. PHARM. 51 3.161 224
THER. (US)
2 13 AM. J. CARDIOL. 44 2.619 321
3 4 NEW ENGJ. 33 21.148 7
MED. (US)
4 3 LANCET (UK) 27 14.48 17
5 >20 AM. HEART J. 25 1.801 606
6 >20 ANN. INTERN. 21 8.467 39
MED. (US)
7 10 CIRCULATION (US) 20 6.676 58
8 >20 J.A.M.A. (US) 20 5.283 86
9 - ZHONG HUA YI XU 18 - -
ZA ZHI (CHINA)
10 1 BJ.C.P. (UK) 17 2.518 343
11 9 J. PHARMA. 16 1.354 894
SCI. (US)
12 - GUO WAI YI XU 16 - -
(CHINA)
13 .5 BRIT. MED. J. 15 3.136 232
14 >20 AM. 1. MED. 15 2.731 292
15 - ANTIBIOT. CHEMO. 14 - -
(Switzerland)
16 7 CLI\'. PHAR\1ACO- 14 3.393 193
KINETICS (US)
179
continued
17 >20 INTERN. ARCH. 14 1.311 934
ALLER. APPL. (US)
18 - OCP (CHINA) 14 - -
19 15 1. CHROMATO. 13 1.414 838
(Netherland)
20 17 1. PHARMACOKI. 13 1.519 754
BIOPHARM. (US)
21 - KANG SHENG SU 13 - -
(CHINA)
22 >20 CONTRACEPTION 12 0.76 1672
(US)
23 >20 MUTATION RES. 12 1.86 578
(US)
24 >20 NEUROLOGY (US) 12 2.965 251
25 - YAO XU XU BAO 12 - -
(CHINA)
2()
- ZHONG GUO YI YUAN 11 - -
YAO
XU ZA ZHI (CHINA)
27 >20 DRUGS 10 1.544 735
(New Zealand)
28 >20 J ANTIMICROB 10 2.365 386
CHEMOTHER (US)
29 >20 CLIN. CHEM. (US) 10 1.941 534
30 6 EURO. J. CLIN. 9 1.520 753
PHARMOCOlOGY
(Germany)
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Table 6.4.9 Journals Ranked by Citations Received during Jan.-June, 1984 in BJCP
rank rank journal citations
in BJCP in CICP
1 10 BJ.C.P. (UK) 260
2 1 CLIN. PHARM. THER. (US) 160
3 4 LANCET (UK) 66
4 3 NEW ENGJ. MED. (US) 65
5 13 BRIT. MED. J. 64
6 30 EURO. J. CLIN. PHARMOCOLO. (Ger- 61
many)
7 16 CLIN. PHARMACOKINETICS (US) 45
8 >30 CLIN. SCIENCE (UK) 36
9 11 J. PHARMA. SCI. (US) 33
10 7 CIRCULATION (US) 30
11 >30 J. PHARMA. EXP. THER. (US) 28
12 >30 1. CLIN. INVEST. (US) 24
13 2 AM. J. CARDIOL. 22
14 >30 J.CLIN. ENDOCRINAL METAB. (US) 22
15 19 1. CHROMATO. (Netherland) 21
16 >30 J.CARDIO. PHARMACO. (US) 20
17 20 1. PHARMACOKI. BIOPHARM. (US) 19
18 >30 LIFE SCIENCE (UK) 19
19 >30 J LAB. CLIN. MED. (US) 18
20 >30 BRIT. J. PHARMACOLOGY 18
1 ｾ 1
There are 12 important western journals have been highly cited among the top 20
by BJCP authors and among the top 30 by CJCP authors.
Some differences in western journal ranking in CJCP and BJCP may be caused by
the different emphases on research in the two countries. For example, the journal
Contraception has been ranked at the 22nd in CJCP but ranked after 60th in BJCP
is because the research priority in that subject in China.
In 1988, SCI-JCR listed total 4233 world scientific journals ranked by impact factors.
The top 24 western journals in CJCP all have high ranks in SCI. There are two with
rank above the 17th; six ranking above the 232nd; six ranking above the 386th; nine
ranking above the 934th (Table 6.4.8). The top 24 western journals highly cited by
Chinese clinical pharmacologists are among the top 1()()() world journals.
The result that Chinese authors cite more foreign papers than Chinese papers,
and rank foreign journals higher than Chinese journals is conformed by the
result in Chapter 5 that 90% of Chinese scientists regard foreign information
as a very important information source and majority of senior scientists regard
foreign information more important than Chinese information. This may reflect
that the academic level of research in China is relatively low than that in
developed countries.
6.5 The Aging of Scientific Literature
Another interesting topic, which reflects the information using ability of scientists, is
the Iiterature aging phenomena. Literature aging is generally recognized by scientists
as well as by bibliometric researchers as the reduction in the use of literature over time.
The phenomena has been defined by Line and Sandison (1974) as the "decline over time
in validity or utility of information".
Griffith (1979) further summarised the aging phenomena:
"Whl'fl a scientist gets a nl'W publication, he exhausts {he usefulness contained in it and
makes himself acquainted with the current prevailing trend in his specific field while
reading, After the integration of the usefulness into his own activity. and when his
endeavour is completed. {he results will appear as another publication. At this time what
he has lrurncdfrom his prcviou..\· reading turns out to he cited documents. This implies
IH2
the contents ofpublished documents gradually become of negligible scientific interest
as they are read; the citing literature makes them old by gradually exhausting portions
of their total usefulness as cited papers."
The factors responsible for the aging usually fall into the two categories:
1. Literature-based factors: such as the growth of literature, subjects of the literature,
types of literature etc.
2. User-based factors: such as users' ability in searching, accessing and assimilating
information or literature; ability in foreign languages: etc.
In this study we assume the literature based variables as ceteris paribus.
B.C. Brookes developed a straight forward technique of measuring aging as follows
(Brookes. 1973):
The measure requires a sample of at least 2000 citations from the literature of the subject
published within some specified year. The frequencies of citations to earlier papers of
the same literature are then noted, taking the year as the unit. These frequencies are then
cumulated in a table so that it is possible to read off how many citations were made to
each specified year or earlier. The frequencies so cumulated, reducing year by year as
the citations to still earlier years decline in frequency, are then plotted against their
corresponding dates on sernilog paper as shown in Figure 6.5.1. In general. it will be
found that the plotted points fall steadily downwards on a straight line. This implies that
literature ages exponentially.
The next step is to draw the best possible straight line through the linear part of the graph
and to extend it to the edges of the graph paper. A second straight line QA is then drawn
parallel to the first straight line and this second line becomes the means by which the
annual aging rate ( a ) can be read. Apart from annual aging rate (a), the other important
indicator-of aging is "half-life" (h) - a phenomena borrowed from physics - which means
the time during which half the currently active literature was published (Line. 1970).
According to Brookes' empirical law of aging. literature ages exponentially and has a
distribution
Uti) =U(O) x a'
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Fig. 6.5.1 Graphical Method of Estimating Obsolescence
(after Brookes, 1973)
Where U(O) is the total number of cumulative citations and Utt) is the presumed number
of cumulative citations during the t years, a is the annual aging rate.
So that
then
Vet) I
--=a
V(O)
1 V(t)]10,. V (0) = t X loga
(2)
(3)
When t = h, we know U(t)/ U(O) = 0.5 according to the definition of half-life; so we
have
h = logO.5
loga
(4)
To apply Brookes' theory to pharmaceutical area, the following five journals have been
chosen:
1. Chinese Journal of Clinical Pharmacology (OCP) (1985-1987):
2. British Journal of Clinical Pharmacology (BJCP) in 1987:
3. Clinical Pharmacology and Therapeutics, USA (CPT) in 1987;
4. European Journal of Clinical Pharmacology, Germany (EJCP) in 1987;
5. Journal of Clinical Pharmacology, USA (1CP) in 1987;
Three sets of citations from 1985. 1986 and 1987 CJCP have been listed in Table 6.5.1
and 6.5.2 and Ｖ Ｎ Ｕ Ｎ ｾ ｬ
II sing Brookes' technique we can draw a literature aging curve according to each series
of cumulative sum with corresponding ages; and then draw the best straight line by
means of regression (Figure 6.5.2, 6.5.3 and 6.5.4). From the straight line, the aging
rate (a) can be read. Or hy the regression calculation, the aging rate (a) and half-life (h)
can be calculated.
The a and h of citations in CJCP is presented in Table 6.5A. Table 6.5.5 and Table
6.5.6.
Table 6.5.1 Citation in OCP (1985)
Age Year Chinese Citation English Citation Total Citation
number sum number sum number sum
0 1985 14 99 1 286 15 396
1 1984 18 85 32 285 54 381
ｾＭＭＭ
2 1983 19 67 37 253 61 327
3 1982 13 48 43 216 57 266
4 1981 10 35 40 173 50 209
5 1980 6 25 23 133 30 159
6 1979 9 19 15 110 24 129
7 1978 3 10 18 95 21 105
8 1977 1 7 10 77 11 84
9 1976 3 6 6 67 9 73
10 1975- 3 3 61 61 64 64
-----
'1975 or earlier
Table 6.5.2 Citation in OCP (1986)
Age Year Chinese Citation English Citation Total Citation
number sum number sum number sum
0 1986 10 76 6 306 16 387
1 1985 15 66 15 300 30 371
2 1984 10 51 20 285 30 341
3 1983 12 41 29 265 41 311
4 1982 8 29 27 236 35 270
5 1981 11 21 33 209 44 235
6 1980 2 10 22 176 25 191
7 1979 1 8 17 154 19 166
8 1978 3 7 16 137 19 147
9 1977 2 4 30 121 33 128
10 1976· 2 2 91 91 95 95
*1976 or earlier
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Table 6.5.3 Citation in OCP (1987)
Age Year Chinese Citation English Citation Total Citation
number sum number sum number sum
0 1987 4 77 2 238 6 317
1 1986 7 66 14 236 21 ) II
2 1985 11 59 32 222 43 290
3 1984 11 48 15 190 27 247
4 1983 9 37 18 175 27 220
-
5 1982 5 28 18 157 24 193
6 1981 12 23 14 139 26 169
7 1980 6 11 13 125 19 143
8 1979 2 5 13 112 15 124
9 1978 I 3 U 99 15 109
10 1977· 2 2 86 86 94 94
*1977 or earl ier
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Table 6.5.4 Literature Aging Rates, Half-Lifes and Pearson Correlation Coefficents
(Citations in OCP)
Aging Rate a Half-Life h Pearson Coefficient
1985 0.82 3.44 0.995
1986 0.87 4.95 0.988
1987 0.88 5.38 0.994
Table 6.5.5 Literature Aging Rates, Half-Lifes and Pearson Correlation Coefficents
(English Citations in CJCP)
Aging Rate a Ilair-Life h Pearson Coefficient
1985 0.84 ).98 0.992
1986 0.89 5.74 0.980
1987 0.90 6.53 0.994
Table 6.5.6 Literature Aging Rates, Half-Lifes and Pearson Correlation Coefficents
(Chinese Citations in CJCP)
Aging Rate a Half-Life h Pearson Coefficient
1985 0.70 1.92 0.992
1986 0.70 1.92 0.987
1987 O.()t) 1.86 0.959
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Generally, fast aging results from focused use by the more effective information
processing while slow aging results from diffuse use by less effective information
processing (Griffith, 1979).
From Table 6.5.4- 6.5.6, we find in general, Chinese authors cite more recent Chinese
literature than they cite English literature. Drone may say that they "age" Chinese papers
quicker than they "age" English papers. On one hand, it reflects the "shorter life" of
Chinese S&T literature, which is not surprised because of the generally short history of
Chinese modern S&T and the uneven recent development during the 1960s and 1970s.
On the other hand, it may also indicate that Chinese scientists can access and absorb
Chinese information more effective than English information.
There are differences in aging speed in CJCP among the three years too. It seems that
Chinese scientists age literature the quickest in 1985, the modest in 1986 and the slowest
in 1987( Table 6.5.4). This may reflect the different information use and cite patterns
among eminent and ordinary Chinese scientists.
Because CJCP was newly founded in 1985, it is understandable that the editors collected
more papers from prominent or "star" authors in the first year than in the second and
the third year. The "star" authors are those who are among the top 40 highly cited, highly
citing and highly productive authors in the field in China. With the time passing by,
the proportion of "star" authors in CJCP had been decreasing while the proportion of
general authors increasing, so that more scientists could get opportunity to publish in
CJCP. (Lu, 1990) (Table 6.5.7).
Table 6.5.7 Structure of Authorship in CJCP
Year General Authors Star Authors
1985 71% 29%
1986 74% 26%
1987 86% 14%
From Table 6.5.4-6.5.7, we find in CJCP from 1985 to 1987, as the proportion of "star"
declined, the literature aging speed has been slowed down. It might suggest that the
eminent or "star" scientists cite more recent literature or "age" literature quicker than
the ordinary scientists. According to Griffith (1979) "the fast aging results from focused
use bv the more effective information processing core, whereas slow aging resultsfrom
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diffuse use by broad scientific community", the eminent authors in DCP represent the
core or centre of information processing in the subject field. they access and absorb
information more effective than ordinary scientists.
Table 6.5.4 "total citations in DCP" shows that the same trend- literature aging being
slowed down from 1985 to 1987- also applies to "English citations in DCP" (Table
6.5.5) but not to "Chinese citations in DCP" (Table 6.5.6).
This may reflectthat difference in information use and cite between eminent and ordinary
Chinese scientists mainly lays in foreign information use and cite.
To compare the literature aging patterns between Chinese scientists and their western
colleagues, we list the citations by BJCP, CPT, EJCP and JCP in 1987 comparing with
the CJCP citations in 1987 (Table 6.5.8). The comparison shows in general, western
authors cite more recent literature or "age" literature a little faster than Chinese authors.
This result, at the first sight, seems contradictory to the result of user studies in Chapter
5. It is reported that less than 40% of Chinese scientists use literature of ten years old,
compared to 100% British scientists; less than 10% of them use literature of 20 years
old, compared to more than ninety percent of British scientists; the Chinese figure of
using literature of more than 30 years old is very small - only 3% of Chinese scientists
in comparison with 60% of British (see Chapter 5). In fact the fast aging rate by British
authors in BJCP reflects only the statistical effect of the concentration in use or citing
the recent literature. Such a statistical result does not exclude dispersion of citations
over a long time span.
Table 6.5.8 Literature Aging Rates, Half-Lifes and Pearson Correlation Coefficents
for CJCP, BJCP, CPT, EJCP and JCP in 1987
Journal Aging Rate a Half-life h Pearson Coefficent
CJCP 0.88 5.38 0.994
BJCP 0.85 4.25 0.994
CPT 0.86 4.65 0.992
EJCP 0.86 4.65 0.987
JCP 0.86 4.65 0.992
Comparing to Chinese scientists, the western scientists information use and citing
behaviour may be described as: they use wider time span of scientific literature. they
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cite more papers in their work, they "age" literature faster. All these may reflect that
compared with Chinese scientists, the western scientists are more effective in usinzｾ
information.
6.6 Concluding Notes
1. Generally, Chinese scientific journal capacity in disseminating the nation's R&D
results is much lower than that of the British scientific journal. The evidences include
(1). there are not enough journals for Chinese scientists to publish their work; China
has a S&T manpower of 7.8 million which is 35 times the UK figure whereas the two
countries have a similar number of scientific journals;
(2). the average refereeing and editing time for submitted journal paper in China is 1.5-2
times the UK figure;
(3). assuming only senior Chinese scientists as potential authors then the average
publication rate is one paper per scientist per year in China; comparing to 2-3 papers
per academic staff per year in UK universities;
(4). the average number of papers per journal per year in China is 100 compared to 171
in the UK.
2. Because the predominant position of English language in world scientific literature
and the leading position of medicines research by British scientists for several decades,
it is safe to say that all journal papers by British scientists are disseminated at the world
communication circuit.
However, it must note that 4% of Chinese papers in world journals and 10% of Chinese
papers in world secondary publications do not indicate that only such proportion of
Chinese literature are at the same academic level as all British journal papers. It only
indicate that Chinese scientists have a much smaller capacity in disseminating
information to the world than British scientists.
3. A standard of "eminence" requires an eminent Chinese scientist having published 3-4
non-Chinese papers in world journals within one year. Under such a standard. it is
estimated that there are several hundred such Chinese scientists currently. They account
for 0.1 % of -tOO.OOO Chinese scientific authors or 0.005 Ck of total 7.8 million S&T
workers in China.
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The most prestigious of the UK learned societies is the Royal Society with 1000 fellows
currently. Those scientists elected Fellows of the Royal Society (FRS) are regarded as
the most eminent scientists in the UK. They account for 0.4% of total 220,000 S&T
workers in the UK. The average productivity for a FRS is 3 papers per year in a life
time. It is noted that a sample of eminent Chinese scientists have their peak publishing
period starting from their work or study abroad. This may be related to better information
communication condition in the West.
Conclusions 4-7 show that Chinese scientists information using ability is lower than
British scientists:
4. That Chinese clinical pharmacological scientists show more diffuse information use
(over subject width) than their British colleagues as well as than their Chinese colleagues
in pharmaceutical analysis field, may be caused by the premature status of the clinical
pharmacology in China.
The information using capabilities of scientists from one nation (as reflected from citing
behaviour) may be influenced by the academic level or the status of research in a subject
field in the country. Lower academic level and premature research status may result in
diffuse information using by Chinese scientists in clinical pharmacology.
5. Chinese scientists cite much less in their work than western scientists. The average
citation rate in Chinese S&T journals is 5.4 citations per paper comparing to 20.8 in the
world journals covered in SCI. Another example is that OCP has an average citation
rate of 8.6 whereas BJCP has a rate of 18.2. The reasons for less citations in Chinese
papers are complex. One possible influence may be the lower information accessing
ability especially to world S&T information, comparing to the situation in UK and other
developed countries.
6. Chinese scientists have to use over 50% of literature in foreign language whereas
British scientist use over 90% of literature in the native language. This agrees with the
user study result that Chinese senior scientist reported relying on foreign literature more
than on Chinese literature. Greatly relying on foreign language literature means great
difficulty in using information by Chinese scientists.
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7. Generally, fast aging results from focused use by the more effective information
processing while slow aging results from diffuse use by less effective information
processing.
Aging analyses indicate
(1) Chinese scientists can use and absorb Chinese information more effectively than
they use and absorb foreign information.
(2) The eminent Chinese scientists represent the centre of information processing or
using in the subject field. They use and absorb S&T information especially foreign
language information more effectively than ordinary Chinese scientists.
(3) Comparing to Chinese scientists, British scientists use wider time span of scientific
literature, they cite more papers in their work, they "age" literature faster. All these may
reflect that compared with Chinese scientists, British scientists are more effective in
using information.
Conclusion 8-9 may reflect that comparing to the leading position of UK, China has
very small impact on medicines research in the world.
8. Chinese eminent authors mainly have great impact on Chinese scientific society rather
than on the world scientific society. By comparison, British eminent scientists have
major impact on the world scientific society.
9. It is generally accepted that there is a "pecking order" of journals within any given
subject area. In such a pecking order, Chinese scientific journals are ranked much lower
than British and western journals; because Chinese journals receive much less citations
and have less impact in the world than British and western journals.
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Chapter 7 Pharmaceutical Information Flow Infrastructure in Britain
A nation's pharmaceutical activity normally consists of the following elements - R&D.
manufacturing, marketing, rational use of drug, legislation and regulation; and with the
following sectors involved- the industry, academic institutions, national health and care
system, and government authority on medicine safety. Pharmaceutical information flow is
associated with pharmaceutical activity in a country. Within the pharmaceutical industry,
the information flow infrastructure is just like the nerve system in a human body, com-
manding every action of the body.
In this thesis we define pharmaceutical information as "the information related to phar-
maceutical research and development and pharmaceutical products" which are divided into
the following five categories:
(a) scientific and technical information; for this kind of information, the users include R&D
staff in pharmaceutical firms and researchers in universities, colleges or other institutions.
(b) business information; the major users for this kind of information are managers in
pharmaceutical companies.
(c) drug information; for this kind of information, most requests are from GPs, hospital
doctors and other health professionals.
(d) patent information; on one hand, pharmaceutical R&D need patent information for
current awareness and retrospective retrieval, on the other hand, for research based phar-
maceutical companies an effective patent protection system is vital for their survival.
(e) statutory information; which is requested by government authority from pharmaceutical
R&D institutions when they apply for the approval of clinical trial or from pharmaceutical
companies when they apply for the approval of marketing a new medicine.
In the following two chapters we attempt to draw a more comprehensive system picture of
pharmaceutical information flow in UK (Chapter 7) and China (Chapter 8). Based on the
advanced UK information flow infrastructure, a conceptual system model will be drawn in
Chapter 9.
The main elements of the UK pharmaceutical information flow infrastructure is shown in
a diagrammatic form in Figure 7.1.
As has been reviewed in Chapter 1, there are a large number of information studies on
pharmaceutical information in UK, since the pharmaceutical information has been of ever
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Fig 7.1 Pharm aceutical Information Infrastruc ure in UK
increasing importance in this country for the last few decades. Many aspects of pharma-
ceutical information have been studied by experienced information staff in industry. in :\HS
and in academic institutions. All these have provided this Ph.D study with a very rich
knowledge resource. To supplement the existing studies, the author have selected and visited
several information systems of each type:
1. S&T information systems
In the S&T information system (as shown in Fig. 7.1), there are three major work forces
i.e. publishers for primary literature, abstracting and indexing services (both printed or
computerized), and S&T libraries and departments.
In October of 1990, with the S&T information delegation from Academia Sinica, the author
visited BLDSC and SRIS. In this Chapter, data on BLOSC and SRIS are collected during
the visit. Also during the same academic tour in UK, the author visited three UK university
libraries at ｌｯｵｾｨ｢ｯｲｯｵｾｨ University. ｾ ｾ University. anQ Southampton University.
In this Chapter, data and discussion on UK academic universities have been discussed with
the librarians in the above libraries.
2. Business information systems
In August of 1989 and September of 1991, the author has twice visited the leading phar-
maceutical information publisher £IB in UK. One American based information company
ｾ and one French based business information company SVP have also been visited
and studied.
3. Company information systems
In August of 1989, the largest UK pharmaceutical company GJaxo and the another world
largest pharmaceutical company Fannitalia's UK branch have been visited. The information
officers there have kindly spent their time to describe and demonstrate the information work
in their companies.
4. Drug information systems
In March of 1989. the author have visited the library of School Qf £hannacy ill LQn.dQn.
and ｾ &2X.al £harmaceutical Society' library and information service. The chief librarian
and information officer there have described and demonstrated the information work in
their organizations.
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5. Patent information systems
In October of 1990, with the Academia Sinica delegation, the author visited the patent
infoonation division at SIRS. The patent information work and network in UK have been
described and demonstrated by the information officers there.
6. Statutory information system
Finally, the Centre for Medicine Research CCMR), as an unique information and scientific
research resource in Europe on some aspects of pharmaceutical industry, was visited by
the authorin the October, 1991. CMR was established by the ABPI in 1981 as an independent
scientific unit to undertake research into the development and safe use of medicines. By
working closely with pharmaceutical companies in European countries, USA and Japan,
CMR has established several databases, including international. ｾ Qf ｾ
medicines, UK product databases. control animal ｰ ｡ ｴ ｨ ｯ ｬ ｯ ｾ ｹ database. internationa11Oxi:
ｾ database and ｾ･ｮ･ｲ｡ｬ practice database etc. which constitute an unique resource for
the international pharmaceutical industry. Its contribution also includes several aspects of
medicines research, such as New Chemical Entities (NCEs), patents, R&D expenditure,
harmonization of toxicology guide-lines, etc ..
7.1 UK Publishers for Primary S&T Literature
In UK, the primary S&T literature is published by commercial publishers and university
presses. The UK publishing industry is among the largest publishing industry in the
world. Since 1950 when output of titles in the UK was under 20,000, the total rose to
over 62,000 by 1988. By the year 2000, it is estimated as likely to reach 90,000 titles
(Enright, 1990). There is no clear picture of the total number of learned or scholarly
journals in UK. According to the Royal Society survey in 1981 (Royal Society), there
are 1500 such journals excluding engineering, clinical medicine and social science.
Another estimation puts the number of UK learned or scholarly journals at some ..t(X)O
(Vickery, 1987).
Before the World War II, the publication of learned scientific journals was a small and
not very profitable business. Since then, however, there has been a massive increase of
journal literature. One effect of the information explosion has been the substantial
improved profitability oflearned scientific journals. Commercial publishers have moved
into what had previously been largely the preserve of learned societies, although the
large proportion (6:'%) of UK learned journals is still in the hands of learned societies
(Royal Society. I (81).
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As a consequence of the improved profitability, for the last twenty or so years. there
has been a rapid inflation in journal price in the UK and world-wide which is said to
have kept higher than general inflation rate (Royal Society, 1981 & Burrows. 1989).
For example, during the past ten years (1980-1990), there has been a rapid escalation
in journal prices, the average increasing by 245%. The UK university pay and price
index, considered to be conservative and in arrears, gave a value of 235.6 at July 1988
(Nov. 1980 =1(0) for books, periodicals and binding compared with 160.9 for all other
non-pay items (Enright, 1990).
The combination of the proliferation of scientific literature and the inflation of its price
has put enormous pressure on library acquisition and collection not only in academic
libraries but also in industrial and other kinds of libraries.
7.2 UK Abstracting and Indexing Services
The major abstracts and indexes databases are international in both their coverage and
their sales. Several major services are based in UK, for example INSPEC. CAB, and
Information Retrieval Limited. Publishers or producers of the UK abstracting and
indexing services are commercial firms, learned or professional societies, government
bodies and academic institutions.
Using Inventory ofAbstracting and Indexing Services Produced in the UK (BL, 1983,
1986), Steptens (1987) presented a brief survey of UK secondary services. He shows
that the UK secondary services community is continuing to develop in response to
demands from the marketplace, both in terms of producing new services and in increasing
the availability of services online. There were 430 UK secondary services available in
1986 which represented an 11% increase since 1983. About 46% of services in 1986
could be accessed online, compared with just 31% in 1983. The number of online
bibliographic databases comprising these services almost doubled over the same period-
from 50 in 1983 to 93 in 1986. The UK abstracting and indexing services produce about
3 million bibliographic references annually.
US dominates both the world S&T secondary publication and the world S&T online
market (70CJc of the world market) while other major market forces are from Europe
and Japan. The share of world online market (S&T section) between US and European
is shown in Table 7.1.
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Table 7.1 West Europe and North American Online Revenues Forecasts
1989-1994 (in US$ million) (Fischer, 1990)
year 1989 1990 1991 1992 1993 1994 growth rate p.a.
S&T in Europe 180 205 225 245 275 295 10%
total in Europe 2417 2844 3432 4120 4929 5828 19.2%
S&T in US 423 503 599 712 848 1010 19%
total in US 8587 9675 10916 12335 13962 15829 13%
Table 7.2 General Secondary Sources in Pharmaceutical Areas (data in 1988)
name year journal country records Issues database online
coverage coverage coverage number per year via hosts
per year
BRS, STN
DATASTAR
CA (US) 1907- 12,000 100 500,000 weekly CA DIALOG.
ESA-IRS,
ORBIT etc.
DATASTAR
1M (US) 1960- 3200 70 250,000 monthly MEDLINE DIALOG
BRS,NLM
etc.
EM DATASTAR,
Nether- 1946- 4500 110 250,000 monthly EMBASE DIALOG
land BRS etc.
SA (US) 1926- 8580 100 262,000 serm- BIOSIS DIALOG
monthly BRS,SDC etc.
serru- DIALOG
IPA 1964- 700 - 12,000 monthly IPA BRS, SDC
(US) NLM etc.
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In pharmaceutical areas, the major large international English language abstracting and
indexing services include Chemical Abstracts (CA), Index Medicus (1\1), Excerpta
Medical (EM), Biological Abstracts (BA), International Pharmaceutical Abstracts
(IPA) and Science Citation Index (SCn. The large world secondary publications could
cover most ofUK scientific literature (Royal Society, 1981). They all are online available
via international hosts (Table 7.2).
The three major services based in USA - CA, 1M and BA use British organizations to
abstract and index the British published literature.
7.3 S&T Libraries and Information Departments in Britain
Libraries have a pivotal position in scientific information dissemination and is one of
the most important channels for scientific and technical information. Libraries in the
UK may be grouped in the following categories:
(a) the British Library, the National Library of Scotland and the National Library of
Wales;
(b) public libraries
(c) university, polytechnic and college libraries;
(d) school libraries;
(e) internal libraries of industrial, commercial, and government establishments, and
hospital libraries;
(f) libraries of learned societies, and other independent not for profit libraries.
In the UK, the S&T library/information systems have been well organized at national
level with a comprehensive and effective back-up documents supply service provided
by the national scientific lending library: BLOSC. There are about 400 S&T libraries
serving the total 220,000 S&T workers in the country (Royal Society, 1981).
National S&T Libraries
During the 1950s, the UK government decided to set up two major national scientific
libraries. one for lending and one for reference. The former is today' s BLOSC. The
Document Supply Centre (BLOSC) is responsible for supplying a wide range of cus-
tomers with documents of any kinds. The latter. today' s Science Reference and Infor-
mation Service (SRIS) provides information and reference services to scientific and
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industrial customers nationwide. Following an internal reorganization of the British
Library in 1985, BLOSe and SRIS became the two units of the newly formed Science.
Technology and Industry division.
The origins of the SRIS go back to the Patent Office Library founded in 1855. In 1966.
the British Museum took over the Patent Office Library to set up a new national S&T
reference library NRLSI which changed name as SRIS in 1985.
SRIS is internationally unique, there being no counterpart anywhere to its very large
collections. S&T periodicals are acquired from most countries, irrespective of the lan-
guage, but in general books are taken only if they are written in English, French or
German, or in the case of other languages, only if they describe a subject on which the
country of origin may be expected to have special knowledge. The only publications
held indefinitely in SRIS are patent specifications and abstracting journals.
In 1989/90, it holds 229,000 monographs, 31 million patents and 67,000 serial including
30,000 current periodicals. In 1989/90 its acquisition are 6,882 monographs, 1.1 million
patent specifications and 29,484 current serial (BL 17th annual report 1989-90). On
this resource, SRIS provides several services including photocopy, industry property,
patent information network, business information, computer searching, biotechnology
information, Japanese information etc .. During the 1980s, Patent Information Network
(PIN) was created in the country. Now it is made up of7 patent libraries (equipped with
patent documents and searching tools) and 12 patent information centres (equipped with
patent searching tools only). They are based in local authority reference libraries. SRIS
with an annual intake of over one million world patents, provides the documentation
itself as well as substantial support to the national network in the areas of training,
promotion and marketing (SRIS, 1990)
BLOSe is regarded as one of the world's most comprehensive and effective library
systems of its kinds. It is concerned with collecting publications and making them
available both within the UK and world-wide. Its special purpose is to supplement the
resources of other libraries and it does this by lending and making photocopies from its
own stock.
Because of the lack in demands for foreign information. BLDSe has made its acquisition
policy as
"to collect serial literature in all subjects from all over the world and in the
vast majority of languages.
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"to try to obtain all serious, academic and research level monographic item
in the English language wherever published but to be very selective in
purchasing foreign language monographs." (BLDSe, 1990)
In 1989190, BLDSe holds 2.8 million monographs, 211,000 serial including 55,000
current serial, 3 million reports in microfilm, and 510,000 theses. In 1989190 it has an
annual intake of40,000 monographs, 55,000 serial, 130,OOOreports in microfilm. 10,000
theses (BL 17th annual report 1989-90). Based on this resource, every two seconds
BLDSe handles another request for documents from anyone of more than 12,000
customers world-wide. In 1989190, it received total of 3,320,321 requests of which 76%
from UK and 24% from overseas. Also in 1989/90, its satisfaction rate was as high as
92.3% (87.6% were satisfied from its own stock) (BLOSe, 1990).
Academic Library
There are about sixty universities in UK which play an important role in R&D in the
country. The number of R&D staff in universities has slightly grown from 6,300 in 1983
to 8,400 in 1989 (Annual Review on Government Funded R&D, 1990).
The UK university libraries may be divided into three groups
1. Large library with
collection: 1.5-4 million volumes;
periodical subscription: over 10,000 titles;
library staff (full time): around 200;
2. Medium sized library with
collection: 0.5-1 million volumes:
periodical subscription: 5,000-10,000 titles;
library staff (full time): around 100;
3. Small library with
collection: 0.1-0.5 million volumes;
periodical subscription: 1,000- 5,000:
library staff (full time): around 50:
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A rough estimate is that there are about 5 in the large library group. 12 in the medium
sized library group, and 25 in the small library group! I (Library Year Book 1985-1987).
As a typical small sized S&T university in UK, the Pilkington Library in Loughborough
University has about 80 staff, just under £800,000 budget and around three hundred
online searches annually. Its collection of over 500,000 volumes and 4000 current
journals serve the university's 800 academic and research staff, 4500 undergraduate
students and 1500 postgraduate students.
For the last ten or more years, British academic libraries have faced major financial,
technological and organizational challenges. Cut in funding, the spread of IT and
changes to the provision of higher education as a whole are combining to alter funda-
mentally the circumstances in which academic libraries operate.
Line (1990) has recently identified the main current issues in UK academic libraries.
"The main fundamental problemfacing academic libraries is their inability to maintain
their acquisitions and services at present levels.
"Even in countries that are relatively wealthy, governments are trying to cut public
expenditure and since higher education accounts for a significant amount ofthis, it has
received reduced government funding over the last decade or two.
"Since staff account for a high percentage of all recurrent expenditure in academic
libraries- in the UK typically about 55%- saving have had to be made here.
"Books and journals have increased in price a good deal faster than general inflation
for several years. Ifa library were to buy the same proportion ofoutput that it acquired
10 or 20 years ago, it would have needed an increase in acquisition funds ofsomething
in the order of15% per annum on average. It is safe to say that no library has received
funds of this kind.
"Information Technology is having a big effect on libraries. though to date this has been
confined mainly to "housekeeping" automation- of catalogues. issues records,
acquisitions and so on."
II Some university libraries have no full records in the source book.
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Resources Sharing and Documents Supply in UK
It is estimated currently there are some 14,000 chemical related S&T journals and some
20,000 biomedical and life science journals in the world (Mullen, 1990 & Duckitt, 1990).
No single S&T library but national library could afford to collect such vast amount of
journals today.
In 1961, the National Lending Library for Science and Technology was establ ished, a
library which has now become BLDSe. The concept for such a national lending centre
has been that a large central collection dedicated to document supply can achieve a
higher fill rate and faster speed of supply than systems involving cooperation between
libraries. The BLDSe own stock could satisfy about 87.6% of all British interlending
demand, the remainder 4.7% is satisfied by other library sources with only 7Cfc unsat-
isfactory. The annual requests to BLDSe has doubled to over 3 million during the period
of 1972-1990. Request from academic sector accounts for 40% of total demands in
BLDSe while industry accounts for 28% (BL 17th annual report 1989-90).
7.4 Business Information
Business information is a boom industry in UK in the 1980s, partly owing to the
"Thatcherism" market economy which is in favour of capitalism and competition, partly
owing to the ever improved IT. Since 1988, Headland Press has carried out an annual
survey on UK business information industry. Using its publication Business Infor-
mation Yearbook (1988/1989, 1989/1990, 1990/1991), one can get a good outlook
over the status and trends of business information industry in UK.
7.4.1 Trends
The trends for the last half of 1980s are summarized as follows:
1. New start-ups
New business start-ups are a continuing trend in an industry like business information.
It is the kind of sector in which the cottage industry is an appropriate form, because
the strength of any publishing organization is its ideas.
2. Public sector involvement
There is a lot of pressure on public bodies who collect and disseminate business
information to realize the wealth that they could create. Thus the Companies Reg-
istration Office is seeing its status change to one of government agency. responsible
for its own income and expenditure. The British library with its commercially
operated business information services. is becoming far more outgoing in marketing
206
....
its services. A self-financing Business Information Network was created by SRIS in
July, 1989. It will take and consolidate information through existing links with public
sector libraries. Likewise, many public libraries are considering whether and how
to become involved in the provision of business information.
3. New formats
After an explosion ofnew products in the mid-1980s, most market niches for business
online databases in the UK are now more or less filled.
In 1990, CD-ROM made a stronger impact on the UK business information scene.
However, CD-ROM appears to have made more headway in the secondary rather
than primary information market. There is some debate as to whether CD-ROM with
monthly or quarterly updates is a suitable medium for fundamental financial data.
Experts' view is that many heavy users of company data will tend to use CD-ROM
data as first resort and update it with online access. The trend in CD-ROM business
databases development is still not clear.
7.4.2 Sources and Services
1. Business Publishing
Business publishing is growing faster than many other sectors of the UK publishing
industry. Apart from the increase in the number of publications, the buoyancy of
business publishing is exhibited in the hectic activity in the marketplace, including
takeover, alliances and new companies launches.
In past few years, the author visited PJB Publications in Surrey several times. PJB
is a UK based pharmaceutical business information company with about 130 staff
and annual turnover of over 9 million pound in 1990. PJB publishes a range of
international business newsletters, annuals and special reports for senior executives
in the pharmaceutical areas world-wide.
PJB currently publishes 5 business newsletters Scrip, Clinica, Animal Pharm,
Agrow, Haznews; and the annual Pharmaprojects.
Scrip - a biweekly journal - covers all types of information concerning world
pharmaceutical industry and market such as sales statistics. medical statistics. product
information. company information, country information and R&D activities etc.
ｾＨＩＷ
Updated monthly, Pharmaprojects provides business information (R&D, products,
marketing etc.) on over 5500 drugs in active research and development in 800
companies and 200 therapeutic fields world-wide.
All business newsletters can also be accessed online via host Data-Star, as part of
PHIND- The Pharmaceutical and Health Industry News. Pharmaprojects is also
available online via Datastar with two files covering current and discontinued drugs.
PJB also produces a wide range of reports relevant to the pharmaceutical industry.
Reports are written by in-house specialists with additional material supplied from
editorial staff on the business newsletters.
Most important in the supply of market data to the pharmaceutical industry is
International Medical Statistics (IMS). IMS international group is an international
business publisher and at the same time a database group with operations in more
than 60 countries and an annual turnover in excess of $400 million. By 1989, it has
got 10 years experience in online services to its users over the world. IMSBASE is
one of its major pharmaceutical business databases containing the full text of many
IMS hard copy publications and online available via IMS.
Among many regular business publications of IMS, there are Index of Drug
Chemicals, Pharmaceutical Market World Review, Leading International Products
Review, Leading International Generics Substances etc ..
Aiming at providing pharmaceutical industry managers current business information,
IMS publishes the well known Marketletter, which perform a very similar function
to Scrip.
Gurnah (1991) has selectively described business information sources available to
pharmaceutical industry. He provided a summary of 26 textual databases covering
information relevant to marketing and commercial departments in pharmaceutical
industry: 13 US based, 10 UK based, other three from Japan, Austria, and Holland.
Except IMSBASE and other two online databases which are hosted by the database
producers, all others are online available via general hosts such as Dialog, Datastar
etc.
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2. Company Information
After many years of stagnation, company directories are going through something
of renaissance. The major recent developments in company information have been
the continuing improvement in the services offered by Companies House (previously
Company Registration Office), anew generation of business directories, and link-ups
between print and online producers.
By law all limited companies (over 1 million pound) are required to submit audited
annual accounts to Companies House. Apart from information services provided by
Companies House, many information providers or "brokers" processing and delivery
annual reports and accounts of specified companies on request. Other suppliers
reproduce financial data in cards, press cutting as well as electronic delivery and
floppy discs; ranking within an industry by performance ratios.
Disclosure is an American company who recently opened their first UK branch in
London. Specialising in US companies reports, the London office provides man-
agement, financial and stockholder information on more than 12,000 companies
whose stock is traded on the N.Y. Stock Exchange, National Association of Securities
Dealers Automated Quotations system or Over-the-Counter, and London Stock
Exchange. It claims to be able to offer a hard copy delivery service within two hours
of order (in centre London) and 24 hours elsewhere.
It also runs a service similar to SDI, providing corporate profiles which contain a
company resume, major financial and earnings data, complete list of subsidiaries,
president's letter, management discussion, and information on officers and directors.
In pharmaceutical areas, PJB commissions studies on individual companies form
time to time. Other PJB publications on companies include Scrip's Pharmaceutical
Company League Tables (annually), and the Directory of Pharmaceutical Com-
panies.
Similarly IMS also regularly publishes information on pharmaceutical companies.
such as Guide to Pharmaceutical Company Sales. v/orld Drug Marker Manual etc.
These information are also available online in I\1SBASE.
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3. Market Information
Sales statistics about sales revenue of competitors, market outlets, and products is
of immense interest to pharmaceutical managers. Most important sales statistics
source is International Medical Statistics (IMS) which collects sales data from either
wholesalers or pharmacies in more than 40 countries in the world. For some of the
developed counties, the data are virtually census data, covering over 80% of the
market there.
All industries need market research surveys to know their customers' opinions. In
the pharmaceutical industry, this kind of market research is carried out with doctors
to determine patterns of usage, potential markets, new therapy needs and so on.
There are innumerable business consultants or organizations specialising in all
subjects who publish a great number of market research reports. Today, the Market
Research Society representing the profession in UK has 6500 individual members
(MRS Yearbook 1989).
In pharmaceutical field, IMS regularly produce medical surveys in several major
countries. It publishes Medica/Indices, Medical Market World Review and other
information providing data on major diseases and therapy areas in the world. PJB
also conducts a certain number of medical market survey and research each year and
publishes reports, monographs and other documents.
Other medical statistics sources include WHO, some countries' official publishers,
such as HMSO in the UK etc ..
Product information can be obtained from the manufacturers data sheet which
accompanies the product. Most major countries publish national datasheets collec-
tion. For example, ABPI Data Sheet Compendium is published annually by
Association of British Pharmaceutical Industry. An international publication on
therapeutic agents with references to the market products is Martindale - the Extra
Pharmacopeia by Pharmaceutical Society of Great Britain. This publication is
updated regularly not necessarily annually and is online available via Datastar.
PJB and IMS also provide regular or occasional products information ether in hard
copy or in electronic forms.
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4. R&D Activities Monitoring
Because the modem pharmaceutical industry is characterized by high R&D
investment and high risk, monitoring competitors' R&D activities and trends is one
of the major task in business information work.
There are two major publications which provide this information; one by PJB group
called Pharmal'rojects (monthly), the other by IMS called Drug License Opportu-
nities (weekly). Both publications are available online.
5. Online Business Information
Online business databases are revolutionising the use of business information.
Headland Press' Online Business Sourcebook (1990) gives the following review of
Changing Landscape:
"Computer technology has shaken up the traditional structure ofpublished business
information. ... Another important and related characteristic of the new electronic
system is a shift away from the physical collection ofinformation to an access-based
strategy. Instead of investing large amounts on materials and staff costs in buying
and organising collections of information, companies and other organisations will
rely much more in the future on accessing relevant external information in response
to a particular demand. "
In the world online market, business information contributes about 90% of the
revenue, the remaining revenue is from legal, S&T, news and other information
(Fischer, 1990).
A forecast on the growth of world online market divided by US and European is
shown in Table 7.3.
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Table 7.3 West Europe and North American Online Revenues Forecasts
1989-1994 (in US$ million)- (Fischer, 1990)
year 1989 1990 1991 1992 1993 1994 growth
rate p.a.
business 2286 2584 3145 3806 4579 5448
(Euro)
total 2417 2844 3432 4120 4929 5828 19.2%
(Euro)
business 8132 9136 10277 11578 13063 14762
(US)
total 8587 9675 10916 12335 13962 15829 13%
(US)
The Headland Press's Online Business Sourcebook (1990) included around three
hundred major business information databases in the West.
6. Information Services/Brokers
The information broker was defined by Crawford in 1988 as "an individual or
organization who on demand seeks to answer questions using all sources available
and who is in business for profit".
By 1987 there has been about 150 such brokers in UK. Although most work force
in business information is in private domain, there has been a trend for public
organizations to move into this area.
Many organizations offer on-demand information services and based on a major
in-house information resource, such as Disclosure UK mentioned above. The author
visited another one of such "brokers"- SVP UK in London in the spring of 1989.
SVP UK is the UK member of the SVP international network of business information
companies. Over 110,000 users in 16 countries ask SVP 8000 business questions
every working day. Questions fall into the following categories:
- companies, products. business services:
- marketing. sales promotion, advertising;
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- finance, taxation, exchange;
- governments, politics and social affairs;
- the economy and international trade.
SVP UK is associated with IFF Research UK L1D - a major independent industrial
marketing research company. IFF has made over to SVP its business information
centre, built up over 18 years in research. IFF survey researchers are available to
carry out project work for SVP clients. SVP researchers are developing and updating
the information centre, and using subscriptions to over 300 databases world-wide to
provide inquiry answering.
SVP operates on a subscription basis with each subscription tailor-made for each
particular company depending on the type of information required.
7.5 Information Services in Pharmaceutical Companies
The pharmaceutical industry is a high-technology, high-investment and heavily
information-based industry. The final output of this effort was the introduction of a small
number of chemically new drugs plus a massive volume of data related to the phar-
macological and clinical properties of these substances and chemically similar sub-
stances that failed to prove safe and effective for the treatment of human disease.
In general, information work in a R&D pharmaceutical company is allocated into the
following units: scientific and technical information unit, medical information unit,
business information unit, statutory information unit, representative/promotion unit, and
internal database system (Fig. 7.1).
Among research based companies, information services may differ from each other,
depending on the organization structure and management of a company. However, S&T
information unit and medical information unit are most likely to be found in all research
based pharmaceutical companies.
A survey on information work in 18 British pharmaceutical companies was carried out
(Clark, 19R5). It reported all large research based companies have S&T library/infor-
mation department. All the companies have medical information service, and have
internal databases (HO% have been computerized by the time of survey). All companies
use online for external databases searching. All companies produce internal information
bulletins.
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In the UK research based pharmaceutical companies, approximately Ylr of the R&D
work force is in information division. Thus a common level of 100 S&T information
staffand 10-20medical information staff in some majorcompanies is not unusual (Ward,
1990).
7.5.1 S&T Information Work
Key activities seen within most scientific and technical information units include:
1. Providing access to all forms of publicly available information: books, journals,
patents, standard, government publications, reports, statistics, the media; primary,
secondary and tertiary material; print and non-print formats.
2. Management of library stock.
3. The review of published literature to support consideration of possible areas of
future research.
4. Searching the world's chemical literature and patents to establish the novelty of
a newly synthesized chemical as a potential drug candidate.
5. Informing research staff of current developments and new methodology in their
particular speciality.
6. The collection and systematic storage of all data generated on research compounds
in a fonn which assists review of activity and comparison with known drugs and
previous research compounds and which also meets legislative requirements.
7. The maintenance of stores of company compounds as a source of samples for
examination in new test areas.
8. The monitoring of changes in legislation affecting the industry.
9. The provision of published and unpublished information to the registration
department for use in product licensing activities.
The following examples are drawn from the two of the top 7 UK companies: GLAXO
and fCl Pharmaceutical Division.
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GLAXO
Glaxo Group has subsidiary companies in nearly 50 countries, employs about 30,000
people among whom 2500 are R&D staff. In UK, Glaxo employs 1900 scientists
and technical supporting staff. To support R&D in Glaxo, the company has an
information system with 110 staffand two units- one in charge ofinternally generated
information company information and user support unit and another in charge of
published information published information unit. The structure of organization is
shown in Figure 7.2.
The allocation of manpower to the main activities is 50% in information services
concerned with internally generated information and collections, 30% in information
services based on external and published sources and 20% in library services.
The mission of the published information unit is to ensure that the employees of
GlaxoGroup Research are able to derive benefit from all the information in the public
domain.
It has made a large investment in current awareness. Journal scanning is used to
compile bulletins on all areas of interests; in all there are 35 thematic bulletins each
month. In addition, there are three weekly news sheets which are accessible online.
Most information retrieval enquiries from company R&D staff are now satisfied
using online searching. In 1987, about 5,300 searches via 25 hosts were carried out,
an increase of 35% on the previous year.
The library services aim to ensure efficient and cost-effective access to published
information: to ensure that the library stock is relevant, comprehensive and current;
to obtain photocopies and loans using BLDSe and other specialist libraries.
Two major internal databases in Glaxo are Glaxo Product Databank and Glaxoline.
The Databank contains key factual information about Glaxo s products: providing
an source of information which may be used to produce consistent replies to the large
number of enquiries for information received by the company world-wide. The
Glaxoline is the database covering the published literature (now up to 30,000 papers)
on Glaxo drugs. These two databases are accessible online throughout International
Packet Switching Network (lPSS) from more than 20 countries by over 20() users
in Glaxo companies world-wide.
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ICI Pharmaceutical Division (Jackson, 1987)
Around 4000 people are employed in the UK by ICI Pharmaceutical Division and
10,000 world-wide. The information service at the headquarter has a staff of 50. The
allocation of information staff is 40% in internally generated information services.
32% in information services based on external and published sources and 20Cft in
library services.
Information services based on external sources include patent information, confer-
ence proceeding information, SDI services, in-house bulletins, journal literature
information, secondary services, company information on competitors. statistics etc.
The percentages of expenditure of ICI pharmaceutical division on the different
categories of purchased materials (1985) are: 26% in Online and SOl. 29% In
monographs, 3% in BLDSC loans, 38% in Journals. and 4% in Patents.
The ratio of expenditure on patents, journals, BLOSC and monographs have not
changed significantly over the last ten to fifteen years, with online searching as an
added cost. Nonetheless the online costs are more than justified by the many
advantages of it.
Over the recent years, the number of unique serial titles to which ICI pharmaceutical
division library has subscribed averages 1,400. Each year the subscription list is
reviewed and about 50 titles fall off and 50 new ones come in. In contrast to the trend
of steadily cancellation of periodicals in UK academic libraries in 1980s (it was
reported that during 1980 -1986, periodical subscription were predominantly reduced
by up to 13% in UK academic libraries (Burrows, 1989) ): the leI example indicates
a relatively good financial situation in UK pharmaceutical industry information
services.
7.5.2 Medical Information Work
During the R&D process for a new drug, the medical information unit takes over
the task of amassing, evaluating and disseminating information so that when
marketing commences the unit is fully prepared to take responsibility for providing
an information service on the product. Internally. it receives inquires from company
physicians, sales representatives, registration personnel, etc. Externally. services
will be provided to doctors. pharmacists and other health care professionals (Table
7.4).
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Table 7.4 Medical Information Services in Pharmaceutical Industry
source from (Ward, 1990)
Enabling services Monitoring published and internal information on company
drugs.
Maintenance of collections of product information.
Development of approved responses to enquiries.
Monitoring competitor information.
Internal services
I.Sales & marketing Training of sales representatives. Approval of product
advertisements, labelling and press releases. Preparation of
technical and product monographs.
2. Regulatory affairs Support for preparation of prescribing information docu-
ments, patient guidance. Compilation of bibliographies for
product registration.
3.Clinical research Editing company papers for publication. Preparation of
slides for external meetings. Literature reviews to provide
background for proposed studies.
4. Drug surveillance Published literature monitoring for adverse events. Ensuring
that external enquiries relating to ADR are formally
reported.
External services Handling enquiries on all aspects of company products and
related areas. Product complaints.
In Britain, most companies recognize that the marketing of products with complex
pharmacological nature requires a back up service to doctors. A product can only be
marketed successfully if its full potential as well as its toxicity and side effects are
understood. Most pharmaceutical companies have their medical or drug information
divisions based on "products profile". According to the ABPI 1982 survey to its 93
members, 61 British pharmaceutical companies received 13.786 external inquiries
in a four week period, an average of 226 inquiries per company per month (Williams,
1984). In 1988, ABPI repeated the survey which indicated the ever increasing
importance and activity of medical information services provided by UK companies.
In 1988,63 UK companies received 16,856 inquiries over a four week period. That
is an average of 268 inquiries per company per month (Huntingford, 1()90).
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Generally, the generic companies in ABPI do not handle such inquiries, and small
companies do not have formal medical information divisions. In 1982,44 companies
of the 61 respondents (72%) had medical information divisions while the others
(28%) dealt with inquiries by other technical or marketing departments. In 1988.63
companies of 74 respondents (85%) had medical information divisions and other
15% of companies dealt inquiries by other departments.
Apart from general reference books, all the 63 medical information divisions use
commercial secondary sources. It should be noted that after the 1982 survey, the
industry recognized the growing value of online commercial secondary sources of
biomedical information. In 1982,70% ofrespondents usedcomputerizedcommercial
secondary sources, whereas by 1988 the figure rose to 87.3%. In 1982, 57% of
respondents used manual commercial secondary sources whereas by 1988 the figure
fell to 31.7%. The number of databases used by UK companies for medical infor-
mation services has risen from 13 in 1982 to 19 in 1988.
There has been little change in the overall number of companies using and main-
taining inhouse specialist collections- 59 of 61 respondents in 1982 comparing to 63
of63 respondents in 1988. However, the emphasis between manual and computerized
systems has changed considerably- from 24 of 61 companies (39%) using com-
puterized systems in 1982 to 49 of 63 companies (78%) in 1988.
7.5.3 Business Information Work
As an example, we quote the description of business information services in Glaxo
Group Research as follows:
"1. To ensure that published information relevant to the business interests of GG R
and other Group Companies is identified and disseminated in a timely and cost-ef-
fective manner:
*To monitor the national daily and weekly press, the business press and
the popular medical press for news of relevance to Glaxos interests.
* To disseminate selected items through the PRESSCAN service to
senior staff in GGR, Glaxo Pharmaceuticals and Glaxochem.
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* To provide defined current awareness services to key individuals by
monitoring the media for information and data on specific companies,
markets and countries.
2. By using the resources of the World's published information, modern techniques
for retrieval, and appropriate skills andjudgement for evaluation, to answer inquiries
from Glaxo staff concerning markets, companies and countries of importance to the
Group." (Material from the visit to Glaxo on August, 1989).
7.5.4 Internal Data Management
1. Internal generated information from each major R&D stage
It is said that for every new drug in the world market, more than 8,000 compounds
are studied and discarded. A databank in a large R&D based company normally
contains at least as many as 50,000 compounds with all sorts of chemical, pharma-
cological, toxicologic information generated during the many years of R&D; all sorts
of medical information during the many years phase I-III clinical trials; and all sorts
ofproduct information during later years ofpostmarket surveillance (Cuddihy. 1975).
It should be pointed out that most research collections in large pharmaceutical
companies have several hundred thousand compounds, but the numbers decrease
very rapidly at and beyond development stages (Bawden, 1991).
During the drug development stages, information scientists in a company usually
have to build a proprietary database system to store every kind of information
generated from each stage. These include information on - preparation, purification
and assay of the new chemical substances; early pharmacologic screening data to
select substances that are potentially biologically active; subsequent more extensive
pharmacologic/toxicologic tests to select the most promising compounds for testing
in humans.
This proprietary database system needs to be maintain in a form which assists
scientific review of compounds and which meets legislation requirements for patent
application, for Clinical Trial Certificate application etc.
During the clinical trial process, the process of collecting and of checking the
information requires regular visits to investigators or doctors. A major task begins
once these records are received inside the pharmaceutical company, the company
must hold the information in a form suitable for interrogation and analysis ready for
compiling regulatory submissions, either to extend the investigational licence or to
be granted a marker licence.
It must also expect questions later on from regulatory authorities, from health care
professional and from internal staff who require ease of access to the information.
The information needs extend beyond the individual clinical trials, to all human
studies and clinical trials, and to the total world-wide experience with the new
medicine.
The information work involved in premarket clinical evaluation phases is massive,
because the number of patients involved (2000 and above), the number of items of
information obtained on each patient over weeks or months. and the complexity of
the information. After marketing, clinical trials continue to provide information to
further refine the manner in which the drug is used and also the company must
establish a general method of surveillance for collection of physician experience.
2. Types of internal databases
The philosophy of today for most multinational companies lies in the creation of a
comprehensive database containing information on efficacy and safety from its
sponsored studies and trials performed world-wide.
There are essentially two major types of internal databases - one group serving the
R&D activities inside a company which is more internal and less known to outsiders;
and another for answering product information enquiries both externally and inter-
nally.
Product information include unpublished internal research reports, product licence
and ingredient data, correspondence, and drug surveillance reports. It also include
published literature on products for example journal papers and other documents.
"It is common to find internal databases which index all papers on company products
for later retrieval. In the large international companies such databases are often
developed by the parent company and are available online to subsidiaries world-
wide." (Ward, 1990) One such database G/axo/ine has been described above.
Supplementing to Glaxoline, there is another product information databases G/llXO
Databank which contains key factual data about Glaxo products.
From these internal databanks, many sorts of documents for different usage are
generated. For example, documents for patent application, for Clinical Trial Cer-
tificate application, for Product Licence application, for authorities or professional
enquiries etc. It is reported that an NDA (new drug application) in US usually consists
of 50,000-100,000 pages of data and information on the potential product (Cuddihy,
1975).
7.6 Drug Information - DI Network in Britain
Drug information here is defined as the information about proscription only medicines.
Needs for this kind of information are mainly from hospital doctors, pharmacists and
GPs.
(a) Sources of drug information
In Britain, needs of doctors for knowing about new drugs can be met by means of
promotional literature in prescribing documents and in scholarly or professional
journals, posted advertisements and representatives from pharmaceutical companies.
In the UK, the manufacturer must produce a data sheet for every product which it is
intending to promote - via advertisement or representative or other activities. The vehicle
for these documents is ABPI Data Sheet Compendium. These prescribing information
documents are legally required to ensure a core unbiased summary of information on
the drugs against other more biased information such as company representatives,
promotion literature and meetings etc ..
It is reported that doctors regard the representative as a significant source of information
though less important than medical journals, contact with colleagues and conferences.
Representatives still account for the largest proportion of promotional expenditure by
the pharmaceutical industry (Ward, 1990).
However, few GPs or hospital doctors would feel confident in promotions of being
reliability and lack of bias. They need presentations being given by someone who knows
about drug trial design and who has developed considerable expertise in critical
assessment of drug research. Every year there are many seminars, meetings and
conferences sponsored by pharmaceutical companies for clinical pharmacologists to
give such convincing presentation about their new drugs.
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To meet the information needs on specific drug or medicine in medical practice. doctors
can tum their inquiries to the following services: the UK national drug information
network which links the regional and area drug information centres based on hospital
pharmacy; the medical information service in pharmaceutical industry, the Royal
Pharmaceutical Society ofGreat Britain information service, and other medical libraries.
(b) the UK national DI network
The formal drug information services in the UK were first introduced in 1970 at the
London Hospital and Leeds General Infirmary. The latter centre became the first regional
centre in 1973. By 1981, 20 regional and 150 area centres have existed in all regions in
the Britain and constituted the national drug information network (Davies, 1982 & Smith,
1982). The DHSS is responsible for national planning and for the allocation of resources
to these regional health authorities.
As a result ofcooperation and co-ordination among the regions, the following have been
achieved.
1. Data Base of Literature Abstracts from over 80 drug oriented journals. The database
has been computerized in the early 1980s.
2. Specialization in Particular Subject Fields, for example Drugs in Breast Milk is the
speciality of West Midlands regional centre.
3. Code of Practice for Drug Information Pharmacists.
4. Production of Speciality Bulletins.
5. Circulation of Information Between Regions.
6. Education and Training. etc. (Calder et aI., 1981).
Each year the hospital pharmacists and regional DI centres answer a great number of
inquiries from hospital doctors, GPs, and other health professionals.
For example, the South Western regional 01 centre handled the total 1049 inquiries in
19HO; while the whole region's hospital pharmacists received 1.254 inquiries over a
period of two weeks in 19HO. Given 52 weeks per year, the whole region' s pharmacies
handled somewhat 65.000 in a year.
Types of enquiry raised by doctors
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Typical questions raised by doctors and other health care professionals include:
1. Availability Drug A is discontinued. What alternatives are there?
2. Identification What is this drug/tablet/foreign preparation?
3. Side effects Which drug has caused a problem? Is this drug safe in pregnancy?
4. Interactions
5. Clinical use, administration, dosage etc ..
Table 7.5 compares the types of inquiries handled by the regional centre with the types
of inquiries handled by hospital pharmacies. It can be seen that hospital pharmacies
dealt with a much higher proportion of inquiries on administration and dosage, whereas
the regional DI centre received more on adverse effects and identification. Some changes
in NHS drug information services have been noticed for the past several years. These
services are now very largely concerned with comparative costs and approved lists of
medicines and do not provide a general drug information service as much as they used
to (Bawden, 1991).
Table 7.5 Types of Enquiries and Sources for Enquiries in the South
Western region in UK (McNulty, 1984)
1254 hospital phar- Rank 1049 regional DI Rank
macy centre
queries (100%) queries (100%)
administration 17.6% 2 11 % 4
/dosage
adverse effects 9.2% 5 19% 2
/ toxicology
availability 9.8% 4 1 JC!c 4
/supply
clinical use 25% 1 22% 1
idcnti fication 2% 8 7% 5
interaction 4% 7 5% 6
pharmacology 5.2% 6 3% 7
pharmaceutical 14.8% 3 159(' 3
problem
(c) Drug Information Services in Pharmaceutical Companies
In August 19R8. the author visited the medical information unit in Farmiltalia UK in S1.
Albans. The information requirements of Farmitalia UK reflect the company's structure
ofa medium size marketing department and field force backed by medical and regulatory
departments, the hulk of whose work is dictated by international requirements.
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There is one full time information officer whose work is entirely involved in both internal
and external enquiries, which makes it impossible for him to provide a full current
awareness service for the company. The information unit is largely self contained;
however, the head office in Milan provides most of the background information needed
by those conducting clinical trials in the UK and provides a regular bibliography of
papers pertinent to Farmitalia's products.
Some internal requests come form the representatives concerning Farmitalia 's products
mainly. Information needs also include specific methodological problems encountered
during clinical trials.
As Farmitalia's products are strongly biased towards anticancers, enquiries are mostly
from hospital pharmacists; there are a few queries from retail pharmacists too.
The information unit only subscribes the core journals of the therapeutic fields in which
the company is involved. About 75 titles are received and scanned. BLDSC is frequently
used for the back up of documents supply. Online searching is used only when the
information is not easily available elsewhere. Medline and Excerpta Medical are the
most frequently used databases. Other used databases include Biosis, Martindale,
Cancerline and Sedbase. Generally, the information unit is working on a manual basis.
(d) Drug Information Service in Royal Pharmaceutical Society of Great Britain
(RPSGB)
The information service of RPSGB was set up in 1968 in response to an increasing
number of inquiries being received from pharmacists about drugs or other matters
relating to the profession. Prior to 1968, these inquiries were handled by the scientific
publications department, i.e. the staff working on Martindale, the British National
Formulary or other publications produced by the Society. The ever increasing number
of inquiries necessitated the formation of a separate section to handle drug information
requests. Three full time pharmacists answer some 16,000 queries each year. In 1987,
3/4 of the inquiries were from pharmacists in community, hospital and industry. The
remainder came from allied professions, government bodies, the public, libraries, the
press, industry, and marketing and advertising agencies.
Information to answer the inquiries comes from a variety of sources. including card
systems, journals and books. Occasionally online databases are used. There are two card
systems - one being subscribed by the Society covers foreign proprietary drugs, and the
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other is compiled within the department. The latter covers 350,000 references and is
continually updated by regular scanning of about 30 pharmaceutical and medical
journals. About 10,000 cards are being added to the index system each year.
7.7 Regulatory Requirements and Statutory Information
In US, since 1963, a sponsor wishing to undertake clinical testing of a new drug candidate
in US is required to submit to the FDA (Food and Drug Administration) an IND (Notice
of Claimed Investigational Exemption for a New Drug). The IND describes in detail
the chemical, pharmacological, pharmaceutical and toxicologic properties of the com-
pound.
Clinical testing in humans is conventionally divided into four or five phases. During
pre-market evaluation (Phase I-III), drugs will be tested among 1-2 thousand patients.
After Phase III trials are completed, the pharmaceutical company will submit a New
Drug Application (NDA) to the FDA to gain the approval of the release of the drug
into the US market.
Phase IV is effectively a controlled postmarket surveillance which carries out the
assessmentofthe relative risks and relative benefits ofdrug therapy. Such activity (either
in the form ofcontrolled studies or of uncontrolled and spontaneous studies) may require
the participation of hundreds of doctors and thousands patients.
Such clinical studies (phase I-IV) can take anywhere between 3 and 5 years.
"Although specific requirements differ, a well prepared NDA targeted for submission
in the US will contain the essential information required by other major countries.
"Western European countries (generally) pattern themselves after the FDA and require
objective evidence of safety and efficacy." (Williams, 1987)
The UK Medicines Act 1968 came into force in 1971. It is complex and lengthy (8 parts
and 200 instruments). I. H. Harrison (1986) has given a comprehensive guide to this
Medicine Act 196H. This guide covers more than 20 subjects on the controls over the
manufacture. packaging, labelling, distribution and promotion; of which the following
are more relevant to this study:
I. The administration of the Act
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2. The licensing system.
The Administration of the Act
In the Act, the government ministers appoint the Chairman and members of the Medi-
cines Commission, set up other expert committees, to date six such have been created
namely-
1. British Pharmacopoeia Commission
2. Committee on Safety of Medicines (CSM)
3. Veterinary Products Committee
4. Committee on the Review of Medicines
5. Committee on Dental and Surgical Materials
6. Committee on Radiation from Radio-active Medicinal Products.
The Licensing System
The licensing system is the Chief novel feature of the Act. The system ensures that
medicines are of good quality, safe and efficacious and are manufactured and dealt with
under optimum conditions. The system also enables batches of products to be traced
and withdrawn from sale with minimum of delay should they prove sequentially to be
defective. The system utilizes three types of licence and two types of certificate each of
which permits a person to engage in certain specified activities, namely- product licences
(similar to NDA in US), manufacturer's licences, wholesale dealer's licences, clinical
trial certificates (similar to IND in US), and animal test certificates.
The product licence is at the heart of the system. To obtain a product licence the applicant
must provide a considerable amount of scientific evidence about the product's chemical,
physical and pharmacological properties. The product licence lays down the manu-
facturing and quality assurance specifications of the product, lists its therapeutic indi-
cations and contra-indications, gives details as to its packaging and labelling, method
of sale, and the conditions for which it can be advertised and promoted.
Information Work Relating to Licensing Procedure
The whole licensing procedure of a product is costly to the applicant not only in terms
of licence fees but also in terms of staff and time involved in producing the necessary
paper work. It has been estimated that the drug regulatory requirements in the UK cost
the community more than £30 million per year. used 1()()() staff in industry and ci vii
service, and delayed for about 2 years the introduction of new drugs onto the market. It
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has also been stated that a com bined application for a clinical trial certificate and product
licence typically exceeded 4000 pages, took 8 months to prepare and cost £35,000 at
1979 prices (Harrison, 1986).
With such sophisticated licensing system, preparation of new drug registration docu-
ments has been proved to be an intensive information work in a pharmaceutical company.
It results in the creation of hundreds of volumes of documents. "The final application
is frequently delivered in a trunk." (Brown, 1985).
7.8 Patent Information
I. Patent and pharmaceutical industry
Since the 1960s, most of developed countries have introduced pharmaceutical products
patents. The function ofa patent is primarily to stimulate inventive activity by preventing
a new product from being imitated during a legally sanctioned period of 20 years from
the date of application (WHO, 1988).
However, because of the increase in drug development time from 5 years in the 1960s
to 12 years currently, there has been an erosion of the effective patent life of British
medicines which has been cut from 13 years to 6 years over the past two decades (ABPI
Pharm. Fact 1990).
The UK Pharmaceutical Industry is said to be unique in its commitment to and fierce
defence of the patent system. The Association of the British Pharmaceutical Industry
(ABPI) is well known for defending the patent system. "The main arguments put forward
by ABPI are that patents encourage ingenuity and invention, offer the prospect of
considerable profit for developing a discovery to the commercial scale, and increase the
inducement to invest capital in finding, manufacturing and marketing new products.
Finally because patents involve disclosure, new ideas are made available to others and
thus competition is encouraged." (Nolan et aI, 1980).
For the last few years, the Centre for Medicines Research (CMR) in ABPI has conducted
several studies on the Erosion of Pharmaceutical Patents Life in CK and Europe.
In the western developed countries, patent systems are particularly well used by the
pharmaceutical industry: this is because the patent protects the R&D (including inter-
mediate results and processes) rather than just the final products. For them. R&D is
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costly to design and products need to be on the market for many years and in many
countries in order to beprofitable. Details on pharmaceutical patent have been given by
T. Eisenschitz (1990).
There is no doubt that pharmaceutical patent generation has been greatly concentrated
in the developed countries in the world. The Annual Review of Government Funded
R&D (1990) provides a comprehensive survey on world patent situation by using patents
granted in US for the period 1963-1988. Table 7.6 shows that although the number of
world patents (granted in US) has fluctuated from 1963 to 1988, the number of phar-
maceutical patents has steadily increased by over two times. The same trend is also
found in the UK patents (granted in US). More significantly, the growth of UK
pharmaceutical patents has been much faster than that of world pharmaceutical patents.
During the period of 1963-1988, the UK pharmaceutical patents has increased by over
6 times. Table 7.6 also shows that from 1963 to 1988, the percentage of UK patents as
the total patents granted in US has declined from 4.1 to 3.4 whereas the percentage of
UK pharmaceutical patents as the total pharmaceutical patents granted in US has grown
from 3.6 to 6.4. The figures indicate that the steady growth in UK pharmaceutical R&D
activity through the past three decades.
Table 7.6 Patents Granted In US From 1963 To 1988
(Annual Review on Government Funded R&D 1990)
Year 1963-68 1969-73 1974-78 1979-83 1984-88
No. of US patents granted 347852 357801 349257 290967 368570
No. of US patents granted in 4034 4965 10062 11497 14742
Drugs/Bioengineering
No. of US patents granted to UK 14147 15553 14529 10849 12478
No. of US patents granted to UK 147 190 687 887 945
in Drugs/Bioengineering
% of US patents granted to UK 3.6 3.8 6.8 7.7 6.4
in DrugslBioengineering
% of US patents granted to UK 4.1 4.3 ＴＮｾ 3.7 3.4
Different from any other primary literature, patents yield, in addition to technological
and scientific information. valuable data about the short- and long- range research
interests of the various patent holders, and may help in finding and predicting possible
corporate mergers.
II. Patent information practice
There is little doubt that patent information provides an example of good documentation
practice. "Not only are the printed documents designed and coded to facilitate rapid
searching, including easy identification of the different parts and of bibliographic data,
but also the layout has been standardised so that every publisher throughout the world
follows a closely similar practice. A universal subject classification is applied to all
documents, even by countries that also still use a national scheme. Microform versions
of many sets are widely available. Electronic databases of the bibliographic and status
details and of the abstracts abound." (Hill, 1985)
In 1978, a new UK Patent Act came into operation. On the same time the European
Patent Convention (EPC) and the Patent Co-operation Treaty (PCT) become operational.
Each of these gave rise to new publications and the three together created quite a com plex
network of interacting publication channels. M. W. Hill (1978) has given a detailed
description on this issue.
Although it sounds quite complex, patent documents have been well organized by
specialistic services.
Firstly, official journals from national patent offices, international organizations (such
as EPO) provide regular and timely information on patent application, granting, expiring,
and legal issues etc.
Secondly, with the ever-improving IT capacity, servallarge secondary publications in
the world have been providing comprehensive means for patent retrieval.
It has been estimated that among the 800,000 or so patent documents published each
year, there are descriptions of only 300,000 different inventions. Of the 60,000 appli-
cations for patents each year in UK, more then 60% are from foreign applicants and it
is not unreasonable to expect that virtually all of these are also being applied for in other
countries (Hill, 1978).
The complex of patent information may be reflected partly from the existence of Patent
Family. The resulting set of equivalent applications or granted patents. one in each
country, is known as a patent family. Tables of them, sometimes called equivalences or
concordances. are published. Today, microfiche indexes and online databases render
the family searching a very quick task requiring little skill.
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Chemists tend to make better use of patent compared with other subject specialists. This
is due partly to the policy of Chemical Abstracts which integrates patents with other
literature. The other reason may be the large amount of patents in Chemistry. Each year
over one million patents are filed world-wide, of which 10% are related to chemistry
(Mullen, 1990).
In 1988, CA indexed about 80,795 patents of which 53.8 % are from Japan, 6.9 % from
US and 10.3% from European Patent Office, 9.3% from Germany, 6.6% from USSR
and 0.9% from UK (Jhaveri, 1989).
Apart from CA, Derwent Publications (WPIL file) is generally regarded as a major
source of world patents. It covers 360,000 patents from 33 patent offices in the world
each year, of which about 160,000 are chemical patents and 14,000 are drug related
patents (Mullen, 1990). INPAOOC is similarly a multinational database covering 55
countries' patent information.
There are as many as 100 online databases plus a certain number of hard copy primary
and secondary publications in the world disseminating patent information. The largest
databases include four international ones: Biotech Abstracts via Orbit with 60,000
records; CA-FILE via STN with 7 million records; INPADOC via Orbit with 15 million
records from 55 countries (which includes a file for China patents since 1985 called
CHINAPATS with 2500 records) and WPIL via Orbit etc. with 4 million records from
31 countries (Mullen, 1990).
Thirdly patent document access in libraries has been improved by the efforts of estab-
lishing national networks in some major countries in the 1980s (Hill, 1985). As far as
library patent information services are concerned, SRIS has been providing a
comprehensive service to UK users which is supplemented by a national patent infor-
mation network of about twenty local patent libraries (7 libraries holding UK and other
countries patent specifications and 12 information centres holding only patent abstracts.
abridgments and journals). The largest of the libraries in the network are now given the
following by the BL:
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EP: "A" specifications, the EPO Bulletin, annual indexes, etc.;
per : specifications, per Gazette, Index;
us: specifications, Official Gazette, Manual of Classification, Index to patent clas-
sification, Patent Status File, Subclass and numeric listings etc.:
INPAOOC: numerical database, Patent Applicant Service, Patent Inventor Service,
Patent Classification Service, INPADOC Patent Gazette etc.
The Patent Office supplies the major libraries with the following:
GB: "A" specifications, the Official Journal (patents), GB Abstracts issued weekly and
cumulated annually, the GB classification, Reports of patent cases etc.
It is reported that the num ber of readers and remote enquiries for the patent information
network (not including SRIS) is about 19,000 per year. At SRIS about one third of the
150,000 readers visits made each year patent enquiries. Additionally, there are 19,000
telephone patent enquiries at SRIS per year (Newton, 1990).
Finally, patent document storage and delivery has been greatly enhanced by the infor-
mation technologies for the past decades. Microfilm, photocopy, facsimile, online
database and CD-ROM are either widely applied or still in experimental stage. SRIS is
a traditional source of supply of patent documents. Patent Express- a rapid photocopying
and delivery service - is one of the fastest growing of the BL commercial enterprises.
Its revenue increased from £0.86 million in 1985/86 to £ 1.42 million in 1989/90.
7.9 Concluding Notes
The pharmaceutical field is research based and wide ranging scientifically. "The
necessity of retrieving information from external sources has led to increased
expenditure by the industry, particularly during the' information explosion' of recent
years. Coupled with the high costs of generating and managing information inhouse,
this rate of expenditure means that the industry spends very freely on information
handling.
"The pharmaceutical industry was one of the first to benefit and is beginning to learn
how to apply IT inhouse with the prospect of further enhancing irs performance."
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(Pickering, 1990)
In the western capitalist system, R&D of medicine is targeted not only in a scientific
sense but also commercially. Therefore, information concerning regional disease pro-
files, health care systems, market sizes, regulatory constraints, competitor activities,
sales statistics and so on are greatly demanded by pharmaceutical companies in the
western countries.
To be able to release a new drug onto a market, the pharmaceutical company has to meet
all requirements of the drug control authorities. The application procedure of clinical
trial certificate and product licence usually turns out hundreds and thousands of volumes
of documentation. To market a product successfully, a company also need to provide
doctors, pharmacists and other health care professionals with sufficient product infor-
mation. Apart from product information for promotional purpose; the company has the
responsibility to answer any inquiries on its products from health care professionals. To
do this, most of pharmaceutical companies have a medical information division with
professional staff and facilities to access internal and external databases.
To provide drug information to doctors and GPs in a less biased manner, there is a
hospital pharmacy based national DI network existing in the UK with some 20 regional
centres and 150 area centres. This network is under the central planing of DHSS and
deals with immense of inquiries every year in a co-ordinated way. Further more, there
are other organizations such as RPSGB which also provide drug information to drug
prescribers and the public.
Chapter 8 Pharmaceutical Information Flow Infrastructure in China
In this chapter, the pharmaceutical information flow infrastructure in China is described in
Figure 8.1. In fact, "pharmaceutical information" is not commonly recognized in China as
having the five elements normally associated with it in the West. Today's information flow
infrastructure in China is dominated by scientific information systems, other information
flows such as business information, drug information, patent information and statutory
information are still emerging.
Unlike the situation in UK, there are few studies on pharmaceutical information in China.
Most of information studies are generally about S&T information.
Sources of data collected and used in this chapter are given as follows:
1. Data on S&T information systems
During the Autumn of 1989, with the help of S&T information Institute at SPAC, the author
conducted a survey on S&T information service within SPAC system. About 25 of the total
35 S&T information services have responded to the survey (Appendix 5.4 giving a sample
of the questionnaire).
Furthermore, the following S&T information organizations and libraries have been visited
for data collection: 11K National Library. ｓ ｨ ｡ ｮ ｾ ｢ Ｎ ｡ ｩ Library Qf ｾ Sinica. ｂ ･ ｩ ｪ ｩ ｮ ｾ
Library Qf Academia Sinica. ISTIC. s..&I In{oonation jnstitute Qf Chinese ｾ Qf
ｾ Science. .and ｾ Qf Militaa ｾ Sciences.
2. Data on business information systems
During the Autumn of 1989, the author conducted a survey on business information service
for China's pharmaceutical industry. Fifty questionnaire were sent out to the large factories
in the Chinese pharmaceutical industry with 30 responses (Appendix 5.5 giving a sample
of the questionnaire). Additionally, the author visited six large factories in Beijing and
Shanghai. Interviews were given to information officers or production managers.
3. Data on drug information systems
For collection of data on drug information. two group of questionnaire have been designed.
One questionnaire was sent to 100 doctors and another to 100 hospital pharmacists with
the help of the Research Institute of Clinical Pharmacology at Beijing Medicine University
(Appendix :\ I and 5.2 giving a sample of the questionnaire).
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4. Data on statutory information systems
During the Autumn of 1989, the author visited the following government departments:
Bureau Qf ｾ ｾ Administration illMflt SPAC. SAICM and 1hk Research Institute
mClinical ｦ ｨ ｡ ｲ ｭ ｡ ｣ ｯ ｬ ｯ ｾ ｹ Ｌ ill ｂ ･ ｩ ｪ ｩ ｮ ｾ ｾ University. Interviews were given to the
officers there for data collection on statutory information situation in China.
This chapter illustrates the less developed Chinese pharmaceutical information flow. Next
chapter will compare it with the advanced UK pharmaceutical information flow.
8.1 Scientific Information Flow
The national science and technology in China is under the direct control of the gov-
ernment. The administrative set up has been given in Figure 3.4; in Chapter 3.
Because the emphasis on academic R&D rather than industrial R&D in China, the
Chinese national scientific information system (Figure 8.2) is dominated by research
libraries and S&T information institutes affiliated to their parent institutions.
8.1.1 The Structure of Chinese National S&T Information System
1M National Library ill China
In 1912 the National Library of China was founded on the previous Metropolitan
Library of Peking (Beijing). In 1987 it held about 6.5 million volumes of book, 6
million volumes of periodicals (9,148 titles of current Chinese periodicals, 13,693
titles of current foreign periodicals), 90 thousand volumes of newspaper in about six
hundred current titles plus 1.3 million volumes of other materials.
In 1989, NL had an acquisition expenditure of¥16.6 million. Its acquisition of7741
world journals accounted for one seventh of the BLDSC annual intake.
The administration is divided into 16 main units, with 1,700 staff members. of whom
about 1,200 are qualified librarians or specialists. It has exchanged agreements with
over 1,600 libraries or organizations in 100 countries.
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It receives about five thousand readers each day or 1.5 million per year which is ten
times the figure of SRIS. Mainly serving and lending to government officials, senior
scholars (those with job grade I or grade II, seeing Chapter 3) and some special
categories of foreigners. The National Library also admits college students and
general workers for reference and reading. The National Library mainly provides
reference library service to its readers but is unable to provide a similar documents
supply service as BLDSC.
The National Library is the head organization in the national public library network.
In practice, those regional and local public libraries are self-governing at the various
level of local authorities: provinces, counties, cities and township (formerly called
communes). There are 28 provincial public libraries, including the two municipalities
Shanghai and Tianjing. They act as the central public library for the provincial capital
city, and most provide a variety of services for particular groups. including factories.
scientific research institutes and local specialists. Apart from the National Library
in Beijing, Shanghai Library is the second largest public library with an acquisition
budget of ¥5.7 million in 1989 and an annual intake of more than 4000 foreign
journals (National Library of China Booklet, 1989 & Academia Sinica, 1991).
Research Libraries
It was reported that by the end of 1988 there are 5275 government scientific research
and development institutions (excluding those in social science, education and
defence sectors, and in factories) at above county level, and one million S&T staff,
of whom one third have job grade I - III. Within each of these R&D institutions there
is usually a library or a information institute (division), or sometime both (White
Paper, 1990). There are about 50 national or ministerial S&T information centres
plus 350 provincial and regional information centres. Those S&T information
establishments serve the information need of the one million S&T workers in the
government R&D sector (not including universities and industry).
Generally. the S&T library/information systems have been well organized at the
national level and ministerial level in China. although there are problems in resources
sharing which are to be discussed in next sections. Under the State of S&T Com-
mission, there is a national S&T information policy making body which
1. Plans for and manages with the nationwide information sharing;
2. Plans for and manages with the national abstracting and indexing services:
3. Plans for and manages with the national computerized S&T databases.
At every ministry, there is a similar S&Tinformation decision making body to advise
on the above three issues to the ministerial leaders and to implement the plans within
the ministry.
Illk University and ｃｯｬｬ･ｾ･ Libraries
In China, there are 800 S&T universities and colleges (including 130 medical uni-
versities with pharmaceutical department/faculty) today. Of them 10%are at the first
class - the government defined "important university"; 54% are at the second class
- the government defined "general university"; and 36% are at the third class which
are similar to the polytechnics in UK. There are total 80,000 academic staff in the
800 universities. Every university has a large central library with departmental
libraries around the campus, serving the information needs of teachi ng and research.
The S&T activities in universities are greatly teaching oriented. R&D is not a major
function of Chinese universities.
It is estimated that R&D in Chinese universities account for somewhat twenty percent
of the national R&D in terms of manpower and annual expenditure (White Paper,
1990). However, the R&D activities in the universities are less organized by the
central government than that in government R&D sector. The S&T information/li-
brary work are also with less central plan and management at national and ministerial
level than that in the government R&D sector.
The Technical Libraries and Information Services in Industry
In addition to the research libraries, there is another group called technical libraries
and information services in industry, aimed specially at providing information
services in support of industrial production.
There are over 10,000 large and medium factories with over 1.6 million S&T staff
in China. In pharmaceutical industry, there are 236 large and medium factories with
over 30,0(X} S&1' workers (White Paper, 1990).
The major work for industrial S&T workers are manufacturing oriented rather than
R&D activities. It is estimated that R&D in Chinese industry account for somewhat
twenty percent of the national R&D in terms of manpower and annual expenditure
(White Paper. 1990).
Large and medium factories normally have their own R&D divisions and technical
libraries or information services. However, the R&D activities and the S&T infor-
mation in the industry are less organized by the central government than that in
government R&D sector.
Furthermore at every level of administration, there are S&T information services.
For example within the SPAC administrative system, there is a central S&T infor-
mation service with 100 staff in Beijing, 9 first grade S&T information services in
five big cities, and 25 second grade S&T information services in provinces. These
pharmaceutical information services vary in size (from one staff to 57 staff) as well
as in organization structure. Figure 8.3 shows the organization of S&T information
service at Shanghai Institute of Pharmaceutical Industry which is the second biggest
one within SPAC administrative system.
S&.I Infonnation Institute System
Apart from libraries, there is another sort of organizations aims at providing S&T
information - institutes of S&T information. The Institute of S&T Information of
China (1958-) is well known as ISTIC. in the world. As a S&T document retrieval
and supply organization, ISTIC has two national centres - Beijing centre and
Chongqing centre.
By 1987, the Beijing centre holds a collection of 5 million items ( including scholarly
journals in banded copy, reports, grey literature and microfilms etc.). About 65% of
the collection are in English. Its annual acquisition expenditure was ¥ 4 million in
1989. Its annual intake of journal is about 4000 titles in foreign language plus four
thousand titles in Chinese. Its annual world journal intake is about 10% of the
BLDSe.
The Chongqing centre holds a collection of about 7 million items (scholarly journals
in banded copy, patents, reports, grey literature and microfilms etc.). Its annual
acquisition expenditure was about ¥2 million in 1989. In 1990 it subscribes to about
2,000 titles of foreign S&T journals and four thousand titles of Chinese journals.
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The staff in the Beijing centre totals over 1,200, and there are another 600 in the
Chongqing branch. The Beijing headquarter receives about 100,000 readers from all
over the country each year which is much less than the numbers of readers in National
Library and 2/3 of that in SRIS in UK. Although it has claimed to serve as a national
scientific reference library (non-book), ISTIC is unable to provide a similar docu-
ments supply service to Chinese users as BLDSC part owing to the limited collection
and partly owing to the limited funds.
Some provinces have their own information institutes. Those institutes are
self-governing, taking supervision from ISTIC. Apart from ISTIC Beijing and
Chongqing centres, Shanghai Institute of S&T Information is the third largest
information centre with an intake of 3000 foreign journals and 2400 Chinese journals
in 1989 (lSTIC Booklet, 1989 and Zhou, 1991)
8.1.2 Primary Literature - Resource Share and Document Supply
Let us now look at Figure 8.1 Pharmaceutical Information Infrastructure in China
again. There are two information inflow channels - one for domestic information
and the other for foreign information. The shortage of hard currency has made the
Chinese government to introduce two information input channels parallel to the two
currency systems in the country (seeing Chapter 2).
In the domestic market, each year China publish several thousands titles of serial
and several ten thousands titles of books. The national S&T literature production is
quite big in terms of both the quantity and the proportion in the world production.
In 1985, it published 45,603 titles of books which accounted for 2/3 of the UK
production (lnfor China, 1989). In 1988, it published about 3,000 S&T journals
which accounts for 3-5% of the world production and 3/4 of the UK figure. (Zhong,
1990)
The state-run Xihua Bookstore network has a monopoly of the national market of
native books. The native journals are distributed either through state post office or
directly by the publishers. In the market, the common currency is RMB (1). The
average price of Chinese S&T literature is relatively low compared with the price
in the western countries. The average Chinese S&T book price and annual journal
price was ¥13 or £1.3 and ¥16.5 or £1.65 in 1990 (Tao. 1991). In 1986, the average
UK academic book price was £ 14 and the annual UK journal price was £60 (Fletcher,
1987). As it has been estimated in Chapter 3. a Chinese employee' s annual wage
can buy 161 Chinese S&T books or subscribe 127 Chinese S&T journals. while a
British employee's annual wage can buy 723 British or American academic books
or subscribe 134 British or American academic journals. Therefore, the major
problem of primary literature resource in China is the very limited capacity in foreign
literature importation due to the shortage of hard currency.
The China National Publishing Import and Export Corporation (CNPIEC) is the
main body dealing with the international book and journal market, in which only
hard currency is valid. Because of the inability of gaining sufficient hard currency.
the Chinese government has to take a over-all control of the book and journal import
and the allocation of hard currency to all departments which need foreign S&T
information/documentation. That has meant the scarcity rather than over-abundance
ofchoice in amount and in variety of foreign books andjournals for Chinese libraries.
The acquisition policy in the national S&T information system in China is
"to try to collect domestic S&T information as comprehensive as
possible while at the mean time to collect the most important foreign
language information under a very selective guide-line.
"The proportion of expenditure in foreign language information to the
whole information purchasing expenditure was 64.8% in ISTIC, 51.5%
in university library system, 63.6% in Chinese Academy of Social
Science and 90% in Chinese Academy of Science in 19R8." (Academia
Sinica, 1991).
According to the acquisition statistical data from Academia Sinica (1991), in 1989
the average Chinese journal price was ¥I5 per year while the average foreign journal
price was ¥I500 (data from its annual intake of several thousands ofChinese journals
and several thousands of foreign journals) (seeing Chapter 3). Because of the big
price difference between Chinese and foreign S&T literature in China, although each
year Chinese S&T information systems spend up to 90% of acquisition expenditure
in foreign information, their ability in purchasing foreign information is in fact very
limited.
Each year, CNPIEC imports some 70,000 titles of foreign academic books and
16,()(X)-19,()(X) titles of foreign S&T journals (ISTIC, 1986 & CNPICE, 198R). The
Chinese national annual intake of world books is 1.75 times the BLOSe while the
Chinese national annual intake of world S&T journals is one third of the BLOSC.
The imported foreign S&T literature scatter over the vast country. There are about
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ten national S&T libraries each having a collection ofmore than 3,000 current foreign
journals. Furthermore, none of the national S&T information systems including
National Library, provide national documents supply service formally.
In China, more than half of the imported S&T literature is concentrated in Beijing.
Most of the remaining imported S&T literature is held in Shanghai, Chongqing.
Shenyang, Wuhan, Guangzhou, Chengdu and Sian (lSTIC, 1986).
To study the resource share and documents supply of foreign S&T information in
Chinese medical and pharmaceutical area, we use three surveys - one is based on
the data from China Medical Academic institution Union Catalogue of Foreign
Journals (1987), the second survey is based on the statistic data (1989) of SPAC
information services, and the third one is based on the survey on information
resources in Academia Sinica (Academia Sinica, 1991).
The China Medical University andAcademic Institution Union Catalogue ofForeign
Journals (1987) includes 77 Chinese medical universities (of total 130) and 5 the
highest medical academic research institutions (of several hundreds in the countries).
Although it is by no means comprehensive in covering all academic institutions in
China's medical and pharmaceutical area, the Union Catalogue is the only one readily
available for the brief outlook on foreign medical information resource share and
distribution in China.
There are about 20,000 current journals in biomedical and life science in the world
(Ward, 1990).
Despite the shortage of hard currency, China has tried its best to import most major
medical journals in the world, especially from the western world. In 1987, it imported
3391 medical journals, of them 2685 in English (including fewer in other western
languages), 466 in Japanese and 200 in Russian. Having compared with Index
Medicus (3200 journal coverage) and Excepta Medical (4500 journal coverage), one
expert estimated that only some 300 major foreign journals are not imported by China
(Xun, 1988).
Of the three thousand importedjournals, most have very small number of subscribers
in China, because of the limited purchasing ability. It was estimated 31% of imported
journals have only one Chinese subscriber each, 32% journals have only two Chinese
subscribers each. for 17% journals each has subscribers ranging from 6 to 21. and
only 20% imported journals have more than 25 subscribers in China.
There is no question that most of imported journals are concentrated in a handful of
big cities such as Beijing and Shanghai.
Among the 82 institutions, the annual subscription of foreign journals ranges from
less then ten to 1479 titles. The average subscription was 162 titles each institution
in 1987. The number one with the highest subscription was Chinese Academy of
Medical Science with an intake of 1479 titles. Shanghai Library of Academia Sinica
ranked at the second with an intake of nearly 900 titles. Of the 82 institutions, there
are three each with intake of more than 800 titles, 4 institutions each with intake of
more than 500 titles. There are 16 institutions (20% of total) each having an intake
of under 500 titles and more than 162 titles (mean figure). More than 70% of
institutions each has an intake of less than 162 titles.
The State Administration of Pharmaceutical Industry (SPAC) has a ministerial
information network, with the headquarter information service centre in Beijing; 9
first grade national information services in 5 big cities (4 in Shanghai, 2 in
Guangzhou, other 3 in Tianjin, Chengdu, and Shenyan): and 25 provincial infor-
mation services affiliated to SPAC provincial branches. The information network
mainly provides S&T information to R&D staff in factories where factory technical
libraries are in relatively poor condition compared with research or university
libraries.
The S&T information service in SPAC headquarter in Beijing has 100 library and
information staff and annual intake of several hundreds of Chinese and foreign
journals.
In 1989, SPAC conducted a survey on the 9 first grade and 25 second grade infor-
mation services in its network. There were 8 and 17 responses from the two groups
respectively.
The eight of the first grade services have total annual information expenditure (in-
cluding all sorts of expenditure such as information purchasing, salary, equipment,
administration etc.) of VI ,350,000. The top one has annual expenditure ofV550,OOO
and bottom one has ¥25,000. The average figure is ¥170,OOO per service. There are
145 information staff in the 8 services with an average of 18 staff per service.
The 17 of the second grade services have total annual information expenditure of
V438,CXX). The biggest one has an expenditure ofV80,(X)() and the smallest has ¥4,OOO.
The average figure is V26,CXX) per service. There are 120 infonnation staff in the 17
services with an average of 7 staff per service.
The survey shows that 75% of SPAC information network expenditure is concen-
trated in 8 first grade services in 4 cities whereas 17 provincial information services
have accounted for only 25% of total information expenditure. The biggest
information service has an annual expenditure of ¥550,000 which is 140 times the
smallest one with annual expenditure of ¥4,000.
The data on the collection and acquisition of the 9 first grade and 25 second grade
information services are not complete and therefore not comparable. The rough
estimate is that only 4-5 first grade services each has an annual intake of several
hundreds of Chinese journals and several hundreds of foreign journals; while other
30 information services each has less than 100 titles of foreign journals. The 15
smallest ones each only has around 10 titles of foreign journals annual intake.
There are some 236 large pharmaceutical factories with R&D units or divisions in
China. Normally there is a technical library or information unit affiliated to each
R&D division. In October 1989, the author visited six of the biggest factories in
Beijing and Shanghai (all among the top 30 in China). The impression is that the
collections and the services in factories are generally very limited. The six factories
have employed from 500 - 3000 people; have R&D laboratory ranging from 10 to
200 R&D staff; and have information service or technical library of annual intake
of foreign journals raging from 2 to 50. The number of information staff is between
3 and 20.
Generally, the S&T libraries or information services in research institutes and uni-
versities are much stronger than that in the factories and that in the administrative
departments, because the great concentration on R&D in government research
institutes and academic institutions.
For example, Shanghai Institute of Pharmaceutical Industry and Tianjin Institute of
Pharmaceutical Industry are the two largest R&D establishments in SPAC. The
former has about 1000 S&Tworkers, 60 information staff, a collection ofover 60,000
volumes and 610 current foreign journals and 150 current Chinese journals. The
latter has about 600 S&T workers, 40 information staff, a collection of RO,OOO
volumes and 500 current foreign journals and 1,000 current Chinese journals.
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To meet the information needs of the 35,000 S&Tworkers in Chinese pharmaceutical
field there is a 4 level national S&T information network:
FIRST LEVEL - annual acquisition budget over ¥ 4 million, over 3000 current foreign
journals and all 3,000 current Chinese journals
1. The National Library in Beijing with annual acquisition budget of YI6,550,OOO
in 1989 and an annual intake of about 10,000 titles of foreign journals;
2. ISTIC (Beijing) with annual acquisition budget of Y4,OOO,OOO in 1989 and an
annual intake of about 4,000 titles of foreign journals;
3. Beijing Library of Academia Sinica with annual acquisition budget ofY 4,000,000
in 1989 and an annual intake of more than 3,000 titles of foreign journals.
4. Shanghai Library with annual acquisition budget of ¥5.7 million in 1989 and an
annual intake of more than 4000 foreign journals.
5. Shanghai Institute of S&T Information with annual intake of more than 3000
foreign journals in 1989.
SECOND LEVEL - annual acquisition budget between YO.5-4 million, 500-3000
current foreign journals and a similar number of current Chinese journals
1. Chinese Academy of Medical Science with an annual intake of just under 1500
titles of foreign journals in 1987;
2. Shanghai Library of Academia Sinica with annual acquisition budget of over one
million Y in 1989 and an annual intake of nearly 900 titles of foreign journals;
3. Shanghai S&T lnforrnation Centre ofPhannaceutical Industry (the biggest library
in SPAC information network) with annual acquisition expenditure of ¥400,OOO in
1989 and annual intake of more than 600 titles of foreign journals;
4. ISTIC Chongqing centre with annual acquisition budget of over¥2 million in 1989
and annual intake of about 2000 titles of foreign journals;
5. About 15% of universities and government research institutes are estimated in
this level (China Medical University and Academic Institution Union Catalogue of
Foreign Journals, 1987 & Academia Sinica, 1991)
THIRD LEVEL - annual acquisition budget of¥50,000-400,000 and 50-500 current
foreign journals and a similar number of current Chinese journals
It is estimated about 25% of universities and research institutes in this level (China
Medical University and Academic Institution Union Catalogue of Foreign Journals.
1987 & Academia Sinica, 1991).
FOURTH LEVEL - annual acquisition budget of ¥1 ,000 - 50.000 and less than 50
titles of current foreign journals and a few hundred current Chinese journals
It is estimated that about 60% of research and university libraries and 80% of SPAC
information services and 90% of factory R&D divisions are in this level (China
Medical University and Academic Institution Union Catalogue of Foreign Journals,
1987 & SPAC Statistics 1989 & Academia Sinica, 1991).
Table 8.1a Annual Change in Foreign Journal Subscription in Library of Acade-
mia Sinica (Academia Sinica, 1991)
year annual annual no. of annual average annual
spending growth % journals decrease % pnce per intlatio%bn
thousand¥ journal ¥ %
1985 1880 5196 361.8
1986 2300 22.3 4766 9 482.6 33A
1987 3000 30.4 4273 11.5 702.1 45.5
1988 3580 19.3 3318 28.8 1078.9 53.7
1989 3270 -9 2108 57A 1551.2 43.8
Since 1987, there has been a serious constraint in S&T information budget in China,
because of the journal price inflation in the domestic and world market. Table 8.la
gives the annual change in foreign journal subscription in the Library of Academia
Sinica. From 1985 to 1989, although annual foreign journal expenditure has grown
at an average rate of 16% p.a., the number of annual intake of foreign journals has
decreased at a faster rate of 27% p.a.. The foreign journal price inflation rate is 44%
p.a.( Academia Sinica, 1991). Similar cut in foreign journal subscription has been
found in other national S&T information centres (Table 8.1b).
Table 8.1b Change in Foreign Journal Subscription
in National Library (NL), ISTIC Beijing and ISTIC Chongqing
year 1987 1990 Change
NL 13693 7741 -50%
ISTIC Beijing 5408 4200 -20%
ISTIC Chongqing 7000 1348 -80%
8.1.3 China Abstracting and Indexing Services
ISTIC has been very much involved with secondary literature publishing since 1961,
when the China Commission for Editing, Translating and Publishing S&T Docu-
ments (CCETP) was established within ISTIC.
In 1980, CCETP issued "The Plan for the National S&T Secondary Publication
System". By 1987, under its supervision, the build up of the national secondary
publication system has been completed with 229 abstracting and indexing serial (158
reporting foreign information and 71 reporting domestic information) and an annual
production of 1,470,000 records (1,170,000 foreign records and 300,000 Chinese
records) in all S&T subjects. However, because of the reduce in funds since 1987,
for the last three years there has been a decline in the titles of secondary serial and
in the annual production of records. The change of the national secondary system
annual production is given in Table 8.2.
ＲｾＹ
Table 8.2 The Annual Production of the Chinese National S&T Secondary Publi-
cation System (1981-1990)
year 81 82 83 84 85 86 87 88 89 90
serials 134 147 159 195 219 224 229 169 157 156
Chinese serials 101 109 161 160 158
foreign serials 58 86 58 64 71
records (OOOs) 850 900 950 1020 1410 1420 1470 1100 1010 1000
Chinese records 760 800 1170 1170 1170
(OOOs)
foreign records 190 220 240 250 300
(OOOs)
From 1981 to 1987, the trends of the Chinese secondary publication include:
1. The increase in secondary publication in titles (increasing by 70%) and in records
(by 70%);
2. The introduce of Chinese secondary publications published in English, since 1985;
(By 1990 there are 7 titles of such abstracting journals aiming at disseminating
Chinese S&T information to the world.)
3. The speed up of producing and publishing procedure; (By 1989, the majority of
the secondary publication were published quarterly: while by 1990 the majority
has been switched to bimonthly, with 24% monthly, 52% bimonthly and 240'(
quarterly.)
4. The centralisation of secondary publication: (Since 1980, all Chinese secondary
publications have been concentrated in about 20 ministerial S&T information
institutes or libraries.
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The annual 1,170,000 records of foreign S&T literature are translated from the world
S&T literature pool of millions items. The production of foreign secondary publi-
cation has engaged 90% offunds and manpower in the Chinese secondary publication
system.
The production of foreign secondary publication normally falls into the two cat-
egories: translation directly from foreign abstracting and indexing serial, and
translation from abstracts in foreign primary journals. For example, the S&T
information institute in Chinese Academy of Medical Science is responsible for the
compilation of "the Foreign S&TDocumentation Index (FSTDI) - Medical Science".
It relies on 500 scientists in 41 academic institutions nationwide for the translation
of bibliographic records of foreign journal papers. Because of the delay in foreign
journal arrival to Chinese libraries and in translation, the time span between a foreign
journal paper publishing and its bibliographic record appearing in FSTDI is some
21 months on average which is 4 times the time span of Medical Index (4.5 months)
(lin, 1988).
Generally, the Chinese national S&T secondary publication system has the biblio-
graphic control on most of high standard domestic S&T literature. However, the
comprehensiveness in coverage of domestic literature is questionable. One example
is from "the Chinese S&T Documentation Index (CSTDI) - Medical Science". The
CSTDI - Medical Science is the most comprehensive index serial on domestic lit-
erature in medical and pharmaceutical area in China. The S&T institute in Chinese
Academy of Medical Science is responsible for the production of it. It is reported
that each year the institute selects 38,000 items from its intake of 80,000-100,000
(journal papers from 400 Chinese journals, reports, monographs, patents, proceed-
ings, grey literature etc.) for the compilation of CSTDI - Medical Science. In this
case, less than 50% of Chinese S&T literature in medical science are covered by the
national S&T secondary publication system.
Apart from the Foreign S&T Documentation Index (FSTDI) - Medical Science and
the Chinese S&T Documentation Index (CSTDI) - Medical Science, the Chinese
Medical Abstracts is a comprehensive source of information in medical sciences in
China. It is published in 14 sections, covers about three hundred journals and indexes
21,00J records each year.
In October, 1989 the author visited the 20 staff editorial division of the China
Pharmaceutical Abstracts (CPA) in SPAC. CPA is the most comprehensive
abstracting journal for the domestic pharmaceutical literature in China.
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CPA had been prepared since 1980 and was published in 1984 with a coverage of
more than 220 Chinese journals. CPA is one of the first to be published with the
assistance ofcomputer typesening in China. By 1989, there are 50,000 records stored
in SPAC central computer. With the computer aid, CPA is published bimonthly with
annual production of9000 records in Chinese. Mainly serving the information needs
of Chinese academic pharmaceutical institution libraries and pharmaceutical
industry libraries, CPA has a subscription of 1,500 nationwide each year. The
abstracts are informative and arranged in classified order with author, generic name
and subject indexes which are cumulated annually. Table 8.3 gives the classification
of CPA.
Table 8.3 CPA Classification and Number of Records in 1989
Code Heading No. of % of total
records records in 1989
01 General theory in pharmaceutical sciences 107 1.2%
02 Pharmacognosy and TCM raw material 596 6.7%
03 Pharmaceutical Chemistry 562 6.3%
04 Pharmaceutical Development and Produc- 194 2.1%
tion
05 Pharmacy and Formulation Development 502 5.6%
06 Pharmacology and Toxicology 1254 14.1%
07 Pharmacokinetics and Pharmacodynamics 225 2.5%
08 Pharmaceutical Analysis 745 8.4%
09 Clinical Evaluation and Use 4390 49.2%
10 Production quality control 80 0.9%
11 Factory Design and others 118 1.3%
12 New Drug Profile 142 1.6%
All the Chinese abstracting journals rely on government funds for publication. For
the last three years, there has been a reduce in government funding for the national
production of secondary publications which has resulted in the decrease in the number
of Chinese abstracting journals and the number of bibliographical records (Table
8.2).
In China, the plan for building up domestic S&T databases in the forms of factual,
numerical and bibliographical has been drawn since early 1980. Some progress has
been made so far. By 1988, there are 262 domestic S&T databases in China, of which
98 bibliographical ones, 102 factual or numerical ones and 62 others.
However, so far only 61 of262 (all are bibliographical) have more than 5,000 records.
Of the sixty one databases, 9 are produced by Academia Sinica. The other 52 bib-
liographical databases are built up by about twenty ministries with mainframe
computer facilities. All the Chinese databases are still at stage of inhouse use so far
(Academia Sinica, 1991).
Table 8.4 lists some Chinese databases relevant to pharmaceutical sciences.
According to ISTIC 1985 statistic, there were 900 microcomputers and 50 mini-
computers and 10 mainframes (with 1MB+ and 1OOOMB+ memory) among the 4000
S&T information services in China. Since then until 1989, the installation of
micro-computers has increased by about 20%. However, there has been no increase
in the number of mainframe. (Zeng, 1987 & White Paper, 1990).
Because of the lack in facilities and funds, none of the 61 Chinese bibliographical
databases are online accessible so far.
8.1.4 Foreign Information Analysis & Research
Apart from primary S&T documents supply and abstracting & indexing services,
the third of the three functions of the Chinese national S&T system is foreign
information analysis and research.
This work started in the 1950s when many university graduates with first degree in
foreign language study were employed by R&D institutions in academic sector and
industry. They established foreign information analysis and research divisions in
the institutions. The major functions of such a division include:
to receive requests from users (scientists. S&T administrative officials etc.):
.....
Table 8.4 Chinese Databases Relevant to Pharmaceuticals With More Than 5000
Records By 1988 - (Academia Sinica, 1991)
File Name Language Journal records producer and host
Coverage by 1988
China Chemstry and Chinese 800 5000 Ministry of Chemical
Chemical Engineering Engineering
Chinese Pharmaceutical Chinese 248 53,000 SPAC
Abstracts
China Biomedical Chinese 80 30,000 Chinese Academy of
Abstracts Medical Sciences
Chinese Patent Chinese 40,000 Chinese Patent Office
Abstracts
Clinical Medicine Chinese 10,000 Military Hospital
Abstracts System
Clinical Trial Abstracts Chinese & 7800 Shanghai Medical
English Institute of S&T
Information
Chinese Chemical Chinese & 592 70,000 Academia Sinica
Abstracts English
Chinese Biological Chinese & 300 Academia Sinica
Abstracts English
d
to establish foreign information analysis and research projects on requests;
to search and collect relevant information by using all sorts of primary, secondary
information sources wherever available;
to write reports or reviews based on the foreign information analysis and research;
to compile and produce subject bibliographies or reference tools:
to produce translated foreign information bulletins, serial, etc.:
to translate full text papers, reports, monographs on demands.
This work has spread to large S&T libraries such as the Beijing Library of Academia
Sinica since the early 1980 when the library introduced a slogan "the combination
of library service and foreign information research". According to ISTIC 1985
statistics, about 20% of library and information staff in 4000 S&T information
organizations in China have the first degree in foreign language study. It is them
who have created such a service with the Chinese characteristics aiming at over-
coming foreign language barriers in S&T information communication. So
approximately we may estimate that about 20% of Chinese information workers are
engaged ui foreign information search.
Each year, thousands of foreign information research reports, reviews, and subject
bibliographies are produced by Chinese S&T information staff in the 4000 infor-
mation organizations. In 1985, there were 34,000 items of translations, 7,741 foreign
information research ongoing projects, 5,920 completed projects (reports and
reviews) and 15,605 titles of subject bibliographies, bulletins etc (ISTIC, 1985).
During the 1980s, the following trends in foreign information analysis and research
have been seen in China:
1. The reduce in the numbers of "foreign information analysis and research projects"
(completed) from 5920 in 1985 to 2685 in 1989 (White Paper. 1990);
2. The switch from mainly serving scientists information needs to mainly serving
S&T administrative officials information needs.
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The above trends reflect the change in the foreign S&T information needs and use
in China.
On one hand, Chinese scientists' ability of reading foreign language (especially
English language) literature has been greatly improved during the 1980s. It was
reported that 93% of Chinese scientists can read S&T literature in English: 27% can
read Russian and 19% can read Japanese (Academia Sinica, 1991). And 50% of
Chinese scientists do not regard "foreign information analysis and research" reports
and reviews as high quality S&T information source (seeing Chapter 5).
On the other hand, Chinese S&T administrative officials' needs for foreign infor-
mation has been increasing during the 1980s. The economic reform and the "open
door" policy needs the decision making to be based on timely and comprehensive
information work, while the foreign information analysis and research service could
save time for the officials in searching, collecting and translating information. In
1986, ISTIC conducted a survey on S&T administrative officials information needs.
The results showed that 65% of officials only use information in Chinese partly
owing to lack of time and partly owing to inability of reading foreign languages. It
also reported that 75% ofofficials regard "foreign information analysis and research"
reports and reviews as a major and valuable information source. This kind of
information service needs careful evaluation and assessment in the light of system
objectives, performance and cost effectiveness, because it represents a significant
part of S&T information work in China.
According to SPAC 1987 statistical data, during 1985-1986, the nine first grade
information services completed more than two hundreds of foreign information
analysis and research projects.
According to SPAC 1989 statistical data, 22 of26 first and second grade information
services in the SPAC provincial branches conduct "foreign information analysis and
research". There are 209 staff in the 22 services with an average of9 staff per service.
In 1989, among the 22 services, the annual output of information research reports
(projects) in a service ranges from one to twenty with an average of 6.
In addition, there are several foreign information research systems inside SPAC.
Each has its speciality and its regular publications - bulletins, serial. There are 30
titles published by the nine first grade information services and 60 titles by the 25
second grade information services.
256
The author interviewed information officers in the following 5 systems in October
1989. Although by no means comprehensive, the five systems reflect the efforts and
emphases on foreign information research and analysis in China.
(1)Shanghai Institute of Pharmaceutical Industry is the head organization in the
foreign information analysis and research system specialised in Western Medicines
R&D. Under its supervision, there are 20 large factories and R&D institutes coop-
erating to carry out foreign information analysis and research and publish a serial
"World Pharmaceutical R&D" bimonthly with 10,000 subscription each year.
During 1985-1987, cooperated with the SPAC headquarter and the Chengdu service,
the Shanghai information service has completed the central government level project
"1980s World Pharmaceutical R&D Progress". It also completed another 12 large
foreign information analysis and research projects during the period.
(2)Shanghai YANAN factory is the head organization in foreign information analysis
and research system specialised in Drug Formulation and Preparation. Within the
system there are about 10 factories exchanging information analysis and research
reports, and publishing several titles of bulletins each year.
(3)Guangzhou Pharmaceutical Economic Information Service has been carrying out
world and domestic market research on three categories of medicines since 1985.
(4)SPAC headquarter information service is carrying out a foreign information
analysis and research project "Chinese and World Pharmaceutical Industry in 2000"
for the State Plan Commission and the State Economy Commission. The project
covers 6 subjects and 30 categories of medicines.
In addition, in cooperation with the nine first grade information services, it also
conducts another large project "Pharmaceuticals Quality Control and Standard in the
World".
(5) JiIin Province Pharmaceutical Information Service has conducted about 5 projects
by "borrowing" 30 S&T staff from provincial factories since 1985. By 1987 about
20 reports or reviews were completed.
8.2 Business Information Flow
8.2.1 Outlook on the Economic Reform in Industry in the 1980s
The national economy of China is mainly a state-planning one, in comparison with
market economy predominant in most of western countries. In other words. to a large
extent the various level governments directly control production, commercial prices,
employment and so on.
The state enterprises constitute the central theme of industry, which is supplemented
by a great amount of small collective and individual enterprises.
The largest enterprises were all state-controlled, under the domain of the central plan
and under the supervision of the central industrial ministries in Beijing (such as State
Pharmaceutical Administration of China (SPAC» and their branches throughout the
country. Medium-sized enterprises were largely owned and administered by prov-
inces and municipalities. Small-scale enterprises were owned and administered by
localities (county, prefect, or village) or collectives: small businesses were primarily
outside of plan control.
Before the economic reform (1979- ), the economy was one of hidden shortages and
inactive market. The 1980s economic reform was intended to decentralise control
and to expand enterprise decision-making autonomy in an effort to raise output from
the same input; and was marked by the continuous introduction of new reform
measures. Two major measures are the autonomy of enterprise management and
the dual-price system (Experimentation in industrial reform began in 1978 when
existing plan quotas for some enterprises were adjusted to permit above quota output
to be marketed independently at prices decided by enterprises according to the market
demands). The process of extending reforms expended the operation of market
mechanisms throughout the 1980s.
The transition has proved vital for the last ten year economical growth. Ten years
after the reform. a surge of production. a rise in living standards. and an explosion
in domestic trade and foreign trade have been seen by the world. in despite of some
serious intensity in the national economy (seeing Chapter 2).
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Correspondingly, the reform gives rise to Chinese industrial enterprises' demands
for business information. However, the business information service was almost a
vacuum in the Chinese information infrastructure until the end of 1980s.
In 1986, ISTIC conducted a series of surveys on Chinese enterprises' business
information needs. It reported that although there have been ever-increasing demands
among enterprises for market information, product information, and other business
information, there is no business information services available for public use in
China (ISTIC, 1986). To investigate the situation in Chinese pharmaceutical industry,
the author conducted a survey during October and December in 1989. Fifty ques-
tionnaires were sent out to large pharmaceutical factories in Beijing, Shanghai,
Guangzhou, and other big cities. Thirty of them replied. In addition, the author visited
six large factories in Beijing and Shanghai, informal interviews were given to about
ten information officers in the factories.
8.2.2 Industrial Enterprises' Needs for Business Information
All of the thirty six factories reported eagerdemands for products information, market
information, Information on competitors, financial information and foreign trade
information. Most of the factories (30) need statutory information (standards, import
and export, governments legislation and regulations). Currently, Chinese factories
are mainly competing among themselves in domestic market and in export of bulk
pharmaceuticals, they are more interested in domestic market information than in
world market of ethical drugs.
All the thirty six factories also reported eager needs for foreign technical information
especially patent information. All the six factories the author visited expressed great
interests in foreign pharmaceutical patent information. One of the factories has twice
contacted the author after her return back to the UK, seeking some foreign patents
which are not available in China.
According to the survey, few of the factories have formal business information
personnel and divisions. There are two each having a business information unit, the
others have product or market managers dealing with business information occa-
sionally.
There are two major problems in business information. On one hand, because of lack
of experience in operation under the new market mechanism, Chinese enterprises in
general are not well aware of many potential information sources available. For
example, the SPAC S&T information service network, with one head service, 9 first
grade and 25 second grade services allover the country, has some business infor-
mation sourcebooks, reference tools containing mainly foreign business information
(Such as Scrip, Phannaproject by PJB and Marketletter by IMS). And one third of
the 35 SPAC information services have some kinds of economic or business infor-
mation enquiry services (either on domestic or on foreign information). However,
only 7 of 36 factories reported use of the SPAC information network for business
information needs.
On the other hand, there are few information services being organized to collecting,
disseminating and supplying domestic and foreign business information to the 236
large and medium-sized and two thousands small pharmaceutical factories, although
there are some scattering business information flows inside the Chinese pharma-
ceutical industry.
All the thirty six respondent factories reported they rely on official channels (China
National Cooperation of Pharmaceutical Industry, China National Cooperation of
Medicine and China National Cooperation of Pharmaceutical Foreign Trade under
SPAC) for product information and market information. Every year, the China
National Cooperation of Pharmaceutical Industry (CNCPI), the China National
Cooperation of Medicines(CNCM), the China National Cooperation of Pharma-
ceutical Foreign Trade (CNCPFT) (the three big corporations under SPAC), and
the provincial and local governments hold many plan and market meetings. This
kind of meetings or fairs are reported as the most important business information
source for all the 36 factories; although the information flows are not well organized.
One plan and market manager in a factory told the author that each year he has to
spend more than half of work time on travelling around the country and attending
various market meetings and plan meetings. "There is no comprehensive, efficient
and reliable business information source or service available nowadays. In some
sense. the difficulty in gaining business information is bigger than the old days before
the economic reform when there was always only one information source - the
government departments. Now there is a free market. You hardly know exactly what
is going on there".
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Indeed, to access Chinese business information has become more and more difficult
as the economic reform processes and more and more factories take pan in free
market economy. Even the top administration SPAC has lost the confident in
mastering the national product information and market information.
To implement an effective control of the national pharmaceutical industry economic
information, a national pharmaceutical product and market database has been under
discussion in SPAC now.
8.2.3 Existing Business Information Flows
During the 1980s economic reform, the SPAC S&T information service network has
gradually enforced its business information work. Under the SPAC administration.
there are three subsystems with specialised functions - industrial production
(administered by CNCPI), domestic market (administered by CNCM) and foreign
trade (administered by CNCPFf). In each of the three subsystems there are some
kinds of business information flow, so far not being well organized.
1. China National Cooperation of Pharmaceutical Industry
CNCPI and its 28 provincial branches are responsible for the plan and supervision
of the production in about 900 large and medium pharmaceutical factories in China.
The 1980s reform has given factories more authority to sale their products at their
own prices and via their own distribution channels. Since 1987, five industrial
corporations have been established to promote and sale products for their member
factories in domestic and world market. These corporations are composed of either
several large factories with similar products or several provincial CNCPI branches
(China Pharmaceutical Yearbook, 1987).
These industrial market forces have constitute a potential source of business infor-
mation in China. However. none use of the potential information source was reported
by the 36 respondent factories in 1989 survey.
2. China National Cooperation of Medicines (CNCM)
Under the administration ofCNCM in SPAC. there are 5 national whole sale centres
in Beijing. Shanghai. Guangzhou, Tianjin, and Shenyan: 2R provincial whole sale
centres; 23(X) county level whole sale centres and 26,000 retail stores over the
country. Before the economic reform, this whole sale network under C:\CM had
monopolised the domestic market of Chinese pharmaceutical products. However.
the 19XOs reform has significantly reduce the power ofCNCM monopoly. .vccording
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to the production manager in Beijing Pharmaceutical Factory (among the top ten in
China), now as much as 70% of the products of his factory are sold by the factorv
- .
itself rather than by the CNCM.
Nevertheless, CNCM still is the biggest market force in Chinese pharmaceutical
industry. Therefore it holds the most comprehensive source of business information
on the domestic market.
Affiliated to the CNCM Guangzhou centre (one of the five national whole sale
centres), the Guangzhou Pharmaceutical Industry Economic Information Service -
one of the nine first grade information services in SPAC information network - is
specialised in pharmaceutical business information on both domestic and world
market.
It is the most used formal business information service in Chinese pharmaceutical
industry. All of the 36 respondent factories in the 1989 survey reported some use of
it.
It is among the only three information services (the other two - one in Shanghai and
one in Shenyan) in the SPAC network which could make money (more than ¥100,000
per year) from providing information. Annual income of ¥550,OOO from business
information services was reported in Guanzhou Economic Information Service in
1988 and 1989. Its major work is to publish three titles of bulletins and to provide
information to thousands Chinese pharmaceutical factories on demands and in
charge. The three bulletins provide information and analysis on domestic pharma-
ceutical R&D, manufacturing, marketing and legislation mainly, supplemented by
world pharmaceutical industry information. "Medicine Economic News" (weekly)
and "Medicine Economy" (monthly) are the two formal publications which can be
subscribed through the Chinese Post Office. The former contains timely news and
the latter provides analyses, researches or reports. The "Medicine Economic Infor-
mation" (monthly) is an inhouse bulletin which contains much more detailed
domestic and world business information. Users can only subscribe it directly from
the Guanzhou Economic Information Service.
Under the supervision of the Guangzhou Economic Information Service. there are
a national pharmaceutical industry economic information network being under
establishment with 19 first class branches and 148 Second class branches. The
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network is to link 4000 factories, whole sale stores and hospitals in the whole country,
to exchange business information among the nodes and to provide business infor-
mation over the country.
The case of Guanzhou economic information service and the cases in Shanghai and
Shenyan pharmaceutical information services, reflect the fact that there are big
demands for business information in Chinese pharmaceutical industry and existing
S&T information services are able and willing to add business information function
to their traditional S&T information work.
3. China National Cooperation of Pharmaceutical Foreign Trade
CNCPFr is the monopoly company dealing with import and export of pharma-
ceutical products. It is a potential business information source for Chinese and foreign
pharmaceutical enterprises. However, there were no reports on the use of CNCPFf
as business information source by the 36 Chinese respondent factories in the 1989
survey.
4. China Enterprises Directory Database (CEDD)
CEDD is a directory database in Chinese language newly established by ISTIC and
is in service since July 1991. CEDD covers 25,000 industrial and commercial
enterprises in China. Its English version is still in building. The database provides
online searching in ISTIC centres in Beijing and Chongqing.
Although there are many business information sources and services in the developed
western countries, the information is very difficult for Chinese factories to access.
The major reason is the lack of hard currency and the huge cost of those foreign
information.
For example, the Shanghai Pharmaceutical Administration Branch of SPAC has
recently spent half of its annual acquisition budget (£ 1610 in 1989) to subscribe
PHARMPROJECf- a monthly updated information system (hard copy) by a UK
publisher PJ8 Ltd. (seeing Chapter 7). The data sheets have been reported to be very
heavily demanded and used by hundreds of factories in and around the Shanghai
city.
The trends in business information development in Chinese pharmaceutical industry
are
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1. For S&T information services in SPAC (9 first grade and 25 second grade) to add
business information function and provide fee based services;
2. For the three big corporations in SPAC - CNCPI, CNCM, and CNCPFT to organize
the fee based business information services within their systems;
3. For the newly established industrial market and sale corporations (there are already
five) to organize the fee based business information services within their systems;
4. Demands and market for Chinese and world business information will continue
to grow, in the mean time, more and more organizations (both traditional S&T
information services and government plan and market departments) will attempt to
control some business information resources and make profit by providing fee based
information services.
8.3 Drug Information Flow
About drug information services provided by the pharmaceutical industry and hospital
based drug information (01) centres in the UK, there have been a certain number of
surveys and reports since 1980. To compare the situation in UK and China, we conducted
a similar survey during October and December of 1989 in China. Questionnaires were
sent to 100 doctors and 100 pharmacists in 20 big hospitals in Beijing and Shanghai;
and to 50 large factories; 49 doctors, 52 pharmacists and 36 factories replied respectively.
(a) Sources of new drug information
The channe Is Chinese factories using to promote the products are similar to those used
by UK companies. All of the 36 factories using promotion literature in academicjournals,
in trade press, in radio and television advertisements. All of the factories rely on plan
and market meetings or fairs held by various level governments and various kinds of
organizations. All the factories send medicine representatives to users at whole sale
centres and at hospital pharmacy.
Table 8.5 show the sources of new drug information for doctors and hospital pharmacists
in China.
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Table 8.5 Awareness of New Drug By Chinese Doctors and Pharmacists
of 49 respondent doctors of 52 repondent pharmacists
promotion literature 24 37
promotion meetings or fairs 7 27
posted advertisments 4 21
factory representatives 4 19
whole sale centre 7 27
representatives
hospital pharmacists 26 -
Table 8.6 Problems Occur to Chinese Doctors and Sources They Use for the Information
(as % of 49 respondents)
..
rank inquiring fac- rank self solution rankmqumng
pharmacists tories
administration 40% 4 6% 3 54% 5
/dosage (100%)
adverse effects 24% 6 10% 2 66% 3
/ toxicology
(100%)
availabili ty 70% 1 10% 2 20% 8
/supply (100%)
clinical use (100%) 18% 7 4% 4 78% 2
identification 62% 3 14% 1 24% 7
(100%)
interaction (100%) 16% 8 4% 4 80% 1
pharmacology 34% 5 2% 5 64% 4
(100%)
pharmaceutical 68% 2 4% 4 28% 6
problem (100%)
Promotions by Chinese factories are not aimed at doctors directly. Chinese doctors
mainly rely on hospital pharmacists for new drug information while hospital pharmacists
act as intermediary between doctors and pharmaceutical factories and between doctors
and whole sale centres. As in the developed countries, Chinese doctors produce many
clinical reports/papers on their prescribing experience. Academic and professional
journals, magazines and newspapers constitute a rich information source for post
marketing surveillance. In 1992, a professional medical journalists association was
founded in China with several largest newspapers, magazines and TV stations involved.
(b) Types of enquiry raised by doctors and received by hospital pharmacists and by
pharmaceutical industry
The problems which occur to doctors are similar in the UK and China, including
administration/dosage, adverse effects/toxicology, availabilitytsupplv, clinical use,
identification, interaction, pharmacology and pharmaceutical problems.
At present, there are no formal drug information service in Chinese hospitals. Nor full
time pharmaceutical information pharmacists or officers. 44 of 52 Chinese respondent
pharmacists reported providing drug information only as part of their jobs while the
remainders do not participate in any sort of information work. Table 8.6 shows problems
occurring to Chinese doctors and the sources they use for the information.
It seems that Chinese doctors rarely use industry information source. This result agrees
with the other survey result that majority of Chinese pharmaceutical factories do not
provide medical information services for external enquiries.
They mainly rely on hospital pharmacists for the following information (in order of
usage):
(1) availability/supply, (2) pharmaceutical problem. (3) identification, (4) administra-
tion/ dosage.
They mainly use own knowledge or read professional journals for the following prob-
lems (in order of usage):
(l) interaction (2) clinical use (3) adverse effects/toxicology (-t) pharmacology and (5)
administration/dosage.
(c) Medical information services provided by pharmaceutical industry
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None of 36 respondent Chinese pharmaceutical factories have a medical information
section or unit. There is no formal channel for communication between Chinese phar-
maceutical industry and health professionals on use of medicines. This result agrees
with the other survey result that Chinese doctors rarely use pharmaceutical industry
information source.
(d) Traditional Chinese Medicine Information
For thousands of years, Chinese people have employed a variety of ways of dealing with
disease. For 80% of the population living in rural areas, TCM is still the major if not
the only form of treatment available to them (seeing Chapter 3). Moreover, even in cities
or towns where the modern health care available to the population, people continue to
seek traditional treatment. Sometimes this traditional treatment is more expensive or
difficult to get because there are far less TCM doctors and hospital beds than WM ones
(a ratio of 2:98, seeing Chapter 3). However, TCM treatments are valued because they
are offered in terms that patients can understand or in the context of cultural values and
practices that shared by patients and doctors alike.
It must be pointed out that the modern scientific R&D, education and clinical practice
of TCM did not start until 1949 when the People's Republic of China was founded and
the half century of wars were ended. Since 1949 in China, TCM R&D, education, and
clinical practice have progressed gradually but not as fast as that in WM. One example
is that currently there are about 900 WM factories comparing to only 500 TCM factories,
there are 92 WM universities with 129,000 students annually enrolled comparing to 24
TCM universities with 29,000 students annually enrolled (seeing Chapter 3).
As a result, TCM information work is small in scale comparing to that for WM in China.
Today, there are 40 TCM libraries and 400 TCM documentationists in the country (TCM
1949-1989). By comparison for WM information, there are 35 information services
within SPAC administrative system, plus 57 SPAC research institution libraries or
information services (seeing §8.1.1 and Chapter 3).
One of the major task of TCM information work is the preservation and revision of
ancient documentation. There are about 13,000 titles of such documentation being
collected and stored in about 115 libraries in China. During 1965-1975, MPH has
completed the revision of 7 titles of them. During 1982-1990, it has greatly raised the
number of revision to 600 titles.
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In 1961, China TCM Academy and the National Library published the first "Xational
Union Catalogue of TCM Documentation" of 7661 titles in 59 libraries nationwide. In
1986, the second edition of 12,124 titles in 115 libraries has been published, which
covers TCM documentation published before 1949.
During April, 1986- July, 1988, China TCM Academy has established a manual index
database of 123,000 TCM papers and documents published in China after 1949. A
computerized database containing 50,000 records has also been set up to provide inhouse
searching and to aid indexing journal publishing. (TCM 1949-1989)
Generally, in China TCM information work is still at the stage of preservation and
revision of old documentation and is gradually proceeding into a stage of collecting,
storing, retrieving and disseminating information to users. There are some causes for
the comparatively slow progress in TCM field. One is the less emphasis on TCM R&D,
education and clinical practice than that on WM. The shortage in resources for TCM
R&D, education and practice has prevent the information work from fast progressing.
The other reason may be more complex. Because the way in which TCM treatments are
given is so different from that in WM treatment, TCM doctors may not able to or may
not willing to provide any information on (1) interaction (2) clinical use (3) adverse
effects/toxicology (4) pharmacology (5) pharmaceutical problem (6) identification,
though these information are essential for WM clinical practice. On the other hand,
patients do not usually ask for the above information from the doctors, since these
treatments have lasted for so long (mostly for several generations) without problems.
8.4 Statutory Information Flow and Chinese Regulatory System
Since 1949, China has built up its own medicines control system which contains four
parts- (1) Medicine Administration Bureau in Ministry of Public Health (MPH) (2)
Medicinal Product Analysis Institutes (3) Imported Medicine Analysis Institutes (4)
Chinese Pharmacopoeia (first edition in 1953). In 1985, China formally introduced the
Medicine Act (1985).
The Chinese Medicine Act (1985) includes 11 chapters and 60 instruments. The chapters
are:
1. Guide-lines 2. Administration of Pharmaceutical Industry .3. Administration of
Pharmaceutical Whole Sale and Retail 4. Administration of Hospital Pharmacy 5.
Control of the Quality. Safety and Efficacy of Pharmaceutical Products 6. Store and
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Package of Pharmaceuticals 7. Control of Special Drugs 8. Labelling and Promotion of
Pharmaceutical Products 9. Inspection of Manufacturers, Wholesalers and Hospitals 10.
Legal Responsibility 11. Appendix.
In May and June of 1986, a delegation from China MPH visited UK and Japan to study
the medicine regulation and legislation in the two countries under the WHO plan. For
the past five years, improvements have been gradually made to enable the Chinese Act
up to the world standards and compatible to USA and UK, Japan medicine acts or
regulations.
TM Administration ofthe Act
In the Act, the Medicine Administration Bureau in Ministry of Public Health (MPH) is
the highest medicine control authority.
TM Licensing System
The licensing system is the Chief novel feature of the Act. The system ensures that
medicines are of good quality, safe and efficacious and are manufactured and dealt with
under optimum conditions. The system also enables batches of products to be traced
and withdrawn from sale with minimum of delay should they prove sequentially to be
defective. The system utilizes five types of licence and two types of certificate each of
which permits a person to engage in certain specified activities, namely- manufacturer's
licences, wholesale/retail dealer's licences, medicine preparationer's licences, and
export/import medicine product licences; clinical trial certificates and new medicine
product certificates.
Because the Chinese Medicine Act has had a very short history (came into force in July,
1985), not only the Act itself is very brief but also the implementation of the Act has
many problems. Toestablish a national, provincial, county level medicine administration
network to implement the Act is still being discussed but not realized.
During the 1980s, the major task of medicine regulation has been focused on setting up
Good Manufacture Practice (GMP) in China. In 1988, Chinese GMP came into force
formally. All pharmaceutical factories need to pass GMP examination first. then will
be granted the Manufacturer's licences.
Sections 21 and 22 of the Act deal with the licensing procedure of new medicine products.
The Medicine Administration Bureau in Ministry of Public Health (MPH) appoint a
Committee for New Medicine Approval (similar to CSM in UK).
Generally the Chinese requirements are comparatively simple or with low standards.
An example of this is from the difference in clinical trial requirement between China
and developed countries.
The Chinese Act divides clinical trials into three phases rather than four phases in UK
and USA:
Phase I requires not less than 30 case studies.
Phase II requires not less 300 case studies. The number of pre-market clinical trials is
quite low in China comparing to 1-2000 trials required in USA.
Another example of the backwardness in Chinese medicine control system is the ADR
monitoring or post market surveillance. In 1964, a yellow card system has been set up
and in operation in UK under which doctors spontaneously report ADR to the public
and the government authority. In China, monitoring ADR has been put on the agenda
only since 1988 when 10 large hospitals in Beijing and Shanghai was appointed as the
first batch of ADR monitoring centres.
For the past five years significant progress and improvement have been made in the
medicine control field in China. Before the introduction of Medicine Act in China in
1985, the "new drug" production and market was not able to under the overall control
of the central government. In 1985, there were 600 "new drugs" launched on the domestic
market. However, after the Medicine Act in force, from October, 1985 to July, 1987,
there were only 39 approved new drugs out of 100 applications being launched on the
domestic market. From Oct., 1985 to July, 1989, 158 new drugs have been granted new
medicine product certificates, with an average number of 40 new drugs per year.
Despite of all these progress and improvement, the Chinese legislation standards and
information requirements are still quite simple, especially in the case of TC\1 12•
A comparison of information requirements by the Chinese authority for WM new drug
and TCM new drug is given in Table 8.7.
12 In 19R7, there are)2 W\1s and 11 TCMs being approved for marketing by the Chinese
authority.
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Table 8.7 Information Requirements for a New Drug Application
(source from MPH Beijing, 1989)
To apply for a product licence, the applicant must provide scientific evidence of (1)
Chemistry and Pharmacy (2) Experimantal and Biological Studies (3) Clinical Trials.
WM new drug TCM new drug
1. Product name, chemical name, Latin name Product name, Latin name etc.
etc.
2. Chemistry of drug substance:a Product formula and preparation
process
various names, physical form, structural
and molecular formula, molecular weight
etc.
3. Chemistry of drug substance:b Chemical and physical studies rel-
evant to quality control
method of synthesis, method of manufac-
ture, specifications of starting materials,
reagents and solvents, purification method
etc.
4. Development of assay methods Chemical and physical characteris-
tics of active ingredients
evidence of molecular structure and physi-
cal characteristics, tests for identity, stan-
dard of potency and purity etc.
5. Development pharmaceutics and biologi- Chemical and physical comparative
cal availability studies on man made substitute vs.
TCM raw material
an outline of work for determining satis-
factory nature of the proposed formulation
for its intended purposes
6. Pharmacology TCM theories which form the foun-
dation of the formula
7. Acute toxicity Development pharmaceutics and
biological availability
an outline of work for determining
satisfactory nature of the proposed
formulation for its intended pur-
poses
8. Chronic toxicity Pharmacology
9. For drug administered by a particular Acute toxicity
route, it needs special studies of pharma-
cokinetics and toxicity by that route
continued
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10. Interaction studies Chronic toxicity
11. Mutagenic properties Mutagenic properties
12. Effects on the foetus and neonate Effects on the foetus and neonate
13. Oncogenetic (carcinogenic) properties Oncogenetic (carcinogenic) prop-
erties
14. Drug addiction Short term stability
15. Pharmacokinetics Quality control specifications for
clinical trial drug
Analytical results of different
batches of the product (3-5 batches)
16. Short term stability TCM raw material
17. Quality control specifications for clinical Preclinical brochure
trial drug
Analytical results of different batches of
the product (3-5 batches)
18. Preclinical brochure Long term stability
19. Clinical pharmacokinetics Quality control specifications for
finished product
Analytical results of different
batches of the product (3-5 batches)
20. Clinical metabolism studies Clinical trial reports
21. Long term stability Packaging
22. Quality control specifications for finished
product
Analytical results of different batches of
the product (3-5 batches)
23. Clinical trial reports
24. Packaging
--
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The information requirement for TCM new drug, unlike that for WM, does not include
ｾ ｣ ｨ ･ ｭ ｩ ｣ ｡ ｬ name. compounclchemical structure. Chemistry of the drug substance
is the major omission.
Also the pharmacological studies and clinical trials are less sophisticated in TCM than
in WM. In the long term, standards and information requirements for TCM new drug
will gradually be raised and improved along with the progress made in TCM R&D,
education, and clinical practice in China. Finally, as the mechanism of medicine control
becomes more mature in China, statutory information flow will grow significantly and
become one of the major information flows.
8.5 Patent Information Flow and Chinese Patent System
In developing countries, patent protection for pharmaceuticals has two aspects. On one
hand, it can provide a favourable atmosphere for foreign investment, protect domestic
innovation, foster foreign innovation in drugs that have their main markets in developing
countries, and facilitate domestic licensing. On the other hand, patents have often been
used to secure import monopolies (stopping the importation of cheaper products) and
to prevent local manufacturers from producing similar products.
Nowadays pressure from research based pharmaceutical industry in the developed
countries is mounting in favour of product protection in developing countries and
extension of the patent term from 15 years to 20 years and more in developed countries
(China Daily, 22 May 1991 and 25 May 1991). The principal reason is to compensate
for the time taken to complete the increasingly stringent tests and trials required by the
authorities to establish safety and efficacy.
The first patent law of the People's Republic of China was promulgated in March 1984.
Furthermore, the National People's Congress made a decision that China is to accede
to the Paris Convention for the Protection of Industrial Property. The Chinese Patent
Law has been effected since March 1985. In this way China clearly declares that it will
provide legal protection for industrial property in the technological exchange between
it and the rest of the world.
Following the record rush of 3455 applications on 1 April of 1985. the first day when
the Chinese Patent Law went into force. as many as 50 applications have kept flooding
into the Chinese Patent Office each day since then. By the end of September 1990, for
the last 5.5 years Chinese Patent Office has received patent applications of 1)).360 with
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an average 28,000 applications per year accounting for 2.8% of the world annual
number of patent applications. Of the total applications for the past 5.5 years, 81.5%
are from domestic applicants and 18.5% are from foreign applicants. For the past 5.5
years China has granted 56,463 patents, of which 90% to domestic applications and
10% to foreign applications (Zhou, 1987 & People's Daily, 1 November, 1990). The
foreign applications have come from more than 60 countries in the world and reached
the amount of 28,682 by September 1990 (People's Daily, 1 November, 1990).
Because it is only six years old, the Chinese Patent System is still in a premature status.
So far, pharmaceutical products and substances obtained by means of a chemical process
have all been excluded from protectable subject matter according to Article 25(4) and
(5) in the Patent Law.
Professor C. S. Zheng, the deputy director of International Law Division in Chinese
Academy of Social Sciences has described the situation concerning pharmaceutical
patent protection in China.
"After publication of the Patent Law (in 1984), a number of complaints were received
on these exclusions (of pharmaceuticals and chemicals) from abroad. Similar criticisms
have also appeared concerning the exclusion of food and pharmaceutical products
(especially the latter) form Chinese interested parties.
"Traditional Chinese medicines frequently combine food with medicine have been
scientifically proven to work quite effectively in curing certain chronic or stubborn
diseases. In some international technology exhibitions, foreign experts often speak
highly of such "food-medicines" innovations from China, while we ourselves refuse to
protect them.
"As far as pharmaceutical goods are concerned, they must under the present law always
be put on the market with their ingredients indicated clearly on their packages in order
to avoid any harmfully effects. To exclude such products from patentable subject matter
may make it easier for imitators. Furthermore, and as a matter of fact, many Chinese
inventions in the field of pharmaceuticals have been prominent for a long, long time.
Even before the existence of the (Chinese) Patent Law. certain Chinese pharmaceutical
product inventions had been granted as patents in Japan and in various western countries.
"The main reason in deciding not to protect pharmaceutical products during the drafting
of the Chinese Patent Law. may have been that a I) year term for the invention might
not have been considered in the public interest. The Indian solution, which is to make
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pharmaceuticals patentable yet to provide a shorterterm of protection, may be adesirable
route for China to follow. To date at least certain experts in the medical, health and legal
fields have made such a suggestion." (Zheng, 1987)
A Chinese official has recently expressed that the Chinese Patent Law is now under
adjustment. The expansion of patent life from 15 years to 20 years and the inclusion of
pharmaceutical patent protection have been reviewed and considered (People's Daily.
25 May 1991).
Although so far in China there is still no patent protection for pharmaceuticals and there
are few Chinese pharmaceutical patents in the world, the pressure from inside and outside
China for the pharmaceutical patent protection in China have made it inevitable that
sooner rather than later such a protection will be established in China.
Having said all that on patent protection, now we look at the patent information practice
in China.
The centralized national patent document service was established at Institute of S&T
Information of China (lSTIC) in Beijing in 1965. In 1981, the patent library was
transferred to the Chinese Patent Office (CPO) for establishment of the Chinese Patent
(Protection) System. In respect of the patent documentation practice, the CPO was
confronted with a totally new situation after the promulgation of the Chinese Patent
Law. The former document service to the public could no longer suit well the forth-
coming needs. The need of building up a classified search file system to serve the
examining procedure arose suddenly.
In "the story of the Chinese search files", 1. L. Shen (1990) has described how a search
file system of 3.65 million patent documents from EP. US, WO and China; and 3.62
million patent abstracts from 9 countries has been built up during eight years
(1981-1988). Most of work has been done manually.
With the industrialization proceeding, more and more S&T workers and industrial
enterprises have recognized the value of patent as an important technological and
economic information source. During the author's survey in 1989, all of 56 R&D
scientists in Chinese pharmaceutical sciences and all 36 large pharmaceutical factories
who responded have expressed eager needs for patent information (at present that means
foreign patents).
275
At present, the CPO publishes each week, the Patent Gazettes for Invention, for Utility
Model, and for Design; Unexamined Applications; Examined Applications and etc ..
One computerized database has been buil t up by the CPO, which contains 60,000 Chinese
patent abstracts by 1990 with about 10,000 records adding in each year. This database
has both Chinese version and English version (Academia Sinica, 1991). The major world
patent databases such as CA, Derwent and INPADOC all have covered Chinese patents.
The Chinapats (Chinese patent abstracts database) is now available on ORBIT.
Access to patent documents and patent information in Chinese libraries has been
improved during the 1980s, partly owning to the efforts made by the CPO in the
propagation of patent knowledge, the co-ordination of national patent information
service system with 62 nodes in the country; partly owning to the enhancement of patent
document services in other thirty or so S&T libraries around the country.
Now, there is a national patent information service network with the head service Patent
Documents Library in Chinese Patent Office and 62 branches around the countries.
During the last 20 years, the CPO library has collected as many as 13 million patents
from 15 foreign countries and two international organizations (EPO and WO) in the
world (Shen, 1990 & Xu, 1989).
The collection was made by purchase during the period of 1950-1985. After 1985, most
of foreign patents have been obtained through bilateral exchange, although there are
still certain amount of patents being purchased. The average annual intake of patents in
Chinese Patent Office are around two million foreign patent documents and more than
twenty thousands domestic patent documentation. In 1989, Chinese Patent Office
imported one million foreign patents in hard copy and 0.7 million in microfilm. The
Chinese Patent Office library annual intake of world patents nearly equals to SRIS of
the British Library (Zhao, 1991).
The CPO library has also been equipped with all major international secondary publi-
cation tools on patent information.
Each day the CPO library receives about 150 readers (or 50,000 readers per year) from
all over the country. In recent years, an average of 1.5-2 million pages of patents (or
about l()(),OOO patent documents) have been photocopied for readers or external users
each year (Shen. 1990). About 60% of users' needs are for chemical and pharmaceutical
patents according to the CPO library statistics on about 1700 readers' requests for a
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period of two months. About 34% of requests are for US patents, 21% for Japan patents.
and another 21% for UK patents, 10% for German patents, 9.5Cj( for USSR patents, and
5% for other countries. A microfilm reading room was set up in 1987, which has col-
lection of patent documents from US, Japan, Germany, France, Australia and Per as
well as Derwent's indexes (Xu, 1989).
The 62 local patent information services are set up to constitute the national patent
information network in 1985. Their main function is to disseminate patent publications
and patent documents published by Chinese Patent Office. They acquire patent docu-
ments and patent publications from the CPO at discount price and provide Chinese
patent information and document service to local people. The use of the 62 services
are relatively small at present - only 80 readers per working day.
Apart from the CPO library in Beijing, there are other 34 S&T libraries providing patent
information and document service- ten in the government ministries in Beijing and 24
in provinces. The 34 patent libraries have certain amount of foreign patent collections.
Except Chongqing Centre of ISTIC and Zhejiang Province, other patent libraries have
much less annual intake than the CPO library in Beijing. As other kinds of imported
information materials, foreign patents are concentrated in a few biggest cities such as
Beijing, Shanghai, Chongqing. In 1985, China imported about 8-9 million foreign patent
documentation (including duplicates). Of the nine million patents, Chinese Patent Office
(Beijing) imported about 2 million, Chongqing ISTIC imported about 1.23 million,
Zhejiang Province imported about 1.13 million, other 4 million foreign patents are
among thirty provincial and ministerial patent libraries around the country (lSTIC
statistics, 1985). However, there is no co-ordination or network among the 34 patent
libraries and the CPO library.
8.6 Concluding Notes
Much greater emphasis on scientific information work than on business information and
drug information work has been found for long time. Since 1949, the S&T modernisation
has been regarded as the first important factor for the development of national phar-
maceutical industry. On the other hand, in China until the mid 1980s, the importance
of business information have long been overlooked, because of the predominantly central
government controlled economy and the self sufficient nature of the pharmaceutical
production. Because the major problem in drug consumption in China has been how to
meet the domestic demands foressential drugs. the other problems common in developed
countries such as information provision for health care personnel and the public, the
post market surveillance etc. are still not on the agenda. The statutory information flow
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is still at its infancy, while China just started to introduce and is still enhancing the
Medicine Act (1985) so that China could reach the world standard on new medicine
registration. So far, there has been no pharmaceutical patent protection system in China.
The major argument is that in countries with developing pharmaceutical industry. a
weak patent protection for pharmaceuticals would ensure its potentially restrictive
effects on domestic development to be minimised. Consequently, there is no pharrna-
ceutical patent information outflow from China.
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Chapter 9 Pharmaceutical Information Flow in China Today and in the
Future
Chapters 7 and 8 have had an overview on pharmaceutical information flow in UK and in
China, which shows the current Chinese pharmaceutical information flow is still
underdeveloped. With the soft systems thinking, in this chapter, we will define a conceptual
system model which is very much drawn from the UK situation; compare the current Chinese
problem situation with the conceptual system model and propose recommendations for the
future Chinese pharmaceutical information flow system.
9.1 Assigning UK Pharmaceutical Information Flow to a Conceptual
System Model
Using Checkland's definition for the system model (Figure 9.1),
S is a formal system if and only if:
1. S has an ongoing purpose or mission.
2. S has a measure of performance. This is the measure which signals progress or regress
in pursuing purposes or trying to achieve objectives.
3. S contains a decision taking process.
4. S has components which are themselves systems having all the properties of S.
5. S has components which interact, which show a degree ofconnective such that effects
and actions can be transmitted through the system.
6. S exists in wider systems and environments with which it interacts.
An environment of S is further composed of environmental or influential factors which
have some sorts of influences or impacts on the system. And normally the factors at a
higher system level would also affect the lower level of systems.
7. S has a boundary. separating it from its environments and wider systems.
8. S has resources which are at the disposal of the decision taking process.
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Fig 9.1 A model of the concept 'human activity system' (after Checkland, 1981)
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9. S has some guarantee of continuity, is not ephemeral, has long term stability.
Note that if the analysis is pressed to lower levels, then below sub-systems, sub-sub-
systems etc. will eventually be found items which are not systems at all but only system
components.
Similarly, analysis in the other direction will eventually reach larger entities which have
to be taken as environments rather than wider systems. The distinction being that an
environment may hopefully be influenced but cannot be "engineered".
Now let us start to assign the UK pharmaceutical information flow to the conceptual
system model.
1. Pharmaceutical information flow in a nation is the target system S.
2. The nation's pharmaceutical industry (including pharmaceutical R&D, manufacture,
distribution and marketing etc.) is the wider system.
3. Purpose and mission of S and the decision making process in S
A well organized pharmaceutical information flow in a nation would function as the
nerve system of the national pharmaceutical industry. It is closely associated with
national pharmaceutical activity, serving information needs of pharmaceutical manu-
facturing and marketing, pharmaceutical R&D, safety use of medicine, and medicine
regulation and legislation; so that:
(I) The national pharmaceutical industry could provide the great range of effective and
safety tested therapeutic agents at a proper economic level, could make contributions
to the original scientific discovery and to the development of practicable medicines as
well as to their safe dissemination.
(2) The national medicines research could occupy the scientific and technological front,
by comprehending the basic nature ofdisease and the mechanism involved in the healthy
functioning of the body so that new medicines could be discovered and developed to
provide treatment and prevention for a wide range of diseases.
(3) The national medical personnel, other prescribers and the public could be rational
in their use of medical products.
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(4) The national regulatory system could be in full control of the drug situation in the
country. An ideal national regulatory system for medicines is not only responsible for
ensuring that medicines on sale are safe, effective and properly labelled, it also controls
the investigation of new agents and monitors adverse drug reactions.
In fact, the UK pharmaceutical information is an existing situation rather than a planned
system. Because of the British political framework, there is no central decision taking
process but decisions are made in pharmaceutical companies, in the NHS. in business
information services etc.. Because of the centralized government system in China,
decisions on any future pharmaceutical information flow system will be made by a
central government department.
4. Measures of performance of S
In the social process of information transfer, the ultimate evaluation must be from the
viewpointofthe potential recipients or users. Have they received the information needed,
wanted, demanded and are the costs ofthis information provision personally or socially
acceptable? There is also the question of evaluation from the viewpoint of the sources
of information, who are concerned to know whether they have got their messages across,
to whom and with what effect (Vickery, 1987).
In this study, we "measure" the performance of scientific information flow in terms of
scientists' information accessing searching disseminating and using ability.
5. Boundary of S and Environment of S.
Pharmaceutical information flow is the information flow existing within the national
pharmaceutical industry (the wider system). It is influenced by its special environment
and its general environment.
6. S has the five subsystems - scientific information flow, business information flow,
drug information flow, statutory information flow and patent information flow. There
are connective and interacts among the subsystems; such that effects and actions can be
transmitted through the system.
7. S has resources at the disposal of the decision taking process. Again in UK phar-
maceutical information flow, resources are decentralized at different decision taking
processes. f lowever, with the future Chinese pharmaceutical information flow system,
resources will be under the central control.
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So far we have defined a conceptual system model based on UK pharmaceutical
information flow in Figure 9.2. Next we will compare the Chinese pharmaceutical
information flow with the conceptual model. Table 9.1 is a summary of the plan for
comparison in this chapter.
Table 9.1 Plan of Systematic Comparison
Subject Comparison Section
System S: pharm. infor. Flow Infrastructure §9.2
Wider system: national pharm. Purpose/mission §9.3
industry
System S: pharm. infor. Flow Purpose/mission, decision taking ｾ Ｙ Ｎ Ｔ
System S: phann. infor. Flow Performance ｾＹＮＵ
System S: phann. infor. Flow Resources §9.6
Subsystems: scientific, Relationship among subsystems §9.7
business, drug, patent and
statutory information flow
Special environment: drug Relationship with system S *9.8
situation/phann. activity
General environment: Relationship with system S §9.8
infor. environment
9.2 Pharmaceutical Information Infrastructure in the Two Countries
Comparing Figure 7.1 and Figure 8.1, we find the following differences in pharma-
ceutical information flow infrastructure between China and UK.
CHINA
Much greater emphasis on scientific information work than on business information and
drug information work has been found for long time. Since 1949, the S&Tm(xicrnisation
has been regarded as the first important factor for the development of the national
pharmaceutical industry. On the other hand, in China until the mid 1980s. the importance
of business information has long been overlooked. because of the predominantly central
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government controlled economy and the self sufficient nature of the pharmaceutical
production. Because the major problem in drug consumption in China has been how to
meet the domestic demands for essential drugs, the other problems common in developed
countries such as information provision for health care personnel and the public, the
post market surveillance etc. are still not on the agenda. The statutory information flow
is still at its infancy, while China has just started to introduce and is still enhancing the
Medicine Act (1985) so that China could reach the world standard on new medicine
registration. So far, there has been no pharmaceutical patent protection system in China.
The major argument is that in countries with developing pharmaceutical industry, a
weak patent protection for pharmaceuticals would ensure its potentially restrictive
effects on domestic development to be minimised. Consequently, there is no pharma-
ceutical patent information outflow from China.
Today the national S&T information system plays a central role in the pharmaceutical
information flow infrastructure in China.
The UK
A much more comprehensive pharmaceutical information flow, including scientific,
business, drug, statutory and patent information, is found in the UK pharmaceutical
industry and pharmaceutical activity; comparing to the situation in China.
In view of the highly competitive market situation, the UK pharmaceutical industry
companies are careful to protect their intellectual property by means of patent protection.
Most research work in pharmaceuticals is targeted not only scientifically but also
commercially. There is a substantial and continuing demand for information concerning
regional disease profiles, health care systems, market sizes, regulatory constraints,
competitor activities, sales statistics, and so on. It is very clear that the heavy R&D
investment has partly gone to scientific information work in the industry. "The necessity
of retrieving information from external sources has led to increased expenditure by the
industry....Coupled with the high cost ofgenerating and managing information inhouse,
this rate of expenditure means that the industry spends very freely on information
handling." (Pickering, 1990) Drug information provision for health care personnel have
been greatly enhanced during the 1980s. The national Drug Information (01) network
in NHS has played a very important role in it. There is also a responsibility for the
industry to make drug information generally available. Most of UK pharmaceutical
companies have a formal medical information service for external enquiries from health
care professionals on their products. The regulatory system in the UK is one of the most
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comprehensive in the world. It is not only responsible for ensuring that medicines on
sale are safe, effective and properly labelled, it also controls the investigation of ｾ ｃ ｅ ｳ
and monitoring adverse drug reactions. These regulatory accomplishments have been
achieved at high cost to the industry in terms of patent life erosion, expensive clinical
trials, intensive documentation requirements and delay of regulatory procedure.
The industry information work plays a central role in the UK pharmaceutical information
flow infrastructure. This is an industry led driven and oriented information flow.
9.3 Wider System: Pharmaceutical Industry in the Two Countries
CHINA
The main objectives of the Chinese pharmaceutical industry have been to meet the
priority needs of the population through local production and to develop the country's
export potential. Major problems encountered and the ongoing purposes have been
related to the need to improve quality control over manufacturing, to increase R&D,
and to strengthen international marketing capacity, especially in ethical drugs.
Today China is 90% self sufficient in drug supply. Currently China has an annual export
capacity ofsome $600 million with a trade surplus of$2oo million. Bulk pharmaceuticals
and TCM constitute the whole volume of Chinese pharmaceutical exports. Although
China is a major international supplier ofpharmaceutical chemicals and TCM, its exports
account for only 15% of the pharmaceutical industry's annual gross output and it has
very little export business in ethical medicines.
Some 2000 pharmaceutical manufacturers produce 24 therapeutic categories of western
medicines including 3500 finished products and 1300 bulk pharmaceuticals. Beside,
they also produce some 4000 brand TCM products in 40 dosage forms. Since 1978,
Chinese pharmaceutical industry has increased production at a rapid rate of average
10% per year. The Chinese population has benefited from the boom in the national
pharmaceutical production and now has access to a much wider range of drugs including
some quite sophisticated drugs.
The UK
The British pharmaceutical industry is one of the top seven in the world. It is an inter-
national industry with products that are results of extensive R&D, are patent protected
and are available on prescription only. In terms of pharmaceutical R&D expenditure,
UK accounts for 8% of the world; in the productivity of :\CEs, UK accounts for 140 ('
of the world; in prescription drugs sales world-wide, UK accounts for 31%. Beside, in
1989, Britain exported some £2 billion worth of pharmaceuticals (more than 6 times the
Chinese export) with a trade surplus of nearly £1 billion. The UK has been maintaining
its position as the third largest exporter in the world pharmaceutical trade through the
1980s. Because UK population accounts for only 1.2% of world population, the home
market for UK pharmaceutical industry is too small. Since 1960. pharmaceutical export
has been the major principal market for the UK pharmaceutical industry accounting for
over 30% of its gross output each year on average.
Around 350 manufacturers from both international and national companies contributed
to the record rise in pharmaceutical output which amounted to £6.3 billion in 1989. The
pharmaceutical productivity has grown by 66% in real term between 1980 and 1989
which is three times greater than that of the UK manufacturing industry as a whole.
In the 1980s, the continuous growth in R&D investment with an average rate of 10%
p.a. and in R&D employment with an average rate of 3.5% p.a. in UK pharmaceutical
industry, have played an important part in maintaining the position of the UK phar-
maceutical industry in the world.
The major problems encountered by the UK pharmaceutical industry include:
1. There has been an erosion of the effective patent life of British medicines which has
been cut from 13 to 6 years over the past two decades. The erosion has been caused by
the drug development and the regulatory delays which contributed to increase devel-
opment times currently 12 years.
2. Under the pressure of intensifying and strengthening drug regulation world-wide since
the 1960s, the pharmaceutical industry has to provide more information to the regulatory
authorities, the health care profession and the public than they used to twenty or thirty
years ago.
3. Many governments' cost saving measures squeeze the UK pharmaceutical industry
to show a treatment is cost effective when compared to alternative treatments.
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In conclusion, the pharmaceutical industry in the UK and China have the following
objectives in common:
Objective 1. To make effective, safe, low-cost drugs available to meet the needs of the
population (essential drugs);
Objective 2. To ensure that drugs are used rationally;
Objective 3. To develop, where economically and technically feasible, national phar-
maceutical production that supports economic growth and the overall development
strategy of the country.
However, UK has its strategical emphasis on objective 2 and objective 3: whereas
China's strategical emphasis is on objective 1. With a population accounting for 1/5 of
the world, China has the main objective to meet the priority needs of the population
with a small pharmaceutical export which is only 15% of its industrial gross output and
only 1/6 of the UK export volume; whereas with a population accounting for 1.2% of
the world, the UK pharmaceutical industry gives export a very high priority. As the third
largest exporter in the world, the UK pharmaceutical industry accounts for 31 % of
world-wide prescription drugs sales and over 30% of its gross output are for export for
the past three decades.
The major problems and ongoing purposes for China pharmaceutical industry are to
improve quality control over manufacturing, to increase R&D, to increase the number
of NCEs approved in other countries, and thereby to strengthen international marketing
capacity, especially in ethical drugs sales.
The major problems and ongoing purposes for UK pharmaceutical industry are to
compete with more players in the world market, to restore the effective patent life to
protect the industrial profitability, to safeguard the consumer interests by compelling
regulatory authorities, by providing sufficient information to guide rational use ofdrugs.
and by monitoring and reporting adverse drug reactions.
9.4 Purpose and Decision Taking of Pharmaceutical Information
Work
In China, corresponding to the status of the wider system "na tional pharmaceutical
industry" and the drug situation/pharmaceutical activity, the system S "pharmaceutical
information flow" has one major mission - to support the S&T activities in the national
pharmaceutical industry. Other information flows such as business information, drug
information, statutory information and patent information are too small to be taken into
account.
By comparison, the pharmaceutical information flow in UK has a broad system mission
which includes:
1. To support the S&T activities in the national pharmaceutical industry.
2. To support the business of the pharmaceutical industry,
3. To provide drug information to the health care personnel and the public,
4. To provide information and documentation to meet requirements of the regulatory
authorities,
5. To protect intellectual property and disclose S&T information by means of patents.
To achieve different system objectives, pharmaceutical information flow has been
organized in the two countries accordingly.
Currently, the S&T library/information systems are being organized at the national level
in China. Under the State S&T Committee, there is a national S&T information policy
making body which is responsible for
1. Planning and co-ordinating the nationwide information sharing;
2. Planning and co-ordinating the national abstracting and indexing services;
3. Planning and co-ordinating the national computerized S&T databases.
At every ministry. there is a similar S&T information decision making body to advise
on the above three issues to the ministerial leaders and to implement the plans within
the ministry system throughout the country.
In China, there are about 50 national and ministerial S&T libraries and information
centres, plus 350 provincial and regional S&T libraries or information centres.
In State Pharmaceutical Administration of China (SPAC), there is a S&T information
system which includes 35 information services at administrative departments throughout
the country. Furthermore, there are 57 research institutes in SPAC. Each of them has a
S&T library or information service. The S&T information Institute at the SPAC head-
quarters is the central body for planning and co-ordinating information work among
these information organizations.
In Ministry of Public Health (MPH), there are about 130 medical universities and col-
leges, in which there are 50 pharmaceutical faculties. In addition, there are over 400
research institutes in the MPH. Information work in the S&T libraries and information
centres in these universities and institutes are planned and co-ordinated by the S&T
Information Institute in Chinese Academy of Medical Sciences in Beijing.
In Academia Sinica, there are 27 research institutes in the life sciences and 15 in
chemistry. Each institute has a S&T library or information service. The information
work of the research institutes are under the plan and co-ordination of the Central
Committee of Information and Publishing Work in Academia Sinica.
Compared to the information work in research institutes and universities, S&T libraries
and information services in Chinese factories are relatively small in terms of resources
and services. The information work in factories are mainly selfcontained without central
planning and co-ordination.
In China, there is a national S&T publishing industry which now includes the publishing
of about 3000 Chinese S&T journals and some 200 national abstracting and indexing
journals with an annual volume of 1.5 million records (15% for domestic literature and
85% for foreign literature). The S&T publishing undertaking is under the management
of Chinese Commission for Editing Translating and Publishing (CCEPT) in the State
S&T Committee. There are about 60 domestic S&T bibliographic databases each with
over 5000 records; plus several hundred small databases in building. These databases
aim at provide computerized version of the two hundred Chinese abstracting and
indexing journals. However there has been no central control over databases building
so far.
Unlike in China, pharmaceutical information work in UK is not organized by central
government but selforganized within each professional area. excepting that the national
drug information network has been well organized by the DHSS in the NHS.
In the UK, an industrial library/information system operates within its parent company
which include S&T information, business information, drug information, drug registry
and patent application related information work.
In the UK, a S&T library/information system operates within its parent organization
with the comprehensive and effective back-up documents supply service provided by
BLDSC. There are about 400 S&T libraries serving the total 220,000 S&T workers in
the country.
In the UK, there is an internationalized information industry which includes traditional
S&T publishing industry and online industry. This industry publishes about 4000 S&T
journals; provides over 400 S&Tabstracting and indexing services (both printedjournals
or online databases); including several of the largest international secondary databases
in the world, such as INSPEC, CAB etc .. Information work in this sector is greatly
market oriented.
In the world online market, business information contributes about 90% of the revenue,
the remain revenue is from legal, S&T. news and other information. There is a boom in
the UK business information industry. There are about 300 business information
databases and 150 brokers in the UK market.
The UK pharmaceutical information flow has existed for a long time. Although it is led
by the research based industry, there is no central decision taking process. On the other
hand, the Chinese S&Tinformation flow is very much under central government control.
Under such a circumstance, we may expect the future Chinese pharmaceutical infor-
mation flow to have a central decision taking process.
9.5 Performance of Scientific Information Flow in the Two
Countries"
One may "measure" S&T information flow performance by studying user opinion on
formal and informal channels, or indirectly by studying scientists' information dis-
seminating and using ability. S&T information flow has been developed in China for
13 All statements and data in this section are summarized from Chapters 5 and h.
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40 years. Now we try to measure it in comparison with the UK S&T information flow.
9.5.1 Predominant Languages and Countries in the Field of
Chemistry
Since the middle of this century, English language has become dominant in the field
of Chemistry and especially biochemistry. English as the original language accounts
for over 70% of total papers in CA. Nowadays USA, USSR, Japan, Germany and
UK dominate the world chemistry literature (Mullen, 1990). UK contributes about
5.6% of CA literature whereas China contributes about 3.5% of CA literature. The
CA only covers 10-15% of Chinese papers in the field. Moreover 98% of Chinese
papers in CA are in the Chinese language.
The implication of the above figures is that foreign S&T information means infor-
mation in foreign language to Chinese scientists, whereas for British scientists most
foreign information are in English.
9.5.2 Small Impact of Chinese Scientists
Mainly because of language barriers, most Chinese papers have very small impact
on scientific communication in the world. This in tum excludes Chinese scientists
from the world communication circuit and means Chinese scientists can get little
S&T information through informal channels from foreign scientists.
Compared to the leading position of UK, China has very small impact on world
medicines research, which is reflected by
(1) Chinese eminent authors mainly have a greater impact on the Chinese scientific
society rather than on the world scientific society. By comparison, British
eminent scientists have major impact on the world scientific society.
(2) It is generally accepted that there is a "pecking order" of journals within any
given subject area. In such a pecking order, Chinese scientific journals are
ranked much lower than British and western journals: because Chinese journals
receive much less citations and have less impact in the world than British and
western journals.
(3) Although a significant proportion of British pharmaceutical scientists admitting
the existence of foreign language barrier. up to 70% of them think all worth-
while work would be published in English.
By comparison, more than 90% of Chinese scientists reported that they regard
foreign language literature very important to their R&D activities. Moreover,
14% of them (those senior research scientists) confirmed that they rei)' on
foreign literature more than they rely on Chinese literature.
(4) British scientists cite English language papers at more than 90% of total citations.
Chinese scientists cite English language papers at 50-70% of total citations.
9.5.3 Scientists' Information Accessing Ability
In general it is perceived that scientists in UK have higher information accessing
ability than scientists in China. The primary information need for obtaining
documents which have been traced is far from satisfactory in China; comparing to
the basic satisfactory situation in UK. The most serious problem is the foreign
documents supply which is inadequate not only in middle sized and small cities but
also in big cities such as Beijing and Shanghai.
British scientists generally enjoy better document supply service than Chinese.
Although funds for academic libraries have been reduced in real terms and show
signs of continuing to be reduced; interloan and national reference services can be
called upon to help out in this event.
About 60% of Chinese scientists are not satisfied with the situation of documents
supply by their institute library or existing library networks, because less than 75%
of their information needs can not be met. Lack of satisfaction is reported by 50%
of scientists in Beijing and Shanghai and by 80% of scientists in remote areas.
Under the circumstance of today' s "information explosion", no single S&T library
could claim to be comprehensive in collection. However, most of Chinese scientists
have been restricted to very limited information collection and resource in their area,
because of the poor communication and transport condition. Sharing of the national
information resource is still far from reality in China. without a national or regional
interloan system or documents supply system available.
9.5.4 Scientists' Information Searching Ability
(1) Generally. because the several large world secondarv publications provide
comprehensive coverage over chemistry and life science literature in the world.
both British and Chinese scientists have few problems in literature
searching. In China the national secondary publication system now produces
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250,000 bibliographic records per year covering about 50% of Chinese lit-
erature. Generally Chinese scientists are satisfied with the situation in searching
domestic literature.
However, there are differences in scientists' information searching ability
between the two countries. The common features and differences are sum-
marised as follows:
(2) Both British and Chinese scientists mainly rely on the traditional mean of
scanning journals for current awareness - it is ranked first in the UK survey
and Chinese survey. The effectiveness of such a searching activity would
greatly depend on the journal collection in scientists' institution library and
local S&T libraries.
(3) SDI service for current awareness is the second most used searching method by
ICI chemical scientists. However, it is much less used by British academic
chemical scientists and by Chinese scientists.
(4) That ICI chemists rely on SDI, inhouse patent bulletins more than academic
chemical scientists reflects that there are better information services in
pharmaceutical industry than in academic libraries, whereas UK academic
scientists are still in favour of traditional ways such as personal contacts,
reviews for current awareness which are greatly self supported. The nature of
heavy market competition means UK pharmaceutical companies could not
afford missing of information and delay in getting information.
(5) Both Chinese scientists and British academic scientists rank abstracts journal and
review as frequently used methods. But British academic scientists show much
more use of colleagues recommending papers than Chinese scientists. British
rank review higher than abstracts journal whereas Chinese give the opposite
rank.
(6) Compared to British industrial scientists, Chinese scientists rank abstracts journal
and reviews relatively high in their index. British industrial scientists rank SDI.
inhouse bulletins and colleagues recommending papers relatively high in their
index.
(7) In China. each big research institute usually has a library and an information
department. The latter is responsible for compiling inhouse information
bulletins. This is similar to the situation in the UK pharmaceutical industry.
That ICI chemists rank inhouse bulletins at the 3rd of total 10 searching acti-
vities whereas Chinese scientists also reported certain use of such information
service for current awareness.
(8) Unlike British scientists, Chinese scientists regarded following up references
as less important. The explanation is that they face greater difficulty in getting
access to and hold of most of relevant papers in the world.
(9) Chinese scientists quite fmnly believe in abstract journal for timely and
comprehensive information searching. They seem to be more confident in their
ability in information searching than in obtaining literature (i.e. accessing the
information).
(10) UK scientists do not regard library catalogue and collection as the major
source for information searching. Instead, they search scientific literature
mainly through secondary publications, computerized databases and informal
communication. They do not have to worry about documents supply. They
assume most of scientific literature which they have traced would be available
either by local library or the national library document supply centre (BLDSC).
By comparison, Chinese scientists still regard library catalogue as major source for
information searching. And they greatly rely on local libraries ' collection, since there
is no national or regional interloan systems available.
9.5.5 Informal Scientific Communication
During the 1960s and 1970s, some western researchers have brought the "invisible
college" and "informal communication" to the attention of information studies (Price,
1963 & Garvey, 1972 & Meadows, 1974). Under the circumstance of "information
explosion", an invisible college of magnitude 100 scientists can effectively solve a
communication crisis by means of exchanging preprints and reprints, personal
contacts and conferences etc.
Personal contact is a much less used information channel in China than in the UK,
because the poor communication and transport facilities in China and the weak links
between Chinese scientific community and the world scientific community. Because
the language barrier and slim impact of Chinese research work or S&T literature on
the world, Chinese scientists are still out of the "invisible colleges" at the world level.
The informal communication between Chinese scientists and their foreign colleagues
is at a relativelv low level - most of Chinese scientists are going abroad to study
. .
whereas most of foreign scientists are coming to China for lecturing.
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The conference is one of the first few channels for outside scientists to get aware of
currently completed research work. In general British scientists are satisfied with
the status of conferences as a communication channel. On average each British
scientist attends 1-2 conferences per year.
There are not enough conferences for Chinese scientists. The conference is not a
frequently used information channel for current awareness in China. On average
each Chinese S&T worker attends conference every 7 year. The great importance of
foreign S&T information to Chinese R&D and the fact that generally Chinese
scientists are outside "invisible colleges" at world level have made international
conference one of the most valuable information source for Chinese scientists.
However each year, only 1% of Chinese pharmaceutical scientists could attend
international conferences in China and only 0.01 % of Chinese pharmaceutical
scientists have chance to attend international conferences abroad.
9.5.6 Enhanced Searching Ability by Online
It is clear, in the early 1980s British industrial scientists relied on online searching
much more than their academic counterparts. In 1981, online was ranked the second
by ICI scientists but the 4th by Oxford scientists. During the period of the 1980s,
online services have been widely spread in the whole research community in the
UK.
By 1988, 100% of UK university libraries offer online searching services. Of them,
75% reported annual number of searches has risen during last two years. However,
British academic scientists still use online less frequently (9th rank) than industrial
scientists (3rd rank).
By the end of the 1980s, IT application has been further improved in UK industrial
R&D sector. About 56% of UK chemical companies have started end user searching
in 1988. In 1988, the online volume in a middle sized pharmaceutical company, such
as Pfizer UK is ten times the average figure in a UK academic or public library.
Computerized information technology (or IT) was introduced into China only in the
early 1980s, it has been mainly concentrated in the big cities.
By the end of 19H6, 60 online searching terminals connecting with European and
North American hosts have been established in 27 big cities of China. The biggest
international online searching centre is at ISTIC headquarters in Beijing with an
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annual volume of online searching of $34,600 in 1986 accounting for 15Ck of the
British Library SRIS online expenditure in 1986/87. In 1988, China conducted some
20,000 international online searches accounting for 0.1% of the world figure and
being only 4 times the online volume in a large UK pharmaceutical company Glaxo.
The average online volume in the 60 Chinese online searching centres is 2-300
searches per year, which is similar to that in a large British academic library. The
current status of online searching in China is similar to that in Europe in the early
1970s.
Generally, both British and Chinese scientists are satisfied with online searching
results. However Chinese scientists do not satisfied with the subsequent documents
supply service. About 17% of journal papers, 73% of conference papers, 45% of
reports and 100% of theses hit are not available in China.
9.5.7 Information Disseminating Ability
Chinese scientists' information disseminating ability is quite a lot lower than
British scientists.
Assuming only senior Chinese scientists as potential authors then the average
publication rate is one paper per scientist per year in China: comparing to 2-3 papers
per academic staff per year in UK universities;
The conservative estimate is that a Chinese scientist's annual publication capacity
is one third that of a British scientist. The lower productivity by Chinese scientist
may have been resulted from the lower S&T journal capacity in disseminating the
nation's R&D results in China sthan in the UK.
Because the predominant position of English language in world scientific literature
and the leading position of medicines research by British scientists for several
decades, it is safe to say that all journal papers by British scientists are disseminated
in the world communication circuit.
However, it must be noted that 4% of Chinese papers in world journals and 1ｏｾ of
Chinese papers in world secondary publications do not indicate that only such
proportion of Chinese literature are at the same academic level as all British journal
papers. It only indicate that Chinese scientists have a much smaller capacity in
disseminating information to the world than British scientists.
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9.5.8 Information Productivity
A standard of "eminence" requires an eminent Chinese scientist having published
3-4 non-Chinese papers in world journals each year. Under such a standard, it is
estimated that there are several hundred of such Chinese scientists currently. They
account for 0.01 % of 400,000 Chinese scientific authors or 0.0005% of total 7.8
million S&T workers in China.
The most prestigious of the UK learned societies is the Royal Society with 1000
fellows currently. Those scientists elected Fellows of the Royal Society (FRS) are
regarded as the most eminent scientists in the UK. They account for 0.4 % of total
220,000 S&T workers in the UK. The average productivity for a FRS is 3 papers
per year in a life time.
9.5.9 Information Using Ability
Chinese scientists information using ability is lower than British scientists as
evidenced from the following points:
(1) That Chinese clinical pharmacological scientists show more diffuse information
use (over subject width) than their British colleagues partly because the premature
status of the clinical pharmacology in China.
A nation's scientists' information using ability may be influenced by the academic
level or the status of research in the subject field in the country. Lower academic
level and premature research status may result in diffuse information using by
Chinese scientists.
(2) Chinese scientists cite fewer papers in their work than western scientists.
The average citation rate in Chinese S&T journals is 5.4 citations per paper
comparing to 20.8 in the world journals covered in SCI. Another example is that
CJCP has an average citation rate of 8.6 whereas BICP has a rate of 18.2. The reasons
for less citations by Chinese papers are complex. One possible influence may be the
lower information accessing ability of Chinese scientists than that of British scien-
tists.
(3) Chinese scientists have to use more than 50% of literature in foreign language
whereas British scientist use over 90% of literature in their native language. This
agrees with the user study result that Chinese senior scientists reported relying on
foreign language literature more than on Chinese literature. Greatly relying on foreign
language literature means great difficulty in using information by Chinese scientists.
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9.5.10 Literature Aging
Generally, fast aging results from focused use by the more effective information
processing while slow aging results from diffuse use by less effective information
processing.
Aging analyses indicate:
(1) Chinese scientists can use and absorb Chinese information more effectively than
they use and absorb foreign information.
(2) The eminent Chinese scientists represent the centre of information processing or
using in the subject field. They use and absorb S&T information especially
foreign language information more effectively than ordinary Chinese scientists.
(3) Compared to Chinese scientists, British scientists use wider time span of scientific
literature, they cite more papers in their work, they "age" literature faster. All
these may reflect that compared with Chinese scientists, British scientists are
more effective in using information.
If we perceive that the scientific information flow in Britain and United States is
characterised by learned journal, "invisible college", conference and IT, in China
the specific feature of scientific information flow is the two circuits of scientific
communication - foreign (language) information communication and Chinese
(language) information communication.
At the foreign communication circuit, there are very few eminent Chinese scientists
- only 1% of Chinese scientists publish papers in foreign languages and have chance
to attend international conferences; about 0.01 % of Chinese scientists publish 3
papers in foreign journals per year and attend conferences abroad. These eminent
Chinese scientists represent the effective information using and processing core.
Mainly the following three factors contribute to the existence of two circuit com-
munication: 1. Language barrier, 2. Premature status of R&D in the country, 3.
Limited information resources in the country. Some eminent Chinese scientists
become active in foreign communication circuit by studying and working abroad to
avoid the above three communication obstacles.
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9.6 Pharmaceutical Information Resources in China and UK
9.6.1 Limited S&T Information Resources
9.6.1.1 Primary Literature Publishing Capacity
Generally, a Chinese scientific journal has a smaller capacity in disseminating
the nation's R&D results than a British scientific journal. Evidence for this
includes
(l). there are not enough journals in which Chinese scientists can publish their
work; China has a S&T manpower of7.8 million which is ｾＩ times the UK figure
whereas the number of S&T journals in China is about 3/4 of the figure in UK;
(2). the average refereeing and editing time for submitted journal paper in China
is 18-24 months which is 1.5-2 times the UK figure;
(3). assuming only senior Chinese scientists as potential authors then the average
publication rate is one paper per scientist per year in China: comparing to 2-3
papers per academic staff per year in UK universities;
(4). the average number of papers per journal per year in China is 100 comparing
to 171 in the UK.
9.6.1.2 Abstracting and Indexing Services
During the 1980s, the UK secondary services community was continuing to
develop in response to demands from the marketplace, both in terms of producing
new services and in increasing the availability of services online. There were 430
UK secondary services available in 1986 which represented an 11 % increase
since 1983. 46% of services in 1986 could be accessed online, compared with
just 31% in 1983. The num ber ofonline bibliographic databases comprising these
services almost doubled over the same period- from 50 in 1983 to 93 in 1986.
The UK abstracting and indexing services produce about 3 million bibliographic
references annually.
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In pharmaceutical areas, the three major services based in USA - CA, 1\1 and
BA use British organizations to abstract and index the British published literature.
The large international secondary publications and databases could cover most
of UK scientific literature.
Under the supervision of the China Commission for Editing, Translating and
Publishing S&T Documents (CCETP), the build up of the national secondary
publication system has been completed with 229 abstracting and indexing serial
(158 reporting foreign information and 71 reporting domestic information) and
an annual production of 1,370,000 records (1,170,000 foreign records and
300,000 Chinese records) by 1987.
The number ofsecondary services and the number of bibliographical records
in China are 50% of the UK figures respectively.
However, there has been rapid growth in the Chinese secondary services. From
1981 to 1987, there has been an increase of 70% in secondary publication in titles
and in records compared to the 11% increase in UK during 1983-1986.
The production of foreign secondary publication has engaged 90% of funds and
manpower in the Chinese secondary publication system. The time span between
a foreign journal paper being published and its bibliographic record appearing in
Chinese abstracts and indexes journals is quite long, in some cases being over 20
months or 5 times the time lag in international secondary publications.
Generally, the Chinese national S&T secondary publication system could cover
most of high standard domestic S&T literature. However, the comprehensiveness
in coverage of the national system is questionable. An estimate is that about 50%
of Chinese S&T literature in medical science are covered by the national S&T
secondary publication system.
By 1989 there are only 61 bibliographical databases with over 5,000 records in
China (none of them are accessible online): comparing to 93 online databases
and many more non-online databases in UK in 1986.
Although China has been left behind in computerized bibliographical database
building, its printed secondary journal system has been well constructed and have
a capacity of producing .300,000 domestic records covering most of high standard
S&T papers in the country.
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9.6.1.3 S&T Library and Information System
(I) Different Acquisition Policy in the Two Countries
In UK, most S&T libraries and information services (excepting BLDSC) con-
centrate in collecting S&T literature in English language. The BLOSC serial
acquisition policy reflects a continuing effort to collect serial in all subjects from
allover the world and in the vast majority of languages. Now it has an annual
intake of 55,000 titles. The policy for monographs is to try to obtain all serious
and research level monographic items in English where-ever published. Now the
annual intake of monographs is 40,000 volumes, plus 155,000 reports and 10,000
US and UK doctoral theses.
China spends up to 90% of acquisition budget in collecting foreign (language)
literature to cover most important S&T literature in the world. Every year, China
imported about 70,000 titles of foreign academic books and 16,000-19,000 titles
of foreign journals. The former is 1.75 times the BLOSC acquisition whereas the
latter is one third of the BLOSC acquisition.
(2) S&T literature collection is not comprehensive at national S&T libraries and
information centres in China.
About five national S&T libraries or information centres concentrate in Beijing
and Shanghai with current foreign journal collection ranging from 3,000 to 7,000;
plus about 3,000 Chinese S&T journals. The biggest current journal collection
is in the National Library of China accounting for In of BLOSC collection. The
Chinese national libraries mainly function as central S&T reference libraries like
SRIS in London. None of the Chinese national S&T libraries provides a docu-
ments supply service like the BLDSC.
(3) General limited information resources in S&T libraries and great differences
among institutions and among areas in China.
(i) In Britain,
Research based pharmaceutical companies have spent "freely" in infor-
mation work compared with the financial constraints in academic
libraries. In the contrary, most of large S&T libraries and information
services are concentrated in government research institutes and univer-
sities. The S&T library or information service in a large Chinese factory
is at the same level of a small government research institute.
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(ii) In China,
Large research institute library (15% of total libraries) normally has
500-3,000 current foreign journals and a similar number of Chinese
journals;
Middle sized research institute library (25% of total libraries) normally
has 50-500 current foreign journals and similar number of Chinese
journals;
Small research institute library (60% of total libraries) normally has less
than 50 current foreign journals and a few hundred Chinese journals;
about 80% of S&T libraries in administrative departments, and 90% in
factory R&D divisions are at this level.
In Britain,
Large academic library (10% of total libraries) normally has over 10,000
current journals;
Middle sized academic library (25% of total) normally has 5,000-1 O,eX)()
current journals;
Small academic library (60% of total) normally has 1,000-5,000 current
journals; large pharmaceutical company library in Glaxo, ICI etc. having
a similar magnitude of current journal
collection.
The top 15% of Chinese libraries have a magnitude of current journal
collection similar to the middle 25% of UK libraries. The middle 25% of
Chinese libraries have a magnitude of current journal collection similar
to the bottom 60% of UK libraries. About 60% of Chinese research
institute libraries, 80% of S&T libraries in administrative departments,
and 90% of S&T libraries in factory R&D divisions have very limited
information resources.
(iii) In China more than half of imported S&T information is concentrated in
Beijing, while most of the remaining part is held by less than ten biggest
cities. However, there is no central documents supply scheme in China.
Consequently. about 50% of scientists in Beijing and Shanghai are not
satisfied with documents supply with the unsatisfactory rate being up to
XO% of scientists in other cities.
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(4) Worldwide Inflation of S&T Literature and Impact on British and Chinese
S&T Libraries
For the past ten years, there has been a rapid escalation in journal price. The UK
university pay and price index - a conservative calculation - gave a value of
235.6% increase. Most of UK academic libraries have reduced their acquisition
for the past two decades.
In China the inflation ofS&T literature price for the pas t five years, are contributed
by two factors: world-wide literature price inflation and rapid inflation at home.
In the Library of Academia Sinica, the average foreign journal price has grown
from ¥361 in 1985 to ¥1551 in 1989 - increasing by 3290/0 during five years.
Although annual foreign journal expenditure has grown at an average rate of 16%
p.a., the annual intake of foreign journals has decreased at a faster rate of 27%
p.a.. The foreign journal price inflation rate is about 30% p.a in China.
In the Library of Academia Sinica in Beijing, from 1985 to 1989, the number of
foreign journals have been reduced by 50%. The National Library subscription
has declined from 13,693 in 1987 to 7741 in 1990 (decrease by 50%). The ISTIC
Beijing centre reduced its foreign journals from 5408 in 1988 to 4200 in 1990
(decrease by 20%). The ISTIC Chongqing centre reduced foreign journals from
7000 in 1987 to 1348 in 1990 (decrease by 80%).
(5) The current S&T information system in UK is characterised by its central
documents supply service (BLDSC) and wide spread IT application.
(6) The current S&T information system in China is characterised by its dual
price system for domestic and foreign information (in 1989, the average Chinese
journal price is V15 whereas foreign journal price is Vl,SOO); up to 90% of
acquisition expenditure in foreign information; and great emphasis in foreign
information work. About 90% of bibliographic records produced in Chinese
abstracting and indexing journals are foreign records. The foreign information
analysis and research is a major information work in almost all S&T libraries
and information services which is estimated engaging nearly 20% of information
staff.
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9.6.2 Other Pharmaceutical Information Resources
9.6.2.1 Business information for pharmaceutical industry
In UK, there has been a boom in business information industry during the 1980s,
partly owing to the increased demands and partly owing to the wide spread IT
application. Business information companies are amongst the stars of the UK
stock market. In the world as well as in the European online market. business
information accounts for more than 90% of the total revenue. The world largest
pharmaceutical business information company IMS (mainly covering European,
North American and Japanese information) makes its income up to $400 million
per year.
In China, the economic reform started since 1979, has given rise to industrial
demands for business information. By the late 1980s, some business information
services have been set up on the basis ofprevious S&T information organizations.
The nature of profit making in business information has been found. Within the
SPAC S&T information system, there are three such business information ser-
vices each with over VI00,000 income per year.
There are hundreds of business information databases, brokers and thousands of
business consultants in the UK. Having benefited from the convenience of
advanced communication network and information technology, they provide a
great variety of services with high speed and quality. Comparatively, there are
very few business information services in China. Furthermore, these Chinese
information services still greatly rely on the traditional and manual means to
disseminate information, such as compiling information bulletins.
In the UK, business information work has been developed to cover very detailed
information ranging from company reports, sales statistics. medical statistics,
products information, R&D monitoring etc. The existing Chinese business
information systems mainly provide directory of enterprises and market infor-
mation.
Above all. the market economy is still in an early stage in China. The business
information needs are not well recognized there. The mechanism of business
information flow is far from sophisticated. The market for business information
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has not been set up yet.
9.6.2.2 Drug information for doctors
In Britain, needs of doctors for new drug information can be met by means of
promotional literature in scholarly or professional journals, postal advertisements
and representatives from pharmaceutical companies. Chinese pharmaceutical
factories disseminate new drug information similarly to the UK companies. The
major difference is that new drug promotion is aimed at doctors directly in the
UK, while it is not directly aimed at doctors but at hospital pharmacists in China.
In other words, Chinese doctors mainly rely on pharmacists for new drug
information.
The problems which occur to doctors are similar in the UK and China, including
administration/dosage, adverse effects/toxicology, availabilitytsupplv, clinical
use, identification, interaction, pharmacology and pharmaceutical problems.
The difference lies where doctors try to find information.
In Britain, hospital pharmacies, area drug information centres and regional drug
information centres constitute the national drug information network. To sup-
plement the network, the pharmaceutical industry provides product information
to doctors and health professionals. Furthermore other professional associations
such as Royal Pharmaceutical Society also provide drug information services.
Each year, a regional centre handles more than one thousand enquiries: the area
centres in a region handles about 65,000 enquiries; a pharmaceutical company
handles about three thousand enquiries; the Royal Pharmaceutical Society
handles about 16,000 enquiries nationwide.
By comparison, the provision of drug information for health workers is
semi-organized in China. There are no formal information services in the Chinese
national health care system. The majority of Chinese pharmaceutical factories
do not provide medical information services to external enquiries. It is also
reported that Chinese doctors rarely use industry information source.
Table 7.4 and Table R.6 compare the information sources used by British doctors
and by Chinese doctors.
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British doctors mainly use hospital pharmacy or area information centres for
the four categories of information (in order of usage):
(1) clinical use, (2) administration/dosage (3) pharmaceutical problems (4)
availabili ty/suppl ｹ ｾ
British doctors mainly use regional Drug Information (01) centre for the four
categories of information (in order of usage):
(1) clinical use, (2) adverse effects/toxicology, (3) pharmaceutical problem. (4)
administration/dosage.
Chinese doctors mainly rely on hospital pharmacists for the following infor-
mation (in order of usage):
(1) availability/supply, (2) pharmaceutical problem, (3) identification, (4)
administration/ dosage.
Chinese doctors mainly rely on their own knowledge or read professional
journals for the following problems (in order of usage):
(1) interaction (2) clinical use (3) adverse effects/toxicology (4) pharmacology
and (5) administration/dosage.
The main difference in using drug information sources is that Chinese doctors
still greatly rely on themselves for information such as drug clinical use, adverse
effects/toxicology,' while their British counterparts could use existing hospital
drug information service and national 01 network for more efficient information
searching.
9.6.2.3 Medicine regulatory system and statutory information
now
Generally. there are similar medicine legislation systems in the UK and China.
The Chinese system is established in 1985 which is 22 years later than US:\ and
17 years later than l 'K.
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The US and UK regulatory systems divide clinical trials into t phases and require
one-two thousand patients during phase I-III; and more clinical evaluations
during Phase IV post market surveillance. Such studies (Phase I-IV) can take
anywhere between 3 and 5 years.
The Chinese regulatory system divides clinical trials into 3 phases and requires
three hundred patients during phase I-II; and more clinical evaluations during
phase III which normally takes 2 years.
In general, regulatory requirements for new drug application are more complex
and restrictive in UK and US than that in China. The standards and information
requirements for new drug application are still quite simple, especially in the case
of TCM.
The information requirement for TCM new drug, unlike that for WM, does not
include product chemical name. compound, chemical structure. Chemistry of the
drug substance is the major omission.
Only TCM ingredients are required, though there are also the problem of stan-
dardization in ingredients. Also the pharmacological studies and clinical trials
are less sophisticated in TCM than in WM.
Since 1964, the UK has been relying on the yellow card system for spontaneous
reporting by prescribers to public in the first case and to CSM in the second case
on adverse drug reaction (ADR). About 1.+ years late, in 1988 China started
establishing a national postmarket surveillance system based on 10 large
hospitals.
In the West, preparation of new drug registration documents has been proved to
be a cause of intensive information work in a pharmaceutical company. It results
in the creation of hundreds of volumes of documents. However this kind of
information work is not well organized by pharmaceutical factories and medicines
research institutes in China.
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9.6.2.4 Pharmaceutical patent system and patent information
flow
Since the 1960s, most of the developed countries have introduced pharmaceutical
products patents. The function of a patent is primarily to stimulate inventive
activity by preventing a new product from being imitated during a legally
sanctioned period of 20 years from the date of application (WHO, 1988).
From 1963 to 1988, the number of world pharmaceutical patents has steadily
increased by over 200%. More significantly, the growth of UK pharmaceutical
patents has been much faster than that of world pharmaceutical patents. During
the period of 1963-1988, the UK pharmaceutical patents has increased by over
600%. For the same period, the percentage of UK pharmaceutical patents as the
total pharmaceutical patents granted in US has grown from 3.6% to 6.4%. The
figures indicate that the steady growth in UK pharmaceutical R&D activity
through the past three decades.
China only established its patent system in 1985. So far there has been no patent
protection for pharmaceuticals. Furthermore the number of Chinese pharma-
ceutical patents being granted abroad is estimated to be very small.
The trends in the pharmaceutical patent system in the near future include:
firstly, in the UK and other developed countries there will be a restoration of
effective patent life from currently 6 years to previous 13 years; secondly, in
China there will be an expansion of patent life from 15 years to 20 years and the
inclusion of pharmaceutical patent protection.
There are similar great demands for patent information in UK and China. Both
countries have built up national patent information service network.
The SRIS of British Library has an annual intake of over one million world
patents and has long provided a comprehensive service to UK users which is
supplemented by a national patent information network of about twenty local
patent libraries/information centres. It is reported that the number of readers and
remote enquiries for the patent information network (not including SRIS) is about
309
_ --oIllIIIIlII
19,000 per year. At. SRIS about one third of the 150,000 readers visits made each
year patent enquiries. Additionally, there are 19,000 telephone patent enquiries
per year.
The Patent Documents Library (PDL) in Chinese Patent Office has an annual
intake of about one million world patents. Each year PDL receives about 45,000
readers from all over the country. The 62 local patent documentation services are
mostly set up in 1985. Their main function is to disseminate patent documents
published by Chinese Patent Office. The use of the 62 services are relatively small
at present - about 24,000 readers each year.
Apart from PDL in Beijing, there are other 34 patent documentation libraries -
ten in the government ministries in Beijing and 24 in provinces. The 34 patent
libraries have certain amount of foreign patent collections. Except Chongqing
Centre of ISTIC and Zhejiang Province, other patent libraries have collection
much less than PDL in the Chinese Patent Office in Beijing. Like other kinds of
imported information materials, foreign patents are concentrated in a few of the
biggest cities such as Beijing, Shanghai, Chongqing. The major problem remains
the patent documents supply and resource sharing in China.
9.7 Relationships Among Five Information Flows (the UK model)
Pharmaceutical information flow is composed of scientific information, business
information, drug information, statutory information and patent information. However,
it is not the simple sum of the five information flows. The five information flows are,
on one hand, different in terms of the function, the nature, and the status. On the other
hand, they are associated with each other in some ways, and all connected with the
pharmaceutical industry.
9.7.1 Overlap Relation
The overlap relation is quite straight forward and clear. There are many overlaps
among the five information flows, such as
I. Scientific information and patent information. It has been well recognized that
patent information is one kind of important S&T information sources.
310
cr1
Under today's highly competitive circumstances, most of pharmaceutical innova-
tions made in the developed countries apply for patent protection in the first place
and then disseminate to the scientific communi ty. Because patents involve disclosure,
new ideas are made available to others and thus competition is encouraged.
2. Scientific information and business information. One example of such overlap is
biotechnology information.
Apart from chemical synthesis, there are other sources for the generation of new
drugs. Medicine has always depended on natural products. Today extensive research
is being conducted to identify, isolate and synthesize pharmacologically active
substances from natural sources. Biotechnology is an interdisciplinary subject which
became popular in the mid 1970s; and known as "the application of biological
organisms, systems or processes to manufacturing and service industry" (Crafts-
Lighty, 1990).
It is difficult to distinguish the boundaries of biotechnology but most people tend to
associate it with its commercial or practical applications. Relevant materials are
widely dispersed and can be drawn from the fields of medicine, biochemistry,
genetics, microbiology, immunology, chemical engineering, chemistry and com-
puting.
In the 1980s, about 40 newsletters monitoring the biotechnology industry have been
started in the world. Additionally there are certain number of research journals
specialised in the field. The proliferation of newsletters and their research oriented
counterparts has also led to a market for abstracting services in biotechnology.
Crafts-Lighty has listed 4 specialised online databases: Abstracts in BioCommerce
(BioCommerce Data), Biobusiness (BIOSIS), Biotechnology Abstracts (Derwent
Publications) and Current Biotechnology Abstracts (Royal Society of Chemistry)
(Crafts-Lighty, 1990).
3. Scientific information and drug information. Drug information is mainly provided
to doctors and health care personnel for rational use of drugs, and is also an important
kind of S&T information for pharmaceutical R&D.
4. Scientific information and statutory information.
The legislation requires the manufacturer of the product to obtain a marketing
authorization for each product. This is granted after some expert group is satisfied
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with the specifications of the product and the biological and clinical tests that have
been performed with it. The regulatory requirements (statutory information
requirements) will determine the R&D procedure and the scientific information
generating during the R&D procedure.
One example of such overlap is the technical development information.
Technical development is further divided into process development. analytical
development.formulation development and production. A significant proportion of
S&T information in development phase is overlapped with statutory information.
The process development scientists need information on alternative methods of
preparation of chemical entities whether by chemical or by biotechnical methods;
need information on compounds or similar structure. They also need to know whether
the projected starting materials are likely to be available in the required quantities
and whether they have been registered under hazardous substance legislation.
Information on reactions and conditions for optimum yields is also needed.
Analytical procedures must be developed for all ingredients in the formulation.
Specifications for all significant ingredients must include confirmation of their
identity, quality and significant impurities with criteria for acceptance of batches.
The formulation development must make sure that the formulation is stable, safe,
reproducible, free form contamination. The formulation of a medicine is designed
to make available to the patient the correct quantity of drug at the correct rate in a
stable, safe and acceptable form.
The most important requirement for an information centre serving development and
production functions is an up to date set of pharmacopoeia. Pharmacopoeia com-
prise monographs specifying the assay, impurity levels, ranges of significant physical
parameters and other properties of drugs available in the country of publication. If
the drug meets the standards laid down it is then considered to be of suitable quality
to be marketed in that country.
5. Business information and drug information. One important kind of business
information - product information is greatly overlapped with drug information.
6. Business information and patent information. One important function of business
information is the monitoring of R&D activities. Patents constituting an important
source of current S&T information could serve this function.
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7. Business information and statutory information. Information on the political
environment within a country is important in terms of business prospects in that
country. The political environment can have an impact on pricing policies, returns
on investments and marketing for multinational corporations, legal requirements for
product licenses, patent protection, etc. For the UK pharmaceutical industry, the
main customer is the NHS, i.e. the government- hence customer information is very
much tied up with policy and social issue.
8. Drug information and statutory information. Under the Yellow Card system in
UK doctors report ADRs to the Committee on Safety of Medicines (CSM). The
regulatory authority is the central figure in this drug information gathering.
9.7.2 Interactive Relation
The best example showing the interactive relation among the five information flows
is the existence of pharmaceutical information specialists in the commercial
environment or the information industry like IMS, PJB etc ..
PJB is a UK based pharmaceutical business information company first funded in the
mid 1970s. Today it has about 130 staff and annual turnover of over 9 million pound
(1990). In response to the increasing information demands from the pharmaceutical
industry, PJB has experienced a stable growth since its foundation which is par-
ticularly remarkable during the recent economic recession in the UK. PJB publishes
a range of international business newsletters, annuals and special reports for senior
executives in the pharmaceutical areas world-wide. Its information products have a
very broad coverage both in subjects, including R&D projects and progress,
manufacturers and products, regulatory and legislation, financial analysis and stat-
istics, situation of disease, health care and market; and in countries mainly focusing
on USA, Japan, and European countries, also including developing countries to
certain extent.
The other example of such an interactive relation among the five information flows
may be found in the internal information databases management and use in a large
research based pharmaceutical company. During the R&D process, the proprietary
databases (containing S&T information) need to be maintained in a form which
will meet legislation requirements for patent application (becoming patent infor-
mation later) and Clinical Trial Certificate application. During clinical trials. the
company must hold the information in a form suitable and ready for compiling
regulatory submissions (work involving statutory information). The company also
needs a post market surveillance database to collect and store information on the
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world-wide experience with its products (drug information). Furthermore, the
company may use such internal databases for training of sales representatives;
approval of product advertisements, labelling, and press releases; preparation of
prescribing information documents etc. (i.e. business information work relating
with marketing).
9.7.3 Effects of Interaction and Connective among Information
Flows
In the UK, pharmaceutical information has already been treated a special category
of information activity. The interaction and connective among S&T information,
business information, drug information, patent information and statutory information
have been recognized. One effect of these is the existence of pharmaceutical
information as a profession both in practice and in academic field.
The pharmaceutical industry has already successfully united scientific information
work, business information work, drug information work, statutory information work
and patent information work together under its general system goals. Because of the
great information demands of the pharmaceutical industry, there has been a booming
in the pharmaceutical information business in the UK as well as in other industrial
western countries. Such a business may have millions US dollars of turnover each
year (see Chapter 7).
In academic area, there are pharmaceutical information studies including scientific
information divided by subjects such as chemical, biological, biotechnology, bio-
medical, toxicologic, technical development and clinical trials; business information;
patent system; legal and regulatory system; pharmaceutical company information
work; drug information and post market surveillance (Pickering, 1990). Some British
universities have been providing postgraduate courses on pharmaceutical informa-
tion and undertaking information retrieval (lR) projects for/with the pharmaceutical
industry for quite long time (Wilson, 1990).
9.8 Pharmaceutical Information Flow and Environments
In a country, pharmaceutical information flow exists within its special environment
"drug situation/pharmaceutical activity" and its general information/communication
environment. Naturally there are influences and counter influences between the system
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"information flow" and the environments. Although it is impossible to measure these
influences by any scientific methods, a descriptive study of them still is necessary to
complete the whole picture of comparison.
9.8.1 Influences from Environments on Pharmaceutical Informa-
tion Flow
The influences from environments on pharmaceutical information flow system S are
simplified in Figure 9.2.
Firstly we look at "drug situation or pharmaceutical activity" in UK and China to
find out its influences on pharmaceutical information flow in the two countries.
British people belong to 25% of the world population in developed countries who
consume 79% of the world drug. Generally, the NHS could provide modern health
care to the population in UK. There is a well organized national drug information
network in NHS on a par with the medical information services provided by the
industry.
By comparison, Chinese people belong to 75% of the world population in the third
world consuming only 21% of the world drug. China is 90% self sufficient in drug
consumption. Howevermainly the urban population (20% of total) has regular access
to modern health care (i.e. hospitals, sophisticated drugs etc.) There is a semi-or-
ganized drug information provision to health workers. The low level of drug con-
sumption may be the major cause for the very limited drug information flow.
The UK pharmaceutical industry is the third largest exporter in the world. The export
capacity of Chinese pharmaceutical industry is only 12.5% of the British one.
Consequently there is a big business information flow in UK while business infor-
mation is quite small in China.
The UK pharmaceutical industry is characterized by multinational R&D companies,
highly patented products, high investment in R&D, high risk and high profit. There
is a highly sophisticated information flow within the industry. The UK industry plays
a leading role in pharmaceutical information flow.
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By comparison, Chinese pharmaceutical industry is mainly the manufacturing type
of industry with very limited R&D activity. Although drug R&D has progressed
significantly in research and academic institutions, there are problems in how to
bridge research activity with industrial development and production. Generally there
is a weak information work in Chinese pharmaceutical industry.
Britain among other 5-6 countries has been leading the world medicines research
for several decades. China, on the other hand, has thousands of years experience in
using TCM and has a very rich resource ofTCM herbs to rely on for new drug R&D.
Since 1949, significant progress has been made in applying the western S&T to TCM
and WM research in China. However, China is still being left behind in pharma-
ceutical R&D by the UK and other few developed countries. Few Chinese NCEs are
recognized by the world while the UK accounts for 14% of the world NCEs.
The UK leading position in medicines research in the world has brought many
benefits to scientific communication in the country - most of British scientific papers
are covered by large international abstracting journals or databases, more British
scientific journals have high reputation in the world, many British scientists have a
world-wide impact. By comparison, most of Chinese scientists are out of the
world-wide scientific communication system. Only 1% of them could publish papers
in non-Chinese language journals, only 0.01% of them publish 3 papers in
non-Chinese journals each year which equals to the average productivity and dis-
semination capacity of a British scientist. Apart from the language factor, the rela-
tively low level of medicines research may have obstructed communication between
Chinese scientists and foreign scientists.
It is easy to understand how the pharmaceutical patent system and the drug regulation
system have brought in patent information flow and statutory information flow in
the UK. It may not be so easy to explain how the backwardness in patent and
regulation systems would influence pharmaceutical information flow in China.
Generally such weak patent and regulation systems could make Chinese pharma-
ceuticals (especially NCEs) less competitive in the world. Sequentially, Chinese
pharmaceutical industry will have little share of the world market and bring in little
hard currency for further R&D investment.
Secondly, we look at how the world-wide growth of science affect scientific com-
munication and S&T information flow.
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For a developing country like China, the government R&D expenditure could not
keep a rapid growth. The two major problems are how to cope with the world 1iterature
proliferation and world literature price inflation and how to increase its scientific
journal and abstracting journal capacity of disseminating the nation's R&D results.
For the scientists in the developed countries like UK, there is another kind of problem:
whether it is safe to ignore the great amount of non-English S&Tinformation existing
in the world? If not, how to cope with this extra "information explosion"? As China
is emerging as a big scientific nation, the pattern of formal and informal scientific
communication in the world will gradually change.
Despite of the overall stagnation in R&D employment in the UK in the 1980s, UK
pharmaceutical industry has maintained a growth in R&D manpower at 3.5% p.a.
and has risen R&D proportion in its whole labour force from 15% in 1980 to 23%
in 1989. Meanwhile the UK pharmaceutical industry R&D expenditure has grown
at 10% p.a. comparing to 2.9% p.a. in the whole UK R&D expenditure. During
1963-1988, the UK pharmaceutical patents have increased by over 6 times. All these
have stimulated the growth of pharmaceutical information flow in this country.
Thirdly, we look at influences from general communication environment.
The relatively low capability of transportation and communication in China,
especially the 20 year lag in IT application between China and UK, has greatly
obstructed the ever growing scientific information flow. By comparison, in the
advanced western countries including UK, there has been a great enhancement in
communication environment. The IT which firstly grew from scientific information
field, has now made its largest application in business information industry. The
relatively big investment in IT by the UK pharmaceutical industry has brought it an
"information rich" environment.
9.8.2 Influences on Environments from Pharmaceutical Informa-
tion Flow
Against the influences from environments, pharmaceutical information flow system
S makes counter affects to its environments in some ways.
The medicines research status in a country would be enhanced if the scientific
communication is significantly improved. If the whole pharmaceutical information
flow, especially business information flow are strengthened, it may promote the
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national pharmaceutical industry especially in the R&D based sector, and therefore
resulting in a greater investment in R&D by the pharmaceutical industry, according
to the examples in UK pharmaceutical industry and in other western countries.
There is little doubt that increased scientific communication would result in the
growth ofscience in the society. The UK pharmaceutical industry is well known by
its great commitment in information work. This has consequently resulted in the high
productivity of R&D activities. During the 1963-1988, in contrast the decreasing
trend of the whole UK patent as a proportion of world patent (4.1 % in 1963 to 3.4%
in 1988); the UK pharmaceutical patent as a proportion of world pharmaceutical
patent has increased from 3.6% in 1963 to 6.4% in 1988. Similarly, the great growth
in Chinese scientific literature during the 1980s, has mostly benefited from the
improvement in national S&T information system during that period.
The communication or information environment in a country will be enhanced in
terms of its resources, its capability, the demands for it, and utilization of it; if its
beneficial effects are well recognized by the society.
The great IT commitment by the UK pharmaceutical industry and the fact that 90%
of world online revenue is from business information reflect that the enhancement
of communication environment and the prospects of information industry rely on
the market demand which in tum is influenced by the beneficial effects of the current
information flow system.
9.9 A Future Pharmaceutical Information Flow System in China
9.9.1 Necessity to Reform
In Table 9.2 we summarize some major differences in current pharmaceutical
information flows in the two countries.
The drug situation peculiar to China includes a national policy for domestic manu-
facturers to supply 90% of the domestic market, a manufacturing type of industry
with little R&D investment, limited export confined to bulk pharmaceuticals and
TCM raw materials, no share of the world ethical drug market a less sophisticated
legislation system and no pharmaceutical patent protection. Under such situation,
pharmaceutical information flow is dominated by S&T information, other infor-
mation flows (business. drug, patent and statutory) are still emerging in China.
Table 9.2 Major Differences in Phann. Infor. Information Flow in China and UK
Britain China
1 A mixture flow of S&T info business S&T information in dominance with
info drug info patent info & statutory smaller patent info flow and business
info info flow
2 British scientists Chinese scientists
(1) English (native language) is predorni- English (foreign language) is pre-
nant language in work dominant language in work
(2) UK leading position in drug R&D in smaller impact on drug R&D in the
the world world
(3) general satisfaction with information general unsatisfactory with informa-
access/document supply tion access/document supply
(4) frequent informal communication less use informal communication
(5) enhanced searching ability by online very limited access to online services
(6) higher publishing capacity lower publishing capacity
(7) disseminating R&D results at world disseminating R&D results at national
level level (only 4% papers published in
world journal, 10% papers covered by
world secondary publication)
(8) Eminent one publishes 3 paper each Eminent one publishes 3 papers each
year in life time (eminence: 0.4% of year in world journal (eminence:
total S&T workers in UK) 0.0005% of total S&T workers in
China)
(9) cite more papers (18.2 in average) and cite less papers (8.6 in average) and
90% citation in Eng. 50% citation in Eng.
(10) focused Infor. use over subject width diffuse Infor. use over subject width
(11) use wider time span of literature, cite use shorter time span of literature, cite
more, "age" literature faster- focused less, "age" literature slowly- diffuse
and effective use of information and less effective use of information
3 S&T literature publishing industry S&T literature publishing industry
bigger capacity in disseminating S&T smaller capacity in disseminating
information (4000 S&T journals S&T information (3000 S&T journals
against 220,000 S&T workers) against 7.8 million S&T workers)
4 Abstracting and indexing services Abstracting and indexing services
430 services, 3 million bibliographic 229 services, 1.5 million bibliographic
record p.a. record p.a.
93 online databases
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5 S&T library system S&T library system
(1) comprehensive collection in BLDSC no comprehensive collection at
(55,000 world journals p.a.) national centres (NL, ISTIC etc.-
3-7,000 world journals at each centre)
(2) a central document supply system for no national or regional document sup-
the whole country ply scheme
(3) better situation in S&T libraries generally limited resources in S&T
especially in Phann. company S&T libraries especially in Pharm. factory
libraries S&T libraries
(4) 235.6% inflation rate in academic 329% inflation rate in foreign aca-
journal price (1980-1988) demic journal price (1985-1989)
(5) dual price system for domestic and
foreign S&T information (annual
price ¥15 for Chinese journal and
¥1500 for foreign journal in 1989)
6 UK business information revenue up China S&T information (including
to one billion US dollars in 1989 small part of business inf.) revenue
¥50 million (or $10 million) in 1989
7 A national drug information network no formal drug information system
exists in NHS
Most UK pharmaceutical companies Most Chinese pharmaceutical fac-
provide formal drug information to tories do not provide formal drug
health professional information
8 A patent system protects phannaceuti- A patent system do not protect phar-
cals maceuticals
National patent information network National patent information network
including SIRS, 7 local libraries and including CPO, 62 local info centres-
12 inf. centres- good situation in not very good in resource sharing
resource sharing
9 A sophisticated drug regulatory sys- A basic drug regulatory system
tern
higher standard in information lower standard in information require-
requirement for new drug application ment for new drug application
10 Pharrn. Infor. as a profession in the General S&T Infor. profession only
practical and academic terms
ＳｾＨｽ
Although S&T information flow has been developed for 40 years, there are still
serious problems in scientific communication in China.
1. Great dependence on foreign S&T information.
There are about seven countries in the leading position of pharmaceutical R&D in
the world. About 70% of the world S&T literature are in English. Two problems
resulting from this are language barriers and financial constraints in importing of
S&T information.
2. Language barriers.
To solve the language problems in information searching, China has put great effort
on compiling secondary publications for foreign literature and on foreign information
analysis and research services. The cost effectiveness of these services need to be
evaluated.
Language barriers have obstructed the worldwide dissemination of Chinese S&T
information. Although CA gives Chinese literature 3.5% coverage each year, 98%
of these papers are in Chinese. Even so, these CA indexed papers are estimated to
represent only 15% of total Chinese papers in the corresponding fields. Also it is
estimated only 4% of Chinese literature are published in international journals.
3. Little impact on the world and poor communication for Chinese scientists.
Chinese scientists (even those eminent ones) have very little impact on the world
scientific community. Major reasons are the backwardness in R&D, lack of means
fordissemination (journal, patent, secondary publication), and language barriers etc ..
The results of little impact are that Chinese scientists are excluded from worldwide
informal communication (invisible college etc.) and could not get information
through informal channels. Little impact also reduce the opportunities for foreign
investment to develop potential Chinese products.
4. Two scientific communication circuits and distinction between eminent and
ordinary scientists in China.
There are two scientific communication circuits/pathways- one at the international
level and one at the national level. The distinction between eminent and ordinary
Chinese scientists are that the former communicate at the international level whereas
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the latter can only communicate at the national level.
An eminent Chinese scientist publishes 3-4 papers in world journals per year whereas
ordinary scientists publish one paper in Chinese journals per year on the average.
About 0.1% of 400,000 Chinese scientific authors are up to this eminent standard.
Most of eminent Chinese scientists have some work experience abroad. They could
access foreign S&T information more widely than ordinary scientists through
informal channels. Literature aging analysis suggests that eminent Chinese scientists
use and absorb foreign information more effectively than ordinary scientists.
5. Compared with British scientists, Chinese scientists have lower information
accessing and searching ability, mainly because of lack of interlending and online
services.
6. Compared with British scientists, Chinese scientists have lower information
disseminating ability, mainly because of lack of journals, secondary publications in
China and low Chinese coverage by world primary and secondary publications.
7. Chinese scientists cite less papers, user shorter time span of literature, "age"
literature more slowly than British scientists. They also show diffuse information
use over subject width. In a sense, these may reflect the difficulty for them to get
hold of foreign S&T information.
Above are some problems identified in this study. By no means comprehensive, the
above problems show that there is a great necessity for improvement or reform on
the current S&T information flow in China.
9.9.2 Prospects for A Future System
This project try to approach the comparison of information flow in the two countries
in a systematic way, that is to compare pharmaceutical information flow in a country
under its wider system "national pharmaceutical industry", its special environment
"national pharmaceutical activity", as well as its general information environment.
Such a comparison shows that differences in national pharmaceutical industry and
national pharmaceutical activity determine the different status and function of
pharmaceutical information flow between the two countries.
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In the UK pharmaceutical information flow system, the industry information work
plays a central role which embraces all major information flows including scientific
information, business information, drug information, statutory information and
patent information, The pharmaceutical information flow is the "nerve system" of
the national pharmaceutical industry. S&Tinfonnation, business information, patent
information are directly related to the industry while statutory information and drug
information are indirectly linked with the industry. In that sense, the pharmaceutical
information flow may be called as industry led information flow and represents the
big information in advanced industrial countries.
By comparison, the pharmaceutical information flow is not being separated from
general S&T information flow in China. The less sophisticated national pharma-
ceutical industry has a premature "nerve system" in which excepting scientific
information, other information flows are still in the infancy. The backwardness in
other information flows will slow the modernization of Chinese pharmaceutical
industry and prevent pharmaceutical R&D from fast growing. This will in tum
prohibit the improvement of scientific information flow. The very limited industry
involvement in R&D activities and therefore in information work seems makes the
fundamental difference in the pharmaceutical information flow between the two
countries. Without the industry demand, commitment and participation, the isolated
scientific information flow represents a little information in the less industrialized
countries.
Such a comparison sheds a light on the reform of current S&T information system
in China. The reform and modernization of current S&T information system must
parallel with the reform and modernization of national industry and national science
& technology.
The current development of the Chinese S&T and pharmaceutical industry has
provided a favourable environment for a future pharmaceutical information flow
system in China. As described early in Chapter 1, the current S&T reform (1985-)
is aiming at speeding up the industrial development and market realization of S&T
activities by linking government research closely with industry. The economic
reform (1979-) has greatly accelerated the shaking up of the Chinese research based
pharmaceutical industry and the internationalization of the Chinese industry and
healthcare market. During the second half of 1980s, the number of Chinese-foreign
joint venture has grown from none to nearly one hundred. In 1985. China introduced
the Medicine Act. In ＱＹＹｾＮ China will introduce pharmaceutical patent protection.
Ｓ Ｒ Ｎ ｾ
In the near future in China, there will be a healthcare market opening to both Chinese
and foreign drug companies. The market competition will mainly be in ethical or
patent drugs. Facing these changes, SPAC is working on a plan for the future Chinese
R&D pharmaceutical industry (Industry Trade News, 1 Jan. 1992).
In China, since 1949 there has been an improved and more widely available health
care system which encouraged an increase in the drug market. The Chinese phar-
maceutical industry has increased its output at a rate of 10% p.a. for the past decade.
Many issues that used to exist only in the developed countries are emerging in China,
such as drug information provision, ADR monitoring, legislation, and mass media
coverage etc..
Above all, a favourable environment has been created for a future Chinese phar-
maceutical information flow system.
9.9.3 Consideration and Recommendation for the Future System
[A] About system missions
Mission 1. to support R&D in the Chinese pharmaceutical industry and ensure that
R&D workers are able to derive benefit from all the information in the public domain.
This means that the current S&T information work should be extended from gov-
ernment research institutes to industry laboratories, from journal source to patent
source and from traditional library work to specialist information services.
Mission 2. to support commercial activities of the Chinese pharmaceutical industry.
Because of the "open door" economic policy and the introduction of Chinese
pharmaceutical patent protection, the Chinese pharmaceutical industry will compete
with foreign companies on a domestic market which used to be monopolized by
itself. Furthermore, the Chinese pharmaceutical industry is expending its export
capacity from bulk pharmaceuticals and TCM raw materials to ethical drugs. The
future competition will be mainly in ethical drug market (nationwide and worldwide)
among the Chinese industry and foreign companies. Therefore, the R&D of Chinese
medicines will be targeted not only in a scientific sense. but also commercially. It is
predicted that the Chinese business information concerning regional disease profiles.
healthcare systems, market sizes, regulatory constraints. competitors. sales statistics
and so on will be in great demand by both the Chinese and foreign companies.
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Mission 3. to provide drug information to the healthcare professional and the public
for rational use of drugs. Along with the improvement of healthcare services and the
increase of drug consumption in China, more and more Chinese people could access
to new drugs and sophisticated drugs than ever before. The transition of the Chinese
pharmaceutical industry into a R&D based industry and the internationalization of
domestic market will result in a gradual development from essential and generic drug
consumption to ethical drug consumption in China. Therefore, it is predicted that
there will be an increase in the importance of drug information provision for safe
and rational use of drugs. Both the MPH hospitals and the Chinese and foreign
companies have the responsibility for the drug information provision.
Mission 4. to build up a statutory information system in the MPH legislation
department to control the whole process from drug research, through development,
clinical trials, market launch to ADR monitoring and postmarket surveillance; to
encourage and organize mass media in monitoring drug use; to enhance the com-
munication among the industry, the authorities and the public.
[B] About the system decision taking process
Because of the central control political situation, there is a possibility to create a
Central Pharmaceutical Information Committee in managing the future pharma-
ceutical information flow system in China. The Committee will appoint directors
for R&D information section, business information section, drug information
section, statutory information section, and the patent information section. The
members of the Committee will include the chief information officers of SPAC,
SATCM, MPH and Academia Sinica, so that in the future there will be information
resource sharing among these major ministries. To integrate scientific, business,
drug, statutory and patent information management under the central control could
help the transition from information for invention to information for innovation.
[C) About the resources at and beyond the disposal of the central Committee
There are 57 research institutes in SPAC, 60 in SATCM, 411 in MPH plus 50
pharmaceutical colleges/university departments. In addition, there are about several
dozen pharmaceutical related research institutes in Academia Sinica. Every institute
has a S&T library and/or information unit.
Furthermore. within SPAC. SATCM. \1PH and Academia Sinica there are S&T
information services under the ministerial control. Beijing Library of Academia
Sinica, S&T Information Institute of Chinese Academy of Medical Sciences.
Shanghai Library of Academia Sinica and Shanghai S&T Information Institute of
Pharmaceutical Industry are the largest information centres each with several
hundred to several thousand foreign journals.
The central Committee will coordinate in acquisition, bibliographical control (i.e.
union catalogue etc.) among these large information centres. There is a further need
to create an interlending network among these large information centres and the
hundreds of R&D institutes/laboratories in the Chinese pharmaceutical industry.
Beyond the control of the central Committee, there are several national S&T
information services that could back up the future Chinese pharmaceutical infor-
mation system. They are the National Library, Shanghai Library, Shanghai Institute
of S&T Information and ISTIC each with annual intake of several thousand foreign
journals. The Chinese Patent Office (CPO) has an annual intake of one million world
patents. The problem in the current S&T information flow in China is that more than
50% of imported foreign S&T documents are concentrated in Beijing and much of
these foreign information are concentrated in the above several national information
centres (see §8.1.2). The central Committee needs to consider the possibility in
building up a special information service to collect documents from the above
national centres and distribute them to R&D workers in the Chinese pharmaceutical
industry.
Apart from the traditional S&T libraries and information centres, the following
resources need to be explored:
(l) About 2-300 large Chinese pharmaceutical manufacturers with R&D units and
S&T information units.
(2) About 100 Chinese-foreign joint ventures with access to the world information
sources through their parent companies abroad.
(3) Several business information services in SPAC and some SPAC industrial cor-
porations having control of some kind of national business information.
(4) MPH hospitals as potential drug information suppliers.
(5) The legislation department in MPH as a potential statutory information system.
(6) The medical representatives of pharmaceutical companies as potential industry
customer information providers.
(7) About five hundred national medical and pharmaceutical journals are not enough
for Chinese scientists to publish. There are very few Chinese journals published in
English. To increase the the journal publishing capacity would increase the impact
of Chinese scientists nationwide and worldwide and improve the scientific com-
munication in China.
(8) SPAC publishes China Pharmaceutical Abstracts bimonthly with annual volume
of9000 records. There is a need to speed up the publication and increase the coverage
of Chinese literature. Finally it is expected to provide online service.
(9) About 20% of S&T information staff have first degrees in foreign language study
and work in the field "foreign information analysis and research". This is one kind
of very important resources. The central Committee needs to evaluate this kind of
information work against the users needs in order to improve this kind of services.
[D] About measuring the performance
The following indicators are recommended for measuring the system performance
but need specific standards:
(1) Scientific journal publishing capacity
Are there enough S&T journals for disseminating Chinese S&T information
nationwide and worldwide?
(2) Secondary services
The coverage of Chinese S&T literature, the publishing speed needs to be increased.
It is needed to review the investment in compiling foreign secondary publications
vs compiling domestic secondary publications. It needs to assess the progress in
computerization of secondary services.
(3) Scientists' information accessing ability
Can scientists get essential document supply locally? Can they get most ofdocuments
needed through local sources and national interlending network?
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(4) Scientists' information searching ability
Can scientists get effective information services such as SOl, inhouse bulletin, offline
and online searching, CD-ROM, translation etc ..
(5) Chinese scientists/journals impacts on the world
This is an indirect measurement. It is likely that as the Chinese impacts increase in
the world, Chinese scientists could get more information through informal com-
munication channels.
(6) Scientists' citing pattern
This is an indirect measurement. It is likely that as the information service and supply
as well as informal communication are improved, Chinese scientists may cite more
papers, use wider time span of literature, "age" literature fast, than they used to.
(7) Effective patent information service
The current national patent information network with CPO as the central collection
and 62 regional searching units will be fully used by the future Chinese pharma-
ceutical information system. The high cost of pharmaceutical R&D means that every
R&D companies or institutes will compete in early patent application and many
marketers will compete in good licensing opportunity. In the future Chinese phar-
maceutical information system, the patent information section will include a central
patent supply service which works closely with CPO and several hundred patent
units in pharmaceutical companies and in research institutes. The measurement of
patent information section should be fast and comprehensive patent supply and
effective patent searching and disseminating.
(8) A profitable business information section
The future Chinese pharmaceutical information system will provide the Chinese and
foreign pharmaceutical industry with cost effective services of market information.
product information, company information, etc .. The first step is to focus on domestic
information sources. The next will expend the coverage to world information. One
measurement is the annual turnover. This is the only section in the future Chinese
pharmaceutical information system which generates significant revenues. The profit
of business information services could be invested in R&D information and drug
information section.
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(9) Information for rational use of drugs
As the Chinese consumption of ethical drugs increases, to ensure safe and rational
use of drugs is the aim of both the healthcare professional and the pharmaceutical
industry. The future information system will include a MPH hospital drug infor-
mation network and consumer information services provided by pharmaceutical
companies.
To measure the performance ofdrug information section both user survey and inquiry
statistics could be applied.
(l0) A statutory information system up to international standards
The MPH legislation authority and statutory information system will raise standards
for drug research, development, registration, production, marketing, and post market
surveillance. So that these standards will be up to the international standards to
protect Chinese customers' right. This will also help the Chinese pharmaceutical
industry to become more competitive in the world market.
Finally, in order to build up an advanced pharmaceutical information flow system
in China, a detailed financial condition assessment must be carried out. The current
government information funding as part of R&D funds in SPAC, SATCM, MPH
and Academia Sinica are not expected to grow significantly under the S&T reform.
Therefore other alternative incomes must be identified and sought. For example, as
the Chinese pharmaceutical industry increases its R&D investment, certain fraction
of the money should be used for information services. The future Chinese pharma-
ceutical information flow system will charge for business information and perhaps
patent information services. The central Committee should find some ways (tax etc.)
to reallocate this income to other non profit services such as S&T interlending
network, S&T publishing, abstracting & indexing services, and hospital drug
information services, and so on.
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Appendices
2.1 Administrative Divisions and Population Distribution
Source: State Statistical Bureau figures as reported in Beijing Review, 3 January 1983
units at provin- area (OOOs population units at pre- cities units at
ciallevel sq. km.) (OOO,OOOs) fectural level county
level
total 30 9,600 1,031 208 230 2136
Beijing 16.8 9.2 10
Tianjin 11.3 7.7 IJ
Hebei 180 53.0 10 10 39
Shanxi 156 25.2 7 7 101
Inner Mongolian 1200 19.2 9 10 79
Liaoning 140 35.7 ") 13 45
Jilin 180 22.5 4 9 37
Heilong- 460 32.6 7 12 66
JIang
Shanghai 6.2 11.8 10
Jiansu 100 60.5 7 11 64
Zhejiang 100 38.8 7 9 62
Anhui 130 49.6 8 12 70
Fujia 120 25.9 7 7 61
Jiangxi 160 33.1 6 10 81
Shandong 150 74.4 9 9 106
Henan 167 74.4 10 17 111
Hubei 180 47.8 8 11 73
Hunan 210 54.0 11 14 89
Guangdong 210 59.2 9 14 96
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Guangxi 230 36.4 8 7 80
Sichuan 560 99.7 14 13 182
Guizhou 170 28.5 7 5 79
Yunnan 390 32.5 15 6 123
Xizang 1200 1.8 5 1 71
Shanxi 200 28.9 7 6 91
Gansu 450 19.5 10 5 73
Qinghai 720 3.8 7 J 37
Ningxia 60 3.8 2 2 16
Xinjiang 1600 13.0 12 8 80
Taiwan 36 18.2
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2.2 Inflation Rate in UK & China (1981-1988)
Source from:
1. European Marketing Data & Statistics 1991, 26th ed. Euromonitor Publication Ltd.
London 1991
2. Hartland-Thunberg, 1990
Year 1981 1982 1983 1984 1985 1986 1987 1988
China 2.5 2 2 2.7 11.9 7 8.8 27
%
UK% 11.9 8.6 4.6 5.0 6.1 3.4 4.2 4.9
2.3 Foreign Exchange Rate in UK and China (1983-1989)
Source from International Financial Statistics Yearbook 1990
Year 1983 1984 1985 1986 1987 1988 1989
$ per¥ 1.9809 2.7957 3.2015 3.7221 3.7221 3.7221 4.7221
£ per $ 1.4506 1.1565 1.4445 1..+745 1.8715 1.8095 1.6055
£ per '¥ 2.87 3.23 4.63 5.49 6.97 6.74 7.58
lie the exchange rate between £ and ¥ is from the calculation of the first two lines
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5.1 Drug Information Services in Hospital
-Questionnaire to Hospital Pharmacists (1989)
1. Are you responsible for drug inquiry?
2. Please point out the category of questions occurring to you:
(1) administration/dosage
(2) availability/supply
(3) adverse reactions/side effects:
(4) identifications
(5) identifications/contraindications/clinical use
(6) interactions
(7) poisoning/toxicity
(8) pharmaceutical information
(9) pharmacology
(10) others
3. Status of inquirers:
(l) doctors and nurses in the hospital
(2) doctors and nurses from other hospital
(3) patients and others
4. How many inquiries do you answer per day?
5. Information sources for drug information:
5.1 using reference collection in the hospital - ( 9c)
using external information sources - ( %)
5.2 consulting pharmacists in other hospitals - ( 9c )
consulting pharmaceutical manufacturers - ( %)
depending on own knowledge - ( %)
6. Please name heavily used reference books:
(3 Chinese books and 3 foreign books)
7. Source for new drug information:
(1) pharmacists in other hospitals
(2) posted advertisements
(3) promotional literature in journals
(4) industrial representatives
(5) market and fair for medicines
(6) others
8. ADR monitoring:
(1) report to the manufacturers
(2) report to the government authority (MPH)
(3) inform doctors in the hospital
(4) report in professional journals
(5) others
9. Name the mostly used journals for drug information
(2 Chinese journals and 2 foreign journals)
5.2 Drug Information Needs and Sources
- Questionnaire to Doctors
1. Sources for new drug information:
(1) hospital pharmacists
(2) promotional literature in journals
(3) posted advertisement
(4) industrial representatives
(5) market and fair for medicines
(6) others
2. Sources for the following questions:
Information sources:
Questions: administration/dosage
availability/supply
ADR/side effects
identification
identification/contraindication/cl
inical use
interactions
poisoning/toxicity
pharmaceutical information
pharmacology
others
pharmacists phanna.
factories
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3. ADR monitoring:
(1) report to pharmaceutical manufacturers
(2) report to the government authority (MPH)
(3) report to pharmacists
(4) report in professional journals
(5) others
4. Do you often use library and information centre?
5. How often do you use internal and external information services?
- using internal information service account for ( %)
- using external information service account for ( %)
6. How do you use Chinese and foreign journals for drug information?
- using Chinese journals account for (%)
using foreign journals account for (%)
7. Please name the mostly used reference books for drug information:
(2 Chinese books and 2 foreign books).
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5.3 Scientific Information Xeeds
. Questionnaire to Pharmaceutical Scientists
1. Please describe your work:
(l) basic research
(2) R&D
(3) the industry related R&D
2. Please name the major foreign languages you use in research work.
3. Please name current information sources ( ) and retrospective searching sources( ):
(l) Scanning journals
(2) Reviews
(3) Following up references
(4) Inhouse information bulletins
(5) Abstracting and indexing journals
(6) Computer information retrieval
(7) Current Contents
(8) Personal contacts
(9) Conference communication
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4. Please name the heavily used information materials:
(1) books
(2) journals
(3) patents
(4) standards
(5) reports
(6) grey literature
5. Have you ever use the following information services?
(1) ISTIC
(2) NL
(3) Chinese Patent Office
(4) Ministerial Information Services
(5) Provincial information services
6. How much can the information service in your research organization satisfy your
information needs?
( I) less than 50%
(2) more than 50%
(3) more than 80%
7. Have you ever done international online searching?
Do you satisfy with the retrieval results?
8. Have you ever missed any important information? What are the causes?
(1) failing to trace literature
(2) failing to gain documents
(3) cannot read foreign language literature
9. Which of the following information services need to be strengthen?
(1) building up databases
(2) foreign information analysis and research
(3) Inhouse information bulletins
(4) searching for users
(5) documents supply
(6) translating
(7) SDI
5.4 Information for Pharmaceutical Factories
- Questionnaire to Factories
1. Is there a business information division in the factory?
If not, is there any other divisions responsible for business or market information in
the factory?
2. Major sources for business information:
(1) market or fair for medicines
(2) the government departments
(3) information services
(4) others
3. Please name the major information sources:
(3 government departments, 3 information services)
4. How do you promote your pharmaceutical products?
(I) promotional literature in journals
(2) posted advertisements
(3) representatives
(4) market / fair / conference
(5) others
5. Have your factory ever used any online business databases?
( I) name 2 Chinese databases
(2) name 2 foreign databases
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5.5 Scientific Information Services
- Questionnaire to S&T Information Organizations
1. Title of the information organization, telephone No., Telex No.
2. Address and post code:
3. Staff number and the director:
4. the divisions or units in the organization
unit title group staff major work
leader number
unit1
unit2
unit3
...
5. information publication or inhouse bulletins:
6. information technology facility:
7. information resource
Chinese foreign video and others
information information tape
8. the number of foreign information analysis and research for the last two years:
9. the income of information services for the last two years:
10. annual fund and expenditure:
11. other information about the organization:
6.4.1 Bradford Distribution of Chinese citations in
-Pharmaceutical Analysis (1984-1987) (China)
No. of journals No. of citations Total citations Rank (n) Cumulative No. of
citations
1 180 180 1 180
1 111 111 2 291
1 78 78 3 369
1 48 48 4 417
2 28 56 6 473
1 22 22 7 495
1 18 18 8 513
1 17 17 9 530
2 16 32 11 562
1 15 15 12 577
1 10 10 13 587
1 9 9 14 596
1 8 8 15 604
7-1 125 813
6.4.2 Bradford Distribution of English citations in
-Pharmaceutical Analysis (1984-1987) (China)
No. of journals No. of citations Total citations Rank (n) Cumulative ｾ ｯ Ｎ of
citations
1 86 86 1 86
1 82 82 2 168
1 63 63 3 231
1 41 41 4 272
1 26 26 5 298
2 24 48 7 346
1 21 21 8 367
2 12 24 10 391
2 11 22 12 413
1 10 10 13 423
1 9 9 14 432
8-1 215 822
6.4.3 Bradford Distribution of citations in
-Pharmaceutical Analysis (1984-1987) (China)
No. of journals No. of citations Total citations Rank (n) Cumulative :\0. of
citations
1 180 180 1 180
1 111 111 2 291
1 86 86 3 377
1 82 82 4 459
1 78 78 5 537
1 63 63 6 600
1 48 48 7 648
1 41 41 8 689
2 28 56 10 7.+5
1 26 26 11 771
2 24 48 13 819
1 22 22 14 841
1 21 21 15 862
1 18 18 16 880
1 17 17 17 897
2 16 32 19 929
1 15 15 20 944
2 12 24 22 968
2 11 22 24 990
2 10 20 26 1010
! 9 18 Ｒｾ 1028
1 8 8 2tJ 1036
311 7-1 599 340 1635
6.4.4 Bradford Distribution of Chinese citations in
CJCP (1985-1987) (China)
No. of journals No. of citations Total citations Rank (n) Cumulative No. of
citations
1 18 18 1 18
1 16 16 2 34
1 14 14 3 48
1 13 13 4 61
1 12 12 5 73
1 11 11 6 84
1 8 8 7 92
3 7 21 10 113
1 6 6 11 119
4 5 20 15 139
3 4 12 18 151
11 3 33 29 184
10 2 20 39 204
37 1 37 76 241
6.4.5 Bradford Distribution of English citations
in CJCP (1985-1987) (China)
No. of journals No. of citations Total citations Rank (n) Cumulative No. of
citations
1 51 51 1 51
1 44 44 2 95
1 33 33 3 128
1 27 27 4 155
1 25 25 5 180
1 21 21 6 201
2 20 40 8 241
1 17 17 9 258
1 16 16 10 274
2 15 30 12 304
3 14 42 15 346
2 13 26 17 372
3 12 36 20 408
3 10 30 23 438
1 9 9 24 447
2 8 16 26 463
1 7 7 27 470
4 6 24 31 494
6 5 30 37 524
12 4 48 49 572
19 3 57 68 629
44 ') 88 112 717
-
112 1 112 224 829
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6.4.6 Bradford Distribution of citations in
CJCP (1985-1987) (China)
No. of journals No. of citations Total citations Rank (n) Cumulative \0. of
citations
1 51 51 1 51
1 44 44 2 95
1 33 33 3 128
1 27 27 4 155
1 25 25 5 180
1 21 21 6 201
2 20 40 8 241
1 18 18 9 259
1 17 17 10 276
2 16 32 12 308
2 15 30 14 338
4 14 56 18 394
3 13 39 21 433
4 12 48 25 481
1 11 11 26 492
3 10 30 29 522
1 9 9 30 531
3 8 24 33 555
4 7 28 37 583
5 6 30 42 613
10 5 50 52 663
15 4 60 67 723
30 3 90 97 813
54 ') 108 151 921
149 1 149 300 1070
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6.4.7 Bradford Distribution of citations in
BJCP (Jan.. June, 1984) (UK)
No. of journals No. of citations Total citations Rank (n) Cumulative No. of
citations
1 260 260 1 260
1 160 160 2 420
1 66 66 3 486
1 65 65 4 551
1 64 64 5 615
1 61 61 6 676
1 45 45 7 721
1 36 36 8 757
1 33 33 9 790
1 30 30 10 820
1 28 28 11 848
1 24 24 12 872
2 22 44 14 916
1 21 21 15 937
1 20 20 16 957
2 19 38 18 995
2 18 36 20 1031
1 17 17 21 1048
2 16 32 23 1080
2 15 30 25 1110
2 13 26 27 1136
2 12 24 29 1160
4 11 44 33 1204
8 10 80 41 1284
5 9 45 46 1329
8 8 64 54 1393
9 7 63 63 1456
6 6 36 69 1492
7 5 35 76 1527
28 4 112 104 1639
20 3 60 124 1699
49 '1 98 173 1797-
133 133 306 1930
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6.4.8 Bradford Distribution of citations in
Annual Reviews of Pharmacology (1968-1970) (LSA)
No. of journals No. of citations Total citations Rank (n) Cumulative :\"0. of
citations
1 555 555 1 555
1 409 409 2 964
1 276 276 3 1240
1 264 264 4 1504
1 245 245 5 1749
1 226 226 6 1975
1 219 219 7 2194
1 217 217 8 2411
1 212 212 9 2623
1 168 168 10 2791
1 150 150 11 2941
2 135 270 13 3211
2 127 254 15 3465
1 125 125 16 3590
1 121 121 17 3711
1 120 120 18 3831
1 116 116 19 3947
1 108 108 20 4055
1 107 107 21 4162
1 105 105 " 4267
1 94 94 23 4361
1 89 89 24 4450
1 86 86 25 4536
, 83 166 27 4702
1 82 82 28 4784
78 78 29 4X62
, 76 1-' 31 5014)-
74 74 32 5088
71 71 33 5159
349
1 70 70 34 5229
1 68 68 35 5297
1 67 67 36 5364
1 64 64 37 5428
2 58 116 39 5544
1 53 53 40 5597
1 51 51 41 5648
2 50 100 43 5748
1 49 49 44 5797
1 44 44 45 5841
2 43 86 47 5927
1 42 42 48 5969
1 41 41 49 6010
2 40 80 51 6090
1 38 38 52 6128
1 37 37 53 6165
2 36 72 55 6237
1 35 35 56 6272
1 34 34 57 6306
1 33 33 58 6339
1 32 32 59 6371
5 31 155 64 6526
2 30 60 66 6586
1 28 28 67 6614
2 27 54 69 6668
1 26 26 70 6694
3 25 75 73 6769
1 24 24 74 6793
4 23 92 78 6885
5 22 110 83 6995
2 21 42 85 7037
4 19 76 H9 7113
7 18 126 96 7239
350
7 17 119 103 7358
5 16 80 108 7438
5 15 75 113 7513
5 14 70 118 7583
6 13 78 124 7661
7 12 84 131 7745
12 11 132 143 7877
7 10 70 150 7947
8 9 72 158 8019
8 8 64 166 8083
27 7 189 193 8272
34 6 204 227 8476
552 1-5 1025 779 9501
6.4.9 Bradford distribution of articles among journals
- case of CJCP(1985-1987)
Rank(n) No of journals No. of EngJr. No. of Ch. Jr. No. of papers
1 1 1 0 51
2 1 1 0 44
3 1 1 0 33
4 1 1 0 27
5 1 1 0 25
6 1 1 0 21
8 2 2 0 20
9 1 0 1 18
10 1 1 0 17
12 2 1 1 16
14 2 2 0 15
18 4 3 1 14
21 3 2 1 13
25 4 3 1 12
26 1 0 1 11
29 3 3 0 10
30 1 1 0 9
33 3 2 1 8
37 4 1 3 7
42 5 4 1 6
52 10 6 4 5
67 15 12 3 4
97 30 19 11 3
151 54 44 10 2
300 149 112 37 1
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